

DO NOT ENTER: /RC/

I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on May 29, 2008.



Frank C. Eisenschenk, Ph.D., Patent Attorney

SUPPLEMENTAL AMENDMENT
UNDER 37 C.F.R. § 1.116
Patent Application
Docket No. TPI-350C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Deirdre Renee Claytor
Art Unit : 1617
Applicants : Örn Almarsson, Magali Bourghol Hickey, Matthew L. Peterson, Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo
Serial No. : 10/660,202
Filed : September 11, 2003
Conf. No. : 6536
For : Pharmaceutical Co-Crystal Compositions

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.116

Sir:

Applicants request that the period for response be extended three months through and including June 10, 2008, the fees for which have been paid at the time this Supplemental Amendment was filed.

In response to the Advisory Action dated March 25, 2008, please amend the above-identified patent application as follows:

J:\TPI\350C1\Amend-Resp\Amd-final-supp.doc\DNB/sl

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Request for Continued Examination (RCE) Transmittal Address to: Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Application Number	10/660,202
	Filing Date	September 11, 2003
	First Named Inventor	Orn Almarsson
	Art Unit	1617
	Examiner Name	Deirdre R. Claytor
	Attorney Docket Number	TPI.350C1


This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.

Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. **Submission required under 37 CFR 1.114** Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).
- a. ☒ Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.
- i. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____
- ii. ☐ Other _____
- b. ☒ Enclosed
- i. ☒ Amendment/Reply
- iii. ☐ Information Disclosure Statement (IDS)
- ii. ☐ Affidavit(s)/ Declaration(s)
- iv. ☐ Other _____
2. **Miscellaneous**
- a. ☐ Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)
- b. ☐ Other _____
3. **Fees** The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.
- The Director is hereby authorized to charge the following fees, any underpayment of fees, or credit any overpayments, to Deposit Account No. _____ I have enclosed a duplicate copy of this sheet.
- a. ☐
- i. ☒ RCE fee required under 37 CFR 1.17(e) \$810 based on large entity status
- ii. ☒ Extension of time fee (37 CFR 1.136 and 1.17) \$490 for a two-month extension of time
- iii. ☐ Other _____
- b. ☐ Check in the amount of \$ _____ enclosed
- c. ☒ Payment by credit card (Form PTO-2038 enclosed)

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED			
Signature		Date	OCTOBER 10, 2008
Name (Print/Type)	FRANK C. EISENSCHENK, PH.D.	Registration No.	45,332

CERTIFICATE OF MAILING OR TRANSMISSION			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.			
Signature		Date	OCTOBER 10, 2008
Name (Print/Type)	FRANK C. EISENSCHENK, PH.D.	Date	OCTOBER 10, 2008

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.


NPC-UNIV-000005731

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 805 of 1101

I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on October 10, 2008.


Frank C. Eisenschenk, Ph.D., Patent Attorney

AMENDMENT UNDER 37 C.F.R. § 1.114
Patent Application
Docket No. TPI.350C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Deirdre Renee Claytor
Art Unit : 1617
Applicants : Örn Almarsson, Magali Bourghol Hickey, Matthew L. Peterson, Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo
Serial No. : 10/660,202
Filed : September 11, 2003
Conf. No. : 6536
For : Pharmaceutical Co-Crystal Compositions

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

AMENDMENT UNDER 37 C.F.R. § 1.114

Sir:

A Notice of Appeal was filed June 10, 2008 in the above-referenced patent application. Applicants request that the period for response be extended two months through and including October 10, 2008, the fees for which have been paid at the time this Amendment was filed.

In response to the Advisory Action dated July 17, 2008, please amend the above-identified patent application as follows:

J:\TPI\350C1\Amend-Resp\Amd-RCE.doc\DNB/sl

In the Claims

1-42 (canceled).

43 (new). A co-crystal comprising an API and a co-crystal former selected from:

- (a) carbamazepine and saccharin;
- (b) carbamazepine and nicotinamide;
- (c) carbamazepine and trimesic acid;
- (d) celecoxib and nicotinamide;
- (e) celecoxib and 18-crown-6;
- (f) 5-fluorouracil and urea;
- (g) acetaminophen and 4,4'-bipyridine;
- (h) phenytoin and pyridone;
- (i) aspirin and 4,4'-bipyridine;
- (j) ibuprofen and 4,4'-bipyridine;
- (k) flurbiprofen and 4,4'-bipyridine;
- (l) flurbiprofen and trans-1,2-bis(4-pyridyl) ethylene;
- (m) carbamazepine and p-phthalaldehyde;
- (n) carbamazepine and 2,6-pyridinecarboxylic acid;
- (o) carbamazepine and 5-nitroisophthalic acid;
- (p) carbamazepine and 1,3,5,7-adamantane tetracarboxylic acid; or
- (q) carbamazepine and benzoquinone.

44 (new). The co-crystal according to claim 43, wherein said co-crystal comprises carbamazepine and saccharin.

45 (new). The co-crystal according to claim 43, wherein said co-crystal comprises carbamazepine and nicotinamide.

46 (new). The co-crystal according to claim 43, wherein said co-crystal comprises carbamazepine and trimesic acid.

47 (new). The co-crystal according to claim 43, wherein said co-crystal comprises celecoxib and nicotinamide.

48 (new). The co-crystal according to claim 43, wherein said co-crystal comprises celecoxib and 18-crown-6.

49 (new). The co-crystal according to claim 43, wherein said co-crystal comprises 5-fluorouracil and urea.

50 (new). The co-crystal according to claim 43, wherein said co-crystal comprises acetaminophen and 4,4'-bipyridine.

51 (new). The co-crystal according to claim 43, wherein said co-crystal comprises phenytoin and pyridine.

52 (new). The co-crystal according to claim 43, wherein said co-crystal comprises aspirin and 4,4'-bipyridine.

53 (new). The co-crystal according to claim 43, wherein said co-crystal comprises ibuprofen and 4,4'-bipyridine.

54 (new). The co-crystal according to claim 43, wherein said co-crystal comprises flurbiprofen and 4,4'-bipyridine.

55 (new). The co-crystal according to claim 43, wherein said co-crystal comprises flurbiprofen and trans-1,2-bis(4-pyridyl) ethylene.

J:\TPI\350C1\Amend-Resp\Amd-RCE.doc\DNB/sl

56 (new). The co-crystal according to claim 43, wherein said co-crystal comprises carbamazepine and p-phthalaldehyde.

57 (new). The co-crystal according to claim 43, wherein said co-crystal comprises carbamazepine and 2,6-pyridinecarboxylic acid.

58 (new). The co-crystal according to claim 43, wherein said co-crystal comprises carbamazepine and 5-nitroisophthalic acid.

59 (new). The co-crystal according to claim 43, wherein said co-crystal comprises carbamazepine and 1,3,5,7-adamantane tetracarboxylic acid.

60 (new). The co-crystal according to claim 43, wherein said co-crystal comprises carbamazepine and benzoquinone.

61 (new). A pharmaceutical composition comprising a pharmaceutically acceptable diluent, excipient, or carrier and a co-crystal comprising an API and a co-crystal former selected from:

- (a) carbamazepine and saccharin;
- (b) carbamazepine and nicotinamide;
- (c) carbamazepine and trimesic acid;
- (d) celecoxib and nicotinamide;
- (e) celecoxib and 18-crown-6;
- (f) 5-fluorouracil and urea;
- (g) acetaminophen and 4,4'-bipyridine;
- (h) phenytoin and pyridone;
- (i) aspirin and 4,4'-bipyridine;
- (j) ibuprofen and 4,4'-bipyridine;
- (k) flurbiprofen and 4,4'-bipyridine;

- (l) flurbiprofen and trans-1,2-bis(4-pyridyl) ethylene;
- (m) carbamazepine and p-phthalaldehyde;
- (n) carbamazepine and 2,6-pyridinecarboxylic acid;
- (o) carbamazepine and 5-nitroisophthalic acid;
- (p) carbamazepine and 1,3,5,7-adamantane tetracarboxylic acid; or
- (q) carbamazepine and benzoquinone.

62 (new). The pharmaceutical composition according to claim 61, wherein said co-crystal comprises carbamazepine and saccharin;

63 (new). The pharmaceutical composition according to claim 61, wherein said co-crystal comprises carbamazepine and nicotinamide.

64 (new). The pharmaceutical composition according to claim 61, wherein said co-crystal comprises carbamazepine and trimesic acid.

65 (new). The pharmaceutical composition according to claim 61, wherein said co-crystal comprises celecoxib and nicotinamide.

66 (new). The pharmaceutical composition according to claim 61, wherein said co-crystal comprises celecoxib and 18-crown-6.

67 (new). The pharmaceutical composition according to claim 61, wherein said co-crystal comprises 5-fluorouracil and urea.

68 (new). The pharmaceutical composition according to claim 61, wherein said co-crystal comprises acetaminophen and 4,4'-bipyridine.

69 (new). The pharmaceutical composition according to claim 61, wherein said co-crystal comprises phenytoin and pyridine.

70 (new). The pharmaceutical composition according to claim 61, wherein said co-crystal comprises aspirin and 4,4'-bipyridine.

71 (new). The pharmaceutical composition according to claim 61, wherein said co-crystal comprises ibuprofen and 4,4'-bipyridine.

72 (new). The pharmaceutical composition according to claim 61, wherein said co-crystal comprises flurbiprofen and 4,4'-bipyridine.

73 (new). The pharmaceutical composition according to claim 61, wherein said co-crystal comprises flurbiprofen and trans-1,2-bis(4-pyridyl) ethylene.

74 (new). The pharmaceutical composition according to claim 61, wherein said co-crystal comprises carbamazepine and p-phthalaldehyde.

75 (new). The pharmaceutical composition according to claim 61, wherein said co-crystal comprises carbamazepine and 2,6-pyridinecarboxylic acid.

76 (new). The pharmaceutical composition according to claim 61, wherein said co-crystal comprises carbamazepine and 5-nitroisophthalic acid.

77 (new). The pharmaceutical composition according to claim 61, wherein said co-crystal comprises carbamazepine and 1,3,5,7-adamantane tetracarboxylic acid.

78 (new). The pharmaceutical composition according to claim 61, wherein said co-crystal comprises carbamazepine and benzoquinone.

Remarks

Claims 1, 2, 9-11 and 38-42 are pending in the subject application and currently before the Examiner. By way of this amendment, claims 1, 2, 9-11 and 38-42 have been canceled and claims 43-78 have been added. Support for the newly added claims can be found in the original and previously pending claims. Accordingly, favorable consideration of claims 43-78 is respectfully requested.

Applicants note that the Advisory Action issued on July 17, 2008 indicates that the last amendment filed in this matter (dated May 29, 2008) has not been entered in this matter. However, Applicants note that the terminal disclaimer and previously presented claim amendments were deemed to have resolved certain double patenting issues previously raised in this application. Accordingly, Applicants respectfully request entry of the previously filed after final amendments in this matter to resolve those double patenting issues and the subsequent entry of this amendment in response to the rejections of record.

Claims 1, 2, 9, 10 and 38-42 are rejected under 35 U.S.C. §112, first paragraph, as failing to comply with the written description requirement. The Office Action argues that Applicants have shown the formation of particular co-crystals, such as those recited within claim 11, but do not exemplify the formation of all co-crystals containing any solid API and any-co-crystal former that is liquid or solid and where the components are hydrogen bonded to one another or co-crystals with any of the numerous and diverse different co-crystal formers recited in claim 2 or the APIs recited within claim 6. The Office Action also indicates that the specification describes only the preparation of the particular co-crystals recited within claim 11 and does not describe the claimed invention in a manner sufficient to convey that the inventors were in possession of the entire claimed invention, including the formation of co-crystals containing any API and any co-crystal former that are hydrogen bonded.

Claims 1, 2, 9, 10 and 38-42 are also rejected under 35 U.S.C. §112, first paragraph, as nonenabled by the subject specification. The Office Action acknowledges that the specification is enabled for the preparation and use of the particular pharmaceutical co-crystals, but it is not enabled for the preparation of all co-crystals having any API that is solid, and any co-crystal former that is solid and liquid, where components are hydrogen bonded to one another, or all co-crystals having the

numerous and diverse APIs and co-crystal formers. Thus, the specification fails to provide sufficient support for the broad recitation of a co-crystal composition containing any solid API, in general, with any solid or liquid co-crystal-former, in general, in which the components are hydrogen bonded to each other.

Applicants respectfully maintain that the claimed invention complies with both the written description and enablement requirements of section 112; however, in order to advance prosecution in this matter the rejected claims have been canceled thereby rendering these issues moot. Accordingly, reconsideration and withdrawal of the rejections is respectfully requested.

Claims 1, 2, and 10 are provisionally rejected on the ground of nonstatutory “obviousness-type” double patenting over claims 86-93 of copending Application No. 10/546,963. Applicants, again, respectfully submit that a nonstatutory “obviousness-type” double patenting rejection for the instantly claimed invention should be withdrawn since it would not appear that the co-crystals recited in the currently pending claims would be obvious in view of the broader class of co-crystals claimed by specific functional groups in the ‘963 application; however, in the interest of expediting prosecution in this matter, a terminal disclaimer was filed in a previous response (dated May 29, 2008) and the entry of that paper and the terminal disclaimer is respectfully requested. Accordingly, reconsideration and withdrawal of this rejection is respectfully requested.

Claims 1, 2, 9-11, and 38-42 are provisionally rejected on the ground of nonstatutory “obviousness-type” double patenting over claims 1-49 and 72-87 of copending Application No. 10/570,405. With respect to this rejection, Applicants, again, respectfully submit that this nonstatutory “obviousness-type” double patenting rejection should be withdrawn as the scope of the currently pending claims does not include modafinil co-crystals. Accordingly, reconsideration and withdrawal of this rejection is respectfully requested.

Claims 1, 2, 9-11, and 38-42 are provisionally rejected on the ground of nonstatutory “obviousness-type” double patenting over claims 66-72 of copending Application No. 10/551,014 and over claims 2-7, 16, and 18 of copending Application No. 10/926,842. Applicants, again, respectfully submit that each of these rejections is inapplicable to the presently claimed invention as the scope of the claims no longer includes co-crystals of olanzapine or itraconazole. Accordingly, reconsideration and withdrawal of these rejections is respectfully requested.


Applicants expressly reserve the right to pursue the invention(s) disclosed in the subject application, including any subject matter canceled or not pursued during prosecution of the subject application, in a related application.

In view of the foregoing remarks and amendments to the claims, Applicants believe that the currently pending claims are in condition for allowance, and such action is respectfully requested.

The Commissioner is hereby authorized to charge any fees under 37 CFR §§1.16 or 1.17 as required by this paper to Deposit Account No. 19-0065.

Applicants invite the Examiner to call the undersigned if clarification is needed on any of this response, or if the Examiner believes a telephonic interview would expedite the prosecution of the subject application to completion.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950
Gainesville, FL 32614-2950

FCE/sl

Electronic Patent Application Fee Transmittal				
Application Number:		10660202		
Filing Date:		11-Sep-2003		
Title of Invention:		Pharmaceutical co-crystal compositions		
First Named Inventor/Applicant Name:		Orn Almarsson		
Filer:		Frank Christopher Eisenschenk/Sherry Loke		
Attorney Docket Number:		TPI-350C1		
Filed as Large Entity				
Utility under 35 USC 111(a) Filing Fees				
Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Extension-of-Time:				
Extension - 2 months with \$0 paid	1252	1	490	490

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Miscellaneous:				
Request for continued examination	1801	1	810	810
Total in USD (\$)				1300

Electronic Acknowledgement Receipt	
EFS ID:	4097136
Application Number:	10660202
International Application Number:	
Confirmation Number:	6536
Title of Invention:	Pharmaceutical co-crystal compositions
First Named Inventor/Applicant Name:	Orn Almarsson
Customer Number:	23557
Filer:	Frank Christopher Eisenschenk/Sherry Loke
Filer Authorized By:	Frank Christopher Eisenschenk
Attorney Docket Number:	TPI-350C1
Receipt Date:	10-OCT-2008
Filing Date:	11-SEP-2003
Time Stamp:	16:07:14
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Credit Card
Payment was successfully received in RAM	\$ 1300
RAM confirmation Number	1474
Deposit Account	190065
Authorized User	EISENSCHENK,FRANK C.
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows: Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees) Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)	

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)					
Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)					
Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)					
File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Request for Continued Examination (RCE)	RCE.pdf	179774	no	1
			07975769c6454bd0d6441f631d8c76353680fd4		
Warnings:					
This is not a USPTO supplied RCE SB30 form.					
Information:					
2		Amd-RCE.pdf	597611	yes	9
			426dd00dc6487e3dfcd7fe8b156fae1427327dd5		
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Amendment Submitted/Entered with Filing of CPA/RCE		1	1	
	Claims		2	6	
	Applicant Arguments/Remarks Made in an Amendment		7	9	
Warnings:					
Information:					
3	Fee Worksheet (PTO-06)	fee-info.pdf	31640	no	2
			39afb6cb861fb8b7176a5050d9b1817287d9f029		
Warnings:					
Information:					
Total Files Size (in bytes):			809025		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875					Application or Docket Number 10/660,202		Filing Date 09/11/2003		☐ To be Mailed				
APPLICATION AS FILED – PART I													
(Column 1)			(Column 2)		SMALL ENTITY ☒ OR			OTHER THAN SMALL ENTITY					
FOR	NUMBER FILED	NUMBER EXTRA	RATE (\$)	FEE (\$)	OR	RATE (\$)	FEE (\$)						
☐ BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A			N/A							
☐ SEARCH FEE (37 CFR 1.16(k), (l), or (m))	N/A	N/A	N/A			N/A							
☐ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A			N/A							
TOTAL CLAIMS (37 CFR 1.16(i))	minus 20 =	*	X \$	=		OR	X \$	=					
INDEPENDENT CLAIMS (37 CFR 1.16(h))	minus 3 =	*	X \$	=			X \$	=					
☐ APPLICATION SIZE FEE (37 CFR 1.16(s)) If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).													
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))													
* If the difference in column 1 is less than zero, enter "0" in column 2.													
APPLICATION AS AMENDED – PART II													
(Column 1)			(Column 2)		(Column 3)			SMALL ENTITY OR			OTHER THAN SMALL ENTITY		
AMENDMENT	10/10/2008	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE (\$)	ADDITIONAL FEE (\$)	OR	RATE (\$)	ADDITIONAL FEE (\$)			
	Total (37 CFR 1.16(i))	* 36	Minus	** 37	= 0	X \$26 =	0	OR	X \$	=			
	Independent (37 CFR 1.16(h))	* 2	Minus	***20	= 0	X \$110 =	0	OR	X \$	=			
	☐ Application Size Fee (37 CFR 1.16(s))												
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))												
						TOTAL ADD'L FEE	0	OR	TOTAL ADD'L FEE				
(Column 1)			(Column 2)		(Column 3)								
AMENDMENT		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE (\$)	ADDITIONAL FEE (\$)	OR	RATE (\$)	ADDITIONAL FEE (\$)			
	Total (37 CFR 1.16(i))	*	Minus	**	=	X \$	=	OR	X \$	=			
	Independent (37 CFR 1.16(h))	*	Minus	***	=	X \$	=	OR	X \$	=			
	☐ Application Size Fee (37 CFR 1.16(s))												
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))												
						TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE				
* If the entry in column 1 is less than the entry in column 2, write "0" in column 3. ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20". *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3". The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.													

Legal Instrument Examiner:
/TINA J. BARDEN/

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/660,202	09/11/2003	Orn Almarsson	TPI-350C1	6536
23557 7590 03/24/2009 SALIWANCHIK LLOYD & SALIWANCHIK A PROFESSIONAL ASSOCIATION PO Box 142950 GAINESVILLE, FL 32614			EXAMINER CLAYTOR, DEIRDRE RENEE	
			ART UNIT 1617	PAPER NUMBER
			MAIL DATE 03/24/2009	DELIVERY MODE PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/660,202	Applicant(s) ALMARSSON ET AL.	
	Examiner Renee Claytor	Art Unit 1617	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) ☒ Responsive to communication(s) filed on 10 October 2008.

2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.

3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) ☒ Claim(s) 43-78 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) ☐ Claim(s) _____ is/are allowed.

6) ☒ Claim(s) 43,45,49,61 and 67 is/are rejected.

7) ☒ Claim(s) 44,46-48,50-60,62-66 and 68-78 is/are objected to.

8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) ☐ The specification is objected to by the Examiner.

10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) ☐ All b) ☐ Some * c) ☐ None of:

1. ☐ Certified copies of the priority documents have been received.

2. ☐ Certified copies of the priority documents have been received in Application No. _____.

3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☒ Notice of References Cited (PTO-892)

2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)

3) ☐ Information Disclosure Statement(s) (PTO/SB/08)
 Paper No(s)/Mail Date _____.

4) ☐ Interview Summary (PTO-413)
 Paper No(s)/Mail Date. _____.

5) ☐ Notice of Informal Patent Application

6) ☐ Other: _____.

DETAILED ACTION

Request for Continued Examination

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 10/10/2008 has been entered. Currently claims 43-78 are pending and are under examination herein.

Response to Arguments

The 35 USC 112, first paragraph rejections have been withdrawn as the claims and the subject matter reading on this rejection have been cancelled.

Further, Applicants have amended the claims which are sufficient to overcome the obviousness-type double patenting rejections.

However, as Applicant's have filed new claims the claims will be rejected accordingly below.

Claim Rejections – 35 USC 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

Claims 43, 45 rejected under 35 U.S.C. 102(b) as being anticipated by Ammar et al (Egypt J. Pharmacol. Sci. 35, No. 1-6, pg 209-223 (1994)).

Ammar et al. teaches the water solubility of carbamazepine in the presence of nicotinamide (page 210, last sentence of first paragraph and figure 1). It is taught that there are spectral changes occurring between the interaction which may give an indication of a molecular interaction between carbamazepine and the compounds tested, including nicotinamide, which forms a complex-formation between carbamazepine and the compounds (page 217, first paragraph).

Claim Rejections – 35 USC 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 43, 49, 61 and 67 rejected under 35 U.S.C. 103(a) as being unpatentable over de Jong et al. (Dermatology, 1999; 199: 313-318).

De Jong teaches lotion formulations comprised of 5-fluorouracil and urea (see last paragraph in Introduction). It is taught that the formulation has a high diffusion rate in vitro compared to other 5-fluorouracil test concentrations.

De Jong does not specify that the 5-fluorouracil and urea are co-crystals; however, as the claims are drawn to a co-crystal comprising and a composition comprising an API and a co-crystal former, it would be obvious that when the two compounds (5-fluorouracil and urea) are together they will automatically form hydrogen bonds and will be bonded to each other. One would be motivated to formulate a compound or composition with 5-fluorouracil and urea per the teachings of de Jong et al. in which it is taught that the combination provides a high diffusion rate in vivo.

Conclusion

Claims 44, 46-48, 50-60, 62-66, 68-78 are objected to as being dependent on rejected claims.

No claims are allowed.

Contact Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Renee Claytor whose telephone number is (571)272-8394. The examiner can normally be reached on M-F 8:00-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on 571-272-0629. The fax phone

Art Unit: 1617

number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Renee Claytor

/SREENI PADMANABHAN/

Supervisory Patent Examiner, Art Unit 1617

Notice of References Cited	Application/Control No. 10/660,202	Applicant(s)/Patent Under Reexamination ALMARSSON ET AL.	
	Examiner Renee Claytor	Art Unit 1617	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Ammar et al. Effect of aromatic hydrotopes on the solubility of carbamazepine. Part II: Effect of nicotinamide, sodium salts of benzoic, naphthoic and nicotinic acids. Egypt J. Pharm. Sci. 35, No. 1-6, pages 209-223.
	V	de Jong et al. et al. Dystrophic psoriatic fingernails treated with 1% 5-Fluorouracil in a nail penetration-enhancing vehicle: a double-blind study. Dermatology 1999; 199: 313-318.
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Search Notes 	Application/Control No. 10660202	Applicant(s)/Patent Under Reexamination ALMARSSON ET AL.
	Examiner Claytor, Renee	Art Unit 1617

SEARCHED			
Class	Subclass	Date	Examiner
424	400	3/20/2009	RC

SEARCH NOTES		
Search Notes	Date	Examiner
PALM Inventor Search	3/20/2009	RC
EAST	3/20/2009	RC
STN (STIC search in eDan)	3/20/2009	RC

INTERFERENCE SEARCH			
Class	Subclass	Date	Examiner

--	--

Index of Claims 	Application/Control No. 10660202	Applicant(s)/Patent Under Reexamination ALMARSSON ET AL.
	Examiner Claytor, Renee	Art Unit 1617

✓	Rejected	-	Cancelled	N	Non-Elected	A	Appeal
=	Allowed	÷	Restricted	I	Interference	O	Objected

☐ Claims renumbered in the same order as presented by applicant				☐ CPA				☐ T.D.				☐ R.1.47			
CLAIM		DATE													
Final	Original	12/07/2007	03/20/2009												
	1	✓	-												
	2	✓	-												
	3	-	-												
	4	-	-												
	5	-	-												
	6	-	-												
	7	-	-												
	8	-	-												
	9	✓	-												
	10	✓	-												
	11	✓	-												
	12	-	-												
	13	-	-												
	14	-	-												
	15	-	-												
	16	-	-												
	17	-	-												
	18	-	-												
	19	-	-												
	20	-	-												
	21	-	-												
	22	-	-												
	23	-	-												
	24	-	-												
	25	-	-												
	26	-	-												
	27	-	-												
	28	-	-												
	29	-	-												
	30	-	-												
	31	-	-												
	32	-	-												
	33	-	-												
	34	-	-												
	35	-	-												
	36	-	-												

Index of Claims 	Application/Control No. 10660202	Applicant(s)/Patent Under Reexamination ALMARSSON ET AL.
	Examiner Claytor, Renee	Art Unit 1617

✓	Rejected	-	Cancelled	N	Non-Elected	A	Appeal
=	Allowed	÷	Restricted	I	Interference	O	Objected


☐ Claims renumbered in the same order as presented by applicant				☐ CPA				☐ T.D.				☐ R.1.47			
CLAIM		DATE													
Final	Original	12/07/2007	03/20/2009												
	37	-	-												
	38	✓	-												
	39	✓	-												
	40	✓	-												
	41	✓	-												
	42	✓	-												
	43		✓												
	44		✓												
	45		✓												
	46		✓												
	47		✓												
	48		✓												
	49		✓												
	50		✓												
	51		✓												
	52		✓												
	53		✓												
	54		✓												
	55		✓												
	56		✓												
	57		✓												
	58		✓												
	59		✓												
	60		✓												
	61		✓												
	62		✓												
	63		✓												
	64		✓												
	65		✓												
	66		✓												
	67		✓												
	68		✓												
	69		✓												
	70		✓												
	71		✓												
	72		✓												

<i>Index of Claims</i> 	Application/Control No. 10660202	Applicant(s)/Patent Under Reexamination ALMARSSON ET AL.
	Examiner Claytor, Renee	Art Unit 1617

✓	Rejected	-	Cancelled	N	Non-Elected	A	Appeal
=	Allowed	÷	Restricted	I	Interference	O	Objected

☐ Claims renumbered in the same order as presented by applicant				☐ CPA		☐ T.D.		☐ R.1.47	
CLAIM		DATE							
Final	Original	12/07/2007	03/20/2009						
	73		✓						
	74		✓						
	75		✓						
	76		✓						
	77		✓						
	78		✓						

I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on June 24, 2009.



Frank C. Eisenschenk, Ph.D., Patent Attorney

RESPONSE UNDER 37 C.F.R. § 1.111
Patent Application
Docket No. TPL350C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Deirdre R. Claytor
Art Unit : 1617
Applicants : Orn Almarsson, Magali Bourghol Hickey, Matthew L. Peterson, Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo
Serial No. : 10/660,202
Filed : September 11, 2003
Conf. No. : 6536
For : Pharmaceutical Co-Crystal Compositions

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

RESPONSE UNDER 37 C.F.R. § 1.111

Sir:

The remarks that follow are submitted for the Examiner's consideration in the above-referenced patent application in response to the Office Action dated March 24, 2009.

Remarks

Claims 43-78 were pending in the subject application. Applicants have not amended the claims by this Response. Accordingly, claims 43-78 remain before the Examiner. Favorable consideration of the pending claims is respectfully requested.

Applicants gratefully acknowledge the Examiner's withdrawal of the rejection under 35 U.S.C. § 112, first paragraph, and the obviousness-type double patenting rejection.

Claims 43 and 45 are rejected under 35 U.S.C. § 102(b) as anticipated by Ammar *et al.* (1994). The Office Action states that Ammar *et al.* teach the water solubility of carbamazepine in the presence of nicotinamide. Applicants respectfully assert that the Ammar *et al.* reference does not anticipate the claimed invention. Anticipation requires that the reference teach every element of the claim. *Verdegaal Bros. v. Union Oil Co. of California*, 814 F.2d 628, 631, 2 USPQ2d 1051, 1053 (Fed. Cir. 1987) ("A claim is anticipated only if each and every element as set forth in the claim is found, either expressly or inherently described, in a single prior art reference.") Ammar *et al.* do not disclose a co-crystal as required by the claims. A co-crystal is "crystalline material" as defined at page 10 of the specification. One of ordinary skill would recognize that the carbamazepine dissolved in solvent and nicotinamide dissolved in solvent as taught by Ammar *et al.* are not a co-crystal, even if it were assumed for the sake of argument that some interaction might occur between individual dissolved molecules.

Separately, Applicants note that hydrogen bonding is required in the co-crystal (see page 10, line 26, *et seq*) and it is doubtful that the solution disclosed in Ammar *et al.* contains direct or indirect hydrogen bonding between carbamazepine and nicotinamide. Were carbamazepine and nicotinamide to hydrogen bond to one another, each would have fewer hydrogen bond acceptors and/or donors with which to interact with the aqueous solvent and would consequently display to the aqueous solvent a relatively decreased amount of hydrophilic surface area (*i.e.*, hydrogen bond donors and acceptors) and a relatively increased amount of hydrophobic surface area (*i.e.*, aromatic carbon rings). One of skill in the art would recognize that this would tend to decrease solubility in water, as opposed to the increase in solubility that was observed by Ammar *et al.* If a solubility-increasing interaction between carbamazepine and nicotinamide exists, it is more likely that the interaction is between the hydrophobic (non-hydrogen bonding) regions of each. The interaction

J:\TPI\350C1\Amend-Resp\Amd-after-RCE.doc\DNB/sl

would then have the potential to decrease the amount of hydrophobic surface area displayed to the aqueous solvent, and one of ordinary skill would recognize that this might result in increased solubility in water. For each of these reasons, reconsideration and withdrawal of the rejection under 35 U.S.C. § 102(b) is respectfully requested.

Claims 43, 49, 61 and 67 are rejected under 35 U.S.C. § 103(a) as obvious over de Jong *et al.* (1999). The Office Action indicates that de Jong *et al.* teach lotion formulations comprised of 5-fluorouracil and urea. Applicants respectfully assert that the claimed invention is not obvious over the cited reference. Applicants note that the asserted reference(s), when combined, must teach all elements of the claimed invention. *CFMT, Inc. v. Yieldup Intern. Corp.*, 349 F.3d 1333, 1342 (Fed. Cir. 2004) (determination of non-obviousness was proper when “no combination of the prior art, even if supported by a motivation to combine, would disclose all the limitations of the claims”). Just as in *CFMT*, Applicants do not believe that all the limitations of the claims are disclosed. De Jong *et al.* do not disclose a co-crystal as required by the claims. A co-crystal is “crystalline material” as defined at page 10 of the specification. In contrast, the lotion formulation of de Jong *et al.* is a solution of propylene glycol and urea in water. (de Jong *et al.*, page 314, first column, second paragraph). One of ordinary skill would recognize that the dissolved 5-fluorouracil and dissolved urea taught by de Jong *et al.* are not a co-crystal. Even if it were assumed for the sake of argument that 5-fluorouracil and urea may hydrogen-bond under some conditions, the ordinarily skilled artisan would recognize that transient hydrogen bonding between isolated dissolved molecules of 5-fluorouracil and urea would not imply the existence of a co-crystal.

Applicants note, too, that obviousness does not exist when the art, in any material respect, teaches away from the claimed invention. *In re Geisler*, 116 F.3d 1465, 1471, 43 USPQ2d 1362, 1366 (Fed. Cir. 1997). In this regard, Applicants assert that de Jong *et al.* teach away from any modification of their own composition that might potentially be encompassed by the claims. As illustrated by the figures at page 316 and the discussion at 317, de Jong *et al.* found that the urea-containing lotion vehicle alone was fully as effective without the added 5-fluorouracil as with it. Indeed, the figures indicate that to the extent there was any difference between vehicle alone and vehicle with 5-fluorouracil, it was vehicle alone that gave the better result. Accordingly, one of ordinary skill would be discouraged from making additional compositions containing both 5-

fluorouracil and urea because the urea-containing preparation was at least as effective without the added 5-fluorouracil and avoided “adverse effects” associated with the “irritating” presence of 5-fluorouracil. (de Jong *et al.* at page 317, last paragraph of the Discussion section). De Jong *et al.* conclude that “the vehicle Belanyx was shown to be preferable over the 1% 5-fluorouracil Belanyx preparation.” For each of the preceding reasons, reconsideration and withdrawal of the rejection under 35 U.S.C. § 103(a) is respectfully requested.

Claims 44, 46-48, 50-60, 62-66, and 68-78 are objected to as being dependent on rejected claims. In light of the arguments presented above, Applicants believe that the referenced independent claims are allowable and that the dependent claims are therefore proper. Accordingly, reconsideration and withdrawal of the objection is respectfully requested.


It should be understood that the amendments presented herein have been made solely to expedite prosecution of the subject application to completion and should not be construed as an indication of Applicants’ agreement with or acquiescence in the Examiner’s position. Applicants expressly reserve the right to pursue the invention(s) disclosed in the subject application, including any subject matter canceled or not pursued during prosecution of the subject application, in a related application.

In view of the foregoing remarks and amendments to the claims, Applicants believe that the currently pending claims are in condition for allowance, and such action is respectfully requested.

The Commissioner is hereby authorized to charge any fees under 37 CFR §§1.16 or 1.17 as required by this paper to Deposit Account No. 19-0065.

Applicants invite the Examiner to call the undersigned if clarification is needed on any of this response, or if the Examiner believes a telephonic interview would expedite the prosecution of the subject application to completion.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950
Gainesville, FL 32614-2950

FCE/jjc/jb

Electronic Acknowledgement Receipt	
EFS ID:	5575939
Application Number:	10660202
International Application Number:	
Confirmation Number:	6536
Title of Invention:	Pharmaceutical co-crystal compositions
First Named Inventor/Applicant Name:	Orn Almarsson
Customer Number:	23557
Filer:	Frank Christopher Eisenschenk/Sherry Loke
Filer Authorized By:	Frank Christopher Eisenschenk
Attorney Docket Number:	TPI-350C1
Receipt Date:	24-JUN-2009
Filing Date:	11-SEP-2003
Time Stamp:	11:29:06
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment		no			
File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		Amd-after-RCE.pdf	367799 c75b47f18b2fbbc1f5e53f8b23d1cc9299d788dc	yes	5

	Multipart Description/PDF files in .zip description		
	Document Description	Start	End
	Amendment/Req. Reconsideration-After Non-Final Reject	1	1
	Applicant Arguments/Remarks Made in an Amendment	2	5
Warnings:			
Information:			
Total Files Size (in bytes):		367799	
This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503. <u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application. <u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course. <u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.			

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875					Application or Docket Number 10/660,202		Filing Date 09/11/2003		☐ To be Mailed				
APPLICATION AS FILED – PART I													
(Column 1)			(Column 2)		SMALL ENTITY ☒		OR		OTHER THAN SMALL ENTITY				
FOR	NUMBER FILED	NUMBER EXTRA	RATE (\$)	FEE (\$)			RATE (\$)	FEE (\$)					
☐ BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A				N/A						
☐ SEARCH FEE (37 CFR 1.16(k), (l), or (m))	N/A	N/A	N/A				N/A						
☐ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A				N/A						
TOTAL CLAIMS (37 CFR 1.16(i))	minus 20 =	*	X \$	=			X \$	=					
INDEPENDENT CLAIMS (37 CFR 1.16(h))	minus 3 =	*	X \$	=			X \$	=					
☐ APPLICATION SIZE FEE (37 CFR 1.16(s)) If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).													
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))													
* If the difference in column 1 is less than zero, enter "0" in column 2.													
APPLICATION AS AMENDED – PART II													
(Column 1)			(Column 2)		(Column 3)		SMALL ENTITY		OR		OTHER THAN SMALL ENTITY		
AMENDMENT	06/24/2009	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE (\$)	ADDITIONAL FEE (\$)			RATE (\$)	ADDITIONAL FEE (\$)			
	Total (37 CFR 1.16(i))	* 36	Minus	** 37	=	0			X \$	=			
	Independent (37 CFR 1.16(h))	* 2	Minus	***20	=	0			X \$	=			
	☐ Application Size Fee (37 CFR 1.16(s))												
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))												
					TOTAL ADD'L FEE	0			TOTAL ADD'L FEE				
(Column 1)			(Column 2)		(Column 3)								
AMENDMENT	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE (\$)	ADDITIONAL FEE (\$)			RATE (\$)	ADDITIONAL FEE (\$)				
	Total (37 CFR 1.16(i))	*	Minus	**	=			X \$	=				
	Independent (37 CFR 1.16(h))	*	Minus	***	=			X \$	=				
	☐ Application Size Fee (37 CFR 1.16(s))												
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))												
					TOTAL ADD'L FEE			TOTAL ADD'L FEE					
* If the entry in column 1 is less than the entry in column 2, write "0" in column 3. ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20". *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3". The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.													

Legal Instrument Examiner:
/VANESSA BARBER/

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/660,202
				Filing Date	September 11, 2003
				First Named Inventor	Örn Almarsson
				Art Unit	1617
				Examiner Name	Deirdre R. Claytor
Sheet	1	of	2	Attorney Docket Number	TPI.350C1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-			
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F1	JP-B 46-33588	10-01-1971	Sanzu Inc.	All	
	F2					
	F3					
	F4					
	F5					
	F6					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		<i>Complete if Known</i>			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Deirdre R. Claytor		
Sheet	2	of	2	Attorney Docket Number	TPI.350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	WUNDERLICH, H. F. <i>et al.</i> "The Derivatives of carbamazepine with ammonium halogenides and formamide" <i>Pharmazie</i> , 1991, pp. 507-509, Vol. 46, No. 7.	
	R2	EL-NAHHAS, S. A. "Physico-chemical characteristics of carbamazepine-β-cyclodextrin inclusion compounds and carbamazepine-PEG solid dispersions" <i>Pharmazie</i> , 1996, pp. 960-963, Vol. 51, No. 12.	
	R3	REYNOLDS, J. E. F. (ed). Martindale, The Extra Pharmacopoeia, 1993, The Pharmaceutical Press, London, England, 13 th edition, p. 1610.	
	R4	PEDIREDDI, V. R. <i>et al.</i> "Layered Structures Formed by Dinitrobenzoic Acids" <i>Tetrahedron Letters</i> , 1998, pp. 9831-9834, Vol. 39.	
	R5	ZAMAN, M. B. <i>et al.</i> "Crystal Engineering Using Anilic Acids and Dipyrldyl Compounds through a New Supramolecular Synthon" <i>J. Org. Chem.</i> , 2001, pp. 5987-5995, Vol. 66,.	
	R6	Japanese Notice of Reasons for Rejection dated October 8, 2009, Japanese Application No. 2003-572946.	X
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Electronic Acknowledgement Receipt	
EFS ID:	6489992
Application Number:	10660202
International Application Number:	
Confirmation Number:	6536
Title of Invention:	Pharmaceutical co-crystal compositions
First Named Inventor/Applicant Name:	Orn Almarsson
Customer Number:	23557
Filer:	Frank Christopher Eisenschenk/Sherry Loke
Filer Authorized By:	Frank Christopher Eisenschenk
Attorney Docket Number:	TPI-350C1
Receipt Date:	19-NOV-2009
Filing Date:	11-SEP-2003
Time Stamp:	17:05:59
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment		no			
File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		IDS-supp5.pdf	481986 a6333f110876b77c6f22f9ed6b33e97c4d888cc3	yes	4

	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Transmittal Letter		1	2	
	Information Disclosure Statement (IDS) Filed (SB/08)		3	4	
Warnings:					
Information:					
2	Foreign Reference	JP-46-33588.pdf	329178	no	3
			976c23a726f5a1fe7950757fd347ceb7a811795a		
Warnings:					
Information:					
3	NPL Documents	Wunderlich.pdf	481775	no	3
			d8b50945bea2f36832273e4992d56e1ab6cbbe51		
Warnings:					
Information:					
4	NPL Documents	ElNahas.pdf	664747	no	4
			5315de2bc37e0424d1cfff997fd67719d22e33e39		
Warnings:					
Information:					
5	NPL Documents	Pedireddi.pdf	360900	no	4
			0e8e9d9b6d0b937f35d8af35be5492b85360e1d		
Warnings:					
Information:					
6	NPL Documents	Zaman.pdf	1408428	no	9
			13abc64a3721523ab3658f87dbeco24d0c8761d2		
Warnings:					
Information:					
7	NPL Documents	Martindale.pdf	512261	no	3
			13e080f4889edfd5214885a9c4460fc4790db140		
Warnings:					
Information:					
8	NPL Documents	JP-OfficeAction.PDF	885502	no	11
			a3f83728c348f4a218196c2a469b2bc2b277273c		
Warnings:					
Information:					
Total Files Size (in bytes):			5124777		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

I hereby certify that this correspondence is being
facsimile transmitted to the United States Patent
and Trademark Office on November 19, 2009.

Frank C. Eisenschenk
Frank C. Eisenschenk, Ph.D., Patent Attorney

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
Patent Application
Docket No. TPI.350C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Deirdre R. Claytor
Art Unit : 1617
Applicants : Örn Almarsson, Magali Bourghol Hickey, Matthew L. Peterson, Michael J.
Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo
Serial No. : 10/660,202
Filed : September 11, 2003
Conf. No. : 6536
For : Pharmaceutical Co-Crystal Compositions

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 AND 1.98

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application.

Applicants recently received a Notice of Reasons for Rejection for an application related to this matter that is under examination in Japan. In that Notice, two of the cited references (listed as R1 and F1 on the attached Form PTO/SB/08) are in a foreign language. The Notice in the related application has been translated by a foreign agent and a copy of the original Japanese language Notice of Reasons for Rejection and the translation are provided in this Supplemental Information Disclosure Statement along with the references cited in the Notice. It is believed that the English language translation of the Japanese Notice of Reasons for Rejection provides a discussion of the foreign language documents and the relevant teachings for which the references were cited.

J:\TPI\350C\INDS\IDS.sup5.doc\DNB/sl

Applicants note that a partial translation is provided for Japanese Patent Application No. JP-B 46-33588, listed as F1 on the attached form.

The undersigned hereby certifies that each item of information contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Supplemental Information Disclosure Statement.

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

Applicants respectfully assert that the substantive provisions of 37 C.F.R. §§ 1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950

Gainesville, FL 32614-2950

FCE/sl

Attachment: Form PTO/SB/08



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

23557 7590 12/14/2009
SALIWANCHIK LLOYD & SALIWANCHIK
A PROFESSIONAL ASSOCIATION
PO Box 142950
GAINESVILLE, FL 32614

EXAMINER	
CLAYTOR, DEIRDRE RENEE	
ART UNIT	PAPER NUMBER
1627	

DATE MAILED: 12/14/2009

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/660,202	09/11/2003	Orn Almarsson	TPI-350C1	6536
TITLE OF INVENTION: PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS				

APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	YES	\$755	\$300	\$0	\$1055	03/15/2010

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. **PROSECUTION ON THE MERITS IS CLOSED.** THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN **THREE MONTHS** FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. **THIS STATUTORY PERIOD CANNOT BE EXTENDED.** SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

- A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.
- B. If the status above is to be removed, check box 5b on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above, or

If the SMALL ENTITY is shown as NO:

- A. Pay TOTAL FEE(S) DUE shown above, or
- B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check box 5a on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and 1/2 the ISSUE FEE shown above.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: **Mail** **Mail Stop ISSUE FEE**
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
or Fax **(571)-273-2885**

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

23557 7590 12/14/2009

SALIWANCHIK LLOYD & SALIWANCHIK
A PROFESSIONAL ASSOCIATION
PO Box 142950
GAINESVILLE, FL 32614

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

(Depositor's name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/660,202 09/11/2003 Orn Almarsson TPI-350C1 6536

TITLE OF INVENTION: PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS

APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
-------------	--------------	---------------	---------------------	----------------------	------------------	----------

nonprovisional YES \$755 \$300 \$0 \$1055 03/15/2010

EXAMINER	ART UNIT	CLASS-SUBCLASS
----------	----------	----------------

CLAYTOR, DEIRDRE RENEE 1627 424-400000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.

☐ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. **Use of a Customer Number is required.**

2. For printing on the patent front page, list

(1) the names of up to 3 registered patent attorneys or agents OR, alternatively, 1 _____

(2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed. 2 _____

3 _____

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE

(B) RESIDENCE: (CITY and STATE OR COUNTRY)

Please check the appropriate assignee category or categories (will not be printed on the patent): ☐ Individual ☐ Corporation or other private group entity ☐ Government

4a. The following fee(s) are submitted:

- ☐ Issue Fee
☐ Publication Fee (No small entity discount permitted)
☐ Advance Order - # of Copies _____

4b. Payment of Fee(s): (Please first reapply any previously paid issue fee shown above)

- ☐ A check is enclosed.
☐ Payment by credit card. Form PTO-2038 is attached.
☐ The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment, to Deposit Account Number _____ (enclose an extra copy of this form).

5. Change in Entity Status (from status indicated above)

- ☐ a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. ☐ b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2).

NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.

Authorized Signature _____

Date _____

Typed or printed name _____

Registration No. _____

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/660,202	09/11/2003	Orn Almarsson	TPI-350C1	6536
23557	7590	12/14/2009		
SALIWANCHIK LLOYD & SALIWANCHIK A PROFESSIONAL ASSOCIATION PO Box 142950 GAINESVILLE, FL 32614				
			EXAMINER CLAYTOR, DEIRDRE RENEE	
			ART UNIT	PAPER NUMBER
			1627	
DATE MAILED: 12/14/2009				

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
(application filed on or after May 29, 2000)

The Patent Term Adjustment to date is 650 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 650 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (<http://pair.uspto.gov>).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

DETAILED ACTION

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Frank C. Eisenschenk on 11/3/2009.

The application has been amended as follows:

IN THE CLAIMS:

1. In claim 43, in line 18, after "carbamazepine and benzoquinone", **insert**
", wherein the API and co-crystal former are hydrogen bonded to each other".
2. In claim 61, in line 20, after "carbamazepine and benzoquinone" **insert**
", wherein the API and co-crystal former are hydrogen bonded to each other".

Reasons for Allowance

The following is an examiner's statement of reasons for allowance: the prior art does not teach or suggest a co-crystal comprising an API and a co-crystal former selected from (a)-(q) wherein the API and co-crystal former are hydrogen bonded to each other.

The closest prior art is Ammar et al., which teaches the water solubility of carbamazepine in the presence of nicotinamide in a solution. However Ammar et al. does not teach that the carbamazepine and nicotinamide are hydrogen bonded together into a co-crystal, which the applicants define as a crystalline material.

De Jong is also considered close prior art in that it teaches formulations comprised of 5-fluorouracil and urea; however, de Jong does not teach that the compounds are hydrogen bonded to one another to form a co-crystal.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Contact Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Renee Claytor whose telephone number is (571)272-8394. The examiner can normally be reached on M-F 8:00-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Renee Claytor

/SREENI PADMANABHAN/
Supervisory Patent Examiner, Art Unit 1627

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S1	4424	carbamazepine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 14:31
S2	29841	saccharin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 14:31
S3	510	S1 and S2	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 14:31
S4	7	S1 near S2	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 15:01
S5	14547	nicotinamide	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 15:01
S6	7	S1 near S5	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 15:02
S7	4788	trimesic adj acid	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 15:02
S8	5	S1 near S7	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 15:03
S9	4881	celecoxib	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 15:03
S10	7	S5 near S9	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 15:14
S11	2183	olanzapine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 15:14
S12	6	S5 near S11	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 15:15
S13	5613	18-crown-6	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 15:15

S14	5	S9 near S13	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 15:15
S15	611	modafinil	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 15:15
S16	35957	malonic adj acid	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 15:15
S17	5	S15 near S16	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 15:16
S18	21665	benzamide	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 15:16
S19	2	S15 near S18	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 15:18
S20	13295	mandelic adj acid	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 15:18
S21	2	S15 near S20	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 15:18
S22	37991	glycolic adj acid	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 15:18
S23	5	S15 near S22	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 15:18
S24	78352	fumaric adj acid	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 15:18
S25	4	S15 near S24	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 15:21
S26	124581	maleic adj acid	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 15:21
S27	5	S15 near S26	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 15:21
S28	20463	5-fluorouracil	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 15:21
S29	238179	urea	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 15:21

S30	7	S28 near S29	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 15:22
S31	10642	acetaminophen	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 15:22
S32	432	4,4'-bipyridine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 15:22
S33	4	S31 near S32	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 15:22
S34	4902	phenytoin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 15:22
S35	9754	pyridone	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 15:22
S36	6	S34 near S35	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 15:23
S37	26817	aspirin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 15:23
S38	6	S32 near S37	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 15:25
S39	19289	ibuprofen	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 15:25
S40	6	S39 near S32	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 15:26
S41	6827	flurbiprofen	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 15:26
S42	6	S32 and S41	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/12/06 15:26

EAST Search History (I nterference)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	551	co-crystal	USPAT; UPAD	OR	ON	2009/11/04 08:52
L2	1980	carbamazepine	USPAT; UPAD	OR	ON	2009/11/04 08:52
L3	11	I1 and I2	USPAT; UPAD	OR	ON	2009/11/04 08:53
L4	1644	celecoxib	USPAT; UPAD	OR	ON	2009/11/04 08:54

L5	34	I1 and I4	USPAT; UPAD	OR	ON	2009/11/04 08:54
L6	8637	5-fluorouracil	USPAT; UPAD	OR	ON	2009/11/04 08:55
L7	31	I6 and I1	USPAT; UPAD	OR	ON	2009/11/04 08:55
L8	5077	acetaminophen	USPAT; UPAD	OR	ON	2009/11/04 08:57
L9	6	I1 and I8	USPAT; UPAD	OR	ON	2009/11/04 08:57
L10	2561	phenytoin	USPAT; UPAD	OR	ON	2009/11/04 08:58
L11	9	I10 and I1	USPAT; UPAD	OR	ON	2009/11/04 08:58
L12	13785	aspirin	USPAT; UPAD	OR	ON	2009/11/04 08:59
L13	58	I1 and I12	USPAT; UPAD	OR	ON	2009/11/04 08:59
L14	8695	ibuprofen	USPAT; UPAD	OR	ON	2009/11/04 08:59
L15	44	I1 and I14	USPAT; UPAD	OR	ON	2009/11/04 08:59
L16	2988	flurbiprofen	USPAT; UPAD	OR	ON	2009/11/04 09:00
L17	30	I1 and I16	USPAT; UPAD	OR	ON	2009/11/04 09:00

11/ 4/ 2009 9:01:38 AM

C:\ Documents and Settings\dclaytor\ My Documents\ EAST\ Workspaces\ 660202.wsp

Index of Claims 	Application/Control No. 10660202	Applicant(s)/Patent Under Reexamination ALMARSSON ET AL.
	Examiner Renee Claytor	Art Unit 1627

✓	Rejected
=	Allowed

-	Cancelled
÷	Restricted

N	Non-Elected
I	Interference

A	Appeal
O	Objected

☐ Claims renumbered in the same order as presented by applicant					☐ CPA					☐ T.D.					☐ R.1.47				
CLAIM		DATE																	
Final	Original	12/07/2007	03/20/2009	11/04/2009															
	1	✓	-	-															
	2	✓	-	-															
	3	-	-	-															
	4	-	-	-															
	5	-	-	-															
	6	-	-	-															
	7	-	-	-															
	8	-	-	-															
	9	✓	-	-															
	10	✓	-	-															
	11	✓	-	-															
	12	-	-	-															
	13	-	-	-															
	14	-	-	-															
	15	-	-	-															
	16	-	-	-															
	17	-	-	-															
	18	-	-	-															
	19	-	-	-															
	20	-	-	-															
	21	-	-	-															
	22	-	-	-															
	23	-	-	-															
	24	-	-	-															
	25	-	-	-															
	26	-	-	-															
	27	-	-	-															
	28	-	-	-															
	29	-	-	-															
	30	-	-	-															
	31	-	-	-															
	32	-	-	-															
	33	-	-	-															
	34	-	-	-															
	35	-	-	-															
	36	-	-	-															

Index of Claims 	Application/Control No. 10660202	Applicant(s)/Patent Under Reexamination ALMARSSON ET AL.
	Examiner Renee Claytor	Art Unit 1627

✓	Rejected
=	Allowed

-	Cancelled
÷	Restricted

N	Non-Elected
I	Interference

A	Appeal
O	Objected

☐ Claims renumbered in the same order as presented by applicant									
☐ CPA									
☐ T.D.									
☐ R.1.47									
CLAIM		DATE							
Final	Original	12/07/2007	03/20/2009	11/04/2009					
	37	-	-	-					
	38	✓	-	-					
	39	✓	-	-					
	40	✓	-	-					
	41	✓	-	-					
	42	✓	-	-					
1	43		✓	=					
2	44		✓	=					
3	45		✓	=					
4	46		✓	=					
5	47		✓	=					
6	48		✓	=					
7	49		✓	=					
8	50		✓	=					
9	51		✓	=					
10	52		✓	=					
11	53		✓	=					
12	54		✓	=					
13	55		✓	=					
14	56		✓	=					
15	57		✓	=					
16	58		✓	=					
17	59		✓	=					
18	60		✓	=					
19	61		✓	=					
20	62		✓	=					
21	63		✓	=					
22	64		✓	=					
23	65		✓	=					
24	66		✓	=					
25	67		✓	=					
26	68		✓	=					
27	69		✓	=					
28	70		✓	=					
29	71		✓	=					
30	72		✓	=					

<i>Index of Claims</i> 	Application/Control No. 10660202	Applicant(s)/Patent Under Reexamination ALMARSSON ET AL.
	Examiner Renee Claytor	Art Unit 1627

✓	Rejected	-	Cancelled	N	Non-Elected	A	Appeal
=	Allowed	÷	Restricted	I	Interference	O	Objected

☐ Claims renumbered in the same order as presented by applicant										☐ CPA										☐ T.D.										☐ R.1.47									
CLAIM		DATE																																					
Final	Original	12/07/2007	03/20/2009	11/04/2009																																			
31	73		✓	=																																			
32	74		✓	=																																			
33	75		✓	=																																			
34	76		✓	=																																			
35	77		✓	=																																			
36	78		✓	=																																			

Search Notes 	Application/Control No. 10660202	Applicant(s)/Patent Under Reexamination ALMARSSON ET AL.
	Examiner Claytor, Renee	Art Unit 1617

SEARCHED			
Class	Subclass	Date	Examiner
424	400	11/3/2009	RC
514	217, 403	11/3/2009	RC

SEARCH NOTES		
Search Notes	Date	Examiner
PALM Inventor Search	11/3/2009	RC
EAST	11/3/2009	RC
STN (STIC search in eDan)	11/3/2009	RC
Patentability Conference with Sreeni Padmanabhan and Johann Richter	2/23/2009	RC

INTERFERENCE SEARCH			
Class	Subclass	Date	Examiner
424	400	11/3/2009	RC
514	217, 403	11/3/2009	RC

--	--



1617 Ifw

Whereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents, P.O. Box 1450
Alexandria, VA 22313 on August 28, 2006

Frank C. Eisenschenk, Ph.D., Patent Attorney

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

Patent Application
Docket No. TPI-350C1
Serial No. 10/660,202

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Örn Almarsson, Magali Bourghol Hickey, Matthew L. Peterson, Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo
Serial No. : 10/660,202
Filed : September 11, 2003
For : Pharmaceutical Co-Crystal Compositions

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §§1.97 and 1.98, Applicants would like to bring to the attention of the Examiner, the references cited in the following patent applications:

U.S. Serial No. 10/378,956, filed March 3, 2003;
U.S. Serial No. 10/637,829, filed August 8, 2003;
U.S. Serial No. 10/295,995, filed November 18, 2002, now U.S. Patent No. 6,699,840;
U.S. Serial No. 10/232,589, filed September 3, 2002, now U.S. Patent No. 6,559,293;
U.S. Serial No. 10/449,307, filed March 30, 2003, now U.S. Patent No. 7,078,526; and
U.S. Serial No. 10/601,092, filed June 20, 2003.

The subject application, Serial No. 10/660,202, claims the benefit under 35 USC §120 of the filing date of patent applications referred to above. Applicants respectfully request that the copies of references supplied in the Information Disclosure Statements of the application referred to above, as


J:\TPI\350C1\PTO\IDS-suppl.doc/DNB/sl

well as any references cited during the prosecution thereof, be made of record in the 10/660,202 application. As copies of the references made of record in the applications referred to above, and cited on the attached form PTO/SB/08, can be found in the casefiles referred to above, copies of those references are not provided herewith.

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statements.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.
Patent Attorney
Registration No. 45,332
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: P.O. Box 142950
Gainesville, FL 32614-2950

FCE/sl

Attachment: Form PTO/SB/08



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/660,202
				Filing Date	September 11, 2003
				First Named Inventor	Örn Almarsson
				Art Unit	1617
				Examiner Name	Leonard Williams
Sheet	1	of	36	Attorney Docket Number	TPI-350C1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	U1	US-2,711,411	06-21-1955	Holbert, <i>et al.</i>	All
	U2	US-4,198,507	04-15-1980	Barry, <i>et al.</i>	All
	U3	US-4,368,197	01-11-1983	Shefter, <i>et al.</i>	All
	U4	US-4,994,604	02-19-1991	Tung, <i>et al.</i>	All
	U5	US-5,177,262	01-15-1993	Taylor, <i>et al.</i>	All
	U6	US-5,332,834	07-26-1994	Bhattacharya, <i>et al.</i>	All
	U7	US-5,338,644	08-16-1994	Taylor, <i>et al.</i>	All
	U8	US-5,380,867	01-10-1995	Bhattacharya, <i>et al.</i>	All
	U9	US-5,412,094	05-02-1995	Amos, <i>et al.</i>	All
	U10	US-5,523,090	06-04-1996	Znaiden, <i>et al.</i>	All
	U11	US-5,614,342	03-25-1997	Molai, <i>et al.</i>	All
	U12	US-5,998,413	12-07-1999	Heeres, <i>et al.</i>	All
	U13	US-6,001,996	12-14-1999	Amos, <i>et al.</i>	All
	U14	US-6,268,385	07-31-2001	Whittle, <i>et al.</i>	All
	U15	US-6,570,036	05-27-2003	Reuter	All
	U16	US-2003/0162226	08-28-2003	Cima, <i>et al.</i>	All
	U17	US-2003/0166581	09-04-2003	Almarsson, <i>et al.</i>	All
	U18	US-2003/0224006	12-04-2003	Zaworotko, <i>et al.</i>	All
	U19	US-2004/0019211	01-29-2004	Remenar, <i>et al.</i>	All
	U20	US-2004/0106052	06-03-2004	Molai	All

Examiner Signature	/Renee Claytor/	Date Considered	11/16/2009
-----------------------	-----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C1\PTO\IDS.form.doc\DNB\gyl

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/660,202
				Filing Date	September 11, 2003
				First Named Inventor	Örn Almarsson
				Art Unit	1617
				Examiner Name	Leonard Williams
Sheet	2	of	36	Attorney Docket Number	TPI-350C1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	U21	US-2004/0106053	06-03-2004	Molaire, <i>et al.</i>	All
	U22	US-2004/0106055	06-03-2004	Molaire, <i>et al.</i>	All
	U23	US-2004/0171062	09-02-2004	Hirth, <i>et al.</i>	All
	U24	US-2004/0176335	09-09-2004	Childs	All
	U25	US-2005/0070551	03-31-1995	Remenar, <i>et al.</i>	All
	U26	US-2005/0181041	08-18-2005	Goldman	All
	U27	US-2005/0169982	08-04-2005	Almarsson, <i>et al.</i>	All
	U28	US-2005/0252649	11-17-2005	Chiu, <i>et al.</i>	All
	U29	US-2005/0256127	11-17-2005	Ku, <i>et al.</i>	All
	U30	US-6,559,293	05-06-2003	Almarsson, <i>et al.</i>	All
	U31	US-6,699,840	03-02-2004	Almarsson, <i>et al.</i>	All
	U32	US-2004-0053853	03-18-2004	Almarsson, <i>et al.</i>	All
	U33	US-2005/0070551 A1	03-31-2005	Remenar, <i>et al.</i>	All
	U34	US-2003/00224006	12-04-2003	Zaworotko <i>et al.</i>	All
	U35	US-3,536,809	04-09-1991	Schaller <i>et al.</i>	All
	U36	US-3,598,123	08-10-1971	Zaffaroni	All
	U37	US-3,845,770	11-05-1974	Theeuwes <i>et al.</i>	All
	U38	US-3,916,899	11-04-1975	Theeuwes <i>et al.</i>	All
	U39	US-4,008,719	02-22-1977	Theeuwes <i>et al.</i>	All
	U40	US-4,267,179	05-12-1981	Heeres <i>et al.</i>	All
	U41	US-4,764,604	08-16-1988	Muller	All

Examiner Signature	/Renee Claytor/	Date Considered	11/16/2009
-----------------------	-----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C1\PTO\IDS.form.doc/DNB/gyl

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	3	of	36	Attorney Docket Number	TPI-350C1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U42	US-4,916,134	04-10-1990	Heeres <i>et al.</i>	All
	U43	US-5,006,513	04-09-1991	Hector <i>et al.</i>	All
	U44	US-5,059,595	10-22-1991	Le Grazie	All
	U45	US-5,073,543	12-17-1991	Marshall <i>et al.</i>	All
	U46	US-5,120,548	06-09-1992	McClelland <i>et al.</i>	All
	U47	US-5,354,556	10-11-1994	Sparks <i>et al.</i>	All
	U48	US-5,414,997	05-16-1995	Tailer	All
	U49	US-5,474,997	12-12-1995	Gray <i>et al.</i>	All
	U50	US-5,591,767	01-07-1997	Mohr <i>et al.</i>	All
	U51	US-5,633,015	05-27-1997	Gilis <i>et al.</i>	All
	U52	US-5,639,476	06-17-1997	Oshlack <i>et al.</i>	All
	U53	US-5,661,151	08-26-1997	Saksena <i>et al.</i>	All
	U54	US-5,674,533	10-07-1997	Santus <i>et al.</i>	All
	U55	US-5,707,975	01-13-1998	Francois <i>et al.</i>	All
	U56	US-5,733,566	03-31-1998	Lewis	All
	U57	US-2003/0096014	05-22-2003	Sherman	All
	U58	US-4,513,006	04-23-1995	Maryanoff <i>et al.</i>	All
	U59	US-6,191,117	02-20-2001	Kozachuk	All
	U60	US-6,201,010	03-13-2001	Cottrell	All
	U61	US-5,753,693	05-19-1998	Shank	All

Examiner Signature	/Renee Claytor/	Date Considered	11/16/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C1\PTO\IDS.form.doc/DNB\gyl

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	4	of	36	Attorney Docket Number	TPI-350C1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U62	US-5,998,380	12-07-1999	Ehrenberg <i>et al.</i>	All
	U63	US-6,319,903	11-20-2001	Carrazana <i>et al.</i>	All
	U64	US-5,935,933	08-10-1999	Shank <i>et al.</i>	All
	U65	US-5,760,007	06-02-1999	Shank <i>et al.</i>	All
	U66	US-5,952,187	09-14-1999	Stenglein <i>et al.</i>	All
	U67	US-5,242,942	09-07-1993	Costanzo <i>et al.</i>	All
	U68	US-5,384,327	01-24-1995	Costanzo <i>et al.</i>	All
	U69	US-6,071,537	06-06-2000	Shank	All
	U70	US-6,503,884	01-07-2003	Ehrenberg <i>et al.</i>	All
	U71	US-2003/0069190	04-10-2003	Abdel-Magid <i>et al.</i>	All
	U72	US-2002/0042446	04-11-2002	Dewey <i>et al.</i>	All
	U73	US-2002/0037925	03-28-2002	Dewey <i>et al.</i>	All
	U74	US-2003/0072802	04-17-2003	Cutler	All
	U75	US-6,488,962	12-03-2002	Berner <i>et al.</i>	All
	U76	US- 7,078,526	07-18-2006	Remenar <i>et al.</i>	All
	U77	US-6,294,192	9-25-2001	Patel <i>et al.</i>	All
	U78	US-5,466,823	11-14-1995	Talley <i>et al.</i>	All
	U79	US-4,008,321	02-15-1977	Kamishita <i>et al.</i>	All
	U80	US-4,853,379	08-01-1989	Shroot <i>et al.</i>	All
	U81	US-5,641,512	06-24-1997	Cimiluca	All

Examiner Signature	/Renee Claytor/	Date Considered	11/16/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C1\PTOIDS.form.doc/DNB/gyl

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	5	of	36	Attorney Docket Number	TPI-350C1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U82	US-6,420,394 B1	07-16-2002	Supersaxo	All
	U83	US-2003/0224006 A1	12-04-2003	Zaworotko <i>et al.</i>	All
	U84	US-			
	U85	US-			
	U86	US-			
	U87	US-			
	U88	US-			
	U89	US-			
	U90	US-			
	U91	US-			
	U92	US-			
	U93	US-			
	U94	US-			
	U95	US-			
	U96	US-			
	U97	US-			
	U98	US-			
	U99	US-			
	U100	US-			
	U101	US-			

Examiner Signature	/Renee Claytor/	Date Considered	11/16/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C1\PTOIDS.form.doc/DNB/gyl

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	6	of	36	Attorney Docket Number	TPI-350C1

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³	- Number ⁴ - Kind Code ⁵ (if known)			
	F1	EP	413528 B1	11-15-1995	Yu, R. <i>et al.</i>	All
	F2	EP	1364649 A1	11-26-2003	Cilag AG	All
	F3	WO	94/16733 A1	08-04-1994	Chiesi Farmaceutici S.P.A.	All
	F4	WO	96/07331 A1	03-14-1996	Xyrofin Oy	All
	F5	WO	98/57967 A1	12-23-1998	Dong-A Pharmaceutical Co., Ltd.	All
	F6	WO	2000/53283 A1	09-14-2000	Reuter Chemische Apparatebau KG	All
	F7	WO	2001/13904 A2	03-01-2001	Ortho-McNeil Pharmaceutical, Inc.	All
	F8	JP	54-16494	02-07-1979	Yamanouchi Pharmaceutical Co., Ltd.	All
	F9	WO	00/50020 A2	08-31-2000	University of Cincinnati	All
	F10	FR	769,586	06-11-1934	Chemische Fabrik von Heyden	All
	F11	IT	01303251	11-06-2000	Industriale Chimica, S.R.L.	All
	F12	WO	2001/97853 A1	12-27-2001	Biochemie Gesellschaft MBH	All
	F13	EP	0310122 B1	04-05-1989	Kaken Pharma	All
	F14	WO	2002/062318 A2	08-15-2002	DSM N.V.	All
	F15	EP	0283992 B1	09-16-1992	Janssen Pharma Transform	All
	F16	WO	2003/101392 A2	12-11-2003	Pharmaceuticals, Inc.	All
	F17	WO	2004/054571 A1	07-01-2004	Cilag AG	All
	F18	WO	2004/078161 A1 (CD-ROM)	09-16-2004	Transform Pharmaceuticals, Inc.	All
	F19	WO	2004/078163 A2 (CD-ROM)	09-16-2004	Transform Pharmaceuticals, Inc.	All

Examiner Signature	/Renee Claytor/	Date Considered	11/16/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

J:\TPI\350C1\PTOIDS.form.doc\DNB\gyl

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/660,202
				Filing Date	September 11, 2003
				First Named Inventor	Örn Almarsson
				Group Art Unit	1617
				Examiner Name	Leonard Williams
Sheet	7	of	36	Attorney Docket Number	TPI-350C1

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F20	WO 2004/089313 A2	10-21-2004	Transform Pharmaceuticals, Inc.	All	
	F21	WO 2005/023198 A2 (CD-ROM)	03-17-2005	Transform Pharmaceuticals, Inc.	All	
	F22	WO 2005/037424 A1	04-28-2005	Salvias AG	All	
	F23	WO 2005/055983 A2	06-23-2005	Medcrystalforms, LCC	All	
	F24	WO 2005/060968 A1 (CD-ROM)	07-07-2005	Sepracor, Inc.	All	
	F25	WO 2005/089375 A2 (CD-ROM)	09-29-2005	S.S.C.I., Inc.	All	
	F26	WO 2005/094804 A1	10-13-2005	The Regents of the University of Michigan	All	
	F27	WO 2006/024930 A1	03-09-2006	Pharmacia and Upjohn Co., LCC	All	
	F28	WO 03/070738 A2	08-28-2003	Transform Pharmaceuticals, Inc.	All	
	F29	WO 03/074474 A2	09-12-2003	Univ. South Fl	All	
	F30	WO 95/17407 A1	06-29-1995	Schering Corp	All	
	F31	WO 00/07583 A2	02-17-2000	Brookhaven Science Associates	All	
	F32	WO 00/72841 A1	12-07-2000	Berlant, Jeffrey	All	
	F33	WO 03 033462 A2	04-23-2003	Regents of Univ. Mich.	All	
	F34	WO 01 51919 A2	07-19-2001	Transform Pharm. Inc.	All	
	F35	WO 01 42222 A1	06-14-2001	Pharmacia Corp.	All	
	F36	WO 95/23596 A1	09-08-1995	The Boots Co.	All	
	F37	WO 00/32189 A1	06-08-2000	G. D. Searle & Co.	All	
	F38	WO 01/41760 A3	06-14-2001	Pharmacia Corporation	All	
	F39	WO 01/78724 A1	10/25/2001	Pharmacia Corporation	All	
	F40	WO 01/91750 A1	12/06/2001	Pharmacia Corporation	All	
	F41	WO 02/00627 A1	01/03/2002	Fako Ilacilari A.S.	All	
	F42	IN 182620	12-24-1994	Bajaj <i>et al.</i>	All	

Examiner Signature	/Renee Claytor/	Date Considered	11/16/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C1\PTOIDS.form.doc\DNB\gyI

NPC-UNIV-000005800

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 871 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	8	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	AAKERÖY, C. <i>et al.</i> "Crystal engineering of hydrogen-bonded assemblies- a progress report" <i>Aust. J. Chem.</i> , 2001, pp. 409-421, Vol. 54.	
	R2	BINGHAM, A. <i>et al.</i> "Over one hundred solvates of sulfathiazole" <i>Chem. Commun.</i> , 2001, pp. 603-604.	
	R3	BYRIEL, K., <i>et al.</i> "Molecular cocrystals of carboxylic acids. IX Carboxylic acid interactions with organic heterocyclic bases. The crystal structures of the adducts of (2,4-dichlorophenoxy) acetic acid with 3-hydroxypyridine, 2,4,6-trinitrobenzoic acid with 2-aminopyrimidine, and 4-nitrobenzoic acid with 3-amino-1,2,4-triazole" <i>Aust. J. Chem.</i> , 1992, pp. 969-981, Vol. 45, No. 6.	
	R4	SALMON, J. <i>et al.</i> "Supramolecular chemistry of boronic acids (Abstract)" 38 th Midwest Regional Meeting of the American Chemical Society in Columbia, MO., November 5-7, 2003, published by the American Chemical Society, Washington, D.C.	
	R5	URBINA, J. <i>et al.</i> "Supramolecular design of inorganic/organic networks using flexible ligands with self-complementary hydrogen bonds (Abstract)" 38 th Midwest Regional Meeting of the American Chemical Society in Columbia, MO., November 5-7, 2003, published by the American Chemical Society, Washington, D.C.	

Examiner Signature	/Bene Clayton/	Date Considered	11/16/2009
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	9	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R6	SMITH, D. <i>et al.</i> "Structure confirmation by single crystal X-ray diffraction of a series of new schiff bases and theoretical computations on 3-(N-2- α , α , α -trifluorotoluidylidene amino) tetrahydrothiophene-1, 1-dioxide (Abstract)" 216 th ACS National Meeting in Boston, MA., August 23-27, 1998, published by the American Chemical Society, Washington, D.C.	
	R7	DESIRAJU, G. "Supramolecular synthons in crystal engineering- A new organic synthesis" <i>Angew. Chem. Int. Ed. Engl.</i> , 1995, pp. 2311-2327, Vol. 34.	
	R8	FRITCHIE, C. <i>et al.</i> "The configuration of phenothiazine in various molecular complexes" <i>Chem. Commun.</i> , 1968, pp. 833-834.	
	R9	HUANG, C.-M. <i>et al.</i> "Molecular packing modes. Part XI. Crystal structures of the 2:1 complexes of benzamide with succinic acid and furamide with oxalic acid" <i>J. Chem. Soc. Perkins Trans. 2: Physical Organic Chemistry</i> , 1973, pp. 503-508, Vol. 5.	
	R10	JACKISCH, M. <i>et al.</i> "Structures of three related biphenyl compounds: 4,4'-biphenyldiol, 3, 3',5,5'-tetra- <i>tert</i> -butyl-4,4'-biphenyldiol, and 3,3',5,5'- tetra- <i>tert</i> -butyl-1,1'-bicyclohexa-2,5-dienylidene-4,4'-dione" <i>Acta Cryst.</i> , 1990, pp. 919-922, Vol. C46.	
	R11	KIM, S. <i>et al.</i> "The structure of a crystalline complex containing one phenobarbital molecule and two adenine derivatives" <i>Proc. Natl. Acad. Sci. USA</i> , 1968, pp. 402-408, Vol. 60.	
	R12	KOBAYASHI, H. <i>et al.</i> "Sinusoidal structure of the 1:1 complex of phenothiazine and 7,7,8,8-tetracyanoquinodimethane, PTZ-TCNQ" <i>Acta Cryst.</i> , 1974, pp. 1010-1017, Vol. B30.	
	R13	ERMER, O. <i>et al.</i> "Molecular recognition among alcohols and amines: super-tetrahedral crystal architectures of linear diphenol-diamine complexes and aminophenols" <i>J. Chem. Soc. Perkins Trans. 2</i> , 1994, pp. 925-944.	
	R14	MARTIN, R. <i>et al.</i> "Polyphenal-caffeine complexation" <i>J. Chem. Soc., Chem. Commun.</i> , 1986, pp. 105-106.	
	R15	LEHN, J.-M. <i>et al.</i> "Molecular recognition directed self-assembly of ordered supramolecular strands by cocrystallization of complementary molecular components" <i>Chem. Soc., Chem. Commun.</i> , 1990, pp. 479-481.	

Examiner Signature	/Renee Claytor/	Date Considered	11/16/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C1\PTO\IDS.form.doc\DNB\gyl

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	10	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R16	LYNCH, D. <i>et al.</i> "Molecular cocrystals of carboxylic acids. XV Preparation and characterization of heterocyclic base adducts with a series of carboxylic acids, and the crystal structures of the adducts of 2-aminopyrimidine with 2,6-dihydroxybenzoic acid, 4-aminobenzoic acid, phenoxyacetic acid, (2,4-dichlorophenoxy) acetic acid, (3,4-dichlorophenoxy)- acetic acid and salicylic acid, and 2-aminopyridine with 2,6-dihydroxybenzoic acid" <i>Aust. J. Chem.</i> , 1994, pp. 1097-1115, Vol. 47.	
	R17	MCINTOSH, J. <i>et al.</i> "Chemotherapeutic drugs in anaerobic infections of wounds" <i>The Lancet</i> , June 26, 1943, pp. 793-795.	
	R18	MCINTOSH, J. <i>et al.</i> "Zinc peroxide, proflavine and penicillin in experimental <i>cl. welchii</i> infections" <i>The Lancet</i> , December 26, 1942, pp. 750-752.	
	R19	SMITH, G. <i>et al.</i> "Molecular cocrystals of carboxylic acids. XXI The role of secondary group interactions in adduct formation between 2-aminopyrimidine and substituted benzoic acids: the crystal structures of the adducts with <i>o</i> -phthalic acid, <i>o</i> -nitrobenzoic acid, <i>o</i> -aminobenzoic acid and <i>m</i> -aminobenzoic acid" <i>Aust. J. Chem.</i> , 1995, pp. 1151-1166, Vol. 48.	
	R20	WEISSBUCH, I. <i>et al.</i> "Crystal morphology control with tailor-made additives; a stereochemical approach" <i>Advances in Crystal Growth Research</i> , 2001, pp. 381-400.	
	R21	MCMAHON, J. <i>et al.</i> "Crystal engineering of the composition of pharmaceutical phases. 3 ¹ . Primary amide supramolecular heterosynthons and their role in the design of pharmaceutical co-crystals" <i>Z. Kristallogr.</i> , 2005, pp. 340-350, Vol. 220.	
	R22	MEEJOO, S. <i>et al.</i> "The interplay of aryl-perfluoroaryl stacking interactions and interstack hydrogen bonding in controlling the structure of a molecular cocrystal" <i>Chemphyschem</i> , 2003, pp. 766-769, Vol. 4.	
	R23	MIRMEHRABI, M. <i>et al.</i> "Improving the filterability and solid density of ranitidine hydrochloride form 1" <i>Journal of Pharmaceutical Sciences</i> , July 2004, pp. 1692-1700, Vol. 93, No. 7.	
	R24	MORRIS, K. <i>et al.</i> "Theoretical approaches to physical transformations of active pharmaceutical ingredients during manufacturing processes" <i>Advanced Drug Delivery Reviews</i> , 2001, pp. 91-114, Vol. 48.	

Examiner Signature	/Renee Claytor/	Date Considered	11/16/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

J:\TPI\350C1\PTO\IDS.form.doc\DNB\gyl

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

NPC-UNIV-000005803

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 874 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/660,202
		Filing Date	September 11, 2003
		First Named Inventor	Örn Almarsson
		Group Art Unit	1617
		Examiner Name	Leonard Williams
		Attorney Docket Number	TPI-350C1
Sheet	11	of	36

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R25	NAKANISHI, I. <i>et al.</i> "X-ray structural studies on two forms of β -cyclodextrin barbital complexes" <i>Journal of Inclusion Phenomena</i> , 1984, pp. 689-699, Vol. 2.	
	R26	NAKAO, S. <i>et al.</i> "The crystal and molecular structure of the 2:1 molecular complex of theophylline with phenobarbital" <i>Acta Cryst.</i> , 1977, pp. 1373-1378, Vol. B33.	
	R27	NATARAJAN, S. <i>et al.</i> "Reinvestigation of the crystal structure of diglycine hydrochloride" <i>Zeitschrift für Kristallographie</i> , 1992, pp. 265-270, Vol. 198.	
	R28	OLENIK, B. <i>et al.</i> "Cooperative and anticooperative effects in the cocrystals of mono- and diazanaphthalenes with meso-1, 2-diphenyl-1,2-ethanediol" <i>Crystal Growth & Design</i> , 2003, pp. 175-181, Vol. 3, No. 2.	
	R29	OLENIK, B. <i>et al.</i> "Supramolecular synthesis by cocrystallization of oxalic and fumaric acid with diazanaphthalenes" <i>Crystal Growth & Design</i> , 2003, pp. 183-188, Vol. 3, No. 2.	
	R30	GROTH, P. "d-Glucose-sodium chloride-monohydrate (glucose-sodium chloride) = $2C_6H_{12}O_6 \cdot NaCl \cdot H_2O$ " <i>Chemische Kristallographie</i> , 1910, pp. 438-439.	X
	R31	OSWALD, I. <i>et al.</i> "Rationalisation of co-crystal formation through knowledge-mining" <i>Crystallography Reviews</i> , 2004, pp. 57-66, Vol. 10, No. 1.	
	R32	OUYANG, X. <i>et al.</i> "Single-crystal-to-single-crystal topochemical polymerizations of a terminal diacetylene: two remarkable transformations give the same conjugated polymer" <i>J. Am. Chem. Soc.</i> , 2003, pp. 12400-12401, Vol. 125.	
	R33	PATEL, U. <i>et al.</i> "Structure of the 1:1 complex between 4-amino-N-(4,6-dimethyl-2-pyrimidinyl)- benzenesulfonamide (sulfadimidine) and 2-hydroxybenzoic acid (salicylic acid)" <i>Acta Cryst.</i> , 1988, pp. 1264-1267, Vol. C44.	
	R34	REDDY, L. <i>et al.</i> "Phenyl-perfluorophenyl synthon mediated cocrystallization of carboxylic acids and amides" <i>Crystal Growth & Design</i> , 2004, pp. 89-94, Vol. 4., No. 1.	
	R35	REMENAR, J. <i>et al.</i> "Crystal engineering of novel cocrystals of a triazole drug with 1,4-dicarboxylic acids" <i>J. Am. Chem. Soc.</i> , 2003, pp. 8456-8457, Vol. 125.	

Examiner Signature	/Renee Clayton/	Date Considered	11/16/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C1\PTO\IDS.form.doc/DNB/gyl

NPC-UNIV-000005804

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 875 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	12	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R36	SCHMIDT, G. "Photodimerization in the solid state" <i>Pure Appl. Chem.</i> , 1971, pp. 647-678, Vol. 27.	
	R37	SHAN, N. <i>et al.</i> "Co-crystal of 4,7-phenanthroline and carboxylic acids: synthon competition and prediction" <i>Tetrahedron Letters</i> , 2002, pp. 8721-8725, Vol. 43.	
	R38	SHAN, N. <i>et al.</i> "Crystal engineering using 4,4'-bipyridyl with di- and tricarboxylic acids" <i>Crystal Engineering</i> , 2002, pp. 9-24, Vol. 5.	
	R39	SHAN, N. <i>et al.</i> "Supramolecular synthons in the co-crystal structures of 2-aminopyrimidine with diols and carboxylic acids" <i>Tetrahedron Letters</i> , 2002, pp. 3101-3104, Vol. 43.	
	R40	MCINTOSH, J. <i>et al.</i> "Further observations on the chemotherapy of experimental gas gangrene: flavazole, marfanil, V187 and V335" <i>British Journal of Experimental Pathology</i> , 1946, pp. 46-54, Vol. 27.	
	R41	SHAVIV, R. <i>et al.</i> "Magnetochemistry of the tetrahaloferrate (III) ions 6. Crystal structure and magnetic ordering in [(pyH) ₃ Cl] [FeCl ₄] ₂ " <i>Inorganica Chimica Acta</i> , 1992, pp. 613-621, Vol. 198-200.	
	R42	SHEFTER, E. "Structural studies on complexes IV: Crystal structure of a 1:1 5-chlorosalicylic acid and theophylline complex" <i>Journal of Pharmaceutical Sciences</i> , 1969, pp. 710-714, Vol. 58.	
	R43	SHIMIZU, N. <i>et al.</i> "Structure of 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine-5,5-diethylbarbituric acid (1:1)" <i>Acta Cryst.</i> , 1982, pp. 2309- 2311, Vol. B38.	
	R44	SINGH, N. B. <i>et al.</i> "Solid state reaction between 8-hydroxyquinoline and <i>p</i> -nitrobenzoic acid" <i>Indian Journal of Chemistry</i> , May 1988, pp. 429-432, Vol. 37B.	
	R45	SMITH, G. <i>et al.</i> "The 1:1 adduct of 4-aminobenzoic acid with 4-aminobenzonitrile" <i>Acta Cryst.</i> , 2000, pp. 1155-1156, Vol. C56.	

Examiner Signature	/Renee Clayton/	Date Considered	11/16/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C1\PTOIDS.form.doc/DNB/gyl

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/660,202
		Filing Date	September 11, 2003
		First Named Inventor	Örn Almarsson
		Group Art Unit	1617
		Examiner Name	Leonard Williams
Sheet	13	of	36
		Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R46	STEINER, T. "Donor and acceptor strengths in C-H...O hydrogen bonds quantified from crystallographic data of small solvent molecules" <i>New. J. Chem.</i> , 1998, pp. 1099-1103.	
	R47	STOREY, R. et al. "Automation of solid form screening procedures in the pharmaceutical industry- how to avoid the bottlenecks" <i>Crystallography Reviews</i> , 2004, pp. 45-56, Vol. 10, No. 1.	
	R48	SZAFRAN, M. et al. "Molecular structures and hydrogen bonding in the 1:1 and 1:2 complexes of pyridine betaine with 2,6-dichloro-4-nitrophenol; an example of strongly coupled hydrogen bonds, O-H...O=C-O-H...O-" <i>Journal of Molecular Structure</i> , 1997, pp. 145-160, Vol. 416.	
	R49	TAKEUCHI, M. et al. "Synchrotron radiation SAXS/WAXS study of polymorph-dependent phase behavior of binary mixtures of saturated monoacid triacylglycerols" <i>Crystal Growth & Design</i> , 2003, pp. 369-374, Vol. 3, No. 3.	
	R50	TANG, C. P. et al. "Reaction pathways in crystalline host-guest inclusion complexes: rotation by a net 180° of the acetyl group on photoaddition of guest- acetophenone and -m-Chloroacetophenone to the atom C5 of host deoxycholic acid" <i>J. Am. Chem. Soc.</i> , 1985, pp. 4058-4070, Vol. 107.	
	R51	TAYLOR, R. et al. "Rules governing the crystal packing of mono- and dialcohols" <i>Acta Crystallographica Section B, Structural Science</i> , 2001, pp. 815-827, Vol. B57.	
	R52	THALLAPALLY, P. et al. "Polymorphism of 1,3,5-trinitrobenzene induced by a trisindane additive" <i>Angew. Chem. Int. Ed.</i> , 2004, pp. 1149-1155, Vol. 43.	
	R53	TIMMERMAN, P. et al. "Noncovalent Assembly of functional groups on calix[4]arene molecular boxes" <i>Chem. Eur. J.</i> , 1997, pp. 1823-1832, Vol. 3., No. 11.	
	R54	SHAN, N. et al. "Mechanochemistry and co-crystal formation: effect of solvent on reaction kinetics" <i>Chem. Commun.</i> , 2002, pp. 2372-2373.	
	R55	CAIRA, M. et al. "X-ray structure and thermal analysis of a 1:1 complex between (S)-naproxen and heptakis (2,3,6-tri-O-methyl)-β-cyclodextrin" <i>Journal of Inclusion Phenomena and Molecular Recognition in Chemistry</i> , 1995, pp. 277-290, Vol. 20.	
Examiner Signature	/Renee Claytor/		Date Considered 11/16/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2

J:\TPI\350C1\PTOIDS.form.doc/DNB/gyl

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

NPC-UNIV-000005806

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 877 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/660,202
		Filing Date	September 11, 2003
		First Named Inventor	Örn Almarsson
		Group Art Unit	1617
		Examiner Name	Leonard Williams
		Attorney Docket Number	TPI-350C1
Sheet	14	of	36

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R56	TRASK, A. <i>et al.</i> "Crystal engineering of organic cocrystals by the solid-state grinding approach" <i>Top Curr. Chem.</i> , 2005, pp. 41-70, Vol. 254.	
	R57	TRASK, A. <i>et al.</i> "Pharmaceutical cocrystallization: engineering a remedy for caffeine hydration" <i>Crystal Growth & Design</i> , 2005, pp. 1013-1021, Vol. 5, No. 3.	
	R58	TRASK, A. <i>et al.</i> "Solvent-drop grinding: green polymorph control of cocrystallisation" <i>Chem. Commun.</i> , 2004, pp. 890-891 in addition to supplemental materials.	
	R59	TROWBRIDGE, L. <i>et al.</i> "Composites for nonlinear optics: Crystal growth and polymorphism" <i>University of Sussex, Falmer Brighton UK, School of Chemistry and Molecular Sciences</i> , pp. 272.1994	
	R60	UNO, T. <i>et al.</i> "Structure of 5,5-diphenylhydantoin-1- (4-bromophenyl)-4-dimethylamino-2,3-dimethyl-3-pyrazolin-5-one (1:1)" <i>Acta Cryst.</i> , 1980, pp. 2794-2796, Vol. B36.	
	R61	VAN ROEY, P. <i>et al.</i> "Structure-activity studies of non-steroidal aromatase inhibitors: the crystal and molecular structures of CGS 16949A and CGS 18320B" <i>J. Enzyme Inhibition</i> , 1991, pp. 119-132, Vol. 5.	
	R62	VAN ROEY, P. <i>et al.</i> "Structure of <i>cis</i> -1-[[4-(1-imidazolylmethyl) cyclohexyl] methyl] imidazole- succinic acid complex" <i>Acta Cryst.</i> , 1991, pp. 1015-1018, Vol. C47.	
	R63	VISHWESHWAR, P. <i>et al.</i> "Crystal engineering of pharmaceutical co-crystals from polymorphic active pharmaceutical ingredients" <i>Chem. Commun.</i> , 2005, pp. 4601-4603.	
	R64	VISHWESHWAR, P. <i>et al.</i> "Recurrence of carboxylic acid- pyridine supramolecular synthon in the crystal structures of some pyrazinecarboxylic acids" <i>J. Org. Chem.</i> , 2002, pp. 556-565, Vol. 67.	
	R65	VISHWESHWAR, P. <i>et al.</i> "Supramolecular synthons based on N-H...N and C-H...O hydrogen bonds. Crystal engineering of a helical structure with 5,5-diethylbarbituric acid" <i>Chem. Commun.</i> , 2002, pp. 1830-1831.	
	R66	VISHWESHWAR, P. <i>et al.</i> "Supramolecular synthons in phenol-isonicotinamide adducts" <i>Cryst. Eng. Comm.</i> 2003, pp. 164-168, Vol. 5, No. 31.	

Examiner Signature	/Renee Claytor/	Date Considered	11/16/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

J:\TPI\350C1\PTO\IDS.form.doc/DNB/gyl

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

NPC-UNIV-000005807

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 878 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	15	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R67	VOET, D. <i>et al.</i> "The crystal and molecular structure of the intermolecular complex 9-ethyladenine-5, 5-diethylbarbituric acid" <i>Journal of the American Chemical Society</i> , November 15, 1972, pp. 8213-8222, Vol. 94, No. 23.	
	R68	VOET, D. <i>et al.</i> "The structure of an intermolecular complex between cytosine and 5-fluorouracil" <i>Journal of the American Chemical Society</i> , May 21, 1969, pp. 3069-3075, Vol. 91, No. 11.	
	R69	STEZOWSKI, J. J. <i>et al.</i> "Characterization of a 1:1 complex of an unusual structure in the phenothiazine/phenazine binary phase diagram" <i>Zeitschrift für Kristallographie in International Journal for Structural, Physical, Chemical Aspects of Crystalline Materials</i> , 1983, pp. 213-215, Vol. 162, No. 1-4.	X
	R70	WANG, A. <i>et al.</i> "Crystal structure of 1:1 complex of barbital with 1-methylimidazole" <i>Journal of Pharmaceutical Sciences</i> , March 1979, pp. 361-363, Vol. 68, No. 3.	
	R71	ALBEROLA, S. <i>et al.</i> "Crystalline and Molecular Structure of Sulfanilimide-Antipyrine" <i>Acta Cryst.</i> , 1977, pp. 3337-3341, Vol. B33.	X
	R72	WOOD, R. A. <i>et al.</i> "2,5-O-methylene-D-mannitol sodium-chloride, C ₇ H ₁₄ O ₆ . NaCl" <i>Cryst. Struct. Comm.</i> , 1976, 207-210, Vol. 5.	
	R73	XU, J. <i>et al.</i> "Effect of composition distribution on miscibility and co-crystallization phenomena in the blends of low density polyethylene with conventional and metallocene-based ethylene-butene copolymers" <i>Polymer</i> , 2001, pp. 3867-3874, Vol. 42.	
	R74	YOO, J. <i>et al.</i> "Cocrystallization of a dinuclear platinum complex as a monomer and a one-dimensional polymer" <i>Polyhedron</i> , 2002, pp. 715-719, Vol. 21.	
	R75	ZAITU, S. <i>et al.</i> "A 2:1 molecular complex of theophylline and 5-fluorouracil as the monohydrate" <i>Acta Cryst.</i> , 1995, pp. 1857-1859, Vol. C51.	
	R76	ZAMAN, M. B. <i>et al.</i> "Linear hydrogen-bonded molecular tapes in the cocrystals of squaric acid with 4,4'-dipyridylacetylene and 1,2-bis(4-pyridyl) ethylene" <i>Acta Cryst.</i> , 2001, pp. 621-624, Vol. C57.	
	R77	ZERKOWSKI, J. <i>et al.</i> "Design of organic structures in the solid state: hydrogen-bonded molecular "tapes" ¹ " <i>J. Am. Chem. Soc.</i> , 1990, pp. 9025-9026, Vol. 112.	
Examiner Signature	/Renee Claytor/		Date Considered 11/16/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

J:\TPI\350C1\PTO\IDS.form.doc/DNB/gyl

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

NPC-UNIV-000005808

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 879 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	16	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R78	ZERKOWSKI, J. <i>et al.</i> "Investigations into the robustness of secondary and tertiary architecture of hydrogen-bonded crystalline tapes" <i>Chem. Mater.</i> , 1994, pp. 1250-1257, Vol. 6.	
	R79	ZERKOWSKI, J. <i>et al.</i> "New varieties of crystalline architecture produced by small changes in molecular structure in tape complexes of melamines and barbiturates" <i>J. Am. Chem. Soc.</i> , 1994, pp. 4305-4315, Vol. 116.	
	R80	ZERKOWSKI, J. <i>et al.</i> "Polymorphic packing arrangements in a class of engineered organic crystals" <i>Chem. Mater.</i> , 1997, pp. 1933-1941, Vol. 9.	
	R81	ZERKOWSKI, J. <i>et al.</i> "Solid-state structures of "Rosette" and "Crinkled Tape" motifs derived from the cyanuric acid-melamine lattice" <i>J. Am. Chem. Soc.</i> , 1992, pp. 5473-5475, Vol. 114.	
	R82	ZHANG, R. <i>et al.</i> "Atmospheric new particle formation enhanced by organic acids" <i>Science</i> , June 4, 2004, pp. 1487-1490 with additional supporting online material, Vol. 304.	
	R83	ZHU, H. <i>et al.</i> "Influence of water activity in organic solvent + water mixtures on the nature of the crystallizing drug phase. 1. theophylline" <i>International Journal of Pharmaceutics</i> , 1996, pp. 151-160, Vol. 135.	
	R84	AAKERÖY, C. <i>et al.</i> "Aromatic dicarboxylic acids as building blocks of extended hydrogen-bonded architectures" <i>Supramolecular Chemistry</i> , 1998, pp. 127-135, Vol. 9.	
	R85	AAKERÖY, C. <i>et al.</i> "Assembly of 2-D inorganic/organic lamellar structures through a combination of copper (I) coordination polymers and self-complimentary hydrogen bonds" <i>J. Chem. Soc., Dalton Trans.</i> , 2000, pp. 3869-3872.	
	R86	AAKERÖY, C. <i>et al.</i> "Building organic assemblies with 2-pyridone and dicarboxylic acids: relating molecular conformation and synthon stability to crystal structure" <i>Crystal Engineering</i> , 1998, pp. 225-241, Vol. 1, No. 3-4.	
	R87	AAKERÖY, C. <i>et al.</i> "The C-H...C1 hydrogen bond: does it exist?" <i>New J. Chem.</i> , 1999, pp. 145-152.	
	R88	AAKERÖY, C. <i>et al.</i> "Crystal engineering of ionic solids" <i>Modular Chemistry</i> (ed. by Michl, J.), 1997, pp. 153-162, Kluwer Academic Publishers, The Netherlands.	

Examiner Signature	/Renee Claytor/	Date Considered	11/16/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

J:\TPI350C1\PTO\IDS.form.doc/DNB/gyl

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

NPC-UNIV-000005809

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 880 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	17	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R89	AAKERÖY, C. <i>et al.</i> "Crystal engineering: strategies and architectures" <i>Acta Cryst.</i> , 1997, pp. 569-586, Vol. B53.	
	R90	AAKERÖY, C. <i>et al.</i> "Crystal engineering using intermolecular hydrogen-bonded connectors and classic coordination chemistry" <i>Transactions ACA</i> , 1998, pp. 97-103, Vol. 33.	
	R91	AAKERÖY, C. <i>et al.</i> "The crystal structure of the molecular cocrystal L-malic acid L-tartaric acid (1/1)" <i>Supramolecular Chemistry</i> , 1996, pp. 153-156, Vol. 7.	
	R92	AAKERÖY, C. <i>et al.</i> "Deliberate combination of coordination polymers and hydrogen bonds in a supramolecular design strategy for inorganic/organic hybrid networks" <i>Chem. Commun.</i> , 2000, pp. 935-936.	
	R93	AAKERÖY, C. <i>et al.</i> "Di-hydroxy malonic acid as a building block of hydrogen-bonded 3-dimensional architectures" <i>Journal of Chemical Crystallography</i> , 1998, pp. 111-117, Vol. 28, No. 2.	
	R94	AAKERÖY, C. <i>et al.</i> "Do polymorphic compounds make good cocrystallizing agents? A structural case study that demonstrates the importance of synthon flexibility" <i>Crystal Growth & Design</i> , 2003, 159-165, Vol. 3, No. 2.	
	R95	AAKERÖY, C. <i>et al.</i> "Heteromeric intermolecular interactions as synthetic tools for the formation of binary co-crystals" <i>Cryst. Eng. Comm.</i> , 2004, pp. 19-24, Vol. 6, No. 5.	
	R96	AAKERÖY, C. <i>et al.</i> "A high-yielding supramolecular reaction" <i>J. Am. Chem. Soc.</i> , 2002, 14425-14432, Vol. 124.	
	R97	AAKERÖY, C. <i>et al.</i> "The hydrogen bond and crystal engineering" <i>Chemical Society Reviews</i> , 1993, pp. 397-407.	
	R98	AAKERÖY, C. <i>et al.</i> "Hydrogen-bond assisted assembly of organic and organic-inorganic solids" <i>Crystal Engineering: From Molecules and Crystals to Materials</i> , 1999, pp. 89-106, Kluwer Academic Publishers, The Netherlands.	
	R99	AAKERÖY, C. <i>et al.</i> "Hydrogen-bonding in solids" <i>Crystal Engineering</i> (ed. by Seddon, K. R. <i>et al.</i>), 1999, pp. 303-324, Kluwer Academic Publishers, The Netherlands.	
Examiner Signature	/Renee Clayton/		Date Considered 11/16/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C1\PTOIDS.form.doc/DNB/gyl

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/660,202
				Filing Date	September 11, 2003
				First Named Inventor	Örn Almarsson
				Group Art Unit	1617
				Examiner Name	Leonard Williams
Sheet	18	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R100	AAKERÖY, C. <i>et al.</i> "Low-dimensional architectures of silver coordination compounds assembled via amide-amide hydrogen bonds" <i>Crystal Engineering</i> , 1998, pp. 39-49, Vol. 1, No. 1.	
	R101	AAKERÖY, C. <i>et al.</i> "Molecular mechanics and crystal engineering" <i>Crystal Engineering</i> (ed. by Seddon, K. R. <i>et al.</i>), 1999, pp. 69-82, Kluwer Academic Publishers, The Netherlands.	
	R102	AAKERÖY, C. <i>et al.</i> "New building blocks for crystal engineering. Syntheses and crystal structures of oxime-substituted pyridines" <i>Cryst. Eng. Comm.</i> , 2000, pp. 1-6, Vol. 27.	
	R103	AAKERÖY, C. <i>et al.</i> "Novel colorless composite materials for nonlinear optics" <i>Adv. Mater.</i> , 1993, pp. 364-367, Vol. 5, No. 5.	
	R104	AAKERÖY, C. <i>et al.</i> "Organic assemblies of 2-pyridones with dicarboxylic acids" <i>Tetrahedron</i> , 2000, pp. 6693-6699, Vol. 56.	
	R105	AAKERÖY, C. <i>et al.</i> "Pitfalls in the supramolecular assembly of silver(I) coordination compounds" <i>Journal of Molecular Structure</i> , 1999, pp. 91-101, Vol. 474.	
	R106	AAKERÖY, C. <i>et al.</i> "A structural study of 2-amino-5-nitropyridine and 2-amino-3-nitropyridine: intermolecular forces and polymorphism" <i>J. Mater. Chem.</i> , 1998, pp. 1385-1389, Vol. 8, No. 6.	
	R107	AAKERÖY, C. <i>et al.</i> "Supramolecular assembly of low-dimensional silver (I) architectures via amide-amide hydrogen bonds" <i>Chem. Commun.</i> , 1998, pp. 1067-1068.	
	R108	AAKERÖY, C. <i>et al.</i> "Total synthesis' supramolecular style: design and hydrogen-bond-directed assembly of ternary supermolecules" <i>Angew. Chem. Int. Ed.</i> , 2001, pp. 3240-3242, Vol. 40, No. 17.	
	R109	AAKERÖY, C. <i>et al.</i> "Two-fold interpenetration of 3-D nets assembled via three-co-ordinate silver(I) ions and amide-amide hydrogen bonds" <i>J. Chem. Soc., Dalton Trans.</i> , 1998, pp. 1943-1945.	
	R110	AHN, S. <i>et al.</i> "Polymorphs of a 1:1 cocrystal with tunnel and layer structures: <i>p,p'</i> -biphenol/dimethyl sulfoxide" <i>Crystal Growth & Design</i> , 2001, pp. 107-111, Vol. 1, No. 2.	
Examiner Signature	/Renee Clayton/		Date Considered 11/16/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C1\PTO\IDS.form.doc\DNB\gyI

NPC-UNIV-000005811

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 882 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	19	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R111	AKAZOME, M. <i>et al.</i> "Enantioselective inclusion of methyl phenyl sulfoxides and benzyl methyl sulfoxides by (R)-phenylglycyl-(R)-phenylglycine and the crystal structures of the inclusion cavities" <i>J. Org. Chem.</i> , 2000, pp. 68-76, Vol. 65.	
	R112	AKHTARUZZAMAN, M.D. <i>et al.</i> "One-dimensional hydrogen-bonded molecular tapes in 1, 4-bis[(4-pyridinio) ethynyl]benzene chloranilate" <i>Acta. Cryst.</i> , 2001, pp. o353-o355, Vol. E57.	
	R113	ALLEN, F. <i>et al.</i> "Systematic analysis of structural data as a research technique in organic chemistry" <i>Acc. Chem. Res.</i> , 1983, pp. 146-153, Vol. 16.	
	R114	ALMARSSON, Ö. <i>et al.</i> "Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines?" <i>Chem. Commun.</i> , 2004, pp. 1889-1896.	
	R115	AMAI, M. <i>et al.</i> "1:1 complex of octadecanoic acid and 3-pyridinecarboxamide" <i>Acta Cryst.</i> , 1998, pp. 1367-1369, Vol. C54.	
	R116	ANDERSON, N. <i>et al.</i> "Sulfonation with inversion by mitsunobu reaction: an improvement on the original conditions" <i>J. Org. Chem.</i> , 1996, pp. 7955-7958, Vol. 61.	
	R117	AOKI, K. <i>et al.</i> "A 1:1 complex of theophylline and <i>p</i> -nitrophenol" <i>Acta Cryst.</i> , 1978, pp. 2333-2336, Vol. B34.	
	R118	ASHTON, P. <i>et al.</i> "Combining different hydrogen-bonding motifs to self-assemble interwoven superstructures" <i>Chem. Eur. J.</i> , 1998, pp. 577-589, Vol. 4, No. 4.	
	R119	BARKER, P. A. <i>et al.</i> "Effect of crystallization temperature on the cocrystallization temperature on the cocrystallization of hydroxybutyrate/ hydroxyvalerate copolymers" <i>Polymer</i> , pp. 913-919, Vol. 38, No. 4.	
	R120	BERKOVITCH-YELLIN, Z. <i>et al.</i> "Electron density distribution in cumulenes: an x-ray study of the complex allenedicarboxylic acid- acetamide (1:1) at -150° C" <i>Acta Cryst.</i> , 1977, pp. 3670-3677, Vol. B33.	
	R121	BERKOVITCH-YELLIN, Z. <i>et al.</i> "The role played by C-H...O and C-H...N interactions in determining molecular packing and conformation" <i>Acta Cryst.</i> , 1984, pp. 159-165, Vol. B40.	
	R122	BERL, V. <i>et al.</i> "Induced fit selection of a barbiturate receptor from a dynamic structural and conformational/configurational library" <i>Eur. J. Org. Chem.</i> , 1999, pp. 3089-3094.	
Examiner Signature	/Renee Clayton/		Date Considered 11/16/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

J:\TPI\350C1\PTO\IDS.form.doc\DNB\gyl

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC

NPC-UNIV-000005812

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 883 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	20	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R123	BERTOLASI, V. <i>et al.</i> "Competition between hydrogen bonding and donor-acceptor interactions in co-crystals of 1,3-dimethylbarbituric acid with aromatic amines" <i>New J. Chem.</i> , 2001, pp. 408-415, Vol. 25.	
	R124	BERTOLASI, V. <i>et al.</i> "General rules for the packing of hydrogen-bonded crystals as derived from the analysis of squaric acid anions: aminoaromatic nitrogen base co-crystals" <i>Acta Cryst.</i> , 2001, pp. 591-598, Vol. B57.	
	R125	BETTINETTI, G. <i>et al.</i> "Structure and solid-state chemistry of anhydrous and hydrated crystal forms of the trimethoprim-sulfamethoxypyridazine 1:1 molecular complex" <i>Journal of Pharmaceutical Sciences</i> , April 2000, pp. 478-489, Vol. 89, No. 4.	
	R126	BETTINETTI, G. <i>et al.</i> "Thermal analysis of binary systems of the pharmaceuticals trimethoprim and benzoic acid" <i>Journal of Thermal Analysis</i> , 1983, pp. 285-294, Vol. 28.	
	R127	BETTIS, J. <i>et al.</i> "Biopharmaceutics and dosage form design" <i>Amer. J. Hosp. Pharm.</i> , March 1973, pp. 240-243, Vol. 30.	
	R128	BOLTON, S. <i>et al.</i> "Complexes formed in solution by homologs of caffeine" <i>Journal of the American Pharmaceutical Association</i> , January 1957, pp. 38-41, Vol. XLVI, No. 1.	
	R129	BOND, A. "In situ co-crystallisation as a tool for low-temperature crystal engineering" <i>Chem. Commun.</i> , 2003, pp. 250-251, Vol. 2.	
	R130	BONIN, M. <i>et al.</i> "Urotropin azelate: a rather unwilling co-crystal" <i>Acta Cryst.</i> , 2003, pp. 72-86, Vol. B59.	
	R131	BOSSHARD, C. <i>et al.</i> "Microscopic nonlinearities of two-component organic crystals" <i>J. Opt. Soc. Am. B</i> , November 2001, pp. 1620-1626, Vol. 18, No. 11.	
	R132	GLUZMAN, M. Kh. <i>et al.</i> "Investigation of Eutectic Melting in Systems Composed of Organic Salts and Acids" <i>Journal of Physical Chemistry</i> , 1960, pp. 2742-2747, Vol. 34.	
	R133	BRAGA, D. <i>et al.</i> "Hydrogen bonding interactions between ions: a powerful tool in molecular crystal engineering" <i>Structure and Bonding</i> , 2004, pp. 1-32, Vol. 111.	
	R134	BRIERLEY, C. <i>et al.</i> "Preparation and structure of the 1:2 π -molecular complex of phenothiazine with pyromellitic dianhydride" <i>J. Chem. Phys.</i> , February 1, 1985, pp. 1522-1528, Vol. 82, No. 1.	
Examiner Signature	/Renee Clayton/		Date Considered 11/16/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

J:\TPI\350C1\PTO\IDS.form.doc\DNB\gyl

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

NPC-UNIV-000005813

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 884 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	21	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R135	BURGI, H. <i>et al.</i> "Crystallisation of supramolecular materials" <i>Current Opinion in Solid State & Materials Science</i> , 1998, pp. 425-430, Vol. 3.	
	R136	BYRN, S. R. <i>et al.</i> "Solid-state pharmaceutical chemistry" <i>Chem. Mater.</i> , 1994, pp. 1148-1158, Vol. 6.	
	R137	CAIRA, M. "Molecular complexes of sulfonamides. Part 1. 1:1 complexes between sulfadimidine [4-amino-N-(4,6-dimethyl-2-pyrimidinyl) benzenesulfonamide] and 2- and 4-aminobenzoic acids" <i>Journal of Crystallographic and Spectroscopic Research</i> , 1991, pp. 641-648, Vol. 21, No. 5.	
	R138	CAIRA, M. "Molecular complexes of sulfonamides. Part 2. 1:1 complexes between drug molecules: sulfadimidine-acetylsalicylic acid and sulfadimidine-4-aminosalicylic acid" <i>Journal of Crystallographic and Spectroscopic Research</i> , 1992, pp. 193-200, Vol. 22, No. 2.	
	R139	CAIRA, M. "Molecular complexes of sulfonamides. 3. Structure of 5-methoxysulfadiazine (Form II) and its 1:1 complex with acetylsalicylic acid" <i>Journal of Chemical Crystallography</i> , 1994, pp. 695-701, Vol. 24, No. 10.	
	R140	CAIRA, M. <i>et al.</i> "Order-disorder enantiotropy, monotropy, and isostructurality in a tetroxoprim-sulfametrole 1:1 molecular complex: crystallographic and thermal studies" <i>Journal of Pharmaceutical Sciences</i> , November 2003, pp. 2164-2176, Vol. 92, No. 11.	
	R141	CAIRA, M. <i>et al.</i> "Selective formation of hydrogen bonded cocrystals between a sulfonamide and aromatic carboxylic acids in the solid state" <i>J. Chem. Soc. Perkin Trans. 2</i> , 1995, pp. 2213-2216.	
	R142	CAIRA, M. <i>et al.</i> "Structure of a 1:1 complex between the anthelmintic drug mebendazole and propionic acid" <i>Journal of Chemical Crystallography</i> , 1998, Vol. 28, No. 1.	
	R143	CAMERMAN, A. <i>et al.</i> "Hydrogen bonding interaction of diphenylbarbituric acid and 9-ethyladenine. Crystal structure of a 1:1 complex" <i>Can. J. Chem.</i> , 2000, pp. 1045-1051, Vol. 78.	
	R144	CAMERMAN, A. <i>et al.</i> "Molecular structure of acetylacetone. A crystallographic determination" <i>J. Am. Chem. Soc.</i> , 1983, pp. 1584-1586, Vol. 105, No. 6.	
	R145	CANNON, A. <i>et al.</i> "Noncovalent derivatization: green chemistry applications of crystal engineering" <i>Crystal Growth & Design</i> , 2002, pp. 255-257, Vol. 2, No. 4.	
Examiner Signature	/Renee Clayton/		Date Considered
			11/16/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

J:\TPI350C1\PTO\IDS.form.doc\DNB\gyl

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

NPC-UNIV-000005814

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 885 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	22	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R146	CHINNAKALI, K. <i>et al.</i> "2-aminopyrimidine and <i>p</i> -phenylene-diacetic acid (1:1) co-crystal" <i>Acta Cryst.</i> , 1999, pp. 399-401, Vol. C55.	
	R147	CHOI, C. <i>et al.</i> "Cocrystallization of melaminium levulinate monohydrate" <i>Acta Cryst.</i> , 2004, pp. o295-o296, Vol. C60.	
	R148	CHOW, Y. P. <i>et al.</i> "Complexation of acetaminophen with methyl xanthines" <i>Journal of Pharmaceutical Sciences</i> , 1972, pp. 1454-1458, Vol. 61.	
	R149	CHRISTIAN, S. <i>et al.</i> "Activity coefficient effects in spectral and solubility studies of molecular complex equilibria" <i>Journal of the American Chemical Society</i> , September 20, 1972, pp. 6861-6862, Vol. 94, No. 19, Communications to the editor.	
	R150	COLL, M. <i>et al.</i> "Molecular structure of the complex formed between the anticancer drug cisplatin and d(pGpG): C222 ₁ crystal form" <i>Journal of Biomolecular Structure & Dynamics</i> , 1990, pp. 315-330, Vol. 8, No. 2.	
	R151	COPP, S. <i>et al.</i> "Supramolecular chemistry of [Mn(CO) ₃ (μ ₃ -OH)] ₄ : Assembly of a cubic hydrogen-bonded diamondoid network with 1,2-diamineothane" <i>J. Am. Chem. Soc.</i> , 1992, pp. 8719-8720, Vol. 114.	
	R152	CORDI, A. <i>et al.</i> "(S)-Spiro [(1, 3-diazacyclopent-1-ene)-5, 2' -(7'-methyl-1',2',3',4'-tetrahydronaphthalene)]: resolution, stereospecific synthesis, and preliminary pharmacological characterization as a partial α-adrenergic agonist" <i>J. Med. Chem.</i> , 1997, pp. 2931-2935, Vol. 40.	
	R153	CRAVEN, M. <i>et al.</i> "The 2:1 crystal complex of 5, 5-diethylbarbituric acid (barbital) and caffeine" <i>Acta Cryst.</i> , 1974, pp. 1191-1195, Vol. B30.	
	R154	CRAVEN, M. <i>et al.</i> "The crystal structures of two polymorphs of 5,5'-diethylbarbituric acid (barbital)" <i>Acta Cryst.</i> , 1969, pp. 1978-1993, Vol. B25.	
	R155	CUDNEY, B. <i>et al.</i> "Screening and optimization strategies for macromolecular crystal growth" <i>Acta Cryst.</i> , 1994, pp. 414-423, Vol. D50.	
Examiner Signature	/Renee Claytor/		Date Considered
			11/16/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/660,202
		Filing Date	September 11, 2003
		First Named Inventor	Örn Almarsson
		Group Art Unit	1617
		Examiner Name	Leonard Williams
		Attorney Docket Number	TPI-350C1
Sheet	23	of	36

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R156	DATTA, S. <i>et al.</i> "Molecular complex formation between riboflavin and salicylate in an aqueous medium" <i>Bull. Chem. Soc. Jpn.</i> , 2003, pp. 1729-1734, Vol. 76.	
	R157	DAVEY, R. J. <i>et al.</i> "Crystal engineering- nucleation, the key step" <i>Cryst. Eng. Comm.</i> , 2002, pp. 257-264, Vol. 4, No. 47.	
	R158	DAVEY, R. J. <i>et al.</i> "Crystallisation in polymer films: control of morphology and kinetics of an organic dye in a polysilicone matrix" <i>J. Mater. Chem.</i> , 1997, pp. 237-241, Vol. 7, No. 2.	
	R159	DEBERNARDIS, J. <i>et al.</i> "Conformationally defined adrenergic agents. 5. Resolution, absolute configuration, and pharmacological characterization of the enantiomers of 2-(5,6-dihydroxy-1,2,3,4-tetrahydro-1-naphthyl) imidazoline: a potent agonist at α -adrenoceptors" <i>J. Med. Chem.</i> , 1987, pp. 1011-1017, Vol. 30.	
	R160	DESIRAJU, G. <i>et al.</i> "Crystal and co-crystal" <i>Cryst. Eng. Comm.</i> , 2003, pp. 466-467, Vol. 5, No. 82.	
	R161	DESIRAJU, G. <i>et al.</i> "Crystal engineering: outlook and prospects" <i>Current Science</i> , October 25, 2001, pp. 1038-1042, Vol. 81, No. 8.	
	R162	DUAX, W. <i>et al.</i> "The structure of the crystalline complex estradiol. Urea (1:1)" <i>Acta Cryst.</i> , 1972, pp. 1864-1871, Vol. B28.	
	R163	DUNITZ, J. "Crystal and co-crystal: a second opinion" <i>Cryst. Eng. Comm.</i> , 2003, pp. 506, Vol. 5, No. 91.	
	R164	DUNITZ, J. "New light on an old story: the solid-state transformation on ammonium cyanate into urea" <i>J. Am. Chem. Soc.</i> , 1998, pp. 13274-13275, Vol. 120.	
	R165	ENRIGHT, G. <i>et al.</i> "Thermally programmable gas storage and release in single crystals of an organic van der Waals host" <i>J. Am. Chem. Soc.</i> , 2003, pp. 9896-9897, Vol. 125.	
	R166	EPSTEIN, R. <i>et al.</i> "The x-ray crystal structure of the molecular complex 8-bromo-9-ethyladenine-5-allyl-5-isobutylbarbituric acid" <i>Acta Cryst.</i> , 1976, pp. 2180-2188, Vol. B32.	
Examiner Signature	/Renee Claytor/		Date Considered 11/16/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C1\PTO\IDS.form.doc\DNB\gyl

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/660,202
		Filing Date	September 11, 2003
		First Named Inventor	Örn Almarsson
		Group Art Unit	1617
		Examiner Name	Leonard Williams
		Attorney Docket Number	TPI-350C1
Sheet	24	of	36

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R167	ETTER, M. "Encoding and decoding hydrogen-bond patterns of organic compounds" <i>Acc. Chem. Res.</i> , 1990, pp. 120-126, Vol. 23.	
	R168	ETTER, M. <i>et al.</i> "Graph-set analysis of hydrogen-bond patterns in organic crystals" <i>Acta Cryst.</i> , 1990, pp. 256-262, Vol. B46.	
	R169	ETTER, M. <i>et al.</i> "Hydrogen bond directed cocrystallization and molecular recognition properties of acyclic imides" <i>J. Am. Chem. Soc.</i> , 1991, pp. 2586-2598, Vol. 113.	
	R170	ETTER, M. "Hydrogen bonds as design elements in organic chemistry" <i>J. Phys. Chem.</i> , 1991, pp. 4601-4610, Vol. 95.	
	R171	FABIAN, L. <i>et al.</i> "Volumetric measure of isostructurality" <i>Acta Cryst.</i> , 1999, pp. 1099-1108, Vol. B55.	
	R172	FALLON III, L. "The crystal and molecular structure of 5-fluorouracil" <i>Acta Cryst.</i> , pp. 2549-2556, Vol. B29, 1973	
	R173	FEIBUSH, B. <i>et al.</i> "Chiral separation of heterocyclic drugs by HPLC: solute-stationary phase base-pair interactions" <i>J. Am. Chem. Soc.</i> , 1986, pp. 3310-3318, Vol. 108.	
	R174	FIFER, E. <i>et al.</i> "Fentanyl analogues 3. 2-(1,2,3,4-tetrahydro)-naphthyl substituted 4-anilidopiperidines" <i>Eur. J. Med. Chem.-Chim. Ther.</i> , 1984, pp. 519-524, Vol. 19, No. 6.	
	R175	RECK, G. <i>et al.</i> "Crystal structures of the carbamazepine/ammonium chloride and carbamazepine/ammonium bromide adducts and their transformation into carbamazepine dihydrate" <i>Pharmazie</i> , 1991, pp. 509-512, Vol. 46, No. 7.	X
	R176	FOXMAN, B. M. <i>et al.</i> "Environmentally benign synthesis using crystal engineering: steric accommodation in non-covalent derivatives of hydroquinones" <i>Crystal Engineering</i> , 1998, pp. 109-118, Vol. 1, No. 1.	
	R177	FOXMAN, B. M. <i>et al.</i> "Noncovalent derivatives of hydroquinone: BIS- (N,N-dialkyl) bicyclo[2.2.2]octane-1,4-dicarboxamide complexes" <i>Crystal Engineering</i> , 1999, pp. 55-64, Vol. 2, No. 1.	
	R178	FUJII, S. <i>et al.</i> "Crystal and molecular structure of a 1:1 molecular complex of adenine and riboflavin" <i>Archives of Biochemistry and Biophysics</i> , 1977, pp. 363-370, Vol. 181.	
Examiner Signature	/Renee Clayton/		Date Considered 11/16/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

J:\TPI\350C1\PTOIDS.form.doc/DNB/gyl

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

NPC-UNIV-000005817

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 888 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	25	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R179	GAO, X. <i>et al.</i> "Supramolecular construction of molecular ladders in the solid state" <i>Angew. Chem. Int. Ed.</i> , 2004, pp. 232-236, Vol. 43.	
	R180	GARTLAND, G. L. <i>et al.</i> "Hydrogen bonding NH...O=C of barbiturates: the (1:1) crystal complex of urea and 5,5-diethylbarbituric acid (barbital)" <i>Acta Cryst.</i> , 1974, pp. 980-987, Vol. B30.	
	R181	GHOSH, M. "Structure and conformation of the 1:1 molecular complex sulfaproxyline-caffeine" <i>Acta Cryst.</i> , 1991, pp. 577-580, Vol. C47.	
	R182	GIUSEPPETTI, G. P. <i>et al.</i> "The crystal structure of a sulfamethoxazole-trimethoprim 1:1 molecular compound" <i>Il Farmaco- Ed. Sc.</i> , pp. 138-151, Vol. 35. 1980	
	R183	GOSWAMI, S. <i>et al.</i> "2-aminopyrimidine-fumaric acid cocrystal" <i>Acta Cryst.</i> , 1999, pp. 583-585, Vol. C55.	
	R184	HAYNES, D. "Supramolecular synthon competition in organic sulfonates: A CSD survey" <i>Cryst. Eng. Comm.</i> , 2004, pp. 584-588, Vol. 6, No. 95.	
	R185	GOSWAMI, S. <i>et al.</i> "1:1 Hetero-assembly of 2-amino-pyrimidine and (+)-camphoric acid" <i>Acta Cryst.</i> , 2000, pp. 477-478, Vol. C56.	
	R186	GOSWAMI, S. <i>et al.</i> "Molecular recognition induced supramolecular array of 2-aminopyrimidine with terephthalic acid, 1,4-phenylenediacetic acid and fumaric acid in solid state via H-bonding and π -stacking interactions" <i>Supramolecular Chemistry</i> , 1999, pp. 25-33, Vol. 11.	
	R187	GRAJA, A. <i>et al.</i> "Interplay of acceptor molecule shape, crystal structure and physical properties of a new molecular complex $C_{70} \cdot 2[(Ph_3P) AuCl]$ " <i>Chemical Physics Letters</i> , November 19, 1999, pp. 725-732. Vol. 313.	
	R188	HAIXIN, L. <i>et al.</i> "Structure of the 1:1 complex of 6,6'-diquinolyl ether with 5,5-diethylbarbituric acid" <i>Acta Cryst.</i> , 1992, pp. 2096-2098, Vol. C48.	
Examiner Signature	/Renee Claytor/		Date Considered 11/16/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C\NPTOIDS.form.doc\DNB\gyI

NPC-UNIV-000005818

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 889 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/660,202
		Filing Date	September 11, 2003
		First Named Inventor	Örn Almarsson
		Group Art Unit	1617
		Examiner Name	Leonard Williams
Sheet	26	of	36
		Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R189	HENCK, J. <i>et al.</i> "Disappearing and reappearing polymorphs. The benzocaine:picric acid system" <i>J. Am. Chem. Soc.</i> , 2001, pp. 1834-1841, Vol. 123.	
	R190	HIGUCHI, T. <i>et al.</i> "Complexation of organic substances in aqueous solution by hydroxyaromatic acids and their salts" <i>J. Pharm. Sci.</i> , 1961, pp. 905-909, Vol. 50.	
	R191	HINO, T. <i>et al.</i> "Assessment of nicotinamide polymorphs by differential scanning calorimetry" <i>Thermochimica Acta</i> , 2001, pp. 85-92, Vol. 374.	
	R192	HÖGBERG, T. <i>et al.</i> "Crystallographic, theoretical and molecular modelling studies on the conformations of the salicylamide, raclopride, a selective dopamine-D ₂ antagonist" <i>J. Pharm. Pharmacol.</i> , 1987, pp. 787-796, Vol. 39.	
	R193	HSU, I. <i>et al.</i> "The 2:1 crystal complex of 2-aminopyridine and 5,5-diethylbarbituric acid (barbital)" <i>Acta Cryst.</i> , 1974, pp. 994-997, Vol. B30.	
	R194	HSU, I. <i>et al.</i> "The 1:1 crystal complex of N-methyl-2-pyridone and 5,5-diethylbarbituric acid (barbital)" <i>Acta Cryst.</i> , 1974, pp. 998-1001, Vol. B30.	
	R195	HSU, I. <i>et al.</i> "The crystalline complex (1:1) of salicylamide and 5-ethyl-5-isoamylbarbituric acid (amobarbital)" <i>Acta Cryst.</i> , 1974, pp. 843-846, Vol. B30.	
	R196	HSU, I. <i>et al.</i> "The crystal structure of the 1:1 complex of acetamide with 5,5-diethylbarbituric acid (barbital)" <i>Acta Cryst.</i> , 1974, pp. 974-979, Vol. B30.	
	R197	HSU, I. <i>et al.</i> "The crystal structure of the triclinic 1:2 complex of hexamethylphosphoramide with 5,5-diethylbarbituric acid (barbital)" <i>Acta Cryst.</i> , 1974, pp. 1299-1304, Vol. B30.	
	R198	HSU, I. <i>et al.</i> "Hydrogen bonding NH...N of barbiturates: The 1:1 crystal complex of imidazole and 5,5-diethylbarbituric acid (barbital)" <i>Acta Cryst.</i> , 1974, pp. 988-993, Vol. B30.	
	R199	IBRAGIMOV, B. "A simple correlation between the structures of different crystal modifications of a given host-guest complex and their crystallization temperatures" <i>Journal of Inclusion of Phenomena and Macrocyclic Chemistry</i> , 1999, pp. 345-353, Vol. 34.	
Examiner Signature	/Renee Claytor/		Date Considered 11/16/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

J:\TPI\350C1\PTO\IDS.form.doc/DNB/gyl

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

NPC-UNIV-000005819

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 890 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/660,202
				Filing Date	September 11, 2003
				First Named Inventor	Örn Almarsson
				Group Art Unit	1617
				Examiner Name	Leonard Williams
				Attorney Docket Number	TPI-350C1
Sheet	27	of	36		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R200	ISHIDA, T. <i>et al.</i> "Structural study of histamine H ₂ -receptor antagonists. Five 3-[2-(diamino-methyleneamino)-4-thiazolymethylthio] propionamidine and -amide derivatives" <i>Acta Cryst.</i> , 1989, pp. 505-512, Vol. B45.	
	R201	KATAKAI, R. <i>et al.</i> "Stepwise synthesis of oligopeptides with N-carboxy-α-amino acid anhydrides. IV. Glycine NCA" <i>J. Org. Chem.</i> , 1972, pp. 327-329, Vol. 37, No. 2.	
	R202	KAWAKAMI, Y. <i>et al.</i> "The rationale for E2020 as a potent acetylcholinesterase inhibitor" <i>Bioorganic & Medicinal Chemistry</i> , 1996, pp. 1429-1446, Vol. 4, No. 9.	
	R203	KELDERS, H. <i>et al.</i> "Automated protein crystallization and a new crystal form of a subtilisin: eglin complex" <i>Protein Engineering</i> , 1987, pp. 301-303, Vol. 1, No. 4.	
	R204	KHALIL, R. M. "Complexation of paracetamol with xanthine derivatives" <i>Egypt. J. Pharm. Sci.</i> , 1992, pp. 757-769, Vol. 33, No. 5-6.	
	R205	KIM, S. "Crystal structure of the 1:1 complex of 5-fluorouracil and 9-ethylhypoxanthine" <i>Science</i> , November 24, 1967, pp. 1046-1048, Vol. 158, No. 3804.	
	R206	KIRYU, S. <i>et al.</i> "Crystal structure of a 1:1 aminopyrine-barbital complex" <i>Journal of Pharmaceutical Sciences</i> , May 1971, pp. 699-703, Vol. 60, No. 5.	
	R207	KIRYU, S. <i>et al.</i> "Crystal structure of a 1:1 aminopyrine-cyclobarbital complex" <i>Chem. Pharm. Bull.</i> , 1974, pp. 1588-1592, Vol. 22.	
	R208	KLEIN, C. <i>et al.</i> "Molecular structure of two conformationally restrained fentanyl analogues: cis- and trans-isomers of N-{3-methyl-1-[1,2,3,4-tetrahydro naphthyl]-4-piperidiny]-N-phenylpropanamide" <i>Journal of Pharmaceutical Sciences</i> , November 1985, pp. 1147-1151, Vol. 74, No. 11.	
	R209	KOSHIMA, H. <i>et al.</i> "Photoreactivities of two kinds of bimolecular crystals formed from acridine and phenothiazine" <i>J. Chem. Soc., Perkins Trans. 2</i> , 1997, pp. 2033-2038.	
	R210	KOSHIMA, H. <i>et al.</i> "Polymorphs of a cocrystal with achiral and chiral structures prepared by pseudoseeding: tryptamine/hydrocinnamic acid" <i>Crystal Growth & Design</i> , 2001, pp. 355-357, Vol. 1, No. 5.	
Examiner Signature	/Renee Claytor/		Date Considered 11/16/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C1\PTOIDS.form.doc\DNB\gyI

NPC-UNIV-000005820

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 891 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/660,202
		Filing Date	September 11, 2003
		First Named Inventor	Örn Almarsson
		Group Art Unit	1617
		Examiner Name	Leonard Williams
Sheet	28	of	36
		Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R211	KRISHNAMOHAN SHARMA, C. V. <i>et al.</i> "X-ray crystal structure of C ₆ H ₃ (CO ₂ H) ₃ -1,3,5-1.5(4,4'-bipy): a 'super trimesic acid' chicken-wire grid" <i>Chem. Commun.</i> , 1996, pp. 2655-2656.	
	R212	KURODA, R. <i>et al.</i> "Generation of a co-crystal phase with coloristic properties <i>via</i> solid state grinding procedures" <i>Chem. Commun.</i> , 2002, pp. 2848-2849.	
	R213	LEISEROWITZ, L. <i>et al.</i> "The molecular packing modes and hydrogen-bonding properties of amide: dicarboxylic acid complexes" <i>Acta Cryst.</i> , 1977, pp. 2719-2733, Vol. B33.	
	R214	LEISEROWITZ, L. "Molecular packing modes. Carboxylic acids" <i>Acta Cryst.</i> , 1976, pp. 775-802, Vol. B32.	
	R215	LYNCH, D. <i>et al.</i> "Molecular cocrystals of carboxylic acids. XXXI* adducts of 2-aminopyrimidine and 3-amino-1,2,4-triazole with heterocyclic carboxylic acids" <i>Aust. J. Chem.</i> , 1998, pp. 403-408, Vol. 51.	
	R216	MACGILLIVRAY, L. <i>et al.</i> "Supramolecular control of reactivity in the solid state using linear molecular templates" <i>J. Am. Chem. Soc.</i> , 2000, pp. 7817-7818, Vol. 122.	
	R217	MATHIAS, J. <i>et al.</i> "Structural preferences of hydrogen-bonded networks in organic solution- the cyclic CA ₃ * M ₃ 'rosette'" <i>J. Am. Chem. Soc.</i> , 1994, pp. 4316-4325, Vol. 116.	
	R218	MASTROPAOLO, D. <i>et al.</i> "Hydrogen bonding interaction of diphenylhydantoin and 9-ethyladenine" <i>Molecular Pharmacology</i> , 1983, pp. 273-277, Vol. 23.	
	R219	MARYANOFF, B. "Stereochemistry in a medium-sized ring. Highly diastereoselective N-oxidation of a substituted 3-benzazonine. X-ray crystal structure of an unusual complex between an amine N-oxide and saccharin" <i>J. Org. Chem.</i> , 1990, pp. 760-764, Vol. 55.	
	R220	MARTIN, R. <i>et al.</i> "The caffeine-potassium chlorogenate molecular complex" <i>Phytochemistry</i> , 1987, pp. 273-279, Vol. 26, No. 1.	
	R221	ANDERSON, J. "Constitution of aurous compounds: Gold mirrors" <i>Nature</i> , October 2, 1937, pp. 583-584, Letters to the Editor.	
Examiner Signature	/Renee Clayton/		Date Considered 11/16/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/660,202
		Filing Date	September 11, 2003
		First Named Inventor	Örn Almarsson
		Group Art Unit	1617
		Examiner Name	Leonard Williams
		Attorney Docket Number	TPI-350C1
Sheet	29	of	36

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R222	ROBBINS, A. H. <i>et al.</i> "The crystal structure of the 1:2 adduct of potassium triiodide and 5,5-diethylbarbituric acid (barbital)" <i>American Crystallographic Association- Series 2, Papers and Abstracts</i> , 1973, p. 87.	
	R223	BEERGES, P. <i>et al.</i> "Phenothiazine tetracyanoethylene" <i>Private Communication</i> , 1994.	
	R224	MADARASZ, J. <i>et al.</i> "Thermal, ftr and xrd study on some 1:1 molecular compounds of theophylline" <i>Journal of Thermal Analysis and Calorimetry</i> , 2002, pp. 281-290, Vol. 69.	
	R225	CARONNA, T. <i>et al.</i> "Halogen bonding and $\pi\cdots\pi$ stacking control reactivity in the solid state" <i>J. Am. Chem. Soc.</i> , 2004, pp. 4500-4501, Vol. 126.	
	R226	ZERKOWSKI, J. <i>et al.</i> "Steric control of secondary, solid-state architecture in 1:1 complexes of melamines and barbiturates that crystallize as crinkled tapes" <i>J. Am. Chem. Soc.</i> , 1994, pp. 4298-4304, Vol. 116.	
	R227	ZAITU, S. <i>et al.</i> "1:1 Molecular complex of theophylline and <i>p</i> -nitroaniline" <i>Acta Cryst.</i> , 1995, pp. 2390-2392, Vol. C51.	
	R228	KOFLER, L. <i>et al.</i> , <i>Thermal micromethods for the study of organic compounds and their mixtures</i> , pp. 1-145, 148-351, 354-386, Innsbruck, Austria, 1980.	
	R229	QUEHENBERGER, H. "Concerning organic molecular compounds and their polymorphism" <i>Monatshefte für Chemie</i> , 1949, pp. 595-606, Vol. 80, No. 5.	X
	R230	WIEDENFELD, H. <i>et al.</i> "The crystal structure of the theophylline-urea complex" <i>Arch. Pharm.</i> , 1986, pp. 654-659, Vol. 319.	X
	R231	BUNICK, G. <i>et al.</i> "The crystal and molecular structure of the complex 2,6-diamino-9-ethylpurine 5,5-diethylbarbituric acid" <i>American Crystallographic Association, Abstract Papers</i> Winter 1976, p. 30.	
	R232	BUZAK, G. <i>et al.</i> "Crystal structure and vibrational spectra of the 1:1 and 1:2 complexes of pyridine betaine with pentachlorophenol" <i>Journal of Molecular Structure</i> , 1997, pp. 143-151, Vol. 436-437.	
Examiner Signature	/Renee Claytor/		Date Considered 11/16/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C1\PTOIDS.form.doc/DNB/gyl

NPC-UNIV-000005822

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 893 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/660,202
		Filing Date	September 11, 2003
		First Named Inventor	Örn Almarsson
		Group Art Unit	1617
		Examiner Name	Leonard Williams
		Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R233	TOMURA, M. <i>et al.</i> "One-dimensional zigzag chain structures with intermolecular C-H... π and C-H...O interactions consisted of phthalic acid and pyridine derivatives" <i>Chemistry Letters</i> , 2001, pp. 532-533.	
	R234	ZERKOWSKI, J. <i>et al.</i> "Design of organic structures in the solid state: molecular tapes based on the network of hydrogen bonds present in the cyanuric acid-melamine complex" <i>J. Am. Chem. Soc.</i> , 1994, pp. 2382-2391, Vol. 116.	
	R235	HARKEMA, S. <i>et al.</i> "The crystal structure of urea oxalic acid (2:1)" <i>Acta Cryst.</i> , 1972, pp. 1646-1648, Vol. B28.	
	R236	KRANTZ, J. <i>et al.</i> "Sodium theophylline glycinate" <i>Journal of the American Pharmaceutical Association</i> , 1946, pp. 248-250.	
	R237	DATTA, S. <i>et al.</i> "Crystal structures of drugs: advances in determination, prediction and engineering" <i>Nature</i> , January 2004, pp. 42-57, Vol. 3.	
	R238	AAKERÖY, C. <i>et al.</i> "Charge-assisted hydrogen bonds and halogen-halogen interactions in organic salts: benzylammonium benzoates and pentafluorobenzoates" <i>Structural Chemistry</i> , 1999, pp. 229-242, Vol. 10, No. 3.	
	R239	CHILDS, S. <i>et al.</i> "Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids" <i>J. Am. Chem. Soc.</i> , 2004, pp. 13335-13342, Vol. 126.	
	R240	AAKERÖY, C. <i>et al.</i> "Modular supramolecular synthesis based on a dominance hierarchy of intermolecular interactions (Abstract)" 223 rd ACS National Meeting in Orlando, FL., April 7-11, 2002, published by the American Chemical Society, Washington, D.C.	
	R241	HELFRICH, B. <i>et al.</i> "Polymorphism as an indication of structural versatility (Abstract)" 223 rd ACS National Meeting in Orlando, FL., April 7-11, 2002, published by the American Chemical Society, Washington, D.C.	
	R242	WEBER, E. <i>et al.</i> "Synthesis of new Schiff bases: reaction of monofluorobenzaldehydes with 3-aminosulfolane hydrochloride (Abstract)" 216 th ACS National Meeting in Boston, MA., August 23-27, 1998, published by the American Chemical Society, Washington, D.C.	

Examiner Signature	/Renee Clayton/	Date Considered	11/16/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C\PTOIDS.form.doc/DNB/gyl

NPC-UNIV-000005823

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 894 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/660,202
		Filing Date	September 11, 2003
		First Named Inventor	Örn Almarsson
		Group Art Unit	1617
		Examiner Name	Leonard Williams
		Attorney Docket Number	TPI-350C1
Sheet	31	of	36

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R243	SCARBROUGH, F. <i>et al.</i> "Crystal structure of a complex between lumiflavin and 2,6-diamino-9-ethylpurine: a flavin adenine dinucleotide model exhibiting charge-transfer interactions" <i>Proc. Natl. Acad. Sci. USA</i> , November 1976, pp. 3807-3811, Vol. 73, No. 11.	
	R244	MUNN, R. <i>et al.</i> "A Model for resonance-assisted hydrogen bonding in crystals and its graph set analysis" <i>J. Phys. Chem. A</i> , 2001, pp. 6938-6942, Vol. 105.	
	R245	LYNCH, D. <i>et al.</i> "1:1 Molecular complexes of 4-amino-N-(4,6-dimethylpyrimidin-2-yl) benzene-sulfonamide (sulfamethazine) with indole-2-carboxylic acid and 2,4-dinitrobenzoic acid" <i>Aust. J. Chem.</i> , 2000, pp. 383-387, Vol. 53.	
	R246	AAKERÖY, C. <i>et al.</i> "Solid state, crystal engineering and hydrogen bonds" <i>Comprehensive Coordination Chemistry II</i> (ed. by McCleverty, J. <i>et al.</i>), pp. 679-688, Elsevier Ltd., Oxford, UK, 2004	
	R247	LEVIN, B. <i>et al.</i> "The not-so-trivial synthesis and characterization of heterocyclic boronic acids (Abstract)" 38 th Midwest Regional Meeting of the American Chemical Society in Columbia, MO., November 5-7, 2003, published by the American Chemical Society, Washington, D.C.	
	R248	SMITH, G. <i>et al.</i> "Interactions of aromatic carboxylic acids with quinolin-8-ol (oxine): Synthesis and the crystal structures of the proton-transfer compounds with the nitro-substituted benzoic acids" <i>Aust. J. Chem.</i> , 2001, pp. 171-175, Vol. 54.	
	R249	STALKER, R. <i>et al.</i> "Asymmetric synthesis of two new conformationally constrained lysine derivatives" <i>Tetrahedron</i> , 2002, pp. 4837-4849, Vol. 58.	
	R250	VOET, D. <i>et al.</i> "Barbiturates and adenine derivatives. Molecular structure of a hydrogen-bonded complex" <i>Journal of the American Chemical Society</i> , August 9, 1972, pp. 5888-5891, Vol. 94, No. 16.	
	R251	VISHWESHWAR, P. <i>et al.</i> "Molecular complexes of homologous alkanedicarboxylic acids with isonicotinamide: X-ray crystal structures, hydrogen bond synthons, and melting point alternation" <i>Crystal Growth & Design</i> , 2003, pp. 783-790, Vol. 3, No. 5.	
	R252	LE JEUNNE, C. <i>et al.</i> "Comparative efficacy and safety of calcium carbasalate plus metoclopramide versus ergotamine tartrate plus caffeine in the treatment of acute migraine attacks" <i>Eur. Neurol.</i> , 1999, pp. 37-43, Vol. 41.	
	R253	AAKERÖY, C. <i>et al.</i> "Hydrogen-bonded layers of hydrogentartrate anions: two-dimensional building blocks for crystal engineering" <i>J. Mater. Chem.</i> , 1993, 1129-1135, Vol. 3, No. 11.	

Examiner Signature	/Renee Claytor/	Date Considered	11/16/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

J:\TPI\350C1\PTOIDS.form.doc\DNB\gyl

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

NPC-UNIV-000005824

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 895 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	32	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R254	HU, Z. <i>et al.</i> "Separation of 4-aminobenzoic acid by cocrystallization: Crystal structure of the complex of 4-aminobenzoic acid with (2R,3R)-tartaric acid" <i>Journal of Chemical Crystallography</i> , December 2002, pp. 525-529, Vol. 32, No. 12.	
	R255	GUARRERA, D. <i>et al.</i> "Molecular self-assembly in the solid state. The combined use of solid state NMR and differential scanning calorimetry for the determination of phase constitution" <i>Chem. Mater.</i> , 1994, pp. 1293-1296, Vol. 6.	
	R256	DOI, M. <i>et al.</i> "Conformational study of a potent human renin inhibitor: x-ray crystal structure of isopropyl (2R, 3S) -4-cyclohexyl-2-hydroxy-3-{N-[(2R)-2-morpholinocarbonylmethyl-3-(1-naphthyl) propionyl] -L-histidylamino}butyrate (KRI-1314), a pentapeptide analogue with amino acid sequence corresponding to the cleavage site of angiotensinogen" <i>J. Chem. Soc. Perkin Trans. 1</i> , 1991, pp. 1153-1158.	
	R257	CRIFIELD, A. <i>et al.</i> "Crystal engineering through halogen bonding. 2. Complexes of diacetylene-linked heterocycles with organic iodides" <i>Crystal Growth & Design</i> , 2003, pp. 313-320, Vol. 3, No. 3.	
	R258	AAKERÖY, C. <i>et al.</i> "A versatile route to porous solids: organic-inorganic hybrid materials assembled through hydrogen bonds" <i>Angew. Chem. Int. Ed.</i> , 1999, pp. 1815-1819, Vol. 38, No. 12.	
	R259	SHEFTER, E. <i>et al.</i> , ACS, Abstr. Papers (Summer), 1970, 35, compound name: sulfathiazole-theophylline complex.	
	R260	SHEFTER, E. <i>et al.</i> , ACS, Abstr. Papers (Summer), 1970, 35, compound name: sulfathiazole-sulfanilamide complex.	
	R261	WIEDENFELD, H. <i>et al.</i> "Solubilization of aminophenazone" <i>Arch. Pharm.</i> , 1982, pp. 633-641, Vol. 315.	x
	R262	CACCIAPUOTI, A. <i>et al.</i> "In vitro and in vivo activities of SCH 56592 (Posaconazole), a new triazole antifungal agent, against <i>Aspergillus</i> and <i>Candida</i> " <i>Antimicrobial Agents and Chemotherapy</i> , August 2000, pp. 2017-2022, Vol. 44, No. 8.	
	R263	CALLAHAN, J.C. <i>et al.</i> "Equilibrium moisture content of pharmaceutical excipients" <i>Drug Development and Industrial Pharmacy</i> , 1982, pp. 355-369, Vol. 8, No. 3.	
	R264	DANNAOUI, E. <i>et al.</i> "Acquired itraconazole resistance in <i>Aspergillus fumigatus</i> " <i>Journal of Antimicrobial Chemotherapy</i> , 2001, pp. 333-340, Vol. 47.	

Examiner Signature	/Renee Claytor/	Date Considered	11/16/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

J:\TPI\350C1\PTO\IDS.form.doc/DNB/gyl

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

NPC-UNIV-000005825

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 896 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/660,202
		Filing Date	September 11, 2003
		First Named Inventor	Örn Almarsson
		Group Art Unit	1617
		Examiner Name	Leonard Williams
		Attorney Docket Number	TPI-350C1
Sheet	33	of	36

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R265	DENNING, D. W. <i>et al.</i> "In vitro activity of Saperconazole (R66 905) compared with Amphotericin B and Itraconazole against <i>Aspergillus</i> species" <i>Eur. J. Clin. Microbial. Infect. Dis.</i> , 1990, pp. 693-697, Vol. 9.	
	R267	DRESSMAN, J. B. <i>et al.</i> "Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms" <i>Pharmaceutical Research</i> , 1998, pp. 11-22, Vol. 15, No. 1.	
	R268	EBERT, W. R. "Soft elastic gelatin capsules: a unique dosage form" <i>Pharmaceutical Technology</i> , October 1977, pp. 44-50, Vol. 1, No. 5.	
	R269	GASCON, M. -P. <i>et al.</i> "In vitro forecasting of drugs which may interfere with the biotransformation of midazolam" <i>Eur. J. Clin. Pharmacol.</i> , 1991, pp. 573-578, Vol. 41.	
	R270	HEERES, J. <i>et al.</i> "Antimycotic azoles. 7. Synthesis and antifungal properties of a series of novel triazol-3-ones" <i>J. Med. Chem.</i> , 1984, pp. 894-900, Vol. 27.	
	R271	HONIG, P. K. <i>et al.</i> "Itraconazole affects single-dose Terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics" <i>J. Clin. Pharmacol.</i> , 1993, pp. 1201-1206, Vol. 33.	
	R272	IMAI, T. <i>et al.</i> "Successful treatment of cerebral Aspergillosis with a high oral dose of Itraconazole after excisional surgery" <i>Internal Medicine</i> , October 1999, pp. 829-832, Vol. 38, No. 10.	
	R273	KOVACS, J. <i>et al.</i> "New type of bridged monoamino-β-cyclodextrins" <i>Journal of Inclusion Phenomena and Molecular Recognition in Chemistry</i> , 1996, pp. 53-56, Vol. 25.	
	R274	LAVRIJSEN, A. P. M. <i>et al.</i> "Hepatic injury associated with itraconazole" <i>The Lancet</i> , July 25, 1992, pp. 251-252, Vol. 340.	
	R275	NEUVONEN, P. J. <i>et al.</i> "Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid" <i>Clinical Pharmacology & Therapeutics</i> , 1996, pp. 54-61, Vol. 60, No. 1.	
	R276	NOMEIR, A. A. <i>et al.</i> "Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys" <i>Antimicrobial Agents and Chemotherapy</i> , March 2000, pp. 727-731, Vol. 44, No. 3.	

Examiner Signature	/Renee Claylor/	Date Considered	11/16/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C1\PTO\IDS.form.doc\DNB\gyI

NPC-UNIV-000005826

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 897 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	34	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R277	ODDS, F. C. "Antifungal activity of saperconazole (R 66 905) <i>in vitro</i> " <i>Journal of Antimicrobial Chemotherapy</i> , 1989, pp. 533-537, Vol. 24.	
	R278	REMENAR, J. F. <i>et al.</i> "Crystal engineering of novel cocrystals of a triazole drug with 1,4-dicarboxylic acids" <i>J. Am. Chem. Soc.</i> , 2003, pp. 8456-8457, Vol. 125.	
	R279	SAKSENA, A. K. <i>et al.</i> "Advances in the chemistry of novel broad-spectrum orally active azole antifungals: recent studies leading to the discovery of SCH 56592" in <i>Advances in the Chemistry of Novel Broad-Spectrum Orally Active Azole Antifungals</i> (Royal Soc. Chem., Cambridge), 1997, pp. 180-199.	
	R280	SAKSENA, A. K. <i>et al.</i> "Concise asymmetric routes to 2,2,4-trisubstituted tetrahydrofurans via chiral titanium imide enolates: key intermediates towards synthesis of highly active azole antifungals SCH 51048 and SCH 56592" <i>Tetrahedron Letters</i> , 1996, pp. 5657-5660, Vol. 37, No. 32.	
	R281	HEPPERLE, M. <i>et al.</i> "Mono <i>N</i> -arylation of piperazine(III): metal-catalyzed <i>N</i> -arylation and its application to the novel preparations of the antifungal posaconazole and its advanced intermediate" <i>Tetrahedron Letters</i> , 2002, pp. 3359-3363, Vol. 43.	
	R282	CUTSEM, J. V. <i>et al.</i> "Oral and parenteral therapy with saperconazole (R 66905) of invasive aspergillosis in normal and immunocompromised animals" <i>Antimicrobial Agents and Chemotherapy</i> , December 1989, pp. 2063-2068, Vol. 33, No. 12.	
	R283	VILLA, L. A. <i>et al.</i> "Central nervous system paracoccidioidomycosis. Report of a case successfully treated with itraconazol" <i>Rev. Inst. Med. Trop. S. Paulo</i> , July-August, 2000, pp. 231-234, Vol. 42, No. 4.	
	R284	WEST, A. R., "Solid Solutions" In: <i>Solid State Chemistry and its Applications</i> , 1988, p. 358, p. 365, Wiley, NY.	
	R285	ARONHIME, J. <i>et al.</i> "Crystalline forms of pharmaceuticals and characterization thereof", Oral Presentation, March 8, 2005, USPTO, Alexandria, VA.	
	R286	DESIRAJU, G. R. "Chemistry beyond the molecule" <i>Nature</i> , July 26, 2001, pp. 397-400, Vol. 412.	
	R287	GAVEZZOTTI, A. "Are crystal structures predictable?" <i>Acc. Chem. Res.</i> , 1994, pp. 309-314, Vol. 27.	

Examiner Signature	/Renee Clayton/	Date Considered	11/16/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C1\PTOIDS.form.doc\DNB\gyl

NPC-UNIV-000005827

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 898 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/660,202
		Filing Date	September 11, 2003
		First Named Inventor	Örn Almarsson
		Group Art Unit	1617
		Examiner Name	Leonard Williams
		Attorney Docket Number	TPI-350C1
Sheet	35	of	36

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R288	Physician's Desk Reference, 56 th Ed., pp. 1800-1804, 2002.	
	R289	KIM, H. <i>et al.</i> "High-performance liquid chromatographic analysis of the anti-fungal agent SCH 56592 in dog serum" <i>Journal of Chromatography B</i> , 2000, pp. 93-98, Vol. 738.	
	R290	VIPPAGUNTA, S. R. <i>et al.</i> "Crystalline solids" <i>Advanced Drug Delivery Reviews</i> , 2001, pp. 3-26, Vol. 48.	
	R291	MCCRONE, W. C. "Polymorphism", In: <i>The Physics and Chemistry of the Organic Solid State</i> , Vol. II, FOX, D. <i>et al.</i> (eds.), 1965, pp. 725-767, Interscience, New York.	
	R292	LEGER, J.M. <i>et al.</i> "Crystal Structure of the 1:1 Sulfacetamide-Caffeine Complex" <i>Acta Cryst.</i> , 1977, pp. 1455-1459, Vol. B33.	X
	R293	SIMONOV, Y. <i>et al.</i> "Structure of the caffeine-copper(II) acetate additional compound", <i>Izvestiya Akademii Nauk Moldavskoi SSR, Seriya Fiziko-Tekhnicheskikh i Matematicheskikh Nauk</i> , 1972, Vol. 3, pp. 83-84, abstract only.	
	R294	WEISSBUCH, I. <i>et al.</i> "Understanding and control of nucleation, growth, habit, dissolution and structure of two- and three-dimensional crystals using 'tailor-made' auxiliaries" <i>Acta Cryst.</i> , 1995, B51:115-148.	
	R295	FAUGHT, E. <i>et al.</i> "Topiramate Dose-Ranging Trial in Refractory Partial Epilepsy", <i>Amer. Epilepsy Soc. Proc.</i> , (1995), pg. 33, Vol. 36, Supp. 4.	
	R296	PRIVITERA, M. <i>et al.</i> "Dose-Ranging Trial with Higher Doses of Topiramate in Patients with Resistant Partial Seizures", <i>Amer. Epilepsy Soc. Proc.</i> , 1995, pg. 33, Vol. 36, Supp. 4.	
	R297	SACHDEO, S. K. <i>et al.</i> "Topiramate: Double-Blind Trial as Monotherapy", <i>Amer. Epilepsy Soc. Proc.</i> , 1995, pg. 33, Vol. 36, Supp. 4.	
	R298	Press Release. "Clinical Development of Topiramate for Obesity Extended to Simplify Dosing, Improve Tolerability". http://www.orthomcneil.com/news/article020402.html (February 4, 2002), N.J.	X

Examiner Signature	/Renee Claytor/	Date Considered	11/16/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	36	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R299	ROSENFELD, W. E. "Topiramate: A Review of Preclinical, Pharmacokinetic, and Clinical Data", <i>Clinical Therapeutics</i> , 1997, pp. 1294-1308, Vol. 19, No. 6.	
	R300	Physician's Desk Reference, 56 th Edition, 2002, pp. 2590-2595.	
	R301	DATABASE WPI, Section Ch, Week 197936, Derwent Publishing Ltd., London, Great Britain, Class B02, AN 1979-65538B, XP002282989 and JP 54 095589A (Sumitomo) 1979 Abstract.	
	R302	FUNG <i>et al.</i> , "Solvent Effects on Comparative Dissolution of Pharmaceutical Solvates," <i>Chem. Farm. Bull.</i> , 22(2), pgs. 454-458 (1974).	
	R303	RUBINO <i>et al.</i> , "Influence of Solvent Composition on the Solubilities and Solid-State Properties of the Sodium Salts of Some Drugs", <i>Int. J. of Pharma</i> , 65, pgs. 141-145 (1990).	
	R304	FITZGERALD, G. A. "The Coxibs, Selective Inhibitors of Cyclooxygenase-2", <i>New England Journal of Medicine</i> , Vol. 345, No. 6, August 9, 2001.	
	R305		
	R306		
	R307		
	R308		
	R309		

Examiner Signature	/Renee Claytor/	Date Considered	11/16/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/



UNITED STATES DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
10660202	9/11/2003	ALMARSSON ET AL.	TPI.350C1

SALIWANCHIK LLOYD & SALIWANCHIK
A PROFESSIONAL ASSOCIATION
PO Box 142950
GAINESVILLE, FL 32614

EXAMINER

Renee Claytor

ART UNIT	PAPER
1627	20100125

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

This is in response to the Printer Query requesting the IDS of 11/19/09. It is attached herein.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/660,202
				Filing Date	September 11, 2003
				First Named Inventor	Örn Almarsson
				Art Unit	1617
				Examiner Name	Deirdre R. Claytor
Sheet	1	of	2	Attorney Docket Number	TPI.350C1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-			
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F1	JP-B 46-33588	10-01-1971	Sanzu Inc.	All	
	F2					
	F3					
	F4					
	F5					
	F6					

Examiner Signature	/Renee Claytor/	Date Considered	01/25/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		<i>Complete if Known</i>			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Deirdre R. Claytor		
Sheet	2	of	2	Attorney Docket Number	TPI.350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	WUNDERLICH, H. F. <i>et al.</i> "The Derivatives of carbamazepine with ammonium halogenides and formamide" <i>Pharmazie</i> , 1991, pp. 507-509, Vol. 46, No. 7. Not in English	
	R2	EL-NAHHAS, S. A. "Physico-chemical characteristics of carbamazepine-β-cyclodextrin inclusion compounds and carbamazepine-PEG solid dispersions" <i>Pharmazie</i> , 1996, pp. 960-963, Vol. 51, No. 12.	
	R3	REYNOLDS, J. E. F. (ed). Martindale, The Extra Pharmacopoeia, 1993, The Pharmaceutical Press, London, England, 13 th edition, p. 1610.	
	R4	PEDIREDDI, V. R. <i>et al.</i> "Layered Structures Formed by Dinitrobenzoic Acids" <i>Tetrahedron Letters</i> , 1998, pp. 9831-9834, Vol. 39.	
	R5	ZAMAN, M. B. <i>et al.</i> "Crystal Engineering Using Anilic Acids and Dipyrldyl Compounds through a New Supramolecular Synthon" <i>J. Org. Chem.</i> , 2001, pp. 5987-5995, Vol. 66,.	
	R6	Japanese Notice of Reasons for Rejection dated October 8, 2009, Japanese Application No. 2003-572946.	x
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		

Examiner Signature	/Renee Claytor/	Date Considered	01/25/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C1\IDS\IDS-form-sup-5.doc/DNB/jb



UNITED STATES DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
10660202	9/11/2003	ALMARSSON ET AL.	TPI.350C1

SALIWANCHIK LLOYD & SALIWANCHIK
A PROFESSIONAL ASSOCIATION
PO Box 142950
GAINESVILLE, FL 32614

EXAMINER

Renee Claytor

ART UNIT	PAPER
1627	20100204

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

Please find enclosed the Printer Rush response.

/Renee Claytor/
Art Unit 1628

PTO-90C (Rev.04-03)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Request for Continued Examination (RCE) Transmittal	
Address to: Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Application Number
	Filing Date
	First Named Inventor
	Art Unit
	Examiner Name
	Attorney Docket Number


This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.

Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. **Submission required under 37 CFR 1.114** Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).
- a. ☐ Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.
- i. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____
- ii. ☐ Other _____
- b. ☒ Enclosed
- i. ☒ Amendment/Reply
- ii. ☐ Affidavit(s)/ Declaration(s)
- iii. ☒ Information Disclosure Statement (IDS)
- iv. ☐ Other _____
2. **Miscellaneous**
- a. ☐ Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)
- b. ☐ Other _____
3. **Fees** The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.
- a. ☐ The Director is hereby authorized to charge the following fees, any underpayment of fees, or credit any overpayments, to Deposit Account No. _____. I have enclosed a duplicate copy of this sheet.
- i. ☒ RCE fee required under 37 CFR 1.17(e) \$810 based on large entity status
- ii. ☐ Extension of time fee (37 CFR 1.136 and 1.17)
- iii. ☐ Other _____
- b. ☐ Check in the amount of \$ _____ enclosed
- c. ☒ Payment by credit card (Form PTO-2038 enclosed)

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.


SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED			
Signature		Date	March 12, 2010
Name (Print/Type)	FRANK C. EISENSCHENK, PH.D.	Registration No.	45,332

CERTIFICATE OF MAILING OR TRANSMISSION			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.			
Signature		Date	March 12, 2010
Name (Print/Type)	FRANK C. EISENSCHENK, PH.D.		

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on March 12, 2010.


Frank C. Eisenschenk, Ph.D., Patent Attorney

AMENDMENT UNDER 37 C.F.R. § 1.114
Patent Application
Docket No. TPI.350C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Deirdre Renee Claytor
Art Unit : 1617
Applicants : Örn Almarsson, Magali Bourghol Hickey, Matthew L. Peterson, Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo
Serial No. : 10/660,202
Filed : September 11, 2003
Conf. No. : 6536
For : Pharmaceutical Co-Crystal Compositions

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

AMENDMENT UNDER 37 C.F.R. § 1.114

Sir:

Please amend the above-identified patent application as follows:

J:\TPI\350C1\Amend-Resp\Amd-RCE-2.doc\DNB/sl

In the Specification

This application claims the benefit of US Provisional Patent Application No. 60/451,213 filed on February 28, 2003; U.S. Provisional Patent Application No. 60/463,962, filed on April 18, 2003; and U.S. Provisional Application No. 60/487,064, filed on July 11, 2003 each of which incorporated herein by reference in its entirety. This application is also a continuation-in-part of PCT/US03/27772, filed on September 4, 2003 which is a continuation-in-part of U.S. Patent Application No. 10/378,956, filed ~~March 4~~ March 3, 2003, which claims the benefit of U.S. Provisional Application No. 60/360,768, filed March 1, 2002; said PCT/US03/27772 also claims the benefit of US Provisional Patent Application No. 60/451,213 filed on February 28, 2003; U.S. Provisional Patent Application No. 60/463,962, filed on April 18, 2003; and U.S. Provisional Application No. 60/487,064, filed on July 11, 2003. ~~This application is also a continuation-in-part of U.S. Patent Application No. 10/637,829, filed August 8, 2003, which is a divisional of U.S. Patent Application No. 10/295,995, filed November 18, 2002, which is a continuation of U.S. Patent Application No. 10/232,589, filed September 3, 2002, which claims the benefit of US Provisional Patent Application No. 60/406,974, filed August 30, 2002 and US Provisional Patent Application No. 60/380,288, filed May 15, 2002 and US Provisional Patent Application No. 60/356,764, filed February 15, 2002. This application is also a continuation-in-part of US Patent Application No. 10/449,307, filed May 30, 2003 which claims the benefit of US Provisional Patent Application No. 60/463,962 filed April 18, 2003 and US Provisional Patent Application No. 60/444,315, filed January 31, 2003 and US Provisional Patent Application No. 60/439,282 filed January 10, 2003 and US Provisional Patent Application No. 60/384,152, filed May 31, 2002. This application is also a continuation-in-part of US Patent Application No. 10/601,092, filed June 20, 2003, which claims the benefit of US Provisional Patent Application No. 60/451,213, filed February 28, 2003. Each of these applications is hereby incorporated by reference in their entireties, including all figures, tables and formulae.~~

Remarks

Claims 43-78 are pending in the subject application and currently before the Examiner. By this Amendment, Applicants have amended the Cross-Reference to Related Applications section and provided a Supplemental Application Data Sheet. Entry and consideration of the amendment presented herein is respectfully requested by way of an updated Filing Receipt. Favorable consideration of the pending claims is respectfully requested.


It should be understood that the amendments presented herein have been made solely to expedite prosecution of the subject application to completion and should not be construed as an indication of Applicants' agreement with or acquiescence in the Examiner's position. Applicants expressly reserve the right to pursue the invention(s) disclosed in the subject application, including any subject matter canceled or not pursued during prosecution of the subject application, in a related application.

In view of the foregoing remarks, Applicants believe that the currently pending claims are in condition for allowance, and such action is respectfully requested.

The Commissioner is hereby authorized to charge any fees under 37 CFR §§1.16 or 1.17 as required by this paper to Deposit Account No. 19-0065.

Applicants invite the Examiner to call the undersigned if clarification is needed on any of this response, or if the Examiner believes a telephonic interview would expedite the prosecution of the subject application to completion.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800


Address: P.O. Box 142950
Gainesville, FL 32614-2950

FCE/sl

Attachment: Supplemental Application Data Sheet

J:\TPI\350C1\Amend-Resp\Amd-RCE-2.doc/sl

I hereby certify that this correspondence is being
facsimile transmitted to the United States Patent
and Trademark Office on March 12, 2010.


Frank C. Eisenschenk, Ph.D., Patent Attorney

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
Patent Application
Docket No. TPI.350C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Deirdre R. Claytor
Art Unit : 1627
Applicants : Örn Almarsson, Magali Bourghol Hickey, Matthew L. Peterson, Michael J.
Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo
Serial No. : 10/660,202
Filed : September 11, 2003
Conf. No. : 6536
For : Pharmaceutical Co-Crystal Compositions

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 AND 1.98

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed. However, Applicants have not submitted copies of the U.S. patents or published U.S. Patent Applications cited on attached Form PTO/SB/08 pursuant to 37 CFR 1.98(a)(2)(ii).

Applicants note that Japan Publication No. 54-095589, cited as F7 on the attached form PTO/SB/08, was written in a foreign language. However, an English language abstract is provided in the reference. Applicants respectfully request that the reference be made of record and considered in the examination of the subject application.


JATPI350C1NDS1DS.sup6.doc/DNB/jb

Applicants note that French Application No. 2,849,029 and cited as F8 on the attached form PTO/SB/08, is written in a foreign language. However, an English language abstract is provided in the reference. In addition, the U.S. Patent, listed as Cite No. U63 on the attached form PTO/SB/08, appears to correspond to FR 2,849,029 as the English language equivalent. Applicants respectfully request that the references be made of record and considered in the examination of the subject application.

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

Applicants respectfully assert that the substantive provisions of 37 C.F.R. §§ 1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950
Gainesville, FL 32614-2950

FCE/jb

Attachments: Form PTO/SB/08; copies of references cited therein.

Substitute for form 1449A/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Application Number	10/660,202
			Filing Date	September 11, 2003
			First Named Inventor	Örn Almarsson
			Art Unit	1617
			Examiner Name	Deirdre R. Claytor
			Attorney Docket Number	TPI.350C1
Sheet	1	of	6	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	U1	US-2,665,277	01-05-1954	Homeyer <i>et al.</i>	All
	U2	US-3,970,651	07-20-1976	Kaplan <i>et al.</i>	All
	U3	US-4,925,674	05-15-1990	Giannini <i>et al.</i>	All
	U4	US-4,927,855	05-22-1990	Lafon	All
	U5	US-4,994,604	02-19-1991	Tung <i>et al.</i>	All
	U6	US-5,023,092	06-11-1991	DuRoss	All
	U7	US-5,521,207	05-28-1996	Graneto	All
	U8	US-5,273,760	12-28-1993	Oshlack <i>et al.</i>	All
	U9	US-5,286,493	02-15-1994	Oshlack <i>et al.</i>	All
	U10	US-5,324,351	06-28-1994	Oshlack <i>et al.</i>	All
	U11	US-5,356,467	10-18-1994	Oshlack <i>et al.</i>	All
	U12	US-5,366,738	11-22-1994	Rork <i>et al.</i>	All
	U13	US-5,472,712	12-05-1995	Oshlack <i>et al.</i>	All
	U14	US-5,510,496	04-23-1996	Talley <i>et al.</i>	All
	U15	US-5,563,165	10-08-1996	Talley <i>et al.</i>	All
	U16	US-5,631,250	05-20-1997	Bunnell <i>et al.</i>	All
	U17	US-5,633,272	05-27-1997	Talley <i>et al.</i>	All
	U18	US-5,703,232	12-30-1997	Bunnell <i>et al.</i>	All
	U19	US-5,736,541	04-07-1998	Bunnell <i>et al.</i>	All
	U20	US-5,753,688	05-19-1998	Talley <i>et al.</i>	All
	U21	US-5,760,068	06-02-1998	Talley <i>et al.</i>	All
	U22	US-5,932,598	08-03-1999	Talley <i>et al.</i>	All

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

JATPR350C1MDS\DS-form-supp-6.doc/DNB/jb

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/660,202	
			Filing Date	September 11, 2003	
			First Named Inventor	Örn Almarsson	
			Art Unit	1617	
			Examiner Name	Deirdre R. Claytor	
Sheet	2	of	6	Attorney Docket Number	TPI.350C1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U23	US-5,972,986	10-26-1999	Seibert <i>et al.</i>	All
	U24	US-5,985,902	11-16-1999	Talley <i>et al.</i>	All
	U25	US-6,054,136	04-25-2000	Farah <i>et al.</i>	All
	U26	US-6,132,420	10-17-2000	Dionne <i>et al.</i>	All
	U27	US-6,156,781	12-05-2000	Talley <i>et al.</i>	All
	U28	US-6,245,357	06-12-2001	Edgren <i>et al.</i>	All
	U29	US-6,270,787	08-07-2001	Ayer	All
	U30	US-6,283,953	09-04-2001	Ayer <i>et al.</i>	All
	U31	US-6,287,295	09-11-2001	Chen <i>et al.</i>	All
	U32	US-6,323,266	11-27-2001	Phillips	All
	U33	US-6,333,050	12-25-2001	Wong <i>et al.</i>	All
	U34	US-6,342,249	01-29-2002	Wong <i>et al.</i>	All
	U35	US-6,348,458	02-19-2002	Hamied <i>et al.</i>	All
	U36	US-6,365,185	04-02-2002	Ritschel <i>et al.</i>	All
	U37	US-6,368,626	04-09-2002	Bhatt <i>et al.</i>	All
	U38	US-6,375,978	04-23-2002	Kleiner <i>et al.</i>	All
	U39	US-6,384,034	05-07-2002	Simitchieva <i>et al.</i>	All
	U40	US-6,403,640	06-11-2002	Stoner <i>et al.</i>	All
	U41	US-6,413,965	07-02-2002	Mylari	All
	U42	US-6,420,394	07-16-2002	Supersaxo	All
	U43	US-6,579,895	06-17-2003	Karim <i>et al.</i>	All
	U44	US-6,613,790	09-02-2003	Carter	All

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

J:\TPI\350C1\IDS\IDS-form-supp-6.doc/DNB/jb

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/660,202
				Filing Date	September 11, 2003
				First Named Inventor	Örn Almarsson
				Art Unit	1617
				Examiner Name	Deirdre R. Claytor
Sheet	3	of	6	Attorney Docket Number	TPI.350C1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U45	US-7,172,769	02-06-2007	Kararli <i>et al.</i>	All
	U46	US-7,205,413	04-17-2007	Morissette <i>et al.</i>	All
	U47	US-7,446,107	11-04-2008	Remenar <i>et al.</i>	All
	U48	US-7,452,555	11-18-2008	Childs	All
	U49	US-7,459,449	12-02-2008	Keltjens	All
	U50	US-2002/0013357	01-31-2002	Nadkarni <i>et al.</i>	All
	U51	US-2002/0006951	01-17-2002	Hageman <i>et al.</i>	All
	U52	US-2002/0015735	02-07-2002	Hedden <i>et al.</i>	All
	U53	US-2002/0034542	03-21-2002	Thombre <i>et al.</i>	All
	U54	US-2002/0071857	06-13-2002	Kararli <i>et al.</i>	All
	U55	US-2002/0107250	08-08-2002	Hariharan <i>et al.</i>	All
	U56	US-2002/0119193	08-29-2002	Le <i>et al.</i>	All
	U57	US-2004/0029946	02-12-2004	Arora <i>et al.</i>	All
	U58	US-2004/0154890	08-12-2004	Liu	All
	U59	US-2004/0242640	12-02-2004	Desai <i>et al.</i>	All
	U60	US-2005/0070551	03-31-2005	Remenar <i>et al.</i>	All
	U61	US-2007/0015841	01-18-2007	Tawa <i>et al.</i>	All
	U62	US-2007/0293674	12-20-2007	Scoppettuolo <i>et al.</i>	All
	U63	US-7,132,570	11-07-2006	Neckebroek <i>et al.</i>	All
	U64	US-			
	U65	US-			
	U66	US-			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known Application Number: 10/660,202 Filing Date: September 11, 2003 First Named Inventor: Örn Almarsson Group Art Unit: 1617 Examiner Name: Deirdre R. Claytor Attorney Docket Number: TPI.350C1		
Sheet	4	of	6		

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F1	WO 01/45706	06-28-2001	Pharmacia Corporation	All	
	F2	WO 2002/102376	12-27-2002	Pharmacia Corporation	All	
	F3	WO 2002/10125	02-07-2002	Teva Pharmaceutical Industries Ltd.	All	
	F4	WO 2002/056915	07-25-2002	Cephalon, Inc.	All	
	F5	WO 2005/053612	06-16-2005	Shire Laboratories, Inc.	All	
	F6	WO 96/33193	10-24-1996	Janssen Pharmaceutica N.V.	All	
	F7	JP 54-095589	07-28-1979	Sumitomo Chemical Co. Ltd.	All	
	F8	FR 2,849,029	06-25-2004	Laboratoire L. Lafon	All	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	BALL, P. "Scandal of crystal design..." <i>Nature</i> , June 20, 1996, pp. 648-650, Vol. 381.	
	R2	BASTIN, R. J. <i>et al.</i> "Salt Selection and Optimization Procedures for Pharmaceutical New Chemical Entities" <i>Organic Process Research & Development</i> , 2000, pp. 427-435, Vol. 4, No. 5.	
	R3	BERNSTEIN, J. <i>et al.</i> "Concomitant Polymorphs" <i>Angew. Chem. Int. Ed.</i> , 1999, pp. 3440-3461, Vol. 38.	
	R4	BOUCHER, E. <i>et al.</i> "Use of Hydrogen Bonds to Control Molecular Aggregation. Behavior of Dipyridones and Pyridone-Pyrimidones Designed to Form Cyclic Triplexes" <i>J. Org. Chem.</i> , 1995, pp. 1408-1412, Vol. 60.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

JATPI350C1MDSMDS-form-supp-6.doc/DNB/jb

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		<i>Complete if Known</i>	
		Application Number	10/660,202
		Filing Date	September 11, 2003
		First Named Inventor	Örn Almarsson
		Group Art Unit	1627
		Examiner Name	Deirdre R. Claytor
Sheet	5	of	6
		Attorney Docket Number	TPI 350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R5	BRITTAİN, H. G., <u>Polymorphism in Pharmaceutical Solids</u> , Marcel Dekker, Inc., 1999, pp. 183, 202-208 and 219.	
	R6	CHANG, Y. <i>et al.</i> "An Approach to the Design of Molecular Solids. Strategies for Controlling the Assembly of Molecules into Two-Dimensional Layered Structures" <i>J. Am. Chem. Soc.</i> , 1993, pp. 5991-6000, Vol. 115.	
	R7	COWAN, J. A. <i>et al.</i> "Neutron diffraction studies of the 1:1 and 2:1 cocrystals of benzene-1,2,4,5-tetracarboxylic acid and 4,4'-bipyridine" <i>Acta Cryst.</i> , 2006, pp. o157-o161, Vol. C62.	
	R8	DAVIDOVICH, M. <i>et al.</i> "Detection of Polymorphism by Powder X-Ray Diffraction: Interference by Preferred Orientation" <i>American Pharmaceutical Review</i> , 2004, pp. 10, 12, 14, 16, and 100, Vol. 7, Issue 1.	
	R9	DAVIES, N. M. <i>et al.</i> "Clinical Pharmacokinetics and Pharmacodynamics of Celecoxib. A Selective Cyclo-Oxygenase-2 Inhibitor" <i>Clin. Pharmacokinet.</i> , March 2000, pp. 225-242, Vol. 38, No. 3.	
	R10	DEAN, J A., <u>Analytical Chemistry Handbook</u> , McGraw-Hill, Inc., 1995, pp. 10.24-10.26.	
	R11	Definition of solvate, The Free Dictionary, http://www.thefreedictionary.com/solvate , accessed online on 21 July 2009, pp. 1-3.	
	R12	DESIRAJU, G.R. "Solid-State Chemistry: Crystal Gazing: Structure Prediction and Polymorphism" <i>Science</i> , October 17, 1997, pp. 404-405, Vol. 278, No. 5337.	
	R13	DOELKER, E. "Physicochemical behavior of active substances. Consequences for the feasibility and stability of pharmaceutical forms" <i>STP Pharma Pratiques</i> , 1999, pp. 399-409, Vol. 9, No.5.	
	R14	DOELKER, E. "Cystalline modifications and polymorphism changes during drug manufacturing" <i>Annales Pharmaceutiques Francaises</i> , 2002, pp. 161-176, Vol. 60, No. 3.	
	R15	DUNITZ, J. D. "Are crystal structures predictable?" <i>Chem Commun.</i> , 2003, pp. 545-548.	
	R16	FEYNMAN, R. P. "There's Plenty of Room at the Bottom" <i>Engineering and Science</i> , February 1960, pp. 22-36.	
	R17	JAIN, N. K. <i>et al.</i> "Polymorphism in Pharmacy" <i>Indian Drugs</i> , 1986, pp. 315-329, Vol. 23, No. 6.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

JATPI350C1NDSIDS-form-supp-6.doc/DNB/jb

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/660,202	
			Filing Date	September 11, 2003	
			First Named Inventor	Örn Almarsson	
			Group Art Unit	1617	
			Examiner Name	Deirdre R. Claytor	
Sheet	6	of	6	Attorney Docket Number	TPI 350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R18	KIRCHNER, M. T. <i>et al.</i> Co-crystals with Acetylene: Small is not Simple!" <i>Chem. Eur. J.</i> , 2010, pp. 2131-2146, Vol. 16.	
	R19	MOULTON, B. <i>et al.</i> "From Molecules to Crystal Engineering: Supramolecular Isomerism and Polymorphism in Network Solids" <i>Chem. Rev.</i> , 2001, pp. 1629-1658, Vol. 101.	
	R20	MUZAFFAR, N. A. <i>et al.</i> "Polymorphism and Drug Availability" <i>Journal of Pharmacy</i> , 1979, pp. 59-66, Vol. 1, No. 1.	
	R21	OSORIO-LOZADA, A. <i>et al.</i> "Synthesis and determination of the absolute stereochemistry of the enantiomers of adrafinil and modafinil" <i>Tetrahedron: Asymmetry</i> , 2004, pp. 3811-3815, Vol. 15.	
	R22	OTSUKA, M. <i>et al.</i> "Effect of Polymorphic Forms of Bulk Powders on Pharmaceutical Properties of Carbamazepine Granules" <i>Chem. Pharm. Bull.</i> , 1999, pp. 852-856, Vol. 47, No. 6.	
	R23	SHATTOCK, T. R. <i>et al.</i> "Hierarchy of Supramolecular Synthons: Persistent Carboxylic Acid...Pyridine Hydrogen Bonds in Cocrystals That also Contain a Hydroxyl Moiety" <i>Cryst. Growth Des.</i> , 2008, pp. 4533-4545, Vol. 8, No. 12.	
	R24	THAYER, A. M. "Form and Function: The choice of pharmaceutical crystalline form can be used to optimize drug properties, and cocrystals are emerging as new alternatives" <i>Chemical & Engineering News</i> , June 18, 2007, pp. 17-30, Vol. 85, No. 25.	
	R25	U.S. Pharmacopodia #23, 1995, p. 1843.	
	R26	VILLA, L. A. <i>et al.</i> "Central Nervous System Paracoccidioidomycosis. Report of a Case Successfully Treated with Itraconazol" <i>Rev. Inst. Med. Trop. S. Paulo</i> , July-August 2000, pp. 231-234, Vol. 42, No. 4.	
	R27	ZAWOROTKO, M. J. "Crystal Engineering of Diamondoid Networks" <i>Chemical Society Reviews</i> , 1994, pp. 283-288, Vol. 23.	
	R28	KLEIN, C. L. <i>et al.</i> "Molecular Structure of Two Conformationally Restrained Fentanyl Analogues: cis- and trans-Isomers of N-{3-Methyl-1-[2-(1,2,3,4-tetrahydro)naphthyl]-4-piperidinyl}-N-phenylpropanamide" <i>Journal of Pharmaceutical Sciences</i> , November 1985, pp. 1147-1151, Vol. 74, No. 11.	
	R29		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Electronic Patent Application Fee Transmittal				
Application Number:		10660202		
Filing Date:		11-Sep-2003		
Title of Invention:		PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS		
First Named Inventor/Applicant Name:		Orn Almarsson		
Filer:		Frank Christopher Eisenschenk/Jenny Bedner		
Attorney Docket Number:		TPI.350C1		
Filed as Large Entity				
Utility under 35 USC 111(a) Filing Fees				
Description		Fee Code	Quantity	Sub-Total in USD(\$)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Extension-of-Time:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Miscellaneous:				
Request for continued examination	1801	1	810	810
Total in USD (\$)				810

Electronic Acknowledgement Receipt	
EFS ID:	7195892
Application Number:	10660202
International Application Number:	
Confirmation Number:	6536
Title of Invention:	PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS
First Named Inventor/Applicant Name:	Orn Almarsson
Customer Number:	23557
Filer:	Frank Christopher Eisenschenk/Jenny Bedner
Filer Authorized By:	Frank Christopher Eisenschenk
Attorney Docket Number:	TPI.350C1
Receipt Date:	12-MAR-2010
Filing Date:	11-SEP-2003
Time Stamp:	10:27:06
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Credit Card
Payment was successfully received in RAM	\$810
RAM confirmation Number	9731
Deposit Account	190065
Authorized User	EISENSCHENK,FRANK C.
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows: Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees) Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)	

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)					
Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)					
Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)					
File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Application Data Sheet	ADS-supp-3.pdf	346095 1c5cdd512900ccc8526d80283a49770004bdac47	no	7
Warnings:					
Information:					
This is not an USPTO supplied ADS fillable form					
2	Request for Continued Examination (RCE)	RCE-2-filed.pdf	187754 becb6e090a7cda9fd269f1596cb03eedbcedcfbb	no	1
Warnings:					
This is not a USPTO supplied RCE SB30 form.					
Information:					
3		Amd-RCE-2.pdf	261292 d7b1fc87565f057daa4e01d539ce64c4f926e881	yes	3
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Amendment Submitted/Entered with Filing of CPA/RCE		1	1	
	Specification		2	2	
	Applicant Arguments/Remarks Made in an Amendment		3	3	
Warnings:					
Information:					
4		IDS-supp6.pdf	1365295 e1e75bb402b5e7531a0945b44c57d0f9ebd3ae6	yes	8
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Transmittal Letter		1	2	
	Information Disclosure Statement (IDS) Filed (SB/08)		3	8	
Warnings:					
Information:					

5	Foreign Reference	WO01-45706.pdf	3356250	no	66
			07d33f373b7b7acd3fd3fe07273ac7767b088b3a		
Warnings:					
Information:					
6	Foreign Reference	WO02102376.pdf	3360090	no	65
			3c13c40d90f23e515029c22fb14beb3d509a075		
Warnings:					
Information:					
7	Foreign Reference	WO02010125.pdf	1488036	no	35
			44cc4561d6cd268be1cb60563d7ba82510b1c0ee		
Warnings:					
Information:					
8	Foreign Reference	WO02056915.pdf	1178158	no	25
			3002d8c361563cb3eb26c429c204b413bdf3283ba		
Warnings:					
Information:					
9	Foreign Reference	WO05053612.pdf	1474912	no	38
			addb68cbe8045c9d545d8a0b3fff294316f528a		
Warnings:					
Information:					
10	Foreign Reference	WO96033193.pdf	998489	no	23
			a20b221937233ac198a8da9d8966b3d1bb29406e		
Warnings:					
Information:					
11	Foreign Reference	JP54095589.pdf	242796	no	5
			5c86a7aa085e64aa88223d1283682d71b2936521		
Warnings:					
Information:					
12	Foreign Reference	FR2849029.pdf	3394992	no	86
			6c743ea4839a5ae5236b34d1839b1d19c7828c9d		
Warnings:					
Information:					
13	NPL Documents	BALL.pdf	567053	no	3
			b33fe03b4f60311d1bfe88754cab0f2ae26ebd12		
Warnings:					
Information:					

14	NPL Documents	BERNSTEIN.pdf	1719530	no	22
			e247e6cd3b8c5f84f416a3a8b168d336425508		
Warnings:					
Information:					
15	NPL Documents	BOUCHER.pdf	584752	no	5
			517c02a9ac0166248710193e07694266f42a0e8b		
Warnings:					
Information:					
16	NPL Documents	Brittain.pdf	1001878	no	11
			f8779de073146dbede4ee4a5a00eee3aec70d123		
Warnings:					
Information:					
17	NPL Documents	CHANG.pdf	1534041	no	10
			ab6ab22ccc9c5943a9e18c234a607414e4e67b04		
Warnings:					
Information:					
18	NPL Documents	Cowan.pdf	436901	no	5
			2bae35c44fcdbe391b21ee031ce63cc055364a4		
Warnings:					
Information:					
19	NPL Documents	Davidovich.pdf	952974	no	5
			e1ed2aadadec90c7d95c63159fc7687a9a030c41		
Warnings:					
Information:					
20	NPL Documents	Davies.pdf	176568	no	19
			bc90e8f89b38de2912bbdf100a1c80024cb4515		
Warnings:					
Information:					
21	NPL Documents	Dean.pdf	771860	no	4
			77d9cd0d2e4440bfbd9ba80b81c6f442b3a9b88		
Warnings:					
Information:					
22	NPL Documents	DefSolvate.pdf	76254	no	3
			f554053aa60b9466076d2540c97301109306f42f		
Warnings:					
Information:					

23	NPL Documents	DESIRAJU1997.pdf	126200 d4fe8a50b55e6b6926c1819e18e1c8f0ede6dfl	no	5
Warnings:					
Information:					
24	NPL Documents	Doelker-2000.pdf	1227944 b3037fb0c0b4aaf1661dffc2fe8579847cdf08ba	no	13
Warnings:					
Information:					
25	NPL Documents	Doelker.pdf	721331 013e03f7ab7bf960be662f9dedca46651abf5538	no	10
Warnings:					
Information:					
26	NPL Documents	Dunitz-2003.pdf	77422 821b8e7c18b345ae621f65c37f336347e7416561	no	1
Warnings:					
Information:					
27	NPL Documents	FEYNMAN.pdf	177253 1eaf56c9fd788cdf14d380bd59f1dc57d479e15	no	13
Warnings:					
Information:					
28	NPL Documents	Jain.pdf	995737 4674c88ad65b8c4acb56efdcba398c0e02d500	no	15
Warnings:					
Information:					
29	NPL Documents	Kirchner2010.pdf	1363957 b9bfe8d71d9224636f61c0f544e47b24e40c7bd5	no	16
Warnings:					
Information:					
30	NPL Documents	MOULTON.pdf	4488111 d5d6239dc5e4b86e7d4f85a24cc121ff2e145261	no	30
Warnings:					
Information:					
31	NPL Documents	Muzaffar.pdf	3874349 71440af29b055a43e32202f0531b4c7ce4d4b37f	no	53
Warnings:					
Information:					

32	NPL Documents	Osorio-Lozada.pdf	329913 55fae9b65d05d36c11f99e5f6b93f3ae577572c8	no	5
Warnings:					
Information:					
33	NPL Documents	Otsuka.pdf	349079 82e1a6129b3566422de40167b4dc11ec75b8482b	no	5
Warnings:					
Information:					
34	NPL Documents	Shattock.pdf	540875 180531c02a074fd999d451cd98fe307684dbf58d	no	14
Warnings:					
Information:					
35	NPL Documents	Thayer.pdf	884286 ada2fcaadc8756a12aca46a60ea65c4266029f35	no	8
Warnings:					
Information:					
36	NPL Documents	USPharmacopia-23.pdf	169868 bf9ddfe4aa1526f6e7ac6b2f015c65fe41f3bec	no	1
Warnings:					
Information:					
37	NPL Documents	Villa.pdf	563014 58afeb57b584f91e07c68c39b3fae1dcb15bc5be	no	4
Warnings:					
Information:					
38	NPL Documents	ZAWOROTKO.pdf	777509 93c87949c8f5edb13e8c539bd17474bf54bb9883	no	6
Warnings:					
Information:					
39	NPL Documents	Klein.pdf	773121 de136901df935f4c5f2263dcbf941c28268c3ade	no	5
Warnings:					
Information:					
40	NPL Documents	Bastin.pdf	2096987 0860c25cf63e191ea18cd8455ebfac6c0fc71de7	no	9
Warnings:					
Information:					

41	Fee Worksheet (PTO-875)	fee-info.pdf	30320 0ef48d433d254e6c84a452e6a1c242a1755285f4	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			45043246		
This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503. <u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application. <u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course. <u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.					

SUPPLEMENTAL APPLICATION DATA SHEET

Docket No. TPI-350C1

Application Information

Application number::	10/660,202
Filing Date::	09/11/2003
Application Type::	Regular
Subject Matter::	Utility
Suggested Classification::	None
Suggested Group Art Unit::	None
CD-ROMor CD-R?::	None
Number of CD disks::	None
Number of copies of CDs::	None
Sequence submission?::	None
Computer Readable Form?::	No
Number of Copies of CRF::	None
Title::	Pharmaceutical Co-Crystal Compositions
Attorney Docket Number::	TPI-350C1
Request for Early Publication::	No
Request for Non-Publication::	No
Suggested Drawing Figure::	None
Total Drawing Sheets::	66
Small Entity?::	Yes
Petition included?::	No
Petition Type::	N/A
Secrecy Order in Parent Appl.?::	No

SUPPLEMENTAL APPLICATION DATA SHEET

Docket No. TPI-350C1

Applicant Information

Applicant Authority Type:: Inventor
 Primary Citizenship Country:: Iceland
 Status:: Unknown
 Inventor One Given Name:: Örn
 Family Name:: Almarsson
 City of Residence:: Shrewsbury
 State or Province of Residence:: MA
 Country of Residence:: US
 Street of Mailing Address:: 22 Farmington Drive
 City of Mailing Address:: Shrewsbury
 State or Province of mailing address:: MA
 Country of Mailing Address:: US
 Postal or Zip Code of Mailing Address:: 01545

Applicant Two Authority Type:: Inventor
 Primary Citizenship Country:: US
 Status:: Unknown
 Inventor Two Given Name:: Magali
 Family Name:: Bourghol Hickey
 City of Residence:: Medford
 State or Province of Residence:: MA
 Country of Residence:: US
 Street of Mailing Address:: 342 Malden Street
 City of Mailing Address:: Medford
 State or Province of mailing address:: MA
 Country of Mailing Address:: US
 Postal or Zip Code of Mailing Address:: 02155

SUPPLEMENTAL APPLICATION DATA SHEET

Docket No. TPI-350C1

Applicant Information

Applicant Three Authority Type:: Inventor
Primary Citizenship Country:: US
Status:: Unknown
Inventor Three Given Name:: Matthew L.
Family Name:: Peterson
City of Residence:: Framingham
State or Province of Residence:: MA
Country of Residence:: US
Street of Mailing Address:: 25 Downey Street
City of Mailing Address:: Hopkinton
State or Province of mailing address:: MA
Country of Mailing Address:: US
Postal or Zip Code of Mailing Address:: 01748

Applicant Four Authority Type:: Inventor
Primary Citizenship Country:: Canada
Status:: Unknown
Inventor Four Given Name:: Michael J.
Family Name:: Zaworotko
City of Residence:: Tampa
State or Province of Residence:: FL
Country of Residence:: US
Street of Mailing Address:: ~~4202 E. Fowler Ave.~~ 19133 Dove Creek Drive
City of Mailing Address:: Tampa
State or Province of mailing address:: FL
Country of Mailing Address:: US
Postal or Zip Code of Mailing Address:: ~~33620~~ 33647

SUPPLEMENTAL APPLICATION DATA SHEET

Docket No. TPI-350C1

Applicant Information

Applicant Five Authority Type:: Inventor
Primary Citizenship Country:: Canada
Status:: Unknown
Inventor Five Given Name:: Brian
Family Name:: Moulton
City of Residence:: Providence
State or Province of Residence:: RI
Country of Residence:: US
Street of Mailing Address:: 324 Brook Street, Box H
City of Mailing Address:: Providence
State or Province of mailing address:: RI
Country of Mailing Address:: US
Postal or Zip Code of Mailing Address:: 02912

Applicant Six Authority Type:: Inventor
Primary Citizenship Country:: US
Status:: Unknown
Inventor Six Given Name:: Nair
Family Name:: Rodriguez-Hornedo
City of Residence:: Ann Arbor
State or Province of Residence:: MI
Country of Residence:: US
Street of Mailing Address:: 1690 Northbrook Dr.
City of Mailing Address:: Ann Arbor
State or Province of mailing address:: MI
Country of Mailing Address:: US
Postal or Zip Code of Mailing Address:: 48103

SUPPLEMENTAL APPLICATION DATA SHEET

Docket No. TPI-350C1

Representative Information

Representative Customer Number:: 000023557

Representative Designation::	Registration Number::	Representative Name::
Primary	45,332	Frank C. Eisenschenk, Ph.D.

Correspondence Information

Name Line One::	Frank C. Eisenschenk, Ph.D.
Name Line Two::	Saliwanchik, Lloyd & Saliwanchik, A Professional Association
Street of Mailing Address::	P.O. Box 142950
City of Mailing Address::	Gainesville
State or Province of Mailing Address::	FL
Postal or Zip Code of Mailing Address::	32614-2950
Telephone Number One::	(352) 375-8100
Telephone Number Two::	
Fax Number::	(352) 372-5800
Electronic Mail Address::	fce@slspatents.com

SUPPLEMENTAL APPLICATION DATA SHEET

Docket No. TPI-350C1

Domestic Priority Information

Each of the applications listed in this domestic priority section are hereby incorporated by reference into this patent application in their entireties (including all figures, tables, and formulae).

Application::	Continuity Type::	Parent Application::	Parent Filing Date::
This application is a	Continuation-In-Part of	PCT/US03/27772	September 4, 2003
which is a	Continuation-In-Part of	10/378,956	March 3, 2003
which claims the benefit of		60/360,768	March 1, 2002
Said		PCT/US03/27772	September 4, 2003
Also claims the benefit of		60/451,213	February 28, 2003
And		60/463,962	April 18, 2003
And		60/487,064	July 11, 2003
~~This application is also a~~	~~Continuation-In-Part of~~	~~10/637,829~~	~~August 8, 2003~~
~~which is a~~	~~Divisional of~~	~~10/295,995~~	~~November 18, 2002~~
~~which is a~~	~~Continuation of~~	~~10/232,589~~	~~September 3, 2002~~
~~which claims benefit of~~		~~60/406,974~~	~~August 30, 2002~~
~~And~~		~~60/380,288~~	~~May 15, 2002~~
~~And~~		~~60/356,764~~	~~February 15, 2002~~
~~This application is also a~~	~~Continuation-In-Part of~~	~~10/449,307~~	~~May 30, 2003~~
~~which claims the benefit of~~		~~60/463,962~~	~~April 18, 2003~~
~~And~~		~~60/444,315~~	~~January 31, 2003~~
~~And~~		~~60/439,282~~	~~January 10, 2003~~
~~And~~		~~60/384,152~~	~~May 31, 2002~~
This application is also a	Continuation-In-Part of	10/601,092	June 20, 2003
This application also		60/451,213	February 28, 2003
claims the benefit of			
And		60/463,962	April 18, 2003
And		60/487,064	July 11, 2003

SUPPLEMENTAL APPLICATION DATA SHEET

Docket No. TPI-350C1

Assignee Information

Assignee Name:: TransForm Pharmaceuticals, Inc.
Street of Mailing Address:: 29 Hartwell Avenue
City of Mailing Address:: Lexington
State or Province or mailing address:: Massachusetts
Country of Mailing Address:: US
Postal or Zip Code of Mailing Address:: 02421

Assignee Information

Assignee Name:: University of South Florida
Street of Mailing Address:: ~~4202 East Fowler Avenue, FAO 1263802 Spectrum Blvd.,~~
Suite 100
City of Mailing Address:: Tampa
State or Province or mailing address:: FL
Country of Mailing Address:: US
Postal or Zip Code of Mailing Address:: ~~33620-7900~~33612-9220

Assignee Information

Assignee Name:: The Regents of the University of Michigan
Street of Mailing Address:: Wolverine Tower, Room 2071, 3003 S. State Street
City of Mailing Address:: Ann Arbor
State or Province or mailing address:: MI
Country of Mailing Address:: US
Postal or Zip Code of Mailing Address:: 48109-1280

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875					Application or Docket Number 10/660,202		Filing Date 09/11/2003		☐ To be Mailed			
APPLICATION AS FILED – PART I												
(Column 1)			(Column 2)		SMALL ENTITY ☒		OR		OTHER THAN SMALL ENTITY			
FOR	NUMBER FILED	NUMBER EXTRA	RATE (\$)	FEE (\$)			RATE (\$)	FEE (\$)				
☐ BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A				N/A					
☐ SEARCH FEE (37 CFR 1.16(k), (l), or (m))	N/A	N/A	N/A				N/A					
☐ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A				N/A					
TOTAL CLAIMS (37 CFR 1.16(i))	minus 20 =	*	X \$	=			X \$	=				
INDEPENDENT CLAIMS (37 CFR 1.16(h))	minus 3 =	*	X \$	=			X \$	=				
☐ APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).											
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))												
* If the difference in column 1 is less than zero, enter "0" in column 2.												
APPLICATION AS AMENDED – PART II												
(Column 1)			(Column 2)		(Column 3)		SMALL ENTITY		OR		OTHER THAN SMALL ENTITY	
AMENDMENT	03/12/2010	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE (\$)	ADDITIONAL FEE (\$)			RATE (\$)	ADDITIONAL FEE (\$)		
	Total (37 CFR 1.16(i))	* 36	Minus	** 37	= 0	X \$26 =	0	OR		X \$ =		
	Independent (37 CFR 1.16(h))	* 2	Minus	***20	= 0	X \$110 =	0	OR		X \$ =		
	☐ Application Size Fee (37 CFR 1.16(s))											
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))											
						TOTAL ADD'L FEE	0	OR		TOTAL ADD'L FEE		
(Column 1)			(Column 2)		(Column 3)		SMALL ENTITY		OR		OTHER THAN SMALL ENTITY	
AMENDMENT	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE (\$)	ADDITIONAL FEE (\$)			RATE (\$)	ADDITIONAL FEE (\$)			
	Total (37 CFR 1.16(i))	*	Minus	**	=	X \$ =	OR		X \$ =			
	Independent (37 CFR 1.16(h))	*	Minus	***	=	X \$ =	OR		X \$ =			
	☐ Application Size Fee (37 CFR 1.16(s))											
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))											
						TOTAL ADD'L FEE		OR		TOTAL ADD'L FEE		
* If the entry in column 1 is less than the entry in column 2, write "0" in column 3. ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20". *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3". The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.												

Legal Instrument Examiner:
/TINA J. BARDEN/

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete If Known		
			Application Number	10/660,202	
			Filing Date	September 11, 2003	
			First Named Inventor	Örn Almarsson	
			Art Unit	1617	
			Examiner Name	Leonard Williams	
Sheet	2	of	36	Attorney Docket Number	TPI-350C1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U21	US-2004/0106053	06-03-2004	Molaire, <i>et al.</i>	All
	U22	US-2004/0106055	06-03-2004	Molaire, <i>et al.</i>	All
	U23	US-2004/0171062	09-02-2004	Hirth, <i>et al.</i>	All
	U24	US-2004/0176335	09-09-2004	Childs	All
	U25	US-2005/0070551	03-31- ~~1995~~	2005 Remenar, <i>et al.</i>	All
	U26	US-2005/0181041	08-18-2005	Goldman	All
	U27	US-2005/0169982	08-04-2005	Almarsson, <i>et al.</i>	All
	U28	US-2005/0252649	11-17-2005	Chiu, <i>et al.</i>	All
	U29	US-2005/0256127	11-17-2005	Ku, <i>et al.</i>	All
	U30	US-6,559,293	05-06-2003	Almarsson, <i>et al.</i>	All
	U31	US-6,699,840	03-02-2004	Almarsson, <i>et al.</i>	All
	U32	US-2004-0053853	03-18-2004	Almarsson, <i>et al.</i>	All
	U33	US-2005/0070551 A1	03-31-2005	Remenar, <i>et al.</i>	All
	U34	US-2003/00224006	12-04-2003	Zaworotko <i>et al.</i>	All
	U35	US-3,536,809	04-09-1991	Schaller <i>et al.</i>	All
	U36	US-3,598,123	08-10-1971	Zaffaroni	All
	U37	US-3,845,770	11-05-1974	Theeuwes <i>et al.</i>	All
	U38	US-3,916,899	11-04-1975	Theeuwes <i>et al.</i>	All
	U39	US-4,008,719	02-22-1977	Theeuwes <i>et al.</i>	All
	U40	US-4,267,179	05-12-1981	Heeres <i>et al.</i>	All
	U41	US-4,764,604	08-16-1988	Muller	All

ce 3/18/10

Examiner Signature	/Renee Claytor/	Date Considered	11/16/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C1\PTO\IDS.form.doc\DNB\gyl

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete If Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	3	of	36	Attorney Docket Number	TPI-350C1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U42	US-4,916,134	04-10-1990	Heeres <i>et al.</i>	All
	U43	US-5,006,513	04-09-1991	Hector <i>et al.</i>	All
	U44	US-5,059,595	10-22-1991	Le Grazie	All
	U45	US-5,073,543	12-17-1991	Marshall <i>et al.</i>	All
	U46	US-5,120,548	06-09-1992	McClelland <i>et al.</i>	All
	U47	US-5,354,556	10-11-1994	Sparks <i>et al.</i>	All
	U48	US-5,414,997	05-16-1995	Tailer	All
	U49	US-5,474,997	12-12-1995	Gray <i>et al.</i>	All
	U50	US-5,591,767	01-07-1997	Mohr <i>et al.</i>	All
	U51	US-5,633,015	05-27-1997	Gilis <i>et al.</i>	All
	U52	US-5,639,476	06-17-1997	Oshlack <i>et al.</i>	All
	U53	US-5,661,151	08-26-1997	Saksena <i>et al.</i>	All
	U54	US-5,674,533	10-07-1997	Santus <i>et al.</i>	All
	U55	US-5,707,975	01-13-1998	Francois <i>et al.</i>	All
	U56	US-5,733,566	03-31-1998	Lewis	All
	U57	US-2003/0096014	05-22-2003	Sherman	All
	U58	US-4,513,006	04-23-1995	PKS Maryanoff <i>et al.</i>	All
	U59	US-6,191,117	02-20-2001	Kozachuk	All
	U60	US-6,201,010	03-13-2001	Cottrell	All
	U61	US-5,753,693	05-19-1998	Shank	All

ce 3/18/10

Examiner Signature	/Renee Claytor/	Date Considered	11/16/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C1\PTO\IDS.form.doc/DNB/gyl

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	4	of	36	Attorney Docket Number	TPI-350C1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U62	US-5,998,380	12-07-1999	Ehrenberg <i>et al.</i>	All
	U63	US-6,319,903	11-20-2001	Carrazana <i>et al.</i>	All
	U64	US-5,935,933	08-10-1999	Shank <i>et al.</i>	All
	U65	US-5,760,007	06-02-1999	1998 Shank <i>et al.</i>	All
	U66	US-5,952,187	09-14-1999	Stenglein <i>et al.</i>	All
	U67	US-5,242,942	09-07-1993	Costanzo <i>et al.</i>	All
	U68	US-5,384,327	01-24-1995	Costanzo <i>et al.</i>	All
	U69	US-6,071,537	06-06-2000	Shank	All
	U70	US-6,503,884	01-07-2003	Ehrenberg <i>et al.</i>	All
	U71	US-2003/0069190	04-10-2003	Abdel-Magid <i>et al.</i>	All
	U72	US-2002/0042446	04-11-2002	Dewey <i>et al.</i>	All
	U73	US-2002/0037925	03-28-2002	Dewey <i>et al.</i>	All
	U74	US-2003/0072802	04-17-2003	Cutler	All
	U75	US-6,488,962	12-03-2002	Berner <i>et al.</i>	All
	U76	US- 7,078,526	07-18-2006	Remenar <i>et al.</i>	All
	U77	US-6,294,192	9-25-2001	Patel <i>et al.</i>	All
	U78	US-5,466,823	11-14-1995	Talley <i>et al.</i>	All
	U79	US-4,008,321	02-15-1977	Kamishita <i>et al.</i>	All
	U80	US-4,853,379	08-01-1989	Shroot <i>et al.</i>	All
	U81	US-5,641,512	06-24-1997	Cimiluca	All

3/18/10

Examiner Signature	/Renee Claytor/	Date Considered	11/16/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI350C1\PTO\IDS.form.doc\DNB\gyI

Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Application Number	10/660,202	
			Filing Date	September 11, 2003	
			First Named Inventor	Örn Almarsson	
			Art Unit	1617	
			Examiner Name	Deirdre R. Claytor	
Sheet	1	of	1	Attorney Docket Number	TPI.350C1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-			
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			
	U10	US-			
	U11	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	F1	GB 2 169 601	07-16-1986	Tate & Lyle Public Limited Company	All	
	F2					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2


Electronic Acknowledgement Receipt	
EFS ID:	7324379
Application Number:	10660202
International Application Number:	
Confirmation Number:	6536
Title of Invention:	PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS
First Named Inventor/Applicant Name:	Orn Almarsson
Customer Number:	23557
Filer:	Frank Christopher Eisenschenk/Jenny Bedner
Filer Authorized By:	Frank Christopher Eisenschenk
Attorney Docket Number:	TPI.350C1
Receipt Date:	31-MAR-2010
Filing Date:	11-SEP-2003
Time Stamp:	13:33:56
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment		no			
File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		IDS-supp7.pdf	247032 c1ec5a999dc5bc52e96dce3cddcf642db8d27b56	yes	3

	Multipart Description/PDF files in .zip description								
	Document Description		Start	End					
	Transmittal Letter		1	2					
	Information Disclosure Statement (IDS) Filed (SB/08)		3	3					
Warnings:									
Information:									
2	Foreign Reference	GB2169601A.pdf	231774	no	6				
			232d7bf0f1d99788addf2b1abfb5606263b05c44						
Warnings:									
Information:									
Total Files Size (in bytes):			478806						
This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503. <u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application. <u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course. <u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.									

I hereby certify that this correspondence is being
facsimile transmitted to the United States Patent
and Trademark Office on March 31, 2010.


Frank C. Eisenschenk, Ph.D., Patent Attorney

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

Patent Application
Docket No. TPI.350C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Deirdre R. Claytor
Art Unit : 1627
Applicants : Örn Almarsson, Magali Bourghol Hickey, Matthew L. Peterson, Michael J.
Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo
Serial No. : 10/660,202
Filed : September 11, 2003
Conf. No. : 6536
For : Pharmaceutical Co-Crystal Compositions

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 AND 1.98

Sir:

In accordance with 37 C.F.R. § 1.56, the reference listed on the attached form PTO/SB/08 is
being brought to the attention of the Examiner for consideration in connection with the examination
of the above-identified patent application. A copy of the cited reference is enclosed.

It is respectfully requested that the reference cited on the attached form PTO/SB/08 be
considered in the examination of the subject application and that its consideration be made of record.

J:\TPI\350C1\IDS\IDS.sup7.doc\DNB/jb

Applicants respectfully assert that the substantive provisions of 37 C.F.R. §§ 1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950
Gainesville, FL 32614-2950

FCE/jb

Attachments: Form PTO/SB/08; copy of reference cited therein.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		<i>Complete if Known</i>			
		Application Number	10/606,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Deirdre R. Claytor		
Sheet	1	of	1	Attorney Docket Number	TPI.350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	SALEM, M.S. <i>et al.</i> "Preparation, characterisation and transformation of terfenadine polymorphic forms" <i>International Journal of Pharmacuetics</i> , 1996, pp. 257-259, Vol. 141.	
	R2		
	R3		
	R4		
	R5		
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Electronic Acknowledgement Receipt	
EFS ID:	7392278
Application Number:	10660202
International Application Number:	
Confirmation Number:	6536
Title of Invention:	PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS
First Named Inventor/Applicant Name:	Orn Almarsson
Customer Number:	23557
Filer:	Frank Christopher Eisenschenk/Jenny Bedner
Filer Authorized By:	Frank Christopher Eisenschenk
Attorney Docket Number:	TPI.350C1
Receipt Date:	12-APR-2010
Filing Date:	11-SEP-2003
Time Stamp:	11:25:22
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment		no			
File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		IDS-supp8.pdf	234804 5fcb383fe337c992274fe3ddb608f6518d789096	yes	3

	Multipart Description/PDF files in .zip description								
	Document Description		Start	End					
	Transmittal Letter		1	2					
	Information Disclosure Statement (IDS) Filed (SB/08)		3	3					
Warnings:									
Information:									
2	NPL Documents	Salem.pdf	203051 8f6b4fe5d57cc2935a456f91b2ce22901d264864	no	3				
Warnings:									
Information:									
Total Files Size (in bytes):			437855						
This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503. <u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application. <u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course. <u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.									

I hereby certify that this correspondence is being electronically filed in the the United States Patent and Trademark Office on April 12, 2010.



Frank C. Eisenschenk, Ph.D., Patent Attorney

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
Patent Application
Docket No. TPI.350C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Deirdre R. Claytor
Art Unit : 1627
Applicants : Örn Almarsson, Magali Bourghol Hickey, Matthew L. Peterson, Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo
Serial No. : 10/660,202
Filed : September 11, 2003
Conf. No. : 6536
For : Pharmaceutical Co-Crystal Compositions

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 AND 1.98

Sir:


In accordance with 37 C.F.R. § 1.56, the reference listed on the attached form PTO/SB/08 is being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of the cited reference is enclosed.

It is respectfully requested that the reference cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that its consideration be made of record.

JATPA350C\IDS\IDS.sup8.doc\DNB/sl

Applicants respectfully assert that the substantive provisions of 37 C.F.R. §§ 1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950
Gainesville, FL 32614-2950

FCE/sl

Attachments: Form PTO/SB/08; copy of reference cited therein.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/606,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Deirdre R. Claytor		
Sheet	1	of	1	Attorney Docket Number	TPI.350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	Office Action dated February 2, 2010 in U.S. application Serial No. 10/546,963, filed August 26, 2005.	
	R2	Pending claims in Serial No. 10/546,963, filed August 26, 2005.	
	R3		
	R4		
	R5		
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.


Electronic Acknowledgement Receipt	
EFS ID:	7651800
Application Number:	10660202
International Application Number:	
Confirmation Number:	6536
Title of Invention:	PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS
First Named Inventor/Applicant Name:	Orn Almarsson
Customer Number:	23557
Filer:	Frank Christopher Eisenschenk/Jenny Bedner
Filer Authorized By:	Frank Christopher Eisenschenk
Attorney Docket Number:	TPI.350C1
Receipt Date:	20-MAY-2010
Filing Date:	11-SEP-2003
Time Stamp:	13:33:12
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment		no			
File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		IDS-supp9.pdf	246080 89a3cc9d645afbc8b8e7a65e21142357c63cb6140	yes	3

	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Transmittal Letter		1	2	
	Information Disclosure Statement (IDS) Filed (SB/08)		3	3	
Warnings:					
Information:					
2	NPL Documents	2-2-10-OA-10-546963.PDF	540769 d0cee48011c1167215a61e9076d3dcf80e323bf6	no	13
Warnings:					
Information:					
3	NPL Documents	pend-03Nov09-10-546963.pdf	134938 cdc180a114871c8853c1c68914018f669a1ed610	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			921787		
This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503. <u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application. <u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course. <u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.					

I hereby certify that this correspondence is being electronically filed in the the United States Patent and Trademark Office on May 20, 2010.



Frank C. Eisenschenk, Ph.D., Patent Attorney

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

Patent Application
Docket No. TPL350C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Deirdre R. Claytor
Art Unit : 1627
Applicants : Örn Almarsson, Magali Bourghol Hickey, Matthew L. Peterson, Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo
Serial No. : 10/660,202
Filed : September 11, 2003
Conf. No. : 6536
For : Pharmaceutical Co-Crystal Compositions

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 AND 1.98

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of the cited references is enclosed.

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

J:\TPI\350C1\IDS\IDS.sup9.doc\DNB/sl

Applicants respectfully assert that the substantive provisions of 37 C.F.R. §§ 1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950
Gainesville, FL 32614-2950

FCE/sl

Attachments: Form PTO/SB/08; copy of references cited therein.

Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Application Number	10/660,202	
			Filing Date	September 11, 2003	
			First Named Inventor	Örn Almarsson	
			Art Unit	1617	
			Examiner Name	Deirdre R. Claytor	
Sheet	1	of	2	Attorney Docket Number	TPI.350C1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-5,994,365	11-30-1999	Zaworotko <i>et al.</i>	All
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			
	U10	US-			
	U11	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F1					
	F2					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		<i>Complete if Known</i>			
		Application Number	10/606,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Deirdre R. Claytor		
Sheet	2	of	2	Attorney Docket Number	TPI.350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	FELTHOUSE, T. R. <i>et al.</i> "MALEIC ANHYDRIDE, MALEIC ACID AND FUMARIC ACID", April 26, 2001, submitted for <i>Kirk Online</i> , http://www.huntsman.com/performance_products/media/komaleic.pdf .	
	R2		
	R3		
	R4		
	R5		
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.


Electronic Acknowledgement Receipt	
EFS ID:	8222686
Application Number:	10660202
International Application Number:	
Confirmation Number:	6536
Title of Invention:	PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS
First Named Inventor/Applicant Name:	Orn Almarsson
Customer Number:	23557
Filer:	Frank Christopher Eisenschenk/Jenny Bedner
Filer Authorized By:	Frank Christopher Eisenschenk
Attorney Docket Number:	TPI.350C1
Receipt Date:	16-AUG-2010
Filing Date:	11-SEP-2003
Time Stamp:	11:33:57
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment		no			
File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		IDS-supp-10.pdf	435498 41e02e24cee40213694b331a8bb11689d88745ad	yes	4

Multipart Description/PDF files in .zip description					
Document Description			Start	End	
Transmittal Letter			1	2	
Information Disclosure Statement (IDS) Filed (SB/08)			3	4	
Warnings:					
Information:					
2	NPL Documents	Felthouse.pdf	2342618	no	58
			d4e4144632d94e83a55a610de0add321f3e3d416		
Warnings:					
Information:					
Total Files Size (in bytes):			2778116		
This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503. <u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application. <u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course. <u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.					

I hereby certify that this correspondence is being electronically filed in the the United States Patent and Trademark Office on August 16, 2010.


Frank C. Eisenschenk, Ph.D., Patent Attorney

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
Patent Application
Docket No. TPI.350C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Deirdre R. Claytor
Art Unit : 1627
Applicants : Örn Almarsson, Magali Bourghol Hickey, Matthew L. Peterson, Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo
Serial No. : 10/660,202
Filed : September 11, 2003
Conf. No. : 6536
For : Pharmaceutical Co-Crystal Compositions

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 AND 1.98

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of the cited non-patent reference is enclosed. However, Applicants have not submitted a copy of the U.S. patent cited on attached Form PTO/SB/08 pursuant to 37 CFR 1.98(a)(2)(ii).

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

J:\TPI\350C1\IDS\IDS.suppl10.doc\DNB/sl

Applicants respectfully assert that the substantive provisions of 37 C.F.R. §§ 1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950
Gainesville, FL 32614-2950

FCE/sl

Attachments: Form PTO/SB/08; copy of references cited therein.



1617 Ifw

Herewith certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents, P.O. Box 1450
Alexandria, VA 22313 on August 28, 2006

Frank C. Eisenschenk, Ph.D., Patent Attorney

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

Patent Application
Docket No. TPI-350C1
Serial No. 10/660,202

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Örn Almarsson, Magali Bourghol Hickey, Matthew L. Peterson, Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo
Serial No. : 10/660,202
Filed : September 11, 2003
For : Pharmaceutical Co-Crystal Compositions

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §§1.97 and 1.98, Applicants would like to bring to the attention of the Examiner, the references cited in the following patent applications:

U.S. Serial No. 10/378,956, filed March 3, 2003;
U.S. Serial No. 10/637,829, filed August 8, 2003;
U.S. Serial No. 10/295,995, filed November 18, 2002, now U.S. Patent No. 6,699,840;
U.S. Serial No. 10/232,589, filed September 3, 2002, now U.S. Patent No. 6,559,293;
U.S. Serial No. 10/449,307, filed March 30, 2003, now U.S. Patent No. 7,078,526; and
U.S. Serial No. 10/601,092, filed June 20, 2003.

The subject application, Serial No. 10/660,202, claims the benefit under 35 USC §120 of the filing date of patent applications referred to above. Applicants respectfully request that the copies of references supplied in the Information Disclosure Statements of the application referred to above, as


J:\TPI\350C1\PTO\IDS-suppl.doc\DNB/sl

well as any references cited during the prosecution thereof, be made of record in the 10/660,202 application. As copies of the references made of record in the applications referred to above, and cited on the attached form PTO/SB/08, can be found in the casefiles referred to above, copies of those references are not provided herewith.

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statements.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.
Patent Attorney
Registration No. 45,332
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: P.O. Box 142950
Gainesville, FL 32614-2950

FCE/sl

Attachment: Form PTO/SB/08



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/660,202
				Filing Date	September 11, 2003
				First Named Inventor	Örn Almarsson
				Art Unit	1617
				Examiner Name	Leonard Williams
Sheet	1	of	36	Attorney Docket Number	TPI-350C1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	U1	US-2,711,411	06-21-1955	Holbert, <i>et al.</i>	All
	U2	US-4,198,507	04-15-1980	Barry, <i>et al.</i>	All
	U3	US-4,368,197	01-11-1983	Shefter, <i>et al.</i>	All
	U4	US-4,994,604	02-19-1991	Tung, <i>et al.</i>	All
	U5	US-5,177,262	01-15-1993	Taylor, <i>et al.</i>	All
	U6	US-5,332,834	07-26-1994	Bhattacharya, <i>et al.</i>	All
	U7	US-5,338,644	08-16-1994	Taylor, <i>et al.</i>	All
	U8	US-5,380,867	01-10-1995	Bhattacharya, <i>et al.</i>	All
	U9	US-5,412,094	05-02-1995	Amos, <i>et al.</i>	All
	U10	US-5,523,090	06-04-1996	Znaiden, <i>et al.</i>	All
	U11	US-5,614,342	03-25-1997	Molairé, <i>et al.</i>	All
	U12	US-5,998,413	12-07-1999	Heeres, <i>et al.</i>	All
	U13	US-6,001,996	12-14-1999	Amos, <i>et al.</i>	All
	U14	US-6,268,385	07-31-2001	Whittle, <i>et al.</i>	All
	U15	US-6,570,036	05-27-2003	Reuter	All
	U16	US-2003/0162226	08-28-2003	Cima, <i>et al.</i>	All
	U17	US-2003/0166581	09-04-2003	Almarsson, <i>et al.</i>	All
	U18	US-2003/0224006	12-04-2003	Zaworotko, <i>et al.</i>	All
	U19	US-2004/0019211	01-29-2004	Remenar, <i>et al.</i>	All
	U20	US-2004/0106052	06-03-2004	Molairé	All

Examiner Signature	/Renee Clayton/	Date Considered	09/15/2010
-----------------------	-----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C1\PTO\IDS.form.doc\DNB\gyl

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/660,202
				Filing Date	September 11, 2003
				First Named Inventor	Örn Almarsson
				Art Unit	1617
				Examiner Name	Leonard Williams
Sheet	2	of	36	Attorney Docket Number	TPI-350C1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U21	US-2004/0106053	06-03-2004	Molaire, <i>et al.</i>	All
	U22	US-2004/0106055	06-03-2004	Molaire, <i>et al.</i>	All
	U23	US-2004/0171062	09-02-2004	Hirth, <i>et al.</i>	All
	U24	US-2004/0176335	09-09-2004	Childs	All
	U25	US-2005/0070551	03-31-1995	Remenar, <i>et al.</i>	All
	U26	US-2005/0181041	08-18-2005	Goldman	All
	U27	US-2005/0169982	08-04-2005	Almarsson, <i>et al.</i>	All
	U28	US-2005/0252649	11-17-2005	Chiu, <i>et al.</i>	All
	U29	US-2005/0256127	11-17-2005	Ku, <i>et al.</i>	All
	U30	US-6,559,293	05-06-2003	Almarsson, <i>et al.</i>	All
	U31	US-6,699,840	03-02-2004	Almarsson, <i>et al.</i>	All
	U32	US-2004-0053853	03-18-2004	Almarsson, <i>et al.</i>	All
	U33	US-2005/0070551 A1	03-31-2005	Remenar, <i>et al.</i>	All
	U34	US-2003/00224006	12-04-2003	Zaworotko <i>et al.</i>	All
	U35	US-3,536,809	04-09-1991	Schaller <i>et al.</i>	All
	U36	US-3,598,123	08-10-1971	Zaffaroni	All
	U37	US-3,845,770	11-05-1974	Theeuwes <i>et al.</i>	All
	U38	US-3,916,899	11-04-1975	Theeuwes <i>et al.</i>	All
	U39	US-4,008,719	02-22-1977	Theeuwes <i>et al.</i>	All
	U40	US-4,267,179	05-12-1981	Heeres <i>et al.</i>	All
	U41	US-4,764,604	08-16-1988	Muller	All

Examiner Signature	/Renee Claytor/	Date Considered	09/15/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

J:\TPI\350C1\PTO\IDS.form.doc\DNB\gyl

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

NPC-UNIV-000006239

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 961 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	3	of	36	Attorney Docket Number	TPI-350C1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U42	US-4,916,134	04-10-1990	Heeres <i>et al.</i>	All
	U43	US-5,006,513	04-09-1991	Hector <i>et al.</i>	All
	U44	US-5,059,595	10-22-1991	Le Grazie	All
	U45	US-5,073,543	12-17-1991	Marshall <i>et al.</i>	All
	U46	US-5,120,548	06-09-1992	McClelland <i>et al.</i>	All
	U47	US-5,354,556	10-11-1994	Sparks <i>et al.</i>	All
	U48	US-5,414,997	05-16-1995	Tailer	All
	U49	US-5,474,997	12-12-1995	Gray <i>et al.</i>	All
	U50	US-5,591,767	01-07-1997	Mohr <i>et al.</i>	All
	U51	US-5,633,015	05-27-1997	Gilis <i>et al.</i>	All
	U52	US-5,639,476	06-17-1997	Oshlack <i>et al.</i>	All
	U53	US-5,661,151	08-26-1997	Saksena <i>et al.</i>	All
	U54	US-5,674,533	10-07-1997	Santus <i>et al.</i>	All
	U55	US-5,707,975	01-13-1998	Francois <i>et al.</i>	All
	U56	US-5,733,566	03-31-1998	Lewis	All
	U57	US-2003/0096014	05-22-2003	Sherman	All
	U58	US-4,513,006	04-23-1995	Maryanoff <i>et al.</i>	All
	U59	US-6,191,117	02-20-2001	Kozachuk	All
	U60	US-6,201,010	03-13-2001	Cottrell	All
	U61	US-5,753,693	05-19-1998	Shank	All

Examiner Signature	/Renee Claytor/	Date Considered	09/15/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C1\PTO\IDS.form.doc/DNB\gyl

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/660,202	
			Filing Date	September 11, 2003	
			First Named Inventor	Örn Almarsson	
			Art Unit	1617	
			Examiner Name	Leonard Williams	
Sheet	4	of	36	Attorney Docket Number	TPI-350C1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U62	US-5,998,380	12-07-1999	Ehrenberg <i>et al.</i>	All
	U63	US-6,319,903	11-20-2001	Carrazana <i>et al.</i>	All
	U64	US-5,935,933	08-10-1999	Shank <i>et al.</i>	All
	U65	US-5,760,007	06-02-1999	Shank <i>et al.</i>	All
	U66	US-5,952,187	09-14-1999	Stenglein <i>et al.</i>	All
	U67	US-5,242,942	09-07-1993	Costanzo <i>et al.</i>	All
	U68	US-5,384,327	01-24-1995	Costanzo <i>et al.</i>	All
	U69	US-6,071,537	06-06-2000	Shank	All
	U70	US-6,503,884	01-07-2003	Ehrenberg <i>et al.</i>	All
	U71	US-2003/0069190	04-10-2003	Abdel-Magid <i>et al.</i>	All
	U72	US-2002/0042446	04-11-2002	Dewey <i>et al.</i>	All
	U73	US-2002/0037925	03-28-2002	Dewey <i>et al.</i>	All
	U74	US-2003/0072802	04-17-2003	Cutler	All
	U75	US-6,488,962	12-03-2002	Berner <i>et al.</i>	All
	U76	US- 7,078,526	07-18-2006	Remenar <i>et al.</i>	All
	U77	US-6,294,192	9-25-2001	Patel <i>et al.</i>	All
	U78	US-5,466,823	11-14-1995	Talley <i>et al.</i>	All
	U79	US-4,008,321	02-15-1977	Kamishita <i>et al.</i>	All
	U80	US-4,853,379	08-01-1989	Shroot <i>et al.</i>	All
	U81	US-5,641,512	06-24-1997	Cimiluca	All

Examiner Signature	/Renee Claytor/	Date Considered	09/15/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C1\PTOIDS.form.doc/DNB/gyl

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	5	of	36	Attorney Docket Number	TPI-350C1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U82	US-6,420,394 B1	07-16-2002	Supersaxo	All
	U83	US-2003/0224006 A1	12-04-2003	Zaworotko <i>et al.</i>	All
	U84	US-			
	U85	US-			
	U86	US-			
	U87	US-			
	U88	US-			
	U89	US-			
	U90	US-			
	U91	US-			
	U92	US-			
	U93	US-			
	U94	US-			
	U95	US-			
	U96	US-			
	U97	US-			
	U98	US-			
	U99	US-			
	U100	US-			
	U101	US-			

Examiner Signature	/Renee Claytor/	Date Considered	09/15/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C\PTOIDS.form.doc\DNB\gyl

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	6	of	36	Attorney Docket Number	TPI-350C1

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³	- Number ⁴ - Kind Code ⁵ (if known)			
	F1	EP	413528 B1	11-15-1995	Yu, R. <i>et al.</i>	All
	F2	EP	1364649 A1	11-26-2003	Cilag AG	All
	F3	WO	94/16733 A1	08-04-1994	Chiesi Farmaceutici S.P.A.	All
	F4	WO	96/07331 A1	03-14-1996	Xyrofin Oy	All
	F5	WO	98/57967 A1	12-23-1998	Dong-A Pharmaceutical Co., Ltd.	All
	F6	WO	2000/53283 A1	09-14-2000	Reuter Chemische Apparatebau KG	All
	F7	WO	2001/13904 A2	03-01-2001	Ortho-McNeil Pharmaceutical, Inc.	All
	F8	JP	54-16494	02-07-1979	Yamanouchi Pharmaceutical Co., Ltd.	All
	F9	WO	00/50020 A2	08-31-2000	University of Cincinnati	All
	F10	FR	769,586	06-11-1934	Chemische Fabrik von Heyden	All
	F11	IT	01303251	11-06-2000	Industriale Chimica, S.R.L.	All
	F12	WO	2001/97853 A1	12-27-2001	Biochemie Gesellschaft MBH	All
	F13	EP	0310122 B1	04-05-1989	Kaken Pharma	All
	F14	WO	2002/062318 A2	08-15-2002	DSM N.V.	All
	F15	EP	0283992 B1	09-16-1992	Janssen Pharma Transform Pharmaceuticals, Inc.	All
	F16	WO	2003/101392 A2	12-11-2003	Cilag AG	All
	F17	WO	2004/054571 A1	07-01-2004	Transform Pharmaceuticals, Inc.	All
	F18	WO	2004/078161 A1 (CD-ROM)	09-16-2004	Transform Pharmaceuticals, Inc.	All
	F19	WO	2004/078163 A2 (CD-ROM)	09-16-2004	Transform Pharmaceuticals, Inc.	All

Examiner Signature	/Renee Claytor/	Date Considered	09/15/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

J:\TPI\350C1\PTOIDS.form.doc\DNB\gyl

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/660,202
				Filing Date	September 11, 2003
				First Named Inventor	Örn Almarsson
				Group Art Unit	1617
				Examiner Name	Leonard Williams
Sheet	7	of	36	Attorney Docket Number	TPI-350C1

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F20	WO 2004/089313 A2	10-21-2004	Transform Pharmaceuticals, Inc.	All	
	F21	WO 2005/023198 A2 (CD-ROM)	03-17-2005	Transform Pharmaceuticals, Inc.	All	
	F22	WO 2005/037424 A1	04-28-2005	Salvias AG	All	
	F23	WO 2005/055983 A2	06-23-2005	Medcrystalforms, LCC	All	
	F24	WO 2005/060968 A1 (CD-ROM)	07-07-2005	Sepracor, Inc.	All	
	F25	WO 2005/089375 A2 (CD-ROM)	09-29-2005	S.S.C.I., Inc.	All	
	F26	WO 2005/094804 A1	10-13-2005	The Regents of the University of Michigan	All	
	F27	WO 2006/024930 A1	03-09-2006	Pharmacia and Upjohn Co., LCC	All	
	F28	WO 03/070738 A2	08-28-2003	Transform Pharmaceuticals, Inc.	All	
	F29	WO 03/074474 A2	09-12-2003	Univ. South Fl	All	
	F30	WO 95/17407 A1	06-29-1995	Schering Corp	All	
	F31	WO 00/07583 A2	02-17-2000	Brookhaven Science Associates	All	
	F32	WO 00/72841 A1	12-07-2000	Berlant, Jeffrey	All	
	F33	WO 03 033462 A2	04-23-2003	Regents of Univ. Mich.	All	
	F34	WO 01 51919 A2	07-19-2001	Transform Pharm. Inc.	All	
	F35	WO 01 42222 A1	06-14-2001	Pharmacia Corp.	All	
	F36	WO 95/23596 A1	09-08-1995	The Boots Co.	All	
	F37	WO 00/32189 A1	06-08-2000	G. D. Searle & Co.	All	
	F38	WO 01/41760 A3	06-14-2001	Pharmacia Corporation	All	
	F39	WO 01/78724 A1	10/25/2001	Pharmacia Corporation	All	
	F40	WO 01/91750 A1	12/06/2001	Pharmacia Corporation	All	
	F41	WO 02/00627 A1	01/03/2002	Fako Ilacilari A.S.	All	
	F42	IN 182620	12-24-1994	Bajaj et al.	All	
Examiner Signature	/Renee Claytor/			Date Considered	09/15/2010	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C1\PTO\IDS.form.doc\DNB\gyI

NPC-UNIV-000006244

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 966 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	8	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	AAKERÖY, C. <i>et al.</i> "Crystal engineering of hydrogen-bonded assemblies- a progress report" <i>Aust. J. Chem.</i> , 2001, pp. 409-421, Vol. 54.	
	R2	BINGHAM, A. <i>et al.</i> "Over one hundred solvates of sulfathiazole" <i>Chem. Commun.</i> , 2001, pp. 603-604.	
	R3	BYRIEL, K., <i>et al.</i> "Molecular cocrystals of carboxylic acids. IX Carboxylic acid interactions with organic heterocyclic bases. The crystal structures of the adducts of (2,4-dichlorophenoxy) acetic acid with 3-hydroxypyridine, 2,4,6-trinitrobenzoic acid with 2-aminopyrimidine, and 4-nitrobenzoic acid with 3-amino-1,2,4-triazole" <i>Aust. J. Chem.</i> , 1992, pp. 969-981, Vol. 45, No. 6.	
	R4	SALMON, J. <i>et al.</i> "Supramolecular chemistry of boronic acids (Abstract)" 38 th Midwest Regional Meeting of the American Chemical Society in Columbia, MO., November 5-7, 2003, published by the American Chemical Society, Washington, D.C.	
	R5	URBINA, J. <i>et al.</i> "Supramolecular design of inorganic/organic networks using flexible ligands with self-complementary hydrogen bonds (Abstract)" 38 th Midwest Regional Meeting of the American Chemical Society in Columbia, MO., November 5-7, 2003, published by the American Chemical Society, Washington, D.C.	

Examiner Signature	/Renee Claytor/	Date Considered	09/15/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	9	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R6	SMITH, D. <i>et al.</i> "Structure confirmation by single crystal X-ray diffraction of a series of new schiff bases and theoretical computations on 3-(N-2- α , α , α -trifluorotoluidylidene amino) tetrahydrothiophene-1, 1-dioxide (Abstract)" 216 th ACS National Meeting in Boston, MA., August 23-27, 1998, published by the American Chemical Society, Washington, D.C.	
	R7	DESIRAJU, G. "Supramolecular synthons in crystal engineering- A new organic synthesis" <i>Angew. Chem. Int. Ed. Engl.</i> , 1995, pp. 2311-2327, Vol. 34.	
	R8	FRITCHIE, C. <i>et al.</i> "The configuration of phenothiazine in various molecular complexes" <i>Chem. Commun.</i> , 1968, pp. 833-834.	
	R9	HUANG, C.-M. <i>et al.</i> "Molecular packing modes. Part XI. Crystal structures of the 2:1 complexes of benzamide with succinic acid and furamide with oxalic acid" <i>J. Chem. Soc. Perkins Trans. 2: Physical Organic Chemistry</i> , 1973, pp. 503-508, Vol. 5.	
	R10	JACKISCH, M. <i>et al.</i> "Structures of three related biphenyl compounds: 4,4'-biphenyldiol, 3, 3',5,5'-tetra- <i>tert</i> -butyl-4,4'-biphenyldiol, and 3,3',5,5'- tetra- <i>tert</i> -butyl-1,1'-bicyclohexa-2,5-dienylidene-4,4'-dione" <i>Acta Cryst.</i> , 1990, pp. 919-922, Vol. C46.	
	R11	KIM, S. <i>et al.</i> "The structure of a crystalline complex containing one phenobarbital molecule and two adenine derivatives" <i>Proc. Natl. Acad. Sci. USA</i> , 1968, pp. 402-408, Vol. 60.	
	R12	KOBAYASHI, H. <i>et al.</i> "Sinusoidal structure of the 1:1 complex of phenothiazine and 7,7,8,8-tetracyanoquinodimethane, PTZ-TCNQ" <i>Acta Cryst.</i> , 1974, pp. 1010-1017, Vol. B30.	
	R13	ERMER, O. <i>et al.</i> "Molecular recognition among alcohols and amines: super-tetrahedral crystal architectures of linear diphenol-diamine complexes and aminophenols" <i>J. Chem. Soc. Perkins Trans. 2</i> , 1994, pp. 925-944.	
	R14	MARTIN, R. <i>et al.</i> "Polyphenal-caffeine complexation" <i>J. Chem. Soc., Chem. Commun.</i> , 1986, pp. 105-106.	
	R15	LEHN, J.-M. <i>et al.</i> "Molecular recognition directed self-assembly of ordered supramolecular strands by cocrystallization of complementary molecular components" <i>Chem. Soc., Chem. Commun.</i> , 1990, pp. 479-481.	

Examiner Signature	/Renee Claytor/	Date Considered	09/15/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C1\PTO\IDS.form.doc\DNB\gyf

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	10	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R16	LYNCH, D. <i>et al.</i> "Molecular cocrystals of carboxylic acids. XV Preparation and characterization of heterocyclic base adducts with a series of carboxylic acids, and the crystal structures of the adducts of 2-aminopyrimidine with 2,6-dihydroxybenzoic acid, 4-aminobenzoic acid, phenoxyacetic acid, (2,4-dichlorophenoxy) acetic acid, (3,4-dichlorophenoxy)- acetic acid and salicylic acid, and 2-aminopyridine with 2,6-dihydroxybenzoic acid" <i>Aust. J. Chem.</i> , 1994, pp. 1097-1115, Vol. 47.	
	R17	MCINTOSH, J. <i>et al.</i> "Chemotherapeutic drugs in anaerobic infections of wounds" <i>The Lancet</i> , June 26, 1943, pp. 793-795.	
	R18	MCINTOSH, J. <i>et al.</i> "Zinc peroxide, proflavine and penicillin in experimental <i>cl. welchii</i> infections" <i>The Lancet</i> , December 26, 1942, pp. 750-752.	
	R19	SMITH, G. <i>et al.</i> "Molecular cocrystals of carboxylic acids. XXI The role of secondary group interactions in adduct formation between 2-aminopyrimidine and substituted benzoic acids: the crystal structures of the adducts with <i>o</i> -phthalic acid, <i>o</i> -nitrobenzoic acid, <i>o</i> -aminobenzoic acid and <i>m</i> -aminobenzoic acid" <i>Aust. J. Chem.</i> , 1995, pp. 1151-1166, Vol. 48.	
	R20	WEISSBUCH, I. <i>et al.</i> "Crystal morphology control with tailor-made additives; a stereochemical approach" <i>Advances in Crystal Growth Research</i> , 2001, pp. 381-400.	
	R21	MCAHON, J. <i>et al.</i> "Crystal engineering of the composition of pharmaceutical phases. 3 ¹ . Primary amide supramolecular heterosynthons and their role in the design of pharmaceutical co-crystals" <i>Z. Kristallogr.</i> , 2005, pp. 340-350, Vol. 220.	
	R22	MEEJOO, S. <i>et al.</i> "The interplay of aryl-perfluoroaryl stacking interactions and interstack hydrogen bonding in controlling the structure of a molecular cocrystal" <i>Chemphyschem</i> , 2003, pp. 766-769, Vol. 4.	
	R23	MIRMEHRABI, M. <i>et al.</i> "Improving the filterability and solid density of ranitidine hydrochloride form 1" <i>Journal of Pharmaceutical Sciences</i> , July 2004, pp. 1692-1700, Vol. 93, No. 7.	
	R24	MORRIS, K. <i>et al.</i> "Theoretical approaches to physical transformations of active pharmaceutical ingredients during manufacturing processes" <i>Advanced Drug Delivery Reviews</i> , 2001, pp. 91-114, Vol. 48.	

Examiner Signature	/Renee Claytor/	Date Considered	09/15/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

J:\TPI\350C1\PTO\IDS.form.doc\DNB\gyl

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

NPC-UNIV-000006247

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 969 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/660,202
		Filing Date	September 11, 2003
		First Named Inventor	Örn Almarsson
		Group Art Unit	1617
		Examiner Name	Leonard Williams
		Attorney Docket Number	TPI-350C1
Sheet	11	of	36

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R25	NAKANISHI, I. <i>et al.</i> "X-ray structural studies on two forms of β -cyclodextrin barbital complexes" <i>Journal of Inclusion Phenomena</i> , 1984, pp. 689-699, Vol. 2.	
	R26	NAKAO, S. <i>et al.</i> "The crystal and molecular structure of the 2:1 molecular complex of theophylline with phenobarbital" <i>Acta Cryst.</i> , 1977, pp. 1373-1378, Vol. B33.	
	R27	NATARAJAN, S. <i>et al.</i> "Reinvestigation of the crystal structure of diglycine hydrochloride" <i>Zeitschrift für Kristallographie</i> , 1992, pp. 265-270, Vol. 198.	
	R28	OLENIK, B. <i>et al.</i> "Cooperative and anticooperative effects in the cocrystals of mono- and diazanaphthalenes with meso-1, 2-diphenyl-1,2-ethanediol" <i>Crystal Growth & Design</i> , 2003, pp. 175-181, Vol. 3, No. 2.	
	R29	OLENIK, B. <i>et al.</i> "Supramolecular synthesis by cocrystallization of oxalic and fumaric acid with diazanaphthalenes" <i>Crystal Growth & Design</i> , 2003, pp. 183-188, Vol. 3, No. 2.	
	R30	GROTH, P. " <i>d</i> -Glucose-sodium chloride-monohydrate (glucose-sodium chloride) = $2C_6H_{12}O_6 \cdot NaCl \cdot H_2O$ " <i>Chemische Kristallographie</i> , 1910, pp. 438-439.	X
	R31	OSWALD, I. <i>et al.</i> "Rationalisation of co-crystal formation through knowledge-mining" <i>Crystallography Reviews</i> , 2004, pp. 57-66, Vol. 10, No. 1.	
	R32	OUYANG, X. <i>et al.</i> "Single-crystal-to-single-crystal topochemical polymerizations of a terminal diacetylene: two remarkable transformations give the same conjugated polymer" <i>J. Am. Chem. Soc.</i> , 2003, pp. 12400-12401, Vol. 125.	
	R33	PATEL, U. <i>et al.</i> "Structure of the 1:1 complex between 4-amino- <i>N</i> -(4,6-dimethyl-2-pyrimidinyl)- benzenesulfonamide (sulfadimidine) and 2-hydroxybenzoic acid (salicylic acid)" <i>Acta Cryst.</i> , 1988, pp. 1264-1267, Vol. C44.	
	R34	REDDY, L. <i>et al.</i> "Phenyl-perfluorophenyl synthon mediated cocrystallization of carboxylic acids and amides" <i>Crystal Growth & Design</i> , 2004, pp. 89-94, Vol. 4., No. 1.	
	R35	REMENAR, J. <i>et al.</i> "Crystal engineering of novel cocrystals of a triazole drug with 1,4-dicarboxylic acids" <i>J. Am. Chem. Soc.</i> , 2003, pp. 8456-8457, Vol. 125.	

Examiner Signature	/Renee Claytor/	Date Considered	09/15/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.
 ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C1\PTO\IDS.form.doc/DNB/gyl

NPC-UNIV-000006248

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 970 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	12	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R36	SCHMIDT, G. "Photodimerization in the solid state" <i>Pure Appl. Chem.</i> , 1971, pp. 647-678, Vol. 27.	
	R37	SHAN, N. <i>et al.</i> "Co-crystal of 4,7-phenanthroline and carboxylic acids: synthon competition and prediction" <i>Tetrahedron Letters</i> , 2002, pp. 8721-8725, Vol. 43.	
	R38	SHAN, N. <i>et al.</i> "Crystal engineering using 4,4'-bipyridyl with di- and tricarboxylic acids" <i>Crystal Engineering</i> , 2002, pp. 9-24, Vol. 5.	
	R39	SHAN, N. <i>et al.</i> "Supramolecular synthons in the co-crystal structures of 2-aminopyrimidine with diols and carboxylic acids" <i>Tetrahedron Letters</i> , 2002, pp. 3101-3104, Vol. 43.	
	R40	MCINTOSH, J. <i>et al.</i> "Further observations on the chemotherapy of experimental gas gangrene: flavazole, marfanil, V187 and V335" <i>British Journal of Experimental Pathology</i> , 1946, pp. 46-54, Vol. 27.	
	R41	SHAVIV, R. <i>et al.</i> "Magnetochemistry of the tetrahaloferrate (III) ions 6. Crystal structure and magnetic ordering in [(pyH) ₃ Cl] [FeCl ₄] ₂ " <i>Inorganica Chimica Acta</i> , 1992, pp. 613-621, Vol. 198-200.	
	R42	SHEFTER, E. "Structural studies on complexes IV: Crystal structure of a 1:1 5-chlorosalicylic acid and theophylline complex" <i>Journal of Pharmaceutical Sciences</i> , 1969, pp. 710-714, Vol. 58.	
	R43	SHIMIZU, N. <i>et al.</i> "Structure of 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine-5,5-diethylbarbituric acid (1:1)" <i>Acta Cryst.</i> , 1982, pp. 2309- 2311, Vol. B38.	
	R44	SINGH, N. B. <i>et al.</i> "Solid state reaction between 8-hydroxyquinoline and <i>p</i> -nitrobenzoic acid" <i>Indian Journal of Chemistry</i> , May 1988, pp. 429-432, Vol. 37B.	
	R45	SMITH, G. <i>et al.</i> "The 1:1 adduct of 4-aminobenzoic acid with 4-aminobenzonitrile" <i>Acta Cryst.</i> , 2000, pp. 1155-1156, Vol. C56.	

Examiner Signature	/Renee Clayton/	Date Considered	09/15/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C1\PTOIDS.form.doc/DNB\gyI

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/660,202
		Filing Date	September 11, 2003
		First Named Inventor	Örn Almarsson
		Group Art Unit	1617
		Examiner Name	Leonard Williams
Sheet	13	of	36
		Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R46	STEINER, T. "Donor and acceptor strengths in C-H...O hydrogen bonds quantified from crystallographic data of small solvent molecules" <i>New. J. Chem.</i> , 1998, pp. 1099-1103.	
	R47	STOREY, R. et al. "Automation of solid form screening procedures in the pharmaceutical industry- how to avoid the bottlenecks" <i>Crystallography Reviews</i> , 2004, pp. 45-56, Vol. 10, No. 1.	
	R48	SZAFRAN, M. et al. "Molecular structures and hydrogen bonding in the 1:1 and 1:2 complexes of pyridine betaine with 2,6-dichloro-4-nitrophenol; an example of strongly coupled hydrogen bonds, O-H...O=C-O-H...O-" <i>Journal of Molecular Structure</i> , 1997, pp. 145-160, Vol. 416.	
	R49	TAKEUCHI, M. et al. "Synchrotron radiation SAXS/WAXS study of polymorph-dependent phase behavior of binary mixtures of saturated monoacid triacylglycerols" <i>Crystal Growth & Design</i> , 2003, pp. 369-374, Vol. 3, No. 3.	
	R50	TANG, C. P. et al. "Reaction pathways in crystalline host-guest inclusion complexes: rotation by a net 180° of the acetyl group on photoaddition of guest- acetophenone and -m-Chloroacetophenone to the atom C5 of host deoxycholic acid" <i>J. Am. Chem. Soc.</i> , 1985, pp. 4058-4070, Vol. 107.	
	R51	TAYLOR, R. et al. "Rules governing the crystal packing of mono- and dialcohols" <i>Acta Crystallographica Section B, Structural Science</i> , 2001, pp. 815-827, Vol. B57.	
	R52	THALLAPALLY, P. et al. "Polymorphism of 1,3,5-trinitrobenzene induced by a trisindane additive" <i>Angew. Chem. Int. Ed.</i> , 2004, pp. 1149-1155, Vol. 43.	
	R53	TIMMERMAN, P. et al. "Noncovalent Assembly of functional groups on calix[4]arene molecular boxes" <i>Chem. Eur. J.</i> , 1997, pp. 1823-1832, Vol. 3., No. 11.	
	R54	SHAN, N. et al. "Mechanochemistry and co-crystal formation: effect of solvent on reaction kinetics" <i>Chem. Commun.</i> , 2002, pp. 2372-2373.	
	R55	CAIRA, M. et al. "X-ray structure and thermal analysis of a 1:1 complex between (S)-naproxen and heptakis (2,3,6-tri-O-methyl)-β-cyclodextrin" <i>Journal of Inclusion Phenomena and Molecular Recognition in Chemistry</i> , 1995, pp. 277-290, Vol. 20.	

Examiner Signature	/Renee Clayton/	Date Considered	09/15/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2

J:\TPI\350C1\PTO\DS.form.doc\DNB\gyl

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

NPC-UNIV-000006250

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 972 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/660,202
		Filing Date	September 11, 2003
		First Named Inventor	Örn Almarsson
		Group Art Unit	1617
		Examiner Name	Leonard Williams
Sheet	14	of	36
		Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R56	TRASK, A. <i>et al.</i> "Crystal engineering of organic cocrystals by the solid-state grinding approach" <i>Top Curr. Chem.</i> , 2005, pp. 41-70, Vol. 254.	
	R57	TRASK, A. <i>et al.</i> "Pharmaceutical cocrystallization: engineering a remedy for caffeine hydration" <i>Crystal Growth & Design</i> , 2005, pp. 1013-1021, Vol. 5, No. 3.	
	R58	TRASK, A. <i>et al.</i> "Solvent-drop grinding: green polymorph control of cocrystallisation" <i>Chem. Commun.</i> , 2004, pp. 890-891 in addition to supplemental materials.	
	R59	TROWBRIDGE, L. <i>et al.</i> "Composites for nonlinear optics: Crystal growth and polymorphism" <i>University of Sussex, Falmer Brighton UK, School of Chemistry and Molecular Sciences</i> , pp. 272. 1994	
	R60	UNO, T. <i>et al.</i> "Structure of 5,5-diphenylhydantoin-1- (4-bromophenyl)-4-dimethylamino-2,3-dimethyl-3-pyrazolin-5-one (1:1)" <i>Acta Cryst.</i> , 1980, pp. 2794-2796, Vol. B36.	
	R61	VAN ROEY, P. <i>et al.</i> "Structure-activity studies of non-steroidal aromatase inhibitors: the crystal and molecular structures of CGS 16949A and CGS 18320B" <i>J. Enzyme Inhibition</i> , 1991, pp. 119-132, Vol. 5.	
	R62	VAN ROEY, P. <i>et al.</i> "Structure of <i>cis</i> -1-[[4-(1-imidazolylmethyl) cyclohexyl] methyl] imidazole- succinic acid complex" <i>Acta Cryst.</i> , 1991, pp. 1015-1018, Vol. C47.	
	R63	VISHWESHWAR, P. <i>et al.</i> "Crystal engineering of pharmaceutical co-crystals from polymorphic active pharmaceutical ingredients" <i>Chem. Commun.</i> , 2005, pp. 4601-4603.	
	R64	VISHWESHWAR, P. <i>et al.</i> "Recurrence of carboxylic acid- pyridine supramolecular synthon in the crystal structures of some pyrazinecarboxylic acids" <i>J. Org. Chem.</i> , 2002, pp. 556-565, Vol. 67.	
	R65	VISHWESHWAR, P. <i>et al.</i> "Supramolecular synthons based on N-H...N and C-H...O hydrogen bonds. Crystal engineering of a helical structure with 5,5-diethylbarbituric acid" <i>Chem. Commun.</i> , 2002, pp. 1830-1831.	
	R66	VISHWESHWAR, P. <i>et al.</i> "Supramolecular synthons in phenol-isonicotinamide adducts" <i>Cryst. Eng. Comm.</i> 2003, pp. 164-168, Vol. 5, No. 31.	

Examiner Signature	/Renee Claytor/	Date Considered	09/15/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

J:\TPI\350C1\PTO\IDS.form.doc\DNB\gyl

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

NPC-UNIV-000006251

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 973 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/660,202
		Filing Date	September 11, 2003
		First Named Inventor	Örn Almarsson
		Group Art Unit	1617
		Examiner Name	Leonard Williams
Sheet	15	of	36
		Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R67	VOET, D. <i>et al.</i> "The crystal and molecular structure of the intermolecular complex 9-ethyladenine-5, 5-diethylbarbituric acid" <i>Journal of the American Chemical Society</i> , November 15, 1972, pp. 8213-8222, Vol. 94, No. 23.	
	R68	VOET, D. <i>et al.</i> "The structure of an intermolecular complex between cytosine and 5-fluorouracil" <i>Journal of the American Chemical Society</i> , May 21, 1969, pp. 3069-3075, Vol. 91, No. 11.	
	R69	STEZOWSKI, J. J. <i>et al.</i> "Characterization of a 1:1 complex of an unusual structure in the phenothiazine/phenazine binary phase diagram" <i>Zeitschrift für Kristallographie in International Journal for Structural, Physical, Chemical Aspects of Crystalline Materials</i> , 1983, pp. 213-215, Vol. 162, No. 1-4.	X
	R70	WANG, A. <i>et al.</i> "Crystal structure of 1:1 complex of barbital with 1-methylimidazole" <i>Journal of Pharmaceutical Sciences</i> , March 1979, pp. 361-363, Vol. 68, No. 3.	
	R71	ALBEROLA, S. <i>et al.</i> "Crystalline and Molecular Structure of Sulfanilimide-Antipyrine" <i>Acta Cryst.</i> , 1977, pp. 3337-3341, Vol. B33.	X
	R72	WOOD, R. A. <i>et al.</i> "2,5-O-methylene-D-mannitol sodium-chloride, C ₇ H ₁₄ O ₆ . NaCl" <i>Cryst. Struct. Comm.</i> , 1976, 207-210, Vol. 5.	
	R73	XU, J. <i>et al.</i> "Effect of composition distribution on miscibility and co-crystallization phenomena in the blends of low density polyethylene with conventional and metallocene-based ethylene-butene copolymers" <i>Polymer</i> , 2001, pp. 3867-3874, Vol. 42.	
	R74	YOO, J. <i>et al.</i> "Cocrystallization of a dinuclear platinum complex as a monomer and a one-dimensional polymer" <i>Polyhedron</i> , 2002, pp. 715-719, Vol. 21.	
	R75	ZAITU, S. <i>et al.</i> "A 2:1 molecular complex of theophylline and 5-fluorouracil as the monohydrate" <i>Acta Cryst.</i> , 1995, pp. 1857-1859, Vol. C51.	
	R76	ZAMAN, M. B. <i>et al.</i> "Linear hydrogen-bonded molecular tapes in the cocrystals of squaric acid with 4,4'-dipyridylacetylene and 1,2-bis(4-pyridyl) ethylene" <i>Acta Cryst.</i> , 2001, pp. 621-624, Vol. C57.	
	R77	ZERKOWSKI, J. <i>et al.</i> "Design of organic structures in the solid state: hydrogen-bonded molecular "tapes" ¹ " <i>J. Am. Chem. Soc.</i> , 1990, pp. 9025-9026, Vol. 112.	
Examiner Signature	/Renee Clayton/		Date Considered 09/15/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

J:\TPI350C1\PTO\IDS.form.doc/DNB/gyl

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

NPC-UNIV-000006252

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 974 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	16	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R78	ZERKOWSKI, J. <i>et al.</i> "Investigations into the robustness of secondary and tertiary architecture of hydrogen-bonded crystalline tapes" <i>Chem. Mater.</i> , 1994, pp. 1250-1257, Vol. 6.	
	R79	ZERKOWSKI, J. <i>et al.</i> "New varieties of crystalline architecture produced by small changes in molecular structure in tape complexes of melamines and barbiturates" <i>J. Am. Chem. Soc.</i> , 1994, pp. 4305-4315, Vol. 116.	
	R80	ZERKOWSKI, J. <i>et al.</i> "Polymorphic packing arrangements in a class of engineered organic crystals" <i>Chem. Mater.</i> , 1997, pp. 1933-1941, Vol. 9.	
	R81	ZERKOWSKI, J. <i>et al.</i> "Solid-state structures of "Rosette" and "Crinkled Tape" motifs derived from the cyanuric acid-melamine lattice" <i>J. Am. Chem. Soc.</i> , 1992, pp. 5473-5475, Vol. 114.	
	R82	ZHANG, R. <i>et al.</i> "Atmospheric new particle formation enhanced by organic acids" <i>Science</i> , June 4, 2004, pp. 1487-1490 with additional supporting online material, Vol. 304.	
	R83	ZHU, H. <i>et al.</i> "Influence of water activity in organic solvent + water mixtures on the nature of the crystallizing drug phase. 1. theophylline" <i>International Journal of Pharmaceutics</i> , 1996, pp. 151-160, Vol. 135.	
	R84	AAKERÖY, C. <i>et al.</i> "Aromatic dicarboxylic acids as building blocks of extended hydrogen-bonded architectures" <i>Supramolecular Chemistry</i> , 1998, pp. 127-135, Vol. 9.	
	R85	AAKERÖY, C. <i>et al.</i> "Assembly of 2-D inorganic/organic lamellar structures through a combination of copper (I) coordination polymers and self-complimentary hydrogen bonds" <i>J. Chem. Soc., Dalton Trans.</i> , 2000, pp. 3869-3872.	
	R86	AAKERÖY, C. <i>et al.</i> "Building organic assemblies with 2-pyridone and dicarboxylic acids: relating molecular conformation and synthon stability to crystal structure" <i>Crystal Engineering</i> , 1998, pp. 225-241, Vol. 1, No. 3-4.	
	R87	AAKERÖY, C. <i>et al.</i> "The C-H...C1 hydrogen bond: does it exist?" <i>New J. Chem.</i> , 1999, pp. 145-152.	
	R88	AAKERÖY, C. <i>et al.</i> "Crystal engineering of ionic solids" <i>Modular Chemistry</i> (ed. by Michl, J.), 1997, pp. 153-162, Kluwer Academic Publishers, The Netherlands.	

Examiner Signature	/Renee Clayton/	Date Considered	09/15/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

J:\TPI\350C1\PTO\IDS.form.doc\DNB\gyl

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

NPC-UNIV-000006253

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 975 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	17	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R89	AAKERÖY, C. <i>et al.</i> "Crystal engineering: strategies and architectures" <i>Acta Cryst.</i> , 1997, pp. 569-586, Vol. B53.	
	R90	AAKERÖY, C. <i>et al.</i> "Crystal engineering using intermolecular hydrogen-bonded connectors and classic coordination chemistry" <i>Transactions ACA</i> , 1998, pp. 97-103, Vol. 33.	
	R91	AAKERÖY, C. <i>et al.</i> "The crystal structure of the molecular cocrystal L-malic acid L-tartaric acid (1/1)" <i>Supramolecular Chemistry</i> , 1996, pp. 153-156, Vol. 7.	
	R92	AAKERÖY, C. <i>et al.</i> "Deliberate combination of coordination polymers and hydrogen bonds in a supramolecular design strategy for inorganic/organic hybrid networks" <i>Chem. Commun.</i> , 2000, pp. 935-936.	
	R93	AAKERÖY, C. <i>et al.</i> "Di-hydroxy malonic acid as a building block of hydrogen-bonded 3-dimensional architectures" <i>Journal of Chemical Crystallography</i> , 1998, pp. 111-117, Vol. 28, No. 2.	
	R94	AAKERÖY, C. <i>et al.</i> "Do polymorphic compounds make good cocrystallizing agents? A structural case study that demonstrates the importance of synthon flexibility" <i>Crystal Growth & Design</i> , 2003, 159-165, Vol. 3, No. 2.	
	R95	AAKERÖY, C. <i>et al.</i> "Heteromeric intermolecular interactions as synthetic tools for the formation of binary co-crystals" <i>Cryst. Eng. Comm.</i> , 2004, pp. 19-24, Vol. 6, No. 5.	
	R96	AAKERÖY, C. <i>et al.</i> "A high-yielding supramolecular reaction" <i>J. Am. Chem. Soc.</i> , 2002, 14425-14432, Vol. 124.	
	R97	AAKERÖY, C. <i>et al.</i> "The hydrogen bond and crystal engineering" <i>Chemical Society Reviews</i> , 1993, pp. 397-407.	
	R98	AAKERÖY, C. <i>et al.</i> "Hydrogen-bond assisted assembly of organic and organic-inorganic solids" <i>Crystal Engineering: From Molecules and Crystals to Materials</i> , 1999, pp. 89-106, Kluwer Academic Publishers, The Netherlands.	
	R99	AAKERÖY, C. <i>et al.</i> "Hydrogen-bonding in solids" <i>Crystal Engineering</i> (ed. by Seddon, K. R. <i>et al.</i>), 1999, pp. 303-324, Kluwer Academic Publishers, The Netherlands.	
Examiner Signature	/Renee Claytor/		Date Considered
			09/15/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C1\PTOIDS.form.doc/DNB/gyl

NPC-UNIV-000006254

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 976 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	18	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R100	AAKERÖY, C. <i>et al.</i> "Low-dimensional architectures of silver coordination compounds assembled via amide-amide hydrogen bonds" <i>Crystal Engineering</i> , 1998, pp. 39-49, Vol. 1, No. 1.	
	R101	AAKERÖY, C. <i>et al.</i> "Molecular mechanics and crystal engineering" <i>Crystal Engineering</i> (ed. by Seddon, K. R. <i>et al.</i>), 1999, pp. 69-82, Kluwer Academic Publishers, The Netherlands.	
	R102	AAKERÖY, C. <i>et al.</i> "New building blocks for crystal engineering. Syntheses and crystal structures of oxime-substituted pyridines" <i>Cryst. Eng. Comm.</i> , 2000, pp. 1-6, Vol. 27.	
	R103	AAKERÖY, C. <i>et al.</i> "Novel colorless composite materials for nonlinear optics" <i>Adv. Mater.</i> , 1993, pp. 364-367, Vol. 5, No. 5.	
	R104	AAKERÖY, C. <i>et al.</i> "Organic assemblies of 2-pyridones with dicarboxylic acids" <i>Tetrahedron</i> , 2000, pp. 6693-6699, Vol. 56.	
	R105	AAKERÖY, C. <i>et al.</i> "Pitfalls in the supramolecular assembly of silver(I) coordination compounds" <i>Journal of Molecular Structure</i> , 1999, pp. 91-101, Vol. 474.	
	R106	AAKERÖY, C. <i>et al.</i> "A structural study of 2-amino-5-nitropyridine and 2-amino-3-nitropyridine: intermolecular forces and polymorphism" <i>J. Mater. Chem.</i> , 1998, pp. 1385-1389, Vol. 8, No. 6.	
	R107	AAKERÖY, C. <i>et al.</i> "Supramolecular assembly of low-dimensional silver (I) architectures via amide-amide hydrogen bonds" <i>Chem. Commun.</i> , 1998, pp. 1067-1068.	
	R108	AAKERÖY, C. <i>et al.</i> "'Total synthesis' supramolecular style: design and hydrogen-bond-directed assembly of ternary supermolecules" <i>Angew. Chem. Int. Ed.</i> , 2001, pp. 3240-3242, Vol. 40, No. 17.	
	R109	AAKERÖY, C. <i>et al.</i> "Two-fold interpenetration of 3-D nets assembled via three-co-ordinate silver(I) ions and amide-amide hydrogen bonds" <i>J. Chem. Soc., Dalton Trans.</i> , 1998, pp. 1943-1945.	
	R110	AHN, S. <i>et al.</i> "Polymorphs of a 1:1 cocrystal with tunnel and layer structures: <i>p,p'</i> -biphenol/dimethyl sulfoxide" <i>Crystal Growth & Design</i> , 2001, pp. 107-111, Vol. 1, No. 2.	
Examiner Signature	/Renee Clayton/		Date Considered 09/15/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C1\PTO\IDS.form.doc\DNB\gyl

NPC-UNIV-000006255

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 977 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	19	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R111	AKAZOME, M. <i>et al.</i> "Enantioselective inclusion of methyl phenyl sulfoxides and benzyl methyl sulfoxides by (R)-phenylglycyl-(R)-phenylglycine and the crystal structures of the inclusion cavities" <i>J. Org. Chem.</i> , 2000, pp. 68-76, Vol. 65.	
	R112	AKHTARUZZAMAN, M.D. <i>et al.</i> "One-dimensional hydrogen-bonded molecular tapes in 1, 4-bis[(4-pyridinio) ethynyl]benzene chloranilate" <i>Acta. Cryst.</i> , 2001, pp. o353-o355, Vol. E57.	
	R113	ALLEN, F. <i>et al.</i> "Systematic analysis of structural data as a research technique in organic chemistry" <i>Acc. Chem. Res.</i> , 1983, pp. 146-153, Vol. 16.	
	R114	ALMARSSON, Ö. <i>et al.</i> "Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines?" <i>Chem. Commun.</i> , 2004, pp. 1889-1896.	
	R115	AMAI, M. <i>et al.</i> "1:1 complex of octadecanoic acid and 3-pyridinecarboxamide" <i>Acta Cryst.</i> , 1998, pp. 1367-1369, Vol. C54.	
	R116	ANDERSON, N. <i>et al.</i> "Sulfonation with inversion by mitsunobu reaction: an improvement on the original conditions" <i>J. Org. Chem.</i> , 1996, pp. 7955-7958, Vol. 61.	
	R117	AOKI, K. <i>et al.</i> "A 1:1 complex of theophylline and <i>p</i> -nitrophenol" <i>Acta Cryst.</i> , 1978, pp. 2333-2336, Vol. B34.	
	R118	ASHTON, P. <i>et al.</i> "Combining different hydrogen-bonding motifs to self-assemble interwoven superstructures" <i>Chem. Eur. J.</i> , 1998, pp. 577-589, Vol. 4, No. 4.	
	R119	BARKER, P. A. <i>et al.</i> "Effect of crystallization temperature on the cocrystallization temperature on the cocrystallization of hydroxybutyrate/ hydroxyvalerate copolymers" <i>Polymer</i> , pp. 913-919, Vol. 38, No. 4.	
	R120	BERKOVITCH-YELLIN, Z. <i>et al.</i> "Electron density distribution in cumulenes: an x-ray study of the complex allenedicarboxylic acid- acetamide (1:1) at -150° C" <i>Acta Cryst.</i> , 1977, pp. 3670-3677, Vol. B33.	
	R121	BERKOVITCH-YELLIN, Z. <i>et al.</i> "The role played by C-H...O and C-H...N interactions in determining molecular packing and conformation" <i>Acta Cryst.</i> , 1984, pp. 159-165, Vol. B40.	
	R122	BERL, V. <i>et al.</i> "Induced fit selection of a barbiturate receptor from a dynamic structural and conformational/configurational library" <i>Eur. J. Org. Chem.</i> , 1999, pp. 3089-3094.	
Examiner Signature	/Renee Clayton/		Date Considered
			09/15/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

J:\TPI\350C\PTO\IDS.form.doc\DNB\gyl

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

NPC-UNIV-000006256

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 978 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	20	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R123	BERTOLASI, V. <i>et al.</i> "Competition between hydrogen bonding and donor-acceptor interactions in co-crystals of 1,3-dimethylbarbituric acid with aromatic amines" <i>New J. Chem.</i> , 2001, pp. 408-415, Vol. 25.	
	R124	BERTOLASI, V. <i>et al.</i> "General rules for the packing of hydrogen-bonded crystals as derived from the analysis of squaric acid anions: aminoaromatic nitrogen base co-crystals" <i>Acta Cryst.</i> , 2001, pp. 591-598, Vol. B57.	
	R125	BETTINETTI, G. <i>et al.</i> "Structure and solid-state chemistry of anhydrous and hydrated crystal forms of the trimethoprim-sulfamethoxypyridazine 1:1 molecular complex" <i>Journal of Pharmaceutical Sciences</i> , April 2000, pp. 478-489, Vol. 89, No. 4.	
	R126	BETTINETTI, G. <i>et al.</i> "Thermal analysis of binary systems of the pharmaceuticals trimethoprim and benzoic acid" <i>Journal of Thermal Analysis</i> , 1983, pp. 285-294, Vol. 28.	
	R127	BETTIS, J. <i>et al.</i> "Biopharmaceutics and dosage form design" <i>Amer. J. Hosp. Pharm.</i> , March 1973, pp. 240-243, Vol. 30.	
	R128	BOLTON, S. <i>et al.</i> "Complexes formed in solution by homologs of caffeine" <i>Journal of the American Pharmaceutical Association</i> , January 1957, pp. 38-41, Vol. XLVI, No. 1.	
	R129	BOND, A. "In situ co-crystallisation as a tool for low-temperature crystal engineering" <i>Chem. Commun.</i> , 2003, pp. 250-251, Vol. 2.	
	R130	BONIN, M. <i>et al.</i> "Urotropin azelate: a rather unwilling co-crystal" <i>Acta Cryst.</i> , 2003, pp. 72-86, Vol. B59.	
	R131	BOSSHARD, C. <i>et al.</i> "Microscopic nonlinearities of two-component organic crystals" <i>J. Opt. Soc. Am. B</i> , November 2001, pp. 1620-1626, Vol. 18, No. 11.	
	R132	GLUZMAN, M. Kh. <i>et al.</i> "Investigation of Eutectic Melting in Systems Composed of Organic Salts and Acids" <i>Journal of Physical Chemistry</i> , 1960, pp. 2742-2747, Vol. 34.	
	R133	BRAGA, D. <i>et al.</i> "Hydrogen bonding interactions between ions: a powerful tool in molecular crystal engineering" <i>Structure and Bonding</i> , 2004, pp. 1-32, Vol. 111.	
	R134	BRIERLEY, C. <i>et al.</i> "Preparation and structure of the 1:2 π -molecular complex of phenothiazine with pyromellitic dianhydride" <i>J. Chem. Phys.</i> , February 1, 1985, pp. 1522-1528, Vol. 82, No. 1.	
Examiner Signature	/Renee Clayton/		Date Considered
			09/15/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

J:\TPI\350C1\PTO\IDS.form.doc/DNB/gyl

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

NPC-UNIV-000006257

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 979 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	21	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R135	BURGI, H. <i>et al.</i> "Crystallisation of supramolecular materials" <i>Current Opinion in Solid State & Materials Science</i> , 1998, pp. 425-430, Vol. 3.	
	R136	BYRN, S. R. <i>et al.</i> "Solid-state pharmaceutical chemistry" <i>Chem. Mater.</i> , 1994, pp. 1148-1158, Vol. 6.	
	R137	CAIRA, M. "Molecular complexes of sulfonamides. Part 1. 1:1 complexes between sulfadimidine [4-amino-N-(4,6-dimethyl-2-pyrimidinyl) benzenesulfonamide] and 2- and 4-aminobenzoic acids" <i>Journal of Crystallographic and Spectroscopic Research</i> , 1991, pp. 641-648, Vol. 21, No. 5.	
	R138	CAIRA, M. "Molecular complexes of sulfonamides. Part 2. 1:1 complexes between drug molecules: sulfadimidine-acetylsalicylic acid and sulfadimidine-4-aminosalicylic acid" <i>Journal of Crystallographic and Spectroscopic Research</i> , 1992, pp. 193-200, Vol. 22, No. 2.	
	R139	CAIRA, M. "Molecular complexes of sulfonamides. 3. Structure of 5-methoxysulfadiazine (Form II) and its 1:1 complex with acetylsalicylic acid" <i>Journal of Chemical Crystallography</i> , 1994, pp. 695-701, Vol. 24, No. 10.	
	R140	CAIRA, M. <i>et al.</i> "Order-disorder enantiotropy, monotropy, and isostructurality in a tetroxoprim-sulfametrole 1:1 molecular complex: crystallographic and thermal studies" <i>Journal of Pharmaceutical Sciences</i> , November 2003, pp. 2164-2176, Vol. 92, No. 11.	
	R141	CAIRA, M. <i>et al.</i> "Selective formation of hydrogen bonded cocrystals between a sulfonamide and aromatic carboxylic acids in the solid state" <i>J. Chem. Soc. Perkin Trans. 2</i> , 1995, pp. 2213-2216.	
	R142	CAIRA, M. <i>et al.</i> "Structure of a 1:1 complex between the anthelmintic drug mebendazole and propionic acid" <i>Journal of Chemical Crystallography</i> , 1998, Vol. 28, No. 1.	
	R143	CAMERMAN, A. <i>et al.</i> "Hydrogen bonding interaction of diphenylbarbituric acid and 9-ethyladenine. Crystal structure of a 1:1 complex" <i>Can. J. Chem.</i> , 2000, pp. 1045-1051, Vol. 78.	
	R144	CAMERMAN, A. <i>et al.</i> "Molecular structure of acetylacetone. A crystallographic determination" <i>J. Am. Chem. Soc.</i> , 1983, pp. 1584-1586, Vol. 105, No. 6.	
	R145	CANNON, A. <i>et al.</i> "Noncovalent derivatization: green chemistry applications of crystal engineering" <i>Crystal Growth & Design</i> , 2002, pp. 255-257, Vol. 2, No. 4.	
Examiner Signature	/Renee Claytor/		Date Considered 09/15/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

J:\TPI350C1\PTO\IDS.form.doc\DNB\gyl

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

NPC-UNIV-000006258

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 980 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	22	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R146	CHINNAKALI, K. <i>et al.</i> "2-aminopyrimidine and <i>p</i> -phenylene-diacetic acid (1:1) co-crystal" <i>Acta Cryst.</i> , 1999, pp. 399-401, Vol. C55.	
	R147	CHOI, C. <i>et al.</i> "Cocrystallization of melaminium levulinate monohydrate" <i>Acta Cryst.</i> , 2004, pp. o295-o296, Vol. C60.	
	R148	CHOW, Y. P. <i>et al.</i> "Complexation of acetaminophen with methyl xanthines" <i>Journal of Pharmaceutical Sciences</i> , 1972, pp. 1454-1458, Vol. 61.	
	R149	CHRISTIAN, S. <i>et al.</i> "Activity coefficient effects in spectral and solubility studies of molecular complex equilibria" <i>Journal of the American Chemical Society</i> , September 20, 1972, pp. 6861-6862, Vol. 94, No. 19, Communications to the editor.	
	R150	COLL, M. <i>et al.</i> "Molecular structure of the complex formed between the anticancer drug cisplatin and d(pGpG): C222 ₁ crystal form" <i>Journal of Biomolecular Structure & Dynamics</i> , 1990, pp. 315-330, Vol. 8, No. 2.	
	R151	COPP, S. <i>et al.</i> "Supramolecular chemistry of [Mn(CO) ₃ (μ ₃ -OH)] ₄ : Assembly of a cubic hydrogen-bonded diamondoid network with 1,2-diamineothane" <i>J. Am. Chem. Soc.</i> , 1992, pp. 8719-8720, Vol. 114.	
	R152	CORDI, A. <i>et al.</i> "(S)-Spiro [(1, 3-diazacyclopent-1-ene)-5, 2' -(7'-methyl-1',2',3',4'-tetrahydronaphthalene)]: resolution, stereospecific synthesis, and preliminary pharmacological characterization as a partial α-adrenergic agonist" <i>J. Med. Chem.</i> , 1997, pp. 2931-2935, Vol. 40.	
	R153	CRAVEN, M. <i>et al.</i> "The 2:1 crystal complex of 5, 5-diethylbarbituric acid (barbital) and caffeine" <i>Acta Cryst.</i> , 1974, pp. 1191-1195, Vol. B30.	
	R154	CRAVEN, M. <i>et al.</i> "The crystal structures of two polymorphs of 5,5'-diethylbarbituric acid (barbital)" <i>Acta Cryst.</i> , 1969, pp. 1978-1993, Vol. B25.	
	R155	CUDNEY, B. <i>et al.</i> "Screening and optimization strategies for macromolecular crystal growth" <i>Acta Cryst.</i> , 1994, pp. 414-423, Vol. D50.	
Examiner Signature	/Renee Claytor/		Date Considered
			09/15/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/660,202
		Filing Date	September 11, 2003
		First Named Inventor	Örn Almarsson
		Group Art Unit	1617
		Examiner Name	Leonard Williams
		Attorney Docket Number	TPI-350C1
Sheet	23	of	36

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R156	DATTA, S. <i>et al.</i> "Molecular complex formation between riboflavin and salicylate in an aqueous medium" <i>Bull. Chem. Soc. Jpn.</i> , 2003, pp. 1729-1734, Vol. 76.	
	R157	DAVEY, R. J. <i>et al.</i> "Crystal engineering- nucleation, the key step" <i>Cryst. Eng. Comm.</i> , 2002, pp. 257-264, Vol. 4, No. 47.	
	R158	DAVEY, R. J. <i>et al.</i> "Crystallisation in polymer films: control of morphology and kinetics of an organic dye in a polysilicone matrix" <i>J. Mater. Chem.</i> , 1997, pp. 237-241, Vol. 7, No. 2.	
	R159	DEBERNARDIS, J. <i>et al.</i> "Conformationally defined adrenergic agents. 5. Resolution, absolute configuration, and pharmacological characterization of the enantiomers of 2-(5,6-dihydroxy-1,2,3,4-tetrahydro-1-naphthyl) imidazoline: a potent agonist at α -adrenoceptors" <i>J. Med. Chem.</i> , 1987, pp. 1011-1017, Vol. 30.	
	R160	DESIRAJU, G. <i>et al.</i> "Crystal and co-crystal" <i>Cryst. Eng. Comm.</i> , 2003, pp. 466-467, Vol. 5, No. 82.	
	R161	DESIRAJU, G. <i>et al.</i> "Crystal engineering: outlook and prospects" <i>Current Science</i> , October 25, 2001, pp. 1038-1042, Vol. 81, No. 8.	
	R162	DUAX, W. <i>et al.</i> "The structure of the crystalline complex estradiol. Urea (1:1)" <i>Acta Cryst.</i> , 1972, pp. 1864-1871, Vol. B28.	
	R163	DUNITZ, J. "Crystal and co-crystal: a second opinion" <i>Cryst. Eng. Comm.</i> , 2003, pp. 506, Vol. 5, No. 91.	
	R164	DUNITZ, J. "New light on an old story: the solid-state transformation on ammonium cyanate into urea" <i>J. Am. Chem. Soc.</i> , 1998, pp. 13274-13275, Vol. 120.	
	R165	ENRIGHT, G. <i>et al.</i> "Thermally programmable gas storage and release in single crystals of an organic van der Waals host" <i>J. Am. Chem. Soc.</i> , 2003, pp. 9896-9897, Vol. 125.	
	R166	EPSTEIN, R. <i>et al.</i> "The x-ray crystal structure of the molecular complex 8-bromo-9-ethyladenine-5-allyl-5-isobutylbarbituric acid" <i>Acta Cryst.</i> , 1976, pp. 2180-2188, Vol. B32.	
Examiner Signature	/Renee Claytor/		Date Considered 09/15/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C1\PTO\IDS.form.doc\DNB\gyl

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/660,202
		Filing Date	September 11, 2003
		First Named Inventor	Örn Almarsson
		Group Art Unit	1617
		Examiner Name	Leonard Williams
		Attorney Docket Number	TPI-350C1
Sheet	24	of	36

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R167	ETTER, M. "Encoding and decoding hydrogen-bond patterns of organic compounds" <i>Acc. Chem. Res.</i> , 1990, pp. 120-126, Vol. 23.	
	R168	ETTER, M. <i>et al.</i> "Graph-set analysis of hydrogen-bond patterns in organic crystals" <i>Acta Cryst.</i> , 1990, pp. 256-262, Vol. B46.	
	R169	ETTER, M. <i>et al.</i> "Hydrogen bond directed cocrystallization and molecular recognition properties of acyclic imides" <i>J. Am. Chem. Soc.</i> , 1991, pp. 2586-2598, Vol. 113.	
	R170	ETTER, M. "Hydrogen bonds as design elements in organic chemistry" <i>J. Phys. Chem.</i> , 1991, pp. 4601-4610, Vol. 95.	
	R171	FABIAN, L. <i>et al.</i> "Volumetric measure of isostructurality" <i>Acta Cryst.</i> , 1999, pp. 1099-1108, Vol. B55.	
	R172	FALLON III, L. "The crystal and molecular structure of 5-fluorouracil" <i>Acta Cryst.</i> , pp. 2549-2556, Vol. B29. 1973	
	R173	FEIBUSH, B. <i>et al.</i> "Chiral separation of heterocyclic drugs by HPLC: solute-stationary phase base-pair interactions" <i>J. Am. Chem. Soc.</i> , 1986, pp. 3310-3318, Vol. 108.	
	R174	FIFER, E. <i>et al.</i> "Fentanyl analogues 3. 2-(1,2,3,4-tetrahydro)-naphthyl substituted 4-anilidopiperidines" <i>Eur. J. Med. Chem.-Chim. Ther.</i> , 1984, pp. 519-524, Vol. 19, No. 6.	
	R175	RECK, G. <i>et al.</i> "Crystal structures of the carbamazepine/ammonium chloride and carbamazepine/ammonium bromide adducts and their transformation into carbamazepine dihydrate" <i>Pharmazie</i> , 1991, pp. 509-512, Vol. 46, No. 7.	X
	R176	FOXMAN, B. M. <i>et al.</i> "Environmentally benign synthesis using crystal engineering: steric accommodation in non-covalent derivatives of hydroquinones" <i>Crystal Engineering</i> , 1998, pp. 109-118, Vol. 1, No. 1.	
	R177	FOXMAN, B. M. <i>et al.</i> "Noncovalent derivatives of hydroquinone: BIS- (N,N-dialkyl) bicyclo[2.2.2]octane-1,4-dicarboxamide complexes" <i>Crystal Engineering</i> , 1999, pp. 55-64, Vol. 2, No. 1.	
	R178	FUJII, S. <i>et al.</i> "Crystal and molecular structure of a 1:1 molecular complex of adenine and riboflavin" <i>Archives of Biochemistry and Biophysics</i> , 1977, pp. 363-370, Vol. 181.	
Examiner Signature	/Renee Claytor/		Date Considered 09/15/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

J:\TPI\350C1\PTOIDS.form.doc/DNB/gyl

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

NPC-UNIV-000006261

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 983 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	25	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R179	GAO, X. <i>et al.</i> "Supramolecular construction of molecular ladders in the solid state" <i>Angew. Chem. Int. Ed.</i> , 2004, pp. 232-236, Vol. 43.	
	R180	GARTLAND, G. L. <i>et al.</i> "Hydrogen bonding NH...O=C of barbiturates: the (1:1) crystal complex of urea and 5,5-diethylbarbituric acid (barbital)" <i>Acta Cryst.</i> , 1974, pp. 980-987, Vol. B30.	
	R181	GHOSH, M. "Structure and conformation of the 1:1 molecular complex sulfaproxyline-caffeine" <i>Acta Cryst.</i> , 1991, pp. 577-580, Vol. C47.	
	R182	GIUSEPPETTI, G. P. <i>et al.</i> "The crystal structure of a sulfamethoxazole-trimethoprim 1:1 molecular compound" <i>Il Farmaco- Ed. Sc.</i> , pp. 138-151, Vol. 35. 1980	
	R183	GOSWAMI, S. <i>et al.</i> "2-aminopyrimidine-fumaric acid cocrystal" <i>Acta Cryst.</i> , 1999, pp. 583-585, Vol. C55.	
	R184	HAYNES, D. "Supramolecular synthon competition in organic sulfonates: A CSD survey" <i>Cryst. Eng. Comm.</i> , 2004, pp. 584-588, Vol. 6, No. 95.	
	R185	GOSWAMI, S. <i>et al.</i> "1:1 Hetero-assembly of 2-amino-pyrimidine and (+)-camphoric acid" <i>Acta Cryst.</i> , 2000, pp. 477-478, Vol. C56.	
	R186	GOSWAMI, S. <i>et al.</i> "Molecular recognition induced supramolecular array of 2-aminopyrimidine with terephthalic acid, 1,4-phenylenediacetic acid and fumaric acid in solid state via H-bonding and π -stacking interactions" <i>Supramolecular Chemistry</i> , 1999, pp. 25-33, Vol. 11.	
	R187	GRAJA, A. <i>et al.</i> "Interplay of acceptor molecule shape, crystal structure and physical properties of a new molecular complex $C_{70} \cdot 2[(Ph_3P) AuCl]$ " <i>Chemical Physics Letters</i> , November 19, 1999, pp. 725-732. Vol. 313.	
	R188	HAIXIN, L. <i>et al.</i> "Structure of the 1:1 complex of 6,6'-diquinolyl ether with 5,5-diethylbarbituric acid" <i>Acta Cryst.</i> , 1992, pp. 2096-2098, Vol. C48.	
Examiner Signature	/Renee Claytor/		Date Considered 09/15/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C\PTO\IDS.form.doc\DNB\gyI

NPC-UNIV-000006262

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 984 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/660,202
		Filing Date	September 11, 2003
		First Named Inventor	Örn Almarsson
		Group Art Unit	1617
		Examiner Name	Leonard Williams
Sheet	26	of	36
		Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R189	HENCK, J. <i>et al.</i> "Disappearing and reappearing polymorphs. The benzocaine:picric acid system" <i>J. Am. Chem. Soc.</i> , 2001, pp. 1834-1841, Vol. 123.	
	R190	HIGUCHI, T. <i>et al.</i> "Complexation of organic substances in aqueous solution by hydroxyaromatic acids and their salts" <i>J. Pharm. Sci.</i> , 1961, pp. 905-909, Vol. 50.	
	R191	HINO, T. <i>et al.</i> "Assessment of nicotinamide polymorphs by differential scanning calorimetry" <i>Thermochimica Acta</i> , 2001, pp. 85-92, Vol. 374.	
	R192	HÖGBERG, T. <i>et al.</i> "Crystallographic, theoretical and molecular modelling studies on the conformations of the salicylamide, raclopride, a selective dopamine-D ₂ antagonist" <i>J. Pharm. Pharmacol.</i> , 1987, pp. 787-796, Vol. 39.	
	R193	HSU, I. <i>et al.</i> "The 2:1 crystal complex of 2-aminopyridine and 5,5-diethylbarbituric acid (barbital)" <i>Acta Cryst.</i> , 1974, pp. 994-997, Vol. B30.	
	R194	HSU, I. <i>et al.</i> "The 1:1 crystal complex of N-methyl-2-pyridone and 5,5-diethylbarbituric acid (barbital)" <i>Acta Cryst.</i> , 1974, pp. 998-1001, Vol. B30.	
	R195	HSU, I. <i>et al.</i> "The crystalline complex (1:1) of salicylamide and 5-ethyl-5-isoamylbarbituric acid (amobarbital)" <i>Acta Cryst.</i> , 1974, pp. 843-846, Vol. B30.	
	R196	HSU, I. <i>et al.</i> "The crystal structure of the 1:1 complex of acetamide with 5,5-diethylbarbituric acid (barbital)" <i>Acta Cryst.</i> , 1974, pp. 974-979, Vol. B30.	
	R197	HSU, I. <i>et al.</i> "The crystal structure of the triclinic 1:2 complex of hexamethylphosphoramide with 5,5-diethylbarbituric acid (barbital)" <i>Acta Cryst.</i> , 1974, pp. 1299-1304, Vol. B30.	
	R198	HSU, I. <i>et al.</i> "Hydrogen bonding NH...N of barbiturates: The 1:1 crystal complex of imidazole and 5,5-diethylbarbituric acid (barbital)" <i>Acta Cryst.</i> , 1974, pp. 988-993, Vol. B30.	
	R199	IBRAGIMOV, B. "A simple correlation between the structures of different crystal modifications of a given host-guest complex and their crystallization temperatures" <i>Journal of Inclusion of Phenomena and Macrocyclic Chemistry</i> , 1999, pp. 345-353, Vol. 34.	
Examiner Signature	/Renee Claytor/		Date Considered 09/15/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

J:\TPI\350C1\PTOIDS.form.doc\DNB\gyl

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

NPC-UNIV-000006263

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 985 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	27	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	R200	ISHIDA, T. <i>et al.</i> "Structural study of histamine H ₂ -receptor antagonists. Five 3-[2-(diamino-methyleneamino)-4-thiazolymethylthio] propionamidine and -amide derivatives" <i>Acta Cryst.</i> , 1989, pp. 505-512, Vol. B45.		
	R201	KATAKAI, R. <i>et al.</i> "Stepwise synthesis of oligopeptides with N-carboxy-α-amino acid anhydrides. IV. Glycine NCA" <i>J. Org. Chem.</i> , 1972, pp. 327-329, Vol. 37, No. 2.		
	R202	KAWAKAMI, Y. <i>et al.</i> "The rationale for E2020 as a potent acetylcholinesterase inhibitor" <i>Bioorganic & Medicinal Chemistry</i> , 1996, pp. 1429-1446, Vol. 4, No. 9.		
	R203	KELDERS, H. <i>et al.</i> "Automated protein crystallization and a new crystal form of a subtilisin: eglin complex" <i>Protein Engineering</i> , 1987, pp. 301-303, Vol. 1, No. 4.		
	R204	KHALIL, R. M. "Complexation of paracetamol with xanthine derivatives" <i>Egypt. J. Pharm. Sci.</i> , 1992, pp. 757-769, Vol. 33, No. 5-6.		
	R205	KIM, S. "Crystal structure of the 1:1 complex of 5-fluorouracil and 9-ethylhypoxanthine" <i>Science</i> , November 24, 1967, pp. 1046-1048, Vol. 158, No. 3804.		
	R206	KIRYU, S. <i>et al.</i> "Crystal structure of a 1:1 aminopyrine-barbital complex" <i>Journal of Pharmaceutical Sciences</i> , May 1971, pp. 699-703, Vol. 60, No. 5.		
	R207	KIRYU, S. <i>et al.</i> "Crystal structure of a 1:1 aminopyrine-cyclobarbital complex" <i>Chem. Pharm. Bull.</i> , 1974, pp. 1588-1592, Vol. 22.		
	R208	KLEIN, C. <i>et al.</i> "Molecular structure of two conformationally restrained fentanyl analogues: cis- and trans-isomers of N-{3-methyl-1-[1,2,3,4-tetrahydro naphthyl]-4-piperidinyll}-N-phenylpropanamide" <i>Journal of Pharmaceutical Sciences</i> , November 1985, pp. 1147-1151, Vol. 74, No. 11.		
	R209	KOSHIMA, H. <i>et al.</i> "Photoreactivities of two kinds of bimolecular crystals formed from acridine and phenothiazine" <i>J. Chem. Soc., Perkins Trans. 2</i> , 1997, pp. 2033-2038.		
	R210	KOSHIMA, H. <i>et al.</i> "Polymorphs of a cocrystal with achiral and chiral structures prepared by pseudoseeding: tryptamine/hydrocinnamic acid" <i>Crystal Growth & Design</i> , 2001, pp. 355-357, Vol. 1, No. 5.		
Examiner Signature	/Renee Claytor/		Date Considered	09/15/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C1\PTO\IDS.form.doc\DNB\gyI

NPC-UNIV-000006264

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 986 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/660,202
		Filing Date	September 11, 2003
		First Named Inventor	Örn Almarsson
		Group Art Unit	1617
		Examiner Name	Leonard Williams
Sheet	28	of	36
		Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R211	KRISHNAMOHAN SHARMA, C. V. <i>et al.</i> "X-ray crystal structure of C ₆ H ₃ (CO ₂ H) ₃ -1,3,5-1.5(4,4'-bipy): a 'super trimesic acid' chicken-wire grid" <i>Chem. Commun.</i> , 1996, pp. 2655-2656.	
	R212	KURODA, R. <i>et al.</i> "Generation of a co-crystal phase with coloristic properties <i>via</i> solid state grinding procedures" <i>Chem. Commun.</i> , 2002, pp. 2848-2849.	
	R213	LEISEROWITZ, L. <i>et al.</i> "The molecular packing modes and hydrogen-bonding properties of amide: dicarboxylic acid complexes" <i>Acta Cryst.</i> , 1977, pp. 2719-2733, Vol. B33.	
	R214	LEISEROWITZ, L. "Molecular packing modes. Carboxylic acids" <i>Acta Cryst.</i> , 1976, pp. 775-802, Vol. B32.	
	R215	LYNCH, D. <i>et al.</i> "Molecular cocrystals of carboxylic acids. XXXI* adducts of 2-aminopyrimidine and 3-amino-1,2,4-triazole with heterocyclic carboxylic acids" <i>Aust. J. Chem.</i> , 1998, pp. 403-408, Vol. 51.	
	R216	MACGILLIVRAY, L. <i>et al.</i> "Supramolecular control of reactivity in the solid state using linear molecular templates" <i>J. Am. Chem. Soc.</i> , 2000, pp. 7817-7818, Vol. 122.	
	R217	MATHIAS, J. <i>et al.</i> "Structural preferences of hydrogen-bonded networks in organic solution- the cyclic CA ₃ * M ₃ 'rosette'" <i>J. Am. Chem. Soc.</i> , 1994, pp. 4316-4325, Vol. 116.	
	R218	MASTROPAOLO, D. <i>et al.</i> "Hydrogen bonding interaction of diphenylhydantoin and 9-ethyladenine" <i>Molecular Pharmacology</i> , 1983, pp. 273-277, Vol. 23.	
	R219	MARYANOFF, B. "Stereochemistry in a medium-sized ring. Highly diastereoselective N-oxidation of a substituted 3-benzazonine. X-ray crystal structure of an unusual complex between an amine N-oxide and saccharin" <i>J. Org. Chem.</i> , 1990, pp. 760-764, Vol. 55.	
	R220	MARTIN, R. <i>et al.</i> "The caffeine-potassium chlorogenate molecular complex" <i>Phytochemistry</i> , 1987, pp. 273-279, Vol. 26, No. 1.	
	R221	ANDERSON, J. "Constitution of aurous compounds: Gold mirrors" <i>Nature</i> , October 2, 1937, pp. 583-584, Letters to the Editor.	
Examiner Signature	/Renee Clayton/		Date Considered 09/15/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C1\PTOIDS.form.doc\DNB\gyl

NPC-UNIV-000006265

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 987 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/660,202
		Filing Date	September 11, 2003
		First Named Inventor	Örn Almarsson
		Group Art Unit	1617
		Examiner Name	Leonard Williams
		Attorney Docket Number	TPI-350C1
Sheet	29	of	36

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R222	ROBBINS, A. H. <i>et al.</i> "The crystal structure of the 1:2 adduct of potassium triiodide and 5,5-diethylbarbituric acid (barbital)" <i>American Crystallographic Association- Series 2, Papers and Abstracts</i> , 1973, p. 87.	
	R223	BEERGES, P. <i>et al.</i> "Phenothiazine tetracyanoethylene" <i>Private Communication</i> , 1994.	
	R224	MADARASZ, J. <i>et al.</i> "Thermal, ftr and xrd study on some 1:1 molecular compounds of theophylline" <i>Journal of Thermal Analysis and Calorimetry</i> , 2002, pp. 281-290, Vol. 69.	
	R225	CARONNA, T. <i>et al.</i> "Halogen bonding and $\pi\cdots\pi$ stacking control reactivity in the solid state" <i>J. Am. Chem. Soc.</i> , 2004, pp. 4500-4501, Vol. 126.	
	R226	ZERKOWSKI, J. <i>et al.</i> "Steric control of secondary, solid-state architecture in 1:1 complexes of melamines and barbiturates that crystallize as crinkled tapes" <i>J. Am. Chem. Soc.</i> , 1994, pp. 4298-4304, Vol. 116.	
	R227	ZAITU, S. <i>et al.</i> "1:1 Molecular complex of theophylline and <i>p</i> -nitroaniline" <i>Acta Cryst.</i> , 1995, pp. 2390-2392, Vol. C51.	
	R228	KOFLER, L. <i>et al.</i> , <i>Thermal micromethods for the study of organic compounds and their mixtures</i> , pp. 1-145, 148-351, 354-386, Innsbruck, Austria, 1980.	
	R229	QUEHENBERGER, H. "Concerning organic molecular compounds and their polymorphism" <i>Monatshefte für Chemie</i> , 1949, pp. 595-606, Vol. 80, No. 5.	X
	R230	WIEDENFELD, H. <i>et al.</i> "The crystal structure of the theophylline-urea complex" <i>Arch. Pharm.</i> , 1986, pp. 654-659, Vol. 319.	X
	R231	BUNICK, G. <i>et al.</i> "The crystal and molecular structure of the complex 2,6-diamino-9-ethylpurine 5,5-diethylbarbituric acid" <i>American Crystallographic Association, Abstract Papers</i> Winter 1976, p. 30.	
	R232	BUZAK, G. <i>et al.</i> "Crystal structure and vibrational spectra of the 1:1 and 1:2 complexes of pyridine betaine with pentachlorophenol" <i>Journal of Molecular Structure</i> , 1997, pp. 143-151, Vol. 436-437.	
Examiner Signature	/Renee Claytor/		Date Considered 09/15/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C1\PTOIDS.form.doc\DNB\gyl

NPC-UNIV-000006266

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 988 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/660,202
		Filing Date	September 11, 2003
		First Named Inventor	Örn Almarsson
		Group Art Unit	1617
		Examiner Name	Leonard Williams
		Attorney Docket Number	TPI-350C1
Sheet	23	of	36

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R233	TOMURA, M. <i>et al.</i> "One-dimensional zigzag chain structures with intermolecular C-H... π and C-H...O interactions consisted of phthalic acid and pyridine derivatives" <i>Chemistry Letters</i> , 2001, pp. 532-533.	
	R234	ZERKOWSKI, J. <i>et al.</i> "Design of organic structures in the solid state: molecular tapes based on the network of hydrogen bonds present in the cyanuric acid-melamine complex" <i>J. Am. Chem. Soc.</i> , 1994, pp. 2382-2391, Vol. 116.	
	R235	HARKEMA, S. <i>et al.</i> "The crystal structure of urea oxalic acid (2:1)" <i>Acta Cryst.</i> , 1972, pp. 1646-1648, Vol. B28.	
	R236	KRANTZ, J. <i>et al.</i> "Sodium theophylline glycinate" <i>Journal of the American Pharmaceutical Association</i> , 1946, pp. 248-250.	
	R237	DATTA, S. <i>et al.</i> "Crystal structures of drugs: advances in determination, prediction and engineering" <i>Nature</i> , January 2004, pp. 42-57, Vol. 3.	
	R238	AAKERÖY, C. <i>et al.</i> "Charge-assisted hydrogen bonds and halogen-halogen interactions in organic salts: benzylammonium benzoates and pentafluorobenzoates" <i>Structural Chemistry</i> , 1999, pp. 229-242, Vol. 10, No. 3.	
	R239	CHILDS, S. <i>et al.</i> "Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids" <i>J. Am. Chem. Soc.</i> , 2004, pp. 13335-13342, Vol. 126.	
	R240	AAKERÖY, C. <i>et al.</i> "Modular supramolecular synthesis based on a dominance hierarchy of intermolecular interactions (Abstract)" 223 rd ACS National Meeting in Orlando, FL., April 7-11, 2002, published by the American Chemical Society, Washington, D.C.	
	R241	HELFRICH, B. <i>et al.</i> "Polymorphism as an indication of structural versatility (Abstract)" 223 rd ACS National Meeting in Orlando, FL., April 7-11, 2002, published by the American Chemical Society, Washington, D.C.	
	R242	WEBER, E. <i>et al.</i> "Synthesis of new Schiff bases: reaction of monofluorobenzaldehydes with 3-aminosulfolane hydrochloride (Abstract)" 216 th ACS National Meeting in Boston, MA., August 23-27, 1998, published by the American Chemical Society, Washington, D.C.	

Examiner Signature	/Renee Clayton/	Date Considered	09/15/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

J:\TPI\350C\PTO\IDS form.doc\DNB\gyl

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

NPC-UNIV-000006267

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 989 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/660,202
		Filing Date	September 11, 2003
		First Named Inventor	Örn Almarsson
		Group Art Unit	1617
		Examiner Name	Leonard Williams
		Attorney Docket Number	TPI-350C1
Sheet	31	of	36

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R243	SCARBROUGH, F. <i>et al.</i> "Crystal structure of a complex between lumiflavin and 2,6-diamino-9-ethylpurine: a flavin adenine dinucleotide model exhibiting charge-transfer interactions" <i>Proc. Natl. Acad. Sci. USA</i> , November 1976, pp. 3807-3811, Vol. 73, No. 11.	
	R244	MUNN, R. <i>et al.</i> "A Model for resonance-assisted hydrogen bonding in crystals and its graph set analysis" <i>J. Phys. Chem. A</i> , 2001, pp. 6938-6942, Vol. 105.	
	R245	LYNCH, D. <i>et al.</i> "1:1 Molecular complexes of 4-amino-N-(4,6-dimethylpyrimidin-2-yl) benzene-sulfonamide (sulfamethazine) with indole-2-carboxylic acid and 2,4-dinitrobenzoic acid" <i>Aust. J. Chem.</i> , 2000, pp. 383-387, Vol. 53.	
	R246	AAKERÖY, C. <i>et al.</i> "Solid state, crystal engineering and hydrogen bonds" <i>Comprehensive Coordination Chemistry II</i> (ed. by McCleverty, J. <i>et al.</i>), pp. 679-688, Elsevier Ltd., Oxford, UK.	
	R247	LEVIN, B. <i>et al.</i> "The not-so-trivial synthesis and characterization of heterocyclic boronic acids (Abstract)" 38 th Midwest Regional Meeting of the American Chemical Society in Columbia, MO., November 5-7, 2003, published by the American Chemical Society, Washington, D.C.	
	R248	SMITH, G. <i>et al.</i> "Interactions of aromatic carboxylic acids with quinolin-8-ol (oxine): Synthesis and the crystal structures of the proton-transfer compounds with the nitro-substituted benzoic acids" <i>Aust. J. Chem.</i> , 2001, pp. 171-175, Vol. 54.	
	R249	STALKER, R. <i>et al.</i> "Asymmetric synthesis of two new conformationally constrained lysine derivatives" <i>Tetrahedron</i> , 2002, pp. 4837-4849, Vol. 58.	
	R250	VOET, D. <i>et al.</i> "Barbiturates and adenine derivatives. Molecular structure of a hydrogen-bonded complex" <i>Journal of the American Chemical Society</i> , August 9, 1972, pp. 5888-5891, Vol. 94, No. 16.	
	R251	VISHWESHWAR, P. <i>et al.</i> "Molecular complexes of homologous alkanedicarboxylic acids with isonicotinamide: X-ray crystal structures, hydrogen bond synthons, and melting point alternation" <i>Crystal Growth & Design</i> , 2003, pp. 783-790, Vol. 3, No. 5.	
	R252	LE JEUNNE, C. <i>et al.</i> "Comparative efficacy and safety of calcium carbasalate plus metoclopramide versus ergotamine tartrate plus caffeine in the treatment of acute migraine attacks" <i>Eur. Neurol.</i> , 1999, pp. 37-43, Vol. 41.	
	R253	AAKERÖY, C. <i>et al.</i> "Hydrogen-bonded layers of hydrogentartrate anions: two-dimensional building blocks for crystal engineering" <i>J. Mater. Chem.</i> , 1993, 1129-1135, Vol. 3, No. 11.	

Examiner Signature	/Renee Claytor/	Date Considered	09/15/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

J:\TPI\350C1\PTOIDS.form.doc/DNB/gyl

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

NPC-UNIV-000006268

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 990 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	32	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R254	HU, Z. <i>et al.</i> "Separation of 4-aminobenzoic acid by cocrystallization: Crystal structure of the complex of 4-aminobenzoic acid with (2R,3R)-tartaric acid" <i>Journal of Chemical Crystallography</i> , December 2002, pp. 525-529, Vol. 32, No. 12.	
	R255	GUARRERA, D. <i>et al.</i> "Molecular self-assembly in the solid state. The combined use of solid state NMR and differential scanning calorimetry for the determination of phase constitution" <i>Chem. Mater.</i> , 1994, pp. 1293-1296, Vol. 6.	
	R256	DOI, M. <i>et al.</i> "Conformational study of a potent human renin inhibitor: x-ray crystal structure of isopropyl (2R, 3S) -4-cyclohexyl-2-hydroxy-3-{N-[(2R)-2-morpholinocarbonylmethyl-3-(1-naphthyl) propionyl] -L-histidylamino}butyrate (KRI-1314), a pentapeptide analogue with amino acid sequence corresponding to the cleavage site of angiotensinogen" <i>J. Chem. Soc. Perkin Trans. 1</i> , 1991, pp. 1153-1158.	
	R257	CRIFIELD, A. <i>et al.</i> "Crystal engineering through halogen bonding. 2. Complexes of diacetylene-linked heterocycles with organic iodides" <i>Crystal Growth & Design</i> , 2003, pp. 313-320, Vol. 3, No. 3.	
	R258	AAKERÖY, C. <i>et al.</i> "A versatile route to porous solids: organic-inorganic hybrid materials assembled through hydrogen bonds" <i>Angew. Chem. Int. Ed.</i> , 1999, pp. 1815-1819, Vol. 38, No. 12.	
	R259	SHEFTER, E. <i>et al.</i> , ACS, Abstr. Papers (Summer), 1970, 35, compound name: sulfathiazole-theophylline complex.	
	R260	SHEFTER, E. <i>et al.</i> , ACS, Abstr. Papers (Summer), 1970, 35, compound name: sulfathiazole-sulfanilamide complex.	
	R261	WIEDENFELD, H. <i>et al.</i> "Solubilization of aminophenazone" <i>Arch. Pharm.</i> , 1982, pp. 633-641, Vol. 315.	x
	R262	CACCIAPUOTI, A. <i>et al.</i> "In vitro and in vivo activities of SCH 56592 (Posaconazole), a new triazole antifungal agent, against <i>Aspergillus</i> and <i>Candida</i> " <i>Antimicrobial Agents and Chemotherapy</i> , August 2000, pp. 2017-2022, Vol. 44, No. 8.	
	R263	CALLAHAN, J.C. <i>et al.</i> "Equilibrium moisture content of pharmaceutical excipients" <i>Drug Development and Industrial Pharmacy</i> , 1982, pp. 355-369, Vol. 8, No. 3.	
	R264	DANNAOUI, E. <i>et al.</i> "Acquired itraconazole resistance in <i>Aspergillus fumigatus</i> " <i>Journal of Antimicrobial Chemotherapy</i> , 2001, pp. 333-340, Vol. 47.	

Examiner Signature	/Renee Clayton/	Date Considered	09/15/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

J:\TPI\350C1\PTO\IDS.form.doc\DNB\gyl

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

NPC-UNIV-000006269

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 991 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/660,202
		Filing Date	September 11, 2003
		First Named Inventor	Örn Almarsson
		Group Art Unit	1617
		Examiner Name	Leonard Williams
		Attorney Docket Number	TPI-350C1
Sheet	33	of	36

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R265	DENNING, D. W. <i>et al.</i> "In vitro activity of Saperconazole (R66 905) compared with Amphotericin B and Itraconazole against <i>Aspergillus</i> species" <i>Eur. J. Clin. Microbial. Infect. Dis.</i> , 1990, pp. 693-697, Vol. 9.	
	R267	DRESSMAN, J. B. <i>et al.</i> "Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms" <i>Pharmaceutical Research</i> , 1998, pp. 11-22, Vol. 15, No. 1.	
	R268	EBERT, W. R. "Soft elastic gelatin capsules: a unique dosage form" <i>Pharmaceutical Technology</i> , October 1977, pp. 44-50, Vol. 1, No. 5.	
	R269	GASCON, M. -P. <i>et al.</i> "In vitro forecasting of drugs which may interfere with the biotransformation of midazolam" <i>Eur. J. Clin. Pharmacol.</i> , 1991, pp. 573-578, Vol. 41.	
	R270	HEERES, J. <i>et al.</i> "Antimycotic azoles. 7. Synthesis and antifungal properties of a series of novel triazol-3-ones" <i>J. Med. Chem.</i> , 1984, pp. 894-900, Vol. 27.	
	R271	HONIG, P. K. <i>et al.</i> "Itraconazole affects single-dose Terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics" <i>J. Clin. Pharmacol.</i> , 1993, pp. 1201-1206, Vol. 33.	
	R272	IMAI, T. <i>et al.</i> "Successful treatment of cerebral Aspergillosis with a high oral dose of Itraconazole after excisional surgery" <i>Internal Medicine</i> , October 1999, pp. 829-832, Vol. 38, No. 10.	
	R273	KOVACS, J. <i>et al.</i> "New type of bridged monoamino-β-cyclodextrins" <i>Journal of Inclusion Phenomena and Molecular Recognition in Chemistry</i> , 1996, pp. 53-56, Vol. 25.	
	R274	LAVRIJSEN, A. P. M. <i>et al.</i> "Hepatic injury associated with itraconazole" <i>The Lancet</i> , July 25, 1992, pp. 251-252, Vol. 340.	
	R275	NEUVONEN, P. J. <i>et al.</i> "Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid" <i>Clinical Pharmacology & Therapeutics</i> , 1996, pp. 54-61, Vol. 60, No. 1.	
	R276	NOMEIR, A. A. <i>et al.</i> "Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys" <i>Antimicrobial Agents and Chemotherapy</i> , March 2000, pp. 727-731, Vol. 44, No. 3.	

Examiner Signature	/Renee Clayton/	Date Considered	09/15/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C1\PTO\IDS.form.doc\DNB\gyI

NPC-UNIV-000006270

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 992 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/660,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Leonard Williams		
Sheet	34	of	36	Attorney Docket Number	TPI-350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R277	ODDS, F. C. "Antifungal activity of saperconazole (R 66 905) <i>in vitro</i> " <i>Journal of Antimicrobial Chemotherapy</i> , 1989, pp. 533-537, Vol. 24.	
	R278	REMENAR, J. F. <i>et al.</i> "Crystal engineering of novel cocrystals of a triazole drug with 1,4-dicarboxylic acids" <i>J. Am. Chem. Soc.</i> , 2003, pp. 8456-8457, Vol. 125.	
	R279	SAKSENA, A. K. <i>et al.</i> "Advances in the chemistry of novel broad-spectrum orally active azole antifungals: recent studies leading to the discovery of SCH 56592" in <i>Advances in the Chemistry of Novel Broad-Spectrum Orally Active Azole Antifungals</i> (Royal Soc. Chem., Cambridge), 1997, pp. 180-199.	
	R280	SAKSENA, A. K. <i>et al.</i> "Concise asymmetric routes to 2,2,4-trisubstituted tetrahydrofurans via chiral titanium imide enolates: key intermediates towards synthesis of highly active azole antifungals SCH 51048 and SCH 56592" <i>Tetrahedron Letters</i> , 1996, pp. 5657-5660, Vol. 37, No. 32.	
	R281	HEPPERLE, M. <i>et al.</i> "Mono <i>N</i> -arylation of piperazine(III): metal-catalyzed <i>N</i> -arylation and its application to the novel preparations of the antifungal posaconazole and its advanced intermediate" <i>Tetrahedron Letters</i> , 2002, pp. 3359-3363, Vol. 43.	
	R282	CUTSEM, J. V. <i>et al.</i> "Oral and parenteral therapy with saperconazole (R 66905) of invasive aspergillosis in normal and immunocompromised animals" <i>Antimicrobial Agents and Chemotherapy</i> , December 1989, pp. 2063-2068, Vol. 33, No. 12.	
	R283	VILLA, L. A. <i>et al.</i> "Central nervous system paracoccidioidomycosis. Report of a case successfully treated with itraconazole" <i>Rev. Inst. Med. Trop. S. Paulo</i> , July-August, 2000, pp. 231-234, Vol. 42, No. 4.	
	R284	WEST, A. R., "Solid Solutions" In: <i>Solid State Chemistry and its Applications</i> , 1988, p. 358, p. 365, Wiley, NY.	
	R285	ARONHIME, J. <i>et al.</i> "Crystalline forms of pharmaceuticals and characterization thereof", Oral Presentation, March 8, 2005, USPTO, Alexandria, VA.	
	R286	DESIRAJU, G. R. "Chemistry beyond the molecule" <i>Nature</i> , July 26, 2001, pp. 397-400, Vol. 412.	
	R287	GAVEZZOTTI, A. "Are crystal structures predictable?" <i>Acc. Chem. Res.</i> , 1994, pp. 309-314, Vol. 27.	

Examiner Signature	/Renee Claytor/	Date Considered	09/15/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

J:\TPI\350C1\PTOIDS.form.doc\DNB\gyl

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

NPC-UNIV-000006271

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 993 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/660,202
		Filing Date	September 11, 2003
		First Named Inventor	Örn Almarsson
		Group Art Unit	1617
		Examiner Name	Leonard Williams
		Attorney Docket Number	TPI-350C1
Sheet	35	of	36

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R288	Physician's Desk Reference, 56 th Ed., pp. 1800-1804, 2002.	
	R289	KIM, H. <i>et al.</i> "High-performance liquid chromatographic analysis of the anti-fungal agent SCH 56592 in dog serum" <i>Journal of Chromatography B</i> , 2000, pp. 93-98, Vol. 738.	
	R290	VIPPAGUNTA, S. R. <i>et al.</i> "Crystalline solids" <i>Advanced Drug Delivery Reviews</i> , 2001, pp. 3-26, Vol. 48.	
	R291	MCCRONE, W. C. "Polymorphism", In: <i>The Physics and Chemistry of the Organic Solid State</i> , Vol. II, FOX, D. <i>et al.</i> (eds.), 1965, pp. 725-767, Interscience, New York.	
	R292	LEGER, J.M. <i>et al.</i> "Crystal Structure of the 1:1 Sulfacetamide-Caffeine Complex" <i>Acta Cryst.</i> , 1977, pp. 1455-1459, Vol. B33.	X
	R293	SIMONOV, Y. <i>et al.</i> "Structure of the caffeine-copper(II) acetate additional compound", <i>Izvestiya Akademii Nauk Moldavskoi SSR, Seriya Fiziko-Tekhnicheskikh i Matematicheskikh Nauk</i> , 1972, Vol. 3, pp. 83-84, abstract only.	
	R294	WEISSBUCH, I. <i>et al.</i> "Understanding and control of nucleation, growth, habit, dissolution and structure of two- and three-dimensional crystals using 'tailor-made' auxiliaries" <i>Acta Cryst.</i> , 1995, B51:115-148.	
	R295	FAUGHT, E. <i>et al.</i> "Topiramate Dose-Ranging Trial in Refractory Partial Epilepsy", <i>Amer. Epilepsy Soc. Proc.</i> , (1995), pg. 33, Vol. 36, Supp. 4.	
	R296	PRIVITERA, M. <i>et al.</i> "Dose-Ranging Trial with Higher Doses of Topiramate in Patients with Resistant Partial Seizures", <i>Amer. Epilepsy Soc. Proc.</i> , 1995, pg. 33, Vol. 36, Supp. 4.	
	R297	SACHDEO, S. K. <i>et al.</i> "Topiramate: Double-Blind Trial as Monotherapy", <i>Amer. Epilepsy Soc. Proc.</i> , 1995, pg. 33, Vol. 36, Supp. 4.	
	R298	Press Release. "Clinical Development of Topiramate for Obesity Extended to Simplify Dosing, Improve Tolerability". http://www.orthomcneil.com/news/article020402.html (February 4, 2002), N.J.	X

Examiner Signature	/Renee Claytor/	Date Considered	09/15/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C1\PTO\IDS.form.doc\DNB\gyI

NPC-UNIV-000006272

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 994 of 1101

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/660,202
		Filing Date	September 11, 2003
		First Named Inventor	Örn Almarsson
		Group Art Unit	1617
		Examiner Name	Leonard Williams
		Attorney Docket Number	TPI-350C1
Sheet	36	of	36

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R299	ROSENFELD, W. E. "Topiramate: A Review of Preclinical, Pharmacokinetic, and Clinical Data", <i>Clinical Therapeutics</i> , 1997, pp. 1294-1308, Vol. 19, No. 6.	
	R300	Physician's Desk Reference, 56 th Edition, 2002, pp. 2590-2595.	
	R301	DATABASE WPI, Section Ch, Week 197936, Derwent Publishing Ltd., London, Great Britain, Class B02, AN 1979-65538B, XP002282989 and JP 54 095589A (Sumitomo) 1979 Abstract.	
	R302	FUNG <i>et al.</i> , "Solvent Effects on Comparative Dissolution of Pharmaceutical Solvates," <i>Chem. Farm. Bull.</i> , 22(2), pgs. 454-458 (1974).	
	R303	RUBINO <i>et al.</i> , "Influence of Solvent Composition on the Solubilities and Solid-State Properties of the Sodium Salts of Some Drugs", <i>Int. J. of Pharma</i> , 65, pgs. 141-145 (1990).	
	R304	FITZGERALD, G. A. "The Coxibs, Selective Inhibitors of Cyclooxygenase-2", <i>New England Journal of Medicine</i> , Vol. 345, No. 6, August 9, 2001.	
	R305		
	R306		
	R307		
	R308		
	R309		

Examiner Signature	/Renee Claytor/	Date Considered	09/15/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

23557 7590 09/20/2010
SALIWANCHIK LLOYD & SALIWANCHIK
A PROFESSIONAL ASSOCIATION
PO Box 142950
GAINESVILLE, FL 32614

EXAMINER	
CLAYTOR, DEIRDRE RENEE	
ART UNIT	PAPER NUMBER
1627	

DATE MAILED: 09/20/2010

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/660,202	09/11/2003	Orn Almarsson	TPI.350C1	6536

TITLE OF INVENTION: PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS

APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	YES	\$755	\$300	\$0	\$1055	12/20/2010

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. **PROSECUTION ON THE MERITS IS CLOSED.** THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN **THREE MONTHS** FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. **THIS STATUTORY PERIOD CANNOT BE EXTENDED.** SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

B. If the status above is to be removed, check box 5b on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above, or

If the SMALL ENTITY is shown as NO:

A. Pay TOTAL FEE(S) DUE shown above, or

B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check box 5a on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and 1/2 the ISSUE FEE shown above.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: **Mail** **Mail Stop ISSUE FEE**
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
or Fax **(571)-273-2885**

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

23557 7590 09/20/2010

SALIWANCHIK LLOYD & SALIWANCHIK
A PROFESSIONAL ASSOCIATION
PO Box 142950
GAINESVILLE, FL 32614

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

(Depositor's name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/660,202 09/11/2003 Orn Almarsson TPI.350C1 6536

TITLE OF INVENTION: PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS

APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
-------------	--------------	---------------	---------------------	----------------------	------------------	----------

nonprovisional YES \$755 \$300 \$0 \$1055 12/20/2010

EXAMINER	ART UNIT	CLASS-SUBCLASS
----------	----------	----------------

CLAYTOR, DEIRDRE RENEE 1627 424-400000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.

☐ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. **Use of a Customer Number is required.**

2. For printing on the patent front page, list

(1) the names of up to 3 registered patent attorneys or agents OR, alternatively, 1 _____

(2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed. 2 _____

3 _____

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE

(B) RESIDENCE: (CITY and STATE OR COUNTRY)

Please check the appropriate assignee category or categories (will not be printed on the patent): ☐ Individual ☐ Corporation or other private group entity ☐ Government

4a. The following fee(s) are submitted:

- ☐ Issue Fee
☐ Publication Fee (No small entity discount permitted)
☐ Advance Order - # of Copies _____

4b. Payment of Fee(s): (Please first reapply any previously paid issue fee shown above)

- ☐ A check is enclosed.
☐ Payment by credit card. Form PTO-2038 is attached.
☐ The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment, to Deposit Account Number _____ (enclose an extra copy of this form).

5. Change in Entity Status (from status indicated above)

- ☐ a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. ☐ b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2).

NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.

Authorized Signature _____

Date _____

Typed or printed name _____

Registration No. _____

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/660,202	09/11/2003	Orn Almarsson	TPL350C1	6536
23557	7590	09/20/2010		
SALIWANCHIK LLOYD & SALIWANCHIK A PROFESSIONAL ASSOCIATION PO Box 142950 GAINESVILLE, FL 32614				
			EXAMINER CLAYTOR, DEIRDRE RENEE	
			ART UNIT	PAPER NUMBER
			1627	
DATE MAILED: 09/20/2010				

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
(application filed on or after May 29, 2000)

The Patent Term Adjustment to date is 572 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 572 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (<http://pair.uspto.gov>).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

Notice of Allowability	Application No.	Applicant(s)	
	10/660,202	ALMARSSON ET AL.	
	Examiner	Art Unit	
	Renee Claytor	1627	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to the RCE filed on 3/12/2010.

2. ☒ The allowed claim(s) is/are 43-78 (renumbered as claims 1-36).

3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) ☐ All b) ☐ Some* c) ☐ None of the:
 1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).
 * Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

4. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.

5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
 (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).

6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☐ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 3. ☒ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date <u>See Continuation Sheet</u> 4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	5. ☐ Notice of Informal Patent Application 6. ☐ Interview Summary (PTO-413), Paper No./Mail Date _____. 7. ☐ Examiner's Amendment/Comment 8. ☒ Examiner's Statement of Reasons for Allowance 9. ☐ Other _____.
--	---

Continuation of Attachment(s) 3. Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date: 3/12/2010; 3/31/2010; 4/12/2010; 5/20/2010 8/16/2010.

Request for Continued Examination

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance or after an Office action under *Ex Parte Quayle*, 25 USPQ 74, 453 O.G. 213 (Comm'r Pat. 1935). Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on 3/12/2010 has been entered.

REASONS FOR ALLOWANCE

The following is an examiner's statement of reasons for allowance: The Examiner's Amendment and the reasons for allowance are the same as set forth in the Notice of Allowance on 12/14/2009. For applicant's convenience the Examiners Amendment and the Reasons for Allowance are restated below.

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Frank C. Eisenschenk on 11/3/2009.

The application has been amended as follows:

IN THE CLAIMS:

1. In claim 43, in line 18, after “carbamazepine and benzoquinone”, **insert**
“, wherein the API and co-crystal former are hydrogen bonded to each other”.
2. In claim 61, in line 20, after “carbamazepine and benzoquinone” **insert**
“, wherein the API and co-crystal former are hydrogen bonded to each other”.

Reasons for Allowance

The following is an examiner’s statement of reasons for allowance: the prior art does not teach or suggest a co-crystal comprising an API and a co-crystal former selected from (a)-(q) wherein the API and co-crystal former are hydrogen bonded to each other.

The closest prior art is Ammar et al., which teaches the water solubility of carbamazepine in the presence of nicotinamide in a solution. However Ammar et al. does not teach that the carbamazepine and nicotinamide are hydrogen bonded together into a co-crystal, which the applicants define as a crystalline material.

De Jong is also considered close prior art in that it teaches formulations comprised of 5-fluorouracil and urea; however, de Jong does not teach that the compounds are hydrogen bonded to one another to form a co-crystal.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably

accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Contact Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Renee Claytor whose telephone number is (571)272-8394. The examiner can normally be reached on M-F 8:00-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Application/Control Number: 10/660,202
Art Unit: 1627

Page 5

Renee Claytor

/SREENI PADMANABHAN/

Supervisory Patent Examiner, Art Unit 1627

Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Application Number	10/660,202	
			Filing Date	September 11, 2003	
			First Named Inventor	Örn Almarsson	
			Art Unit	1617	
			Examiner Name	Deirdre R. Claytor	
			Attorney Docket Number	TPI.350C1	
Sheet	1	of	6		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	U1	US-2,665,277	01-05-1954	Homeyer <i>et al.</i>	All
	U2	US-3,970,651	07-20-1976	Kaplan <i>et al.</i>	All
	U3	US-4,925,674	05-15-1990	Giannini <i>et al.</i>	All
	U4	US-4,927,855	05-22-1990	Lafon	All
	U5	US-4,994,604	02-19-1991	Tung <i>et al.</i>	All
	U6	US-5,023,092	06-11-1991	DuRoss	All
	U7	US-5,521,207	05-28-1996	Graneto	All
	U8	US-5,273,760	12-28-1993	Oshlack <i>et al.</i>	All
	U9	US-5,286,493	02-15-1994	Oshlack <i>et al.</i>	All
	U10	US-5,324,351	06-28-1994	Oshlack <i>et al.</i>	All
	U11	US-5,356,467	10-18-1994	Oshlack <i>et al.</i>	All
	U12	US-5,366,738	11-22-1994	Rork <i>et al.</i>	All
	U13	US-5,472,712	12-05-1995	Oshlack <i>et al.</i>	All
	U14	US-5,510,496	04-23-1996	Talley <i>et al.</i>	All
	U15	US-5,563,165	10-08-1996	Talley <i>et al.</i>	All
	U16	US-5,631,250	05-20-1997	Bunnell <i>et al.</i>	All
	U17	US-5,633,272	05-27-1997	Talley <i>et al.</i>	All
	U18	US-5,703,232	12-30-1997	Bunnell <i>et al.</i>	All
	U19	US-5,736,541	04-07-1998	Bunnell <i>et al.</i>	All
	U20	US-5,753,688	05-19-1998	Talley <i>et al.</i>	All
	U21	US-5,760,068	06-02-1998	Talley <i>et al.</i>	All
	U22	US-5,932,598	08-03-1999	Talley <i>et al.</i>	All

Examiner Signature	/Renee Claytor/	Date Considered	09/10/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

JATPR350C1MDSIDS-form-supp-6.doc/DNB/jb

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/660,202
				Filing Date	September 11, 2003
				First Named Inventor	Örn Almarsson
				Art Unit	1617
				Examiner Name	Deirdre R. Claytor
Sheet	2	of	6	Attorney Docket Number	TPI.350C1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U23	US-5,972,986	10-26-1999	Seibert <i>et al.</i>	All
	U24	US-5,985,902	11-16-1999	Talley <i>et al.</i>	All
	U25	US-6,054,136	04-25-2000	Farah <i>et al.</i>	All
	U26	US-6,132,420	10-17-2000	Dionne <i>et al.</i>	All
	U27	US-6,156,781	12-05-2000	Talley <i>et al.</i>	All
	U28	US-6,245,357	06-12-2001	Edgren <i>et al.</i>	All
	U29	US-6,270,787	08-07-2001	Ayer	All
	U30	US-6,283,953	09-04-2001	Ayer <i>et al.</i>	All
	U31	US-6,287,295	09-11-2001	Chen <i>et al.</i>	All
	U32	US-6,323,266	11-27-2001	Phillips	All
	U33	US-6,333,050	12-25-2001	Wong <i>et al.</i>	All
	U34	US-6,342,249	01-29-2002	Wong <i>et al.</i>	All
	U35	US-6,348,458	02-19-2002	Hamied <i>et al.</i>	All
	U36	US-6,365,185	04-02-2002	Ritschel <i>et al.</i>	All
	U37	US-6,368,626	04-09-2002	Bhatt <i>et al.</i>	All
	U38	US-6,375,978	04-23-2002	Kleiner <i>et al.</i>	All
	U39	US-6,384,034	05-07-2002	Simitchieva <i>et al.</i>	All
	U40	US-6,403,640	06-11-2002	Stoner <i>et al.</i>	All
	U41	US-6,413,965	07-02-2002	Mylari	All
	U42	US-6,420,394	07-16-2002	Supersaxo	All
	U43	US-6,579,895	06-17-2003	Karim <i>et al.</i>	All
	U44	US-6,613,790	09-02-2003	Carter	All

Examiner Signature	/Renee Claytor/	Date Considered	09/10/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C1\IDS\IDS-form-supp-6.doc/DNB/jb

NPC-UNIV-000006284

NOVARTIS EXHIBIT 1523
Novartis v. Regents, IPR2023-01347
Page 1006 of 1101

Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/660,202	
			Filing Date	September 11, 2003	
			First Named Inventor	Örn Almarsson	
			Art Unit	1617	
			Examiner Name	Deirdre R. Claytor	
Sheet	3	of	6	Attorney Docket Number	TPI.350C1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U45	US-7,172,769	02-06-2007	Kararli <i>et al.</i>	All
	U46	US-7,205,413	04-17-2007	Morissette <i>et al.</i>	All
	U47	US-7,446,107	11-04-2008	Remenar <i>et al.</i>	All
	U48	US-7,452,555	11-18-2008	Childs	All
	U49	US-7,459,449	12-02-2008	Keltjens	All
	U50	US-2002/0013357	01-31-2002	Nadkarni <i>et al.</i>	All
	U51	US-2002/0006951	01-17-2002	Hageman <i>et al.</i>	All
	U52	US-2002/0015735	02-07-2002	Hedden <i>et al.</i>	All
	U53	US-2002/0034542	03-21-2002	Thombre <i>et al.</i>	All
	U54	US-2002/0071857	06-13-2002	Kararli <i>et al.</i>	All
	U55	US-2002/0107250	08-08-2002	Hariharan <i>et al.</i>	All
	U56	US-2002/0119193	08-29-2002	Le <i>et al.</i>	All
	U57	US-2004/0029946	02-12-2004	Arora <i>et al.</i>	All
	U58	US-2004/0154890	08-12-2004	Liu	All
	U59	US-2004/0242640	12-02-2004	Desai <i>et al.</i>	All
	U60	US-2005/0070551	03-31-2005	Remenar <i>et al.</i>	All
	U61	US-2007/0015841	01-18-2007	Tawa <i>et al.</i>	All
	U62	US-2007/0293674	12-20-2007	Scoppettuolo <i>et al.</i>	All
	U63	US-7,132,570	11-07-2006	Neckebroek <i>et al.</i>	All
	U64	US-			
	U65	US-			
	U66	US-			

Examiner Signature	/Renee Claytor/	Date Considered	09/10/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C\INDS\IDS-form-supp-6.doc/DNB/jb

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/660,202	
			Filing Date	September 11, 2003	
			First Named Inventor	Örn Almarsson	
			Group Art Unit	1617	
			Examiner Name	Deirdre R. Claytor	
Sheet	4	of	6	Attorney Docket Number	TPI.350C1

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F1	WO 01/45706	06-28-2001	Pharmacia Corporation	All	
	F2	WO 2002/102376	12-27-2002	Pharmacia Corporation	All	
	F3	WO 2002/10125	02-07-2002	Teva Pharmaceutical Industries Ltd.	All	
	F4	WO 2002/056915	07-25-2002	Cephalon, Inc.	All	
	F5	WO 2005/053612	06-16-2005	Shire Laboratories, Inc.	All	
	F6	WO 96/33193	10-24-1996	Janssen Pharmaceutica N.V.	All	
	F7	JP 54-095589	07-28-1979	Sumitomo Chemical Co. Ltd.	All	
	F8	FR 2,849,029	06-25-2004	Laboratoire L. Lafon	All	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	BALL, P. "Scandal of crystal design..." <i>Nature</i> , June 20, 1996, pp. 648-650, Vol. 381.	
	R2	BASTIN, R. J. <i>et al.</i> "Salt Selection and Optimization Procedures for Pharmaceutical New Chemical Entities" <i>Organic Process Research & Development</i> , 2000, pp. 427-435, Vol. 4, No. 5.	
	R3	BERNSTEIN, J. <i>et al.</i> "Concomitant Polymorphs" <i>Angew. Chem. Int. Ed.</i> , 1999, pp. 3440-3461, Vol. 38.	
	R4	BOUCHER, E. <i>et al.</i> "Use of Hydrogen Bonds to Control Molecular Aggregation. Behavior of Dipyridones and Pyridone-Pyrimidones Designed to Form Cyclic Triplexes" <i>J. Org. Chem.</i> , 1995, pp. 1408-1412, Vol. 60.	

Examiner Signature	/Renee Claytor/	Date Considered	09/10/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

JATPI350C1NDSMDS-form-supp-6.doc/DNB/jb

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		<i>Complete if Known</i>	
		Application Number	10/660,202
		Filing Date	September 11, 2003
		First Named Inventor	Örn Almarsson
		Group Art Unit	1627
		Examiner Name	Deirdre R. Claytor
Sheet	5	of	6
		Attorney Docket Number	TPI 350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R5	BRITTAİN, H. G., <u>Polymorphism in Pharmaceutical Solids</u> , Marcel Dekker, Inc., 1999, pp. 183, 202-208 and 219.	
	R6	CHANG, Y. <i>et al.</i> "An Approach to the Design of Molecular Solids. Strategies for Controlling the Assembly of Molecules into Two-Dimensional Layered Structures" <i>J. Am. Chem. Soc.</i> , 1993, pp. 5991-6000, Vol. 115.	
	R7	COWAN, J. A. <i>et al.</i> "Neutron diffraction studies of the 1:1 and 2:1 cocrystals of benzene-1,2,4,5-tetracarboxylic acid and 4,4'-bipyridine" <i>Acta Cryst.</i> , 2006, pp. o157-o161, Vol. C62.	
	R8	DAVIDOVICH, M. <i>et al.</i> "Detection of Polymorphism by Powder X-Ray Diffraction: Interference by Preferred Orientation" <i>American Pharmaceutical Review</i> , 2004, pp. 10, 12, 14, 16, and 100, Vol. 7, Issue 1.	
	R9	DAVIES, N. M. <i>et al.</i> "Clinical Pharmacokinetics and Pharmacodynamics of Celecoxib. A Selective Cyclo-Oxygenase-2 Inhibitor" <i>Clin. Pharmacokinet.</i> , March 2000, pp. 225-242, Vol. 38, No. 3.	
	R10	DEAN, J A., <u>Analytical Chemistry Handbook</u> , McGraw-Hill, Inc., 1995, pp. 10.24-10.26.	
	R11	Definition of solvate, The Free Dictionary, http://www.thefreedictionary.com/solvate , accessed online on 21 July 2009, pp. 1-3.	
	R12	DESIRAJU, G.R. "Solid-State Chemistry: Crystal Gazing: Structure Prediction and Polymorphism" <i>Science</i> , October 17, 1997, pp. 404-405, Vol. 278, No. 5337.	
	R13	DOELKER, E. "Physicochemical behavior of active substances. Consequences for the feasibility and stability of pharmaceutical forms" <i>STP Pharma Pratiques</i> , 1999, pp. 399-409, Vol. 9, No.5.	
	R14	DOELKER, E. "Cystalline modifications and polymorphism changes during drug manufacturing" <i>Annales Pharmaceutiques Francaises</i> , 2002, pp. 161-176, Vol. 60, No. 3.	
	R15	DUNITZ, J. D. "Are crystal structures predictable?" <i>Chem Commun.</i> , 2003, pp. 545-548.	
	R16	FEYNMAN, R. P. "There's Plenty of Room at the Bottom" <i>Engineering and Science</i> , February 1960, pp. 22-36.	
	R17	JAIN, N. K. <i>et al.</i> "Polymorphism in Pharmacy" <i>Indian Drugs</i> , 1986, pp. 315-329, Vol. 23, No. 6.	

Examiner Signature	/Renee Claytor/	Date Considered	09/10/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

JATPI350C1NDSMS-form-supp-6.doc/DNB/jb

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known Application Number 10/660,202 Filing Date September 11, 2003 First Named Inventor Örn Almarsson Group Art Unit 1617 Examiner Name Deirdre R. Claytor Attorney Docket Number TPI 350C1	
Sheet	6	of	6	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	R18	KIRCHNER, M. T. <i>et al.</i> Co-crystals with Acetylene: Small is not Simple!" <i>Chem. Eur. J.</i> , 2010, pp. 2131-2146, Vol. 16.		
	R19	MOULTON, B. <i>et al.</i> "From Molecules to Crystal Engineering: Supramolecular Isomerism and Polymorphism in Network Solids" <i>Chem. Rev.</i> , 2001, pp. 1629-1658, Vol. 101.		
	R20	MUZAFFAR, N. A. <i>et al.</i> "Polymorphism and Drug Availability" <i>Journal of Pharmacy</i> , 1979, pp. 59-66, Vol. 1, No. 1.		
	R21	OSORIO-LOZADA, A. <i>et al.</i> "Synthesis and determination of the absolute stereochemistry of the enantiomers of adrafinil and modafinil" <i>Tetrahedron: Asymmetry</i> , 2004, pp. 3811-3815, Vol. 15.		
	R22	OTSUKA, M. <i>et al.</i> "Effect of Polymorphic Forms of Bulk Powders on Pharmaceutical Properties of Carbamazepine Granules" <i>Chem. Pharm. Bull.</i> , 1999, pp. 852-856, Vol. 47, No. 6.		
	R23	SHATTOCK, T. R. <i>et al.</i> "Hierarchy of Supramolecular Synthons: Persistent Carboxylic Acid...Pyridine Hydrogen Bonds in Cocrystals That also Contain a Hydroxyl Moiety" <i>Cryst. Growth Des.</i> , 2008, pp. 4533-4545, Vol. 8, No. 12.		
	R24	THAYER, A. M. "Form and Function: The choice of pharmaceutical crystalline form can be used to optimize drug properties, and cocrystals are emerging as new alternatives" <i>Chemical & Engineering News</i> , June 18, 2007, pp. 17-30, Vol. 85, No. 25.		
	R25	U.S. Pharmacopodia #23, 1995, p. 1843.		
	R26	VILLA, L. A. <i>et al.</i> "Central Nervous System Paracoccidioidomycosis. Report of a Case Successfully Treated with Itraconazol" <i>Rev. Inst. Med. Trop. S. Paulo</i> , July-August 2000, pp. 231-234, Vol. 42, No. 4.		
	R27	ZAWOROTKO, M. J. "Crystal Engineering of Diamondoid Networks" <i>Chemical Society Reviews</i> , 1994, pp. 283-288, Vol. 23.		
	R28	KLEIN, C. L. <i>et al.</i> "Molecular Structure of Two Conformationally Restrained Fentanyl Analogues: cis- and trans-Isomers of N-{3-Methyl-1-[2-(1,2,3,4-tetrahydro)naphthyl]-4-piperidinyl]-N-phenylpropanamide" <i>Journal of Pharmaceutical Sciences</i> , November 1985, pp. 1147-1151, Vol. 74, No. 11.		
	R29			

Examiner Signature	/Renee Claytor/	Date Considered	09/10/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C\INDS\DS-form-sup-6.doc\DNB/jb

Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Application Number	10/660,202	
			Filing Date	September 11, 2003	
			First Named Inventor	Örn Almarsson	
			Art Unit	1617	
			Examiner Name	Deirdre R. Claytor	
Sheet	1	of	1	Attorney Docket Number	TPI.350C1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-			
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			
	U10	US-			
	U11	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	F1	GB 2 169 601	07-16-1986	Tate & Lyle Public Limited Company	All	
	F2					

Examiner Signature	/Renee Claytor/	Date Considered	09/10/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

Index of Claims 	Application/Control No. 10660202	Applicant(s)/Patent Under Reexamination ALMARSSON ET AL.
	Examiner Renee Claytor	Art Unit 1627

✓	Rejected
=	Allowed

-	Cancelled
÷	Restricted

N	Non-Elected
I	Interference

A	Appeal
O	Objected

☐ Claims renumbered in the same order as presented by applicant		☐ CPA		☐ T.D.		☐ R.1.47			
CLAIM		DATE							
Final	Original	12/07/2007	03/20/2009	11/04/2009	09/10/2010				
	1	✓	-	-	-				
	2	✓	-	-	-				
	3	-	-	-	-				
	4	-	-	-	-				
	5	-	-	-	-				
	6	-	-	-	-				
	7	-	-	-	-				
	8	-	-	-	-				
	9	✓	-	-	-				
	10	✓	-	-	-				
	11	✓	-	-	-				
	12	-	-	-	-				
	13	-	-	-	-				
	14	-	-	-	-				
	15	-	-	-	-				
	16	-	-	-	-				
	17	-	-	-	-				
	18	-	-	-	-				
	19	-	-	-	-				
	20	-	-	-	-				
	21	-	-	-	-				
	22	-	-	-	-				
	23	-	-	-	-				
	24	-	-	-	-				
	25	-	-	-	-				
	26	-	-	-	-				
	27	-	-	-	-				
	28	-	-	-	-				
	29	-	-	-	-				
	30	-	-	-	-				
	31	-	-	-	-				
	32	-	-	-	-				
	33	-	-	-	-				
	34	-	-	-	-				
	35	-	-	-	-				
	36	-	-	-	-				

Index of Claims 	Application/Control No. 10660202	Applicant(s)/Patent Under Reexamination ALMARSSON ET AL.
	Examiner Renee Claytor	Art Unit 1627

✓	Rejected
=	Allowed

-	Cancelled
÷	Restricted

N	Non-Elected
I	Interference

A	Appeal
O	Objected

☐ Claims renumbered in the same order as presented by applicant						☐ CPA		☐ T.D.		☐ R.1.47	
CLAIM		DATE									
Final	Original	12/07/2007	03/20/2009	11/04/2009	09/10/2010						
	37	-	-	-	-						
	38	✓	-	-	-						
	39	✓	-	-	-						
	40	✓	-	-	-						
	41	✓	-	-	-						
	42	✓	-	-	-						
1	43		✓	=	=						
2	44		✓	=	=						
3	45		✓	=	=						
4	46		✓	=	=						
5	47		✓	=	=						
6	48		✓	=	=						
7	49		✓	=	=						
8	50		✓	=	=						
9	51		✓	=	=						
10	52		✓	=	=						
11	53		✓	=	=						
12	54		✓	=	=						
13	55		✓	=	=						
14	56		✓	=	=						
15	57		✓	=	=						
16	58		✓	=	=						
17	59		✓	=	=						
18	60		✓	=	=						
19	61		✓	=	=						
20	62		✓	=	=						
21	63		✓	=	=						
22	64		✓	=	=						
23	65		✓	=	=						
24	66		✓	=	=						
25	67		✓	=	=						
26	68		✓	=	=						
27	69		✓	=	=						
28	70		✓	=	=						
29	71		✓	=	=						
30	72		✓	=	=						

<i>Index of Claims</i> 	Application/Control No. 10660202	Applicant(s)/Patent Under Reexamination ALMARSSON ET AL.
	Examiner Renee Claytor	Art Unit 1627

✓	Rejected	-	Cancelled	N	Non-Elected	A	Appeal
=	Allowed	÷	Restricted	I	Interference	O	Objected

☐ Claims renumbered in the same order as presented by applicant						☐ CPA		☐ T.D.		☐ R.1.47	
CLAIM		DATE									
Final	Original	12/07/2007	03/20/2009	11/04/2009	09/10/2010						
31	73		✓	=	=						
32	74		✓	=	=						
33	75		✓	=	=						
34	76		✓	=	=						
35	77		✓	=	=						
36	78		✓	=	=						

Search Notes 	Application/Control No. 10660202	Applicant(s)/Patent Under Reexamination ALMARSSON ET AL.
	Examiner Claytor, Renee	Art Unit 1617

SEARCHED			
Class	Subclass	Date	Examiner
424	400	9/10/2010	RC
514	217, 403	9/10/2010	RC

SEARCH NOTES		
Search Notes	Date	Examiner
PALM Inventor Search	9/10/2010	RC
EAST	9/10/2010	RC
STN (STIC search in eDan)	9/10/2010	RC
Patentability Conference with Sreeni Padmanabhan and Johann Richter	2/23/2009	RC

INTERFERENCE SEARCH			
Class	Subclass	Date	Examiner
424	400	9/10/2010	RC
514	217, 403	9/10/2010	RC

--	--

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/660,202	
			Filing Date	September 11, 2003	
			First Named Inventor	Örn Almarsson	
			Art Unit	1617	
			Examiner Name	Deirdre R. Claytor	
Sheet	1	of	2	Attorney Docket Number	TPI.350C1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-5,994,365	11-30-1999	Zaworotko <i>et al.</i>	All
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			
	U10	US-			
	U11	US-			

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	F1				
	F2				

Examiner Signature	/Renee Claytor/	Date Considered	/Renee Claytor/
-----------------------	-----------------	--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		<i>Complete if Known</i>			
		Application Number	10/606,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Deirdre R. Claytor		
Sheet	2	of	2	Attorney Docket Number	TPI.350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	FELTHOUSE, T. R. <i>et al.</i> "MALEIC ANHYDRIDE, MALEIC ACID AND FUMARIC ACID", April 26, 2001, submitted for <i>Kirk Online</i> , http://www.huntsman.com/performance_products/media/komaleic.pdf .	
	R2		
	R3		
	R4		
	R5		
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		

Examiner Signature	/Renee Claytor/	Date Considered	09/10/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C1\IDS\IDS-form-supp-10.doc/DNB/sl

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/606,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Deirdre R. Claytor		
Sheet	1	of	1	Attorney Docket Number	TPI.350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	SALEM, M.S. <i>et al.</i> "Preparation, characterisation and transformation of terfenadine polymorphic forms" <i>International Journal of Pharmacuetics</i> , 1996, pp. 257-259, Vol. 141.	
	R2		
	R3		
	R4		
	R5		
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		

Examiner Signature	/Renee Claytor/	Date Considered	09/10/2010
--------------------	-----------------	-----------------	------------

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		<i>Complete if Known</i>			
		Application Number	10/606,202		
		Filing Date	September 11, 2003		
		First Named Inventor	Örn Almarsson		
		Group Art Unit	1617		
		Examiner Name	Deirdre R. Claytor		
Sheet	1	of	1	Attorney Docket Number	TPI.350C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	Office Action dated February 2, 2010 in U.S. application Serial No. 10/546,963, filed August 26, 2005.	
	R2	Pending claims in Serial No. 10/546,963, filed August 26, 2005.	
	R3		
	R4		
	R5		
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		

Examiner Signature	/Renee Claytor/	Date Considered	09/10/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/

J:\TPI\350C1\IDS\IDS-form-supp-9.doc/DNB/sl

Substitute for form 1449A/PTO		Confirmation Number	6536
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 1 of 1		Application Number	10/660,202
		Filing Date	September 11, 2003
		First Named Inventor	Orn Almarsson
		Group Art Unit	1627
		Examiner Name	Claytor, Deirdre Renee
		Attorney Docket Number	TPI.350C1

U.S. PATENT DOCUMENTS

Exam Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	U1	Heinrich Stahl P ED- Wermuth C G: "The Practice of Medicinal Chemistry; 35 Preparation of water-soluble compounds through salt formation" 1 January 2003, The Practice of Medicinal Chemistry, Elsevier, NL, pp. 601-615, XP002566271 ISBN: 978-0-12-744481-9.	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of U.S. Patent Documents at www.uspto.gov. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. ⁶ If possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

NPC-UNIV-000006299

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 1021 of 1101

Electronic Patent Application Fee Transmittal				
Application Number:		10660202		
Filing Date:		11-Sep-2003		
Title of Invention:		PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS		
First Named Inventor/Applicant Name:		Orn Almarsson		
Filer:		Frank Christopher Eisenschenk/Jenny Bedner		
Attorney Docket Number:		TPI.350C1		
Filed as Large Entity				
Utility under 35 USC 111(a) Filing Fees				
Description		Fee Code	Quantity	Sub-Total in USD(\$)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Extension-of-Time:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Miscellaneous:				
Submission- Information Disclosure Stmt	1806	1	180	180
Total in USD (\$)				180

Electronic Acknowledgement Receipt	
EFS ID:	8934089
Application Number:	10660202
International Application Number:	
Confirmation Number:	6536
Title of Invention:	PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS
First Named Inventor/Applicant Name:	Orn Almarsson
Customer Number:	23557
Filer:	Frank Christopher Eisenschenk/Jenny Bedner
Filer Authorized By:	Frank Christopher Eisenschenk
Attorney Docket Number:	TPI.350C1
Receipt Date:	30-NOV-2010
Filing Date:	11-SEP-2003
Time Stamp:	15:47:11
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Credit Card
Payment was successfully received in RAM	\$ 180
RAM confirmation Number	2687
Deposit Account	190065
Authorized User	EISENSCHENK,FRANK C.
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows: Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees) Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)	

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)					
Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)					
Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)					
File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		IDS-Supp-11.pdf	722426 da1ccf1878092440c8793b835e492027afac e6d9	yes	8
Multipart Description/PDF files in .zip description					
	Document Description		Start		End
	Transmittal Letter		1		7
	Information Disclosure Statement (IDS) Filed (SB/08)		8		8
Warnings:					
Information:					
2	NPL Documents	Heinrich.pdf	377751 bbe1ad93da0bb9a59b0e5198cd385a592d b4f52a	no	15
Warnings:					
Information:					
3	Fee Worksheet (PTO-875)	fee-info.pdf	30337 ba37072933112fc2c9052e8071767242451 0a128	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			1130514		
This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503. <u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application. <u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course. <u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.					

I hereby certify that this correspondence is being electronically filed in the the United States Patent and Trademark Office on November 30, 2010.


Frank C. Eisenschenk, Ph.D., Patent Attorney

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
Patent Application
Docket No. TPI.350C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Deirdre R. Claytor
Art Unit : 1627
Applicants : Örn Almarsson, Magali Bourghol Hickey, Matthew L. Peterson, Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo
Serial No. : 10/660,202
Filed : September 11, 2003
Conf. No. : 6536
For : Pharmaceutical Co-Crystal Compositions

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 AND 1.98

Sir:

In accordance with 37 C.F.R. § 1.56, the reference listed on the attached form PTO/SB/08 is being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of the cited reference is enclosed.

The undersigned hereby certifies that each item of information contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Supplemental Information Disclosure Statement. Applicants are attaching a copy of the European Examination Report dated September 30, 2010.

The fee of \$180.00 was authorized at the time this Information Disclosure Statement was filed.

J:\TPI\350C\IDS\IDS.suppl1.doc\DNB/sl

It is respectfully requested that the reference cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that its consideration be made of record.

Applicants respectfully assert that the substantive provisions of 37 C.F.R. §§ 1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950
Gainesville, FL 32614-2950

FCE/sl

Attachments: Form PTO/SB/08; copy of reference cited therein; European Examination Report

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: **Mail** Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
or **Fax** (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

23557 7590 09/20/2010
SALIWANCHIK LLOYD & SALIWANCHIK
A PROFESSIONAL ASSOCIATION
PO Box 142950
GAINESVILLE, FL 32614
Ph: (352) 375-8100 Fax: (352) 372-5800

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

N/A - Filed EFS	(Depositor's name)
	(Signature)
	(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/660,202	09/11/2003	Orn Almarsson	TPI.350C1	6536
------------	------------	---------------	-----------	------

TITLE OF INVENTION: PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS

APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	YES- NO	\$755 \$1510	\$300	\$0	\$1955 \$1810	12/20/2010

EXAMINER	ART UNIT	CLASS-SUBCLASS
CLAYTOR, DEIRDRE RENEE	1627	424-400000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

- ☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.
☐ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required.

2. For printing on the patent front page, list

- (1) the names of up to 3 registered patent attorneys or agents OR, alternatively,
(2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

SALIWANCHIK, LLOYD

1 & SALIWANCHIK

2

3

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE

1) UNIVERSITY OF SOUTH FLORIDA

2) THE REGENTS OF THE UNIVERSITY OF MICHIGAN

3) TRANSFORM PHARMACEUTICALS, INC.

(B) RESIDENCE: (CITY and STATE OR COUNTRY)

1) TAMPA, FLORIDA

2) ANN ARBOR, MICHIGAN

3) LEXINGTON, MASSACHUSETTS

Please check the appropriate assignee category or categories (will not be printed on the patent): ☐ Individual ☒ Corporation or other private group entity ☐ Government

4a. The following fee(s) are submitted:

- ☒ Issue Fee
☒ Publication Fee (No small entity discount permitted)
☐ Advance Order - # of Copies

4b. Payment of Fee(s): (Please first reapply any previously paid issue fee shown above)

- ☐ A check is enclosed.
☒ Payment by credit card. Form PTO-2038 is attached.
☐ The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment, to Deposit Account Number (enclose an extra copy of this form).

5. Change in Entity Status (from status indicated above)

- ☐ a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. ☒ b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2).

NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.

Authorized Signature

Frank C. Eizenschenk

Date

December 7, 2010

Typed or printed name FRANK C. EISENSCHENK, PH.D.

Registration No. 45,332

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Electronic Patent Application Fee Transmittal				
Application Number:		10660202		
Filing Date:		11-Sep-2003		
Title of Invention:		PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS		
First Named Inventor/Applicant Name:		Orn Almarsson		
Filer:		Frank Christopher Eisenschenk/Amanda LaScala		
Attorney Docket Number:		TPI.350C1		
Filed as Large Entity				
Utility under 35 USC 111(a) Filing Fees				
Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Utility Appl issue fee	1501	1	1510	1510
Publ. Fee- early, voluntary, or normal	1504	1	300	300

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Extension-of-Time:				
Miscellaneous:				
Total in USD (\$)				1810

Electronic Acknowledgement Receipt	
EFS ID:	8981952
Application Number:	10660202
International Application Number:	
Confirmation Number:	6536
Title of Invention:	PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS
First Named Inventor/Applicant Name:	Orn Almarsson
Customer Number:	23557
Filer:	Frank Christopher Eisenschenk/Amanda LaScala
Filer Authorized By:	Frank Christopher Eisenschenk
Attorney Docket Number:	TPI.350C1
Receipt Date:	07-DEC-2010
Filing Date:	11-SEP-2003
Time Stamp:	14:25:20
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Credit Card
Payment was successfully received in RAM	\$ 1810
RAM confirmation Number	689
Deposit Account	190065
Authorized User	EISENSCHENK,FRANK C.
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows: Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees) Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)	

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)					
Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)					
Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)					
File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Issue Fee Payment (PTO-85B)	IssueFeePaid.pdf	215334 f1f17769d048ae49054dd69378bb1c728d67c95	no	1
Warnings:					
Information:					
2	Fee Worksheet (PTO-875)	fee-info.pdf	31566 3c563c6b3be9e140a821b540cea040b51c7def41	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			246900		
This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503. <u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application. <u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course. <u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.					



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov



Bib Data Sheet

CONFIRMATION NO. 6536

SERIAL NUMBER 10/660,202	FILING OR 371(c) DATE 09/11/2003 RULE	CLASS 424	GROUP ART UNIT 1627	ATTORNEY DOCKET NO. TPI.350C1
------------------------------------	---	---------------------	-------------------------------	---

APPLICANTS

Orn Almarsson, Shrewsbury, MA;
 Magali Bourghol Hickey, Medford, MA;
 Matthew L. Peterson, Framingham, MA;
 Michael J. Zaworotko, Tampa, FL;
 Brian Moulton, Providence, RI;
 Nair Rodriguez-Hornedo, Ann Arbor, MI;

**** CONTINUING DATA *******

This application is a CIP of PCT/US03/27772 09/04/2003
 which is a CIP of 10/378,956 03/03/2003
 which claims benefit of 60/360,768 03/01/2002
 and said PCT/US03/27772 09/04/2003
 claims benefit of 60/451,213 02/28/2003
 and claims benefit of 60/463,962 04/18/2003
 and claims benefit of 60/487,064 07/11/2003
 This application 10/660,202
 is a CIP of 10/637,829 08/08/2003 ABN
 which is a DIV of 10/295,995 11/18/2002 PAT 6,699,840
 which is a CON of 10/232,589 09/03/2002 PAT 6,559,293
 which claims benefit of 60/406,974 08/30/2002
 and claims benefit of 60/380,288 05/15/2002
 and claims benefit of 60/356,764 02/15/2002
 This application 10/660,202
 is a CIP of 10/449,307 05/30/2003 PAT 7,078,526
 which claims benefit of 60/463,962 04/18/2003
 and claims benefit of 60/444,315 01/31/2003
 and claims benefit of 60/439,282 01/10/2003
 and claims benefit of 60/384,152 05/31/2002
 This application 10/660,202
 is a CIP of 10/601,092 06/20/2003 ABN
 and claims benefit of 60/451,213 02/28/2003
 and claims benefit of 60/463,962 04/18/2003
 and claims benefit of 60/487,064 07/11/2003

**** FOREIGN APPLICATIONS *******

IF REQUIRED, FOREIGN FILING LICENSE GRANTED
**** 07/20/2004**

Foreign Priority claimed ☐ yes ☐ no	STATE OR COUNTRY MA	SHEETS DRAWING 66	TOTAL CLAIMS 37	INDEPENDENT CLAIMS 20
35 USC 119 (a-d) conditions met ☐ yes ☐ no ☐ Met after Allowance				
Verified and Acknowledged	Examiner's Signature	Initials		

NPC-UNIV-000006311

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 1033 of 1101

ADDRESS 23557		
TITLE PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS		
FILING FEE RECEIVED 1607	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:	☐ All Fees
		☐ 1.16 Fees (Filing)
		☐ 1.17 Fees (Processing Ext. of time)
		☐ 1.18 Fees (Issue)
		☐ Other _____
		☐ Credit



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/660,202	09/11/2003	Orn Almarsson	TPL350C1	6536
23557 7590 01/28/2011 SALIWANCHIK, LLOYD & EISENSCHENK A PROFESSIONAL ASSOCIATION PO Box 142950 GAINESVILLE, FL 32614			EXAMINER CLAYTOR, DEIRDRE RENEE	
			ART UNIT 1627	PAPER NUMBER
			NOTIFICATION DATE 01/28/2011	DELIVERY MODE ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

euspto@slpatents.com



UNITED STATES DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office

Address : COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
10660202	9/11/2003	ALMARSSON ET AL.	TPL350C1

SALIWANCHIK, LLOYD & EISENSCHENK
A PROFESSIONAL ASSOCIATION
PO Box 142950
GAINESVILLE, FL 32614

EXAMINER

Renee Claytor

ART UNIT	PAPER
----------	-------

1627

20110121

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

The Supplemental Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98 has been considered and is disclosed herein.

/SREENI PADMANABHAN/
Supervisory Patent Examiner, Art Unit 1627

PTO-90C (Rev.04-03)

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Confirmation Number	6536
Application Number	10/660,202
Filing Date	September 11, 2003
First Named Inventor	Orn Almarsson
Group Art Unit	1627
Examiner Name	Claytor, Deirdre Renee
Attorney Docket Number	TPI.350C1

U.S. PATENT DOCUMENTS

Exam Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	U1	Heinrich Stahl P ED- Wermuth C G: "The Practice of Medicinal Chemistry; 35 Preparation of water-soluble compounds through salt formation" 1 January 2003, The Practice of Medicinal Chemistry, Elsevier, NL, pp. 601-615, XP002566271 ISBN: 978-0-12-744481-9.	

Examiner Signature	/Renee Claytor/	Date Considered	01/21/2011
-----------------------	-----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of U.S. Patent Documents at www.uspto.gov. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. ⁶ If possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.C./

NPC-UNIV-000006315

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 1037 of 1101



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	ISSUE DATE	PATENT NO.	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/660,202	04/19/2011	7927613	TPL350C1	6536

23557 7590 03/30/2011

SALIWANCHIK, LLOYD & EISENSCHENK
A PROFESSIONAL ASSOCIATION
PO Box 142950
GAINESVILLE, FL 32614

ISSUE NOTIFICATION

The projected patent number and issue date are specified above.

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b) (application filed on or after May 29, 2000)

The Patent Term Adjustment is 1101 day(s). Any patent to issue from the above-identified application will include an indication of the adjustment on the front page.

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.


Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (<http://pair.uspto.gov>).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Application Assistance Unit (AAU) of the Office of Data Management (ODM) at (571)-272-4200.

APPLICANT(s) (Please see PAIR WEB site <http://pair.uspto.gov> for additional applicants):

Orn Almarsson, Shrewsbury, MA;
Magali Bourghol Hickey, Medford, MA;
Matthew L. Peterson, Framingham, MA;
Michael J. Zaworotko, Tampa, FL;
Brian Moulton, Providence, RI;
Nair Rodriguez-Hornedo, Ann Arbor, MI;

I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on April 17, 2012.


Frank C. Eisenschenk, Ph.D., Patent Attorney

REQUEST FOR CERTIFICATE OF
CORRECTION UNDER 37 CFR 1.322
AND UNDER 37 CFR 1.323
Docket No. TPI.350C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Orn Almarsson, Magali Bourghol Hickey, Matthew L. Peterson, Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo
Issued : April 19, 2011
Patent No. : 7,927,613
Conf. No. : 6536
For : Pharmaceutical Co-Crystal Compositions

Mail Stop Certificate of Corrections Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST FOR CERTIFICATE OF CORRECTION
UNDER 37 CFR 1.322 (OFFICE MISTAKE) AND
UNDER 37 CFR 1.323 (APPLICANT MISTAKE)

Sir:

A Certificate of Correction for the above-identified patent has been prepared and is attached hereto.

In the left-hand column below is the column and line number where errors occurred in the patent. In the right-hand column is the page and line number in the application where the correct information appears or should have appeared.

Patent Reads:

Column 6, lines 18-19:

“Pure phenyloin and a co-crystal with phenyloin”

Application Reads:

Page 9, line 1:

--Pure phenytoin and a co-crystal with phenytoin--

J:\TPI\350C1\PTO\COC.Req.doc\DNB/jb

Patent Reads:Column 12, line 32:

“200 150 100,”

Column 12, line 34:

“200 150, 100 90,”

Column 14, line 33:“C_{max}”**Patent Reads:**Column 20, line 23:“AgF₃CSO₃”Column 30, line 6:

“+/- 10 degrees”

Column 30, line 11:

“(82001 TA”

Column 37, line 7:

“β80.291(2),”

Column 37, line 16:

“by π-ν”

Column 37, line 27:

“Phenyloin:”

Column 37, line 28:

“phenyloin and”

Application Should Read:Page 17, line 30:

--200, 150, 100,--

Page 17, line 31:

--200, 150, 100, 90,--

Page 20, line 34:--C_{max}--**Application Reads:**Page 30, line 14:--AgF₃CSO₃--Page 44, line 21:

--+/- 1.0 degrees--

Page 44, line 26:

--(82001 TA--

Page 55, line 16:

--β=80.291(2),--

Page 55, line 23:

--by π- π--

Page 55, line 31:

--Phenytoin:--

Page 55, line 32:

--phenytoin and--

Column 37, line 31:

“phenyloin/”

Column 37, line 46:

“phenyloin-phenyloin”

Column 37, lines 56-57:

“(phenyloin”

Column 37, line 66:

“0.02= 2θ”

Column 38, lines 59-60:

“λ=200 (2) K”

Column 40, line 23:

“I>2θ (I),”

Column 41, line 52:“2θ_{max} = 56.600°,”**Patent Reads:**Column 42, line 17:

“(22.)”

Column 42, line 26:

“cocrystal”

Patent Reads:Column 51, Table 1, Column “MP”, Row “Adenine”:

“200 (sub.)”

Page 56, line 1:

--phenytoin/--

Page 56, line 13:

--phenytoin-phenytoin--

Page 56, line 20:

--(phenytoin--

Page 56, line 27:

--0.02° 2θ--

Page 58, line 3:

--T=200 (2) K--

Page 60, line 11:

--I>2σ (I),--

Page 62, line 17:--2θ_{max} = 56.60°--**Application Should Read:**Page 63, line 9:

--(22.0)--


Page 63, line 15:

--co-crystal--


Application Reads:Page 96, Table 1, Column “MP”, Row “Adenine”:

--220 (sub.)--


Column 58, Table 1, Column “Molecular Structure”, Row “Lactobionic acid”:




Page 102, Table 1, Column “Molecular Structure”, Row “Lactobionic acid”:



Column 62, Table 1, Column “Molecular Structure”, Row “Pyridoxine”:



Page 105, Table 1, Column “Molecular Structure”, Row “Pyridoxine”:



Patent Reads

Column 104, Table III, Column “Functional Group”:

“pyridine thiol n-heterocyclic ring thionedisulfide pyrrolidindione iodine
hydrazone thiocyanate *bromine aromatic”

Application Reads:

Page 153, Table III, Column “Functional Group”:

--pyridine *chlorine alkyne thiol n-heterocyclic ring thionedisulfide
pyrrolidindione iodine hydrazone--

Column 105, Table III, Column “Functional Group”:

Page 153, Table III, Column “Functional Group”:

“thio ster”

--thioester--

<u>Column 107, Table III, Column “Functional Group”:</u>	<u>Page 158, Table III, Column “Functional Group”:</u>
“nitrate est r alcohol ether acetate”	--nitrate ester bromine alcohol ether acetate--
<u>Column 108, Table III, Column “Functional Group”:</u>	<u>Page 161, Table III, Column “Functional Group”:</u>
“nitrat ester”	--nitrate ester--
<u>Column 108, Table III, Column “Functional Group”:</u>	<u>Page 161, Table III, Column “Functional Group”:</u>
“st r-O”	--ester-O--
<u>Column 110, Table III, Column “Functional Group”:</u>	<u>Page 169, Table III, Column “Functional Group”:</u>
“Amin t riary”	--Amine tertiary--
<u>Column 119, Table IV, Column “API Chemical Name”, Row “(R)-salbutamol”:</u>	<u>Page 187, Table IV, Column “API Chemical Name”, Row “(R)-salbutamol”:</u>
“1,3-Benzenedimethanol, Alpha1-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-[CAS]”	--1,3-Benzenedimethanol, Alpha1-(((1,1-dimithylethyl)amino)methyl)-4-hydroxy-[CAS]--
<u>Column 125, Table IV, Column “API Chemical Name”, Row “aceglutamide”:</u>	<u>Page 191, Table IV, Column “API Chemical Name”, Row “aceglutamide”:</u>
“Aluminum, pentakis(N2-acetyl-L-glutaminoato)tetrahydroxytri- [CAS]”	--Aluminum, pentakis(N2-acetyl-L-glutaminato)tetrahydroxytri- [CAS]--
<u>Column 127, Table IV, Column “CAS No.”, Row “ACTH”:</u>	<u>Page 192, Table IV, Column “CAS No.”, Row “ACTH”:</u>
“900-60-2”	--9002-60-2--

<u>Column 130, Table IV, Column “API Chemical Name”, Row “albaconazole”:</u>	<u>Page 194, Table IV, Column “API Chemical Name”, Row “albaconazole”:</u>
“4(3H)-Quinazolinone, 7-chloro-3-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]- [CAS]”	--4(3H)-Quinazolinone, 7-chloro-3-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]- [CAS]--
<u>Column 134, Table IV, Column “API Chemical Name”, Row “alsactide”:</u>	<u>Page 196, Table IV, Column “API Chemical Name”, Row “alsactide”:</u>
“Alpha1-17-Carticotropin, 1-β-alanine-17-[N-(4-aminobutyl)-L-lysineamide]- [CAS]”	--Alpha1-17-Corticotropin, 1-β-alanine-17-[N-(4-aminobutyl)-L-lysineamide]- [CAS]--
<u>Column 134, Table IV, Column “API Generic Name”:</u>	<u>Page 196, Table IV, Column “API Generic Name”:</u>
“Althiazid”	--Althiazide--
<u>Column 136, Table IV, Column “API Generic Name”:</u>	<u>Page 198, Table IV, Column “API Generic Name”:</u>
“Ambazon”	--Ambazone--
<u>Column 136, Table IV, Column “API Generic Name”:</u>	<u>Page 198, Table IV, Column “API Generic Name”:</u>
“Ambusid”	--Ambuside--
<u>Column 141, Table IV, Column “API Generic Name”:</u>	<u>Page 201, Table IV, Column “API Generic Name”:</u>
“amrinose”	--amrinone--
<u>Column 141, Table IV, Column “Example of Indication”, Row “amtolmetin guacil”:</u>	<u>Page 201, Table IV, Column “Example of Indication”, Row “amtolmetin guacil”:</u>
“rheumatiod”	--rheumatoid--
<u>Column 144, Table IV, Column “Patent Reference”, Row “Antiprogestin”:</u>	<u>Page 203, Table IV, Column “Patent Reference”, Row “Antiprogestin”:</u>
“19703061”	--19706061--

<u>Column 148, Table IV, Column “API Generic Name”:</u>	<u>Page 205, Table IV, Column “API Generic Name”:</u>
“Aesthinol”	--Arsthinol--
<u>Column 149, Table IV, Column “CAS No.”, Row “asoprisnil”:</u>	<u>Page 206, Table IV, Column “CAS No.”, Row “asoprisnil”:</u>
“199396-76-1”	--199396-76-4--
<u>Column 151, Table IV, Column “CAS No.”, Row “atomoxetine”:</u>	<u>Page 208, Table IV, Column “CAS No.”, Row “atomoxetine”:</u>
“83015-36-3”	--83015-26-3--
<u>Column 153, Table IV, Column “API Generic Name”:</u>	<u>Page 209, Table IV, Column “API Generic Name”:</u>
“azasertron”	--azasetron--
<u>Column 153, Table IV, Column “API Generic Name”:</u>	<u>Page 209, Table IV, Column “API Generic Name”:</u>
“azathioprine”	--azathioprine--
<u>Column 162, Table IV, Column “API Chemical Name”, Row “bexarotene”:</u>	<u>Page 214, Table IV, Column “API Chemical Name”, Row “bexarotene”:</u>
“Benzoic acid, 4-(1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-[CAS]”	--Benzoic acid, 4-(1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)-[CAS]--
<u>Column 164, Table IV, Column “API Generic Name”:</u>	<u>Page 216, Table IV, Column “API Generic Name”:</u>
“bircodar”	--biricodar--
<u>Column 166, Table IV, Column “API Generic Name”:</u>	<u>Page 216, Table IV, Column “API Generic Name”:</u>
“Bitoscanat”	--Bitoscanate--

<u>Column 168, Table IV, Column “API Generic Name”:</u>	<u>Page 220, Table IV, Column “API Generic Name”:</u>
“Brozuridine”	--Broxuridine--
<u>Column 176, Table IV, Column “CAS No.”, Row “calcium polycarbophil”:</u>	<u>Page 224, Table IV, Column “CAS No.”, Row “calcium polycarbophil”:</u>
“9003-97-9”	--9003-97-8--
<u>Column 180, Table IV, Column “API Chemical Name”, Row “carboplatin”:</u>	<u>Page 226, Table IV, Column “API Chemical Name”, Row “carboplatin”:</u>
“Platinum, diammine[1,1-cyclobutanedicarboxylate(2-)]-, (SP-4-2)-[CAS]”	--Platinum, diammine[1,1-cyclobutanedicarboxylato(2-)]-, (SP-4-2)-[CAS]--
<u>Column 187, Table IV, Column “API Generic Name”:</u>	<u>Page 231, Table IV, Column “API Generic Name”:</u>
“cefotazime”	--cefotaxime--
<u>Column 189, Table IV, Column “API Chemical Name”, Row “cefprozil”:</u>	<u>Page 232, Table IV, Column “API Chemical Name”, Row “cefprozil”:</u>
“5-Thio-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[amino(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-(1-propenyl)-, [6R-[6Alpha,7Beta(R*)]]- [CAS]”	--5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[amino(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-(1-propenyl)-, [6R-[6Alpha,7Beta(R*)]]- [CAS--
<u>Column 189, Table IV, Column “CAS No.”, Row “cefprozil”:</u>	<u>Page 232, Table IV, Column “CAS No.”, Row “cefprozil”:</u>
“92665-29-7”	--92665-29-7 121123-17-9--
<u>Column 189, Table IV, Column “Patent Reference.”, Row “cefsulodin”:</u>	<u>Page 232, Table IV, Column “Patent Reference.”, Row “cefsulodin”:</u>
“GB”	--GB 1387656--

Column 190, Table IV, Column “Patent Reference”, Row “ceftibuten”:

“EP”

Column 191, Table IV, Row “Cefuzonam”:

“ Patent Reference	Example of Therapeutic Use	Example of Indication
U.S. 5,760,068	Antiarthritic, other	Arthritis rheumatoid”

Column 191, Table IV, Row “celecoxib”:

“ Patent Reference	Example of Therapeutic Use	Example of Indication
---------------------------	-----------------------------------	------------------------------

Column 191, Table IV, Row “Cellulose Ethyl Hydroxyethyl Ether”:

“ API Generic Name	API Chemical Name	CAS No.
Cellulose Ethyl		
Hydroxyethyl Ether”		

Page 233, Table IV, Column “Patent Reference”, Row “ceftibuten”:

--EP 136721--

Page 233, Table Table IV, Row “Cefuzonam”:

--Patent Reference	Example of Therapeutic Use	Example of Indication--
---------------------------	-----------------------------------	--------------------------------

Page 233, Table IV, Row “celecoxib”:

--Patent Reference	Example of Therapeutic Use	Example of Indication
U.S. 5,760,068	Antiarthritic, other	Arthritis rheumatoid--

Page 234, Table IV, Row “Cellulose Ethyl Hydroxyethyl Ether”:

--API Generic Name	API Chemical Name	CAS No.
Cellulose Ethyl		9004-58-4
Hydroxyethyl Ether--		

Patent Reads:Column 191, Table IV:

"API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Cellulose Ethyl Hydroxyethyl Ether CEP-1347	9,12-Epoxy-1H- diindolo[1,2,3-fg:3',2',1'-	156177-65-0	WO 9731002	Antiparkinsonian	Parkinson's disease"

Application Reads:Page 234, Table IV:

--API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Cellulose Ethyl Hydroxyethyl Ether		9004-58-4			
Centchroman		31477-60-8			
CEP-1347	9,12-Epoxy-1H- diindolo[1,2,3-fg:3',2',1'-	156177-65-0	WO 9731002	Antiparkinsonian	Parkinson's disease--

Column 193, Table IV, Column "API
Chemical Name", Row "cethromycin":

"2H-Oxacyclotetradecino(4,3-d)oxazole-
2,6,8,14(1H,7H,9H)-tetrone 4-
ethyloctahydro-3a,7,9,11,13,15-
hexamethyl-11-((3-(3-quinolinyl)-2-
propenyl)oxy)-10-((3,4,6-trideoxy-3-
(dimethylamino)-β-D-xylo-
hexapyranosyl)oxy)-, (3aS,4R,7R,9R,10R,
11R,13R,15R,15aR)- [CAS]"

Page 235, Table IV, Column "API Chemical
Name", Row "cethromycin":

--2H-Oxacyclotetradecino(4,3-d)oxazole-
2,6,8,14(1H,7H,9H)-tetrone 4-
ethyloctahydro-3a,7,9,11,13,15-
hexamethyl-11-((3-(3-quinolinyl)-2-
propenyl)oxy)-10-((3,4,6-trideoxy-3-
(dimethylamino)-β-D-xylo-
hexapyranosyl)oxy)-, (3aS,
4R,7R,9R,10R,11R,13R,15R,15aR)- [CAS]--

Column 195, Table IV, Column "API Generic
Name":

"Chloriazepoxide"

Page 236, Table IV, Column "API Generic
Name":

--Chlordiazepoxide--

<u>Column 197, Table IV, Column “API Generic Name”:</u>	<u>Page 237, Table IV, Column “API Generic Name”:</u>
“Chlorthenoxazine(e)”	--Chlorthenoxazin(e)--
<u>Column 203, Table IV, Column “API Generic Name”:</u>	<u>Page 241, Table IV, Column “API Generic Name”:</u>
“Clemizol”	--Clemizole--
<u>Column 205, Table IV, Column “API Generic Name”:</u>	<u>Page 243, Table IV, Column “API Generic Name”:</u>
“Clofibrat”	--Clofibrate--
<u>Column 207, Table IV, Column “Patent Reference”, Row “cloxazolam”:</u>	<u>Page 244, Table IV, Column “Patent Reference”, Row “cloxazolam”:</u>
“3,442,371”	--3,772,371--
<u>Column 214, Table IV, Column “API Generic Name”:</u>	<u>Page 248, Table IV, Column “API Generic Name”:</u>
“Cycloniumelodide”	--Cyclonium Iodide--
<u>Column 218, Table IV, Column “API Generic Name”:</u>	<u>Page 251, Table IV, Column “API Generic Name”:</u>
“DAX<SciClone”	--DAX, SciClone--
<u>Column 218, Table IV, Column “API Generic Name”:</u>	<u>Page 251, Table IV, Column “API Generic Name”:</u>
“d-Camphocarboxylic”	--d-Camphocarboxylic Acid--
<u>Column 221, Table IV, Column “CAS No.”, Row “Deoxycorticosterone”:</u>	<u>Page 253, Table IV, Column “CAS No.”, Row “Deoxycorticosterone”:</u>
“64-85-7”	--64-58-7 56-47-3--

<u>Column 236, Table IV, Column “CAS No.”, Row “doxylamine”:</u>	<u>Page 263, Table IV, Column “CAS No.”, Row “doxylamine”:</u>
“469-21-4”	--469-21-6--
<u>Column 239, Table IV, Column “API Generic Name”:</u>	<u>Page 265, Table IV, Column “API Generic Name”:</u>
“Dyphyllin”	--Dyphylline--
<u>Column 248, Table IV, Column “API Generic Name”:</u>	<u>Page 271, Table IV, Column “API Generic Name”:</u>
“eoinephrine”	--epinephrine--
<u>Column 253, Table IV, Column “API Generic Name”:</u>	<u>Page 274, Table IV, Column “API Generic Name”:</u>
“Ethadion”	--Ethadione--
<u>Column 263, Table IV, Column “CAS No.”, Row “fepradinol”:</u>	<u>Page 279, Table IV, Column “CAS No.”, Row “fepradinol”:</u>
“36981-91-6 67704-50-1 63075-57-8”	--36981-91-6 67704-50-1 63075-47-8--
<u>Column 263, Table IV, Column “Patent Reference”, Row “fexofenadine”:</u>	<u>Page 280, Table IV, Column “Patent Reference”, Row “fexofenadine”:</u>
“5,345,693”	--5,375,693--
<u>Column 268, Table IV, Column “API Generic Name”:</u>	<u>Page 283, Table IV, Column “API Generic Name”:</u>
“Fluroxen”	--Fluroxene--
<u>Column 273, Table IV, Column “API Generic Name”:</u>	<u>Page 286, Table IV, Column “API Generic Name”:</u>
“Gadobenat Dimeglumine”	--Gadobenate Dimeglumine--

<u>Column 279, Table IV, Column “API Generic Name”:</u>	<u>Page 290, Table IV, Column “API Generic Name”:</u>
“Gold Sodium Thiomalat”	--Gold Sodium Thiomalate--
<u>Column 291, Table IV, Column “API Generic Name”:</u>	<u>Page 299, Table IV, Column “API Generic Name”:</u>
“Indecainid”	--Indecainide--
<u>Column 292, Table IV, Column “API Generic Name”:</u>	<u>Page 299, Table IV, Column “API Generic Name”:</u>
“Induclem”	--Inducterm--
<u>Column 295, Table IV, Column “API Generic Name”:</u>	<u>Page 301, Table IV, Column “API Generic Name”:</u>
“Iproclozid”	--Iproclozide--
<u>Column 295, Table IV, Column “API Generic Name”:</u>	<u>Page 301, Table IV, Column “API Generic Name”:</u>
“Ipsapiron”	--Ipsapirone--
<u>Column 297, Table IV, Column “API Generic Name”:</u>	<u>Page 302, Table IV, Column “API Generic Name”:</u>
“Asocarboxazid”	--Isocarboxazid--
<u>Column 299, Table IV, Column “CAS No.”, Row “itraconazole”:</u>	<u>Page 304, Table IV, Column “CAS No.”, Row “itraconazole”:</u>
“84625-61-8”	--84625-61-6--
<u>Column 303, Table IV, Column “Patent Reference”, Row “KNI-272”:</u>	<u>Page 306, Table IV, Column “Patent Reference”, Row “KNI-272”:</u>
“5,466,028”	--5,644,028--

<u>Column 304, Table IV, Column “Example of Therapeutic Use”, Row “L-758298”:</u>	<u>Page 307, Table IV, Column “Example of Therapeutic Use”, Row “L-758298”:</u>
“Antimetic”	--Antiemetic--
<u>Column 312, Table IV, Column “CAS No.”, Row “LH”:</u>	<u>Page 312, Table IV, Column “CAS No.”, Row “LH”:</u>
“902-67-9”	--9002-67-9--
<u>Column 312, Table IV, Column “CAS No.”, Row “LH-RH”:</u>	<u>Page 312, Table IV, Column “CAS No.”, Row “LH-RH”:</u>
“934-40-6”	--9034-40-6--
<u>Column 312, Table IV, Column “API Generic Name”:</u>	<u>Page 312, Table IV, Column “API Generic Name”:</u>
“liarozote”	--liarozole--
<u>Column 312, Table IV, Column “API Generic Name”:</u>	<u>Page 313, Table IV, Column “API Generic Name”:</u>
“Lindan”	--Lindane--
<u>Column 313, Table IV, Column “API Generic Name”:</u>	<u>Page 313, Table IV, Column “API Generic Name”:</u>
“Lipo-dexamethasone”	--Lipo-dexamethasone palmitate--
<u>Column 313, Table IV, Column “API Generic Name”:</u>	<u>Page 313, Table IV, Column “API Generic Name”:</u>
“Lisofyllin”	--Lisofylline--
<u>Column 325, Table IV, Column “API Generic Name”:</u>	<u>Page 321, Table IV, Column “API Generic Name”:</u>
“Meglumin”	--Meglumine--

<u>Column 328, Table IV, Column “Patent Reference”, Row “merimepodib”:</u>	<u>Page 323, Table IV, Column “Patent Reference”, Row “merimepodib”:</u>
“5,807,878”	--5,807,876--
<u>Column 331, Table IV, Column “API Generic Name”:</u>	<u>Page 325, Table IV, Column “API Generic Name”:</u>
“Methylhexaneamide”	--Methylhexaneamine--
<u>Column 336, Table IV, Column “API Generic Name”:</u>	<u>Page 328, Table IV, Column “API Generic Name”:</u>
“,iltefosine”	--miltefosine--
<u>Column 342, Table IV, Column “API Generic Name”:</u>	<u>Page 332, Table IV, Column “API Generic Name”:</u>
“Muscarin”	--Muscarine--
<u>Column 360, Table IV, Column “API Generic Name”:</u>	<u>Page 344, Table IV, Column “API Generic Name”:</u>
“loanzapine”	--olanzapine--
<u>Column 366, Table IV, Column “API Generic Name”:</u>	<u>Page 348, Table IV, Column “API Generic Name”:</u>
“Oxetoron”	--Oxetorone--
<u>Column 366, Table IV, Column “API Generic Name”:</u>	<u>Page 349, Table IV, Column “API Generic Name”:</u>
“Oxolamin”	--Oxolamine--
<u>Column 366, Table IV, Column “API Generic Name”:</u>	<u>Page 349, Table IV, Column “API Generic Name”:</u>
“Oxolnix Acid”	--Oxolinic Acid--

<u>Column 368, Table IV, Column “API Generic Name”:</u>	<u>Page 350, Table IV, Column “API Generic Name”:</u>
“pactitaxel”	--paclitaxel--
<u>Column 369, Table IV, Column “API Generic Name”:</u>	<u>Page 351, Table IV, Column “API Generic Name”:</u>
“pamicogral”	--pamicogrel--
<u>Column 374, Table IV, Column “API Generic Name”:</u>	<u>Page 353, Table IV, Column “API Generic Name”:</u>
“Pentam thonium”	--Pentamethonium--
<u>Column 407, Table IV, Column “Patent Reference”, Row “ribavirin”:</u>	<u>Page 375, Table IV, Column “Patent Reference”, Row “ribavirin”:</u>
“4,122,771”	--4,211,771--
<u>Column 410, Table IV, Column “Cas No.”, Row “Risedronic Acid”:</u>	<u>Page 377, Table IV, Column “Cas No.”, Row “Risedronic Acid”:</u>
“105492-24-6”	--105462-24-6--
<u>Column 413, Table IV, Column “API Generic Name”:</u>	<u>Page 379, Table IV, Column “API Generic Name”:</u>
“Roxindol”	--Roxindole--
<u>Column 415, Table IV, Column “API Chemical Name”, Row “RWJ-54428”:</u>	<u>Page 381, Table IV, Column “API Chemical Name”, Row “RWJ-54428”:</u>
“5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2Z)-(2-amino-5-chloro-4-thiazolyl)(hydroxyimino)acetyl]amino]-3-[(3-[[[(2-aminoethyl)thio]methyl]-4-pyridinyl]thio]-methyl]-4-pyridinyl]thio]-8-oxo-, (6R,7R)-[CAS]”	--5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2Z)-(2-amino-5-chloro-4-thiazolyl)(hydroxyimino)acetyl]amino]-3-[(3-[[[(2-aminoethyl)thio]methyl]-4-pyridinyl]thio]-8-oxo-, (6R,7R)- [CAS]--


<u>Column 415, Table IV, Column “Patent Reference”, Row “RWJ-54428”:</u>	<u>Page 381, Table IV, Column “Patent Reference”, Row “RWJ-54428”:</u>
“3,713,772”	--9,713,772--
<u>Column 418, Table IV, Column “API Generic Name”:</u>	<u>Page 382, Table IV, Column “API Generic Name”:</u>
“Salicylsulfuric Acid”	--Salicylsulfuric Acid--
<u>Column 435, Table IV, Column “API Generic Name”:</u>	<u>Page 393, Table IV, Column “API Generic Name”:</u>
“stepronin”	--stepronin--
<u>Column 439, Table IV, Column “API Generic Name”:</u>	<u>Page 396, Table IV, Column “API Generic Name”:</u>
“silprostone”	--sulprostone--
<u>Column 451, Table IV, Column “Cas No.”, Row “terbinafine”:</u>	<u>Page 403, Table IV, Column “Cas No.”, Row “terbinafine”:</u>
“91191-71-6”	--91161-71-6--
<u>Column 455, Table IV, Column “API Generic Name”:</u>	<u>Page 406, Table IV, Column “API Generic Name”:</u>
“Thioimrag”	--Thioimreg--
<u>Column 455, Table IV, Column “API Chemical Name”, Row “Thioimrag”:</u>	<u>Page 406, Table IV, Column “API Chemical Name”, Row “Thioimrag”:</u>
“L-Thiolyrosinyl-glycynyl-glycine”	--L-Thiotyrosinyl-glycynyl-glycine--
<u>Column 461, Table IV, Column “API Generic Name”:</u>	<u>Page 410, Table IV, Column “API Generic Name”:</u>
“Tolazamid”	--Tolazamide--

<u>Column 461, Table IV, Column “API Generic Name”:</u>	<u>Page 410, Table IV, Column “API Generic Name”:</u>
“Tolazolin”	--Tolazoline--
<u>Column 463, Table IV, Column “Patent Reference”, Row “topotecan”:</u>	<u>Page 411, Table IV, Column “Patent Reference”, Row “topotecan”:</u>
“231122”	--321122--
<u>Column 465, Table IV, Column “Cas No.”, Row “tretoquinol”:</u>	<u>Page 413, Table IV, Column “Cas No.”, Row “tretoquinol”:</u>
“18559-59-8”	--18559-59-6--
<u>Column 466, Table IV, Column “Cas No.”, Row “triapine”:</u>	<u>Page 414, Table IV, Column “Cas No.”, Row “triapine”:</u>
“236392-56-5”	--236392-56-6--
<u>Column 484, Table IV, Column “Cas No.”, Row “zofenopril”:</u>	<u>Page 425, Table IV, Column “Cas No.”, Row “zofenopril”:</u>
“75176-37-3 81872-10-8 81972-10-8 81938-43-4”	--75176-37-3 81872-10-8 81938-43-4--
<u>Column 486, Table IV, Column “Patent Reference”, Row “zuclopenthixol”:</u>	<u>Page 426, Table IV, Column “Patent Reference”, Row “zuclopenthixol”:</u>
“27082”	--270282--.

The fee of \$100.00 was paid at the time this Request was filed. The Commissioner is also authorized to charge any additional fees as required under 37 CFR 1.20(a) to Deposit Account No. 19-0065.

Approval of the Certificate of Correction is respectfully requested.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950
Gainesville, FL 32614-2950

FCE/jb

Attachment: Certificate of Correction

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,927,613

Page 1 of 23

APPLICATION NO.: 10/660,202

DATED : April 19, 2011

INVENTORS : Orn Almarsson, Magali Bourghol Hickey, Matthew L. Peterson,
Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 6.

Lines 18-19, "Pure phenyloin and a co-crystal with phenyloin" should read
--Pure phenytoin and a co-crystal with phenytoin--.

Column 12.

Line 32, "200 150 100," should read --200, 150, 100,--.

Line 34, "200 150, 100 90," should read --200, 150, 100, 90,--.

Column 14.

Line 33, "Cmax" should read --C_{max}--.

Column 20.

Line 23, "AgF₃ CSO₃" should read --AgF₃CSO₃--.

Column 30.

Line 6, "+/- 10 degrees" should read --+/- 1.0 degrees--.

Line 11, "(82001 TA" should read --(⁸2001 TA--.

Column 37.

Line 7, "β80.291(2)," should read --β=80.291(2),--.

Line 16, "by π-v" should read --by π- π--.

Line 27, "Phenyloin:" should read --Phenytoin:--.

Line 28, "phenyloin and" should read --phenytoin and--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

NPC-UNIV-000006336

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 1058 of 1101

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,927,613

Page 2 of 23

APPLICATION NO.: 10/660,202

DATED : April 19, 2011

INVENTORS : Orn Almarsson, Magali Bourghol Hickey, Matthew L. Peterson,
Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 37.

Line 31, "phenyloin/" should read --phenytoin/--.

Line 46, "phenyloin-phenyloin" should read --phenytoin-phenytoin--.

Lines 56-57, "(phenyloin)" should read --(phenytoin--.

Line 66, "0.02= 2 θ " should read --0.02° 2 θ --.

Column 38.

Lines 59-60, " λ =200 (2) K" should read --T=200 (2) K--.

Column 40.

Line 23, "I>2 θ (I)," should read --I>2 σ (I)--.

Column 41.

Line 52, "2 $\theta_{\max}$ = 56.600°," should read --2 $\theta_{\max}$ = 56.60°--.

Column 42.

Line 17, "(22.0)" should read --(22.0)--.

Line 26, "cocrystal" should read --co-crystal--.

Column 51, Table 1.

Column "MP", Row "Adenine"

"200 (sub.)" should read --220 (sub.)--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

NPC-UNIV-000006337

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 1059 of 1101

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,927,613

Page 3 of 23

APPLICATION NO.: 10/660,202

DATED : April 19, 2011



INVENTORS : Orn Almarsson, Magali Bourghol Hickey, Matthew L. Peterson,
Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 58, Table 1,

Column "Molecular Structure", Row "Lactobionic acid"



" " should read --



Column 62, Table 1,

Column "Molecular Structure", Row "Pyridoxine"

" " should read --



MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,927,613

Page 4 of 23

APPLICATION NO.: 10/660,202

DATED : April 19, 2011

INVENTORS : Orn Almarsson, Magali Bourghol Hickey, Matthew L. Peterson,
Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Patent Reads:

Column 104, Table III, Column "Functional Group":

"pyridine thiol n-heterocyclic ring thionedisulfide pyrrolidindione iodine
hydrazone thiocyanate *bromine aromatic"

Application Reads:

Page 153, Table III, Column "Functional Group":

--pyridine *chlorine alkyne thiol n-heterocyclic ring thionedisulfide
pyrrolidindione iodine hydrazone--.

Column 105, Table III,

Column "Functional Group"

"thio ster" should read --thioester--.

Column 107, Table III,

Column "Functional Group"

"nitrate est r alcohol ether acetate" should read
--nitrate ester bromine alcohol ether acetate--.

Column 108, Table III,

Column "Functional Group"

"nitrat ester" should read --nitrate ester--.
"st r-O" should read --ester-O--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk
P.O. Box 142950
Gainesville, FL 32614-2950

NPC-UNIV-000006339

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 1061 of 1101

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,927,613

Page 5 of 23

APPLICATION NO.: 10/660,202

DATED : April 19, 2011

INVENTORS : Orn Almarsson, Magali Bourghol Hickey, Matthew L. Peterson,
Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 110, Table III.

Column "Functional Group"

"Amin t rtiary" should read --Amine tertiary--.

Column 119, Table IV.

Column "API Chemical Name", Row "(R)-salbutamol"

"1,3-Benzenedimethanol, Alpha1-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-
[CAS]"

should read

--1,3-Benzenedimethanol, Alpha1-(((1,1-dimithylethyl)amino)methyl)-4-
hydroxy-[CAS]--.

Column 125, Table IV.

Column "API Chemical Name", Row "aceglutamide"

"Aluminum, pentakis(N2-acetyl-L-glutaminoato)tetrahydroxytri- [CAS]"
should read

--Aluminum, pentakis(N2-acetyl-L-glutaminato)tetrahydroxytri- [CAS]--.

Column 127, Table IV.

Column "CAS No.", Row "ACTH"

"900-60-2" should read --9002-60-2--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

NPC-UNIV-000006340

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 1062 of 1101

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,927,613

Page 6 of 23

APPLICATION NO.: 10/660,202

DATED : April 19, 2011

INVENTORS : Orn Almarsson, Magali Bourghol Hickey, Matthew L. Peterson,
Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 130, Table IV,

Column "API Chemical Name", Row "albaconazole"

"4(3H)-Quinazolinone, 7-chloro-3-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H01,2,4-triazol-1-yl)propyl]- [CAS]"

should read

--4(3H)-Quinazolinone, 7-chloro-3-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]- [CAS]--.

Column 134, Table IV,

Column "API Chemical Name", Row "alsactide"

"Alpha1-17-Carticotropin, 1-β-alanine-17-[N-(4-aminobutyl)-L-lysineamide]-[CAS]"

should read

-- Alpha1-17-Corticotropin, 1-β-alanine-17-[N-(4-aminobutyl)-L-lysineamide]-[CAS]--.

Column "API Generic Name"

"Althiazid" should read --Althiazide--.

Column 136, Table IV,

Column "API Generic Name"

"Ambazon" should read --Ambazone--.

"Ambusid" should read --Ambuside--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,927,613

Page 7 of 23

APPLICATION NO.: 10/660,202

DATED : April 19, 2011

INVENTORS : Orn Almarsson, Magali Bourghol Hickey, Matthew L. Peterson,
Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 141, Table IV,

Column "API Generic Name"

"amrinose" should read --amrinone--.

Column "Example of Indication", Row "amtolmetin guacil"

"rheumatiod" should read --rheumatoid--.

Column 144, Table IV,

Column "Patent Reference Row", Row "Antiprogesterin"

"19703061" should read --19706061--.

Column 148, Table IV,

Column "API Generic Name"

"Aesthinol" should read --Arsthinol--.

Column 149, Table IV,

Column "CAS No.", Row "asoprisnil"

"199396-76-1" should read --199396-76-4--.

Column 151, Table IV,

Column "CAS No.", Row "atomoxetine"

"83015-36-3" should read --83015-26-3--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

NPC-UNIV-000006342

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 1064 of 1101

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,927,613

Page 8 of 23

APPLICATION NO.: 10/660,202

DATED : April 19, 2011

INVENTORS : Orn Almarsson, Magali Bourghol Hickey, Matthew L. Peterson,
Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 153, Table IV,

Column "API Generic Name"

"azasertron" should read --azasetron--.

"azathipprine" should read --azathioprine--.

Column 162, Table IV,

Column "API Chemical Name", Row "bexarotene"

"Benzoic acid, 4-(1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-[CAS])" should read

--Benzoic acid, 4-(1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)- [CAS]--.

Column 164, Table IV,

Column "API Generic Name"

"birlcodar" should read --biricodar--.

Column 166, Table IV,

Column "API Generic Name"

"Bitoscanat" should read --Bitoscanate--.

Column 168, Table IV,

Column "API Generic Name"

"Brozuridine" should read --Broxuridine--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

NPC-UNIV-000006343

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 1065 of 1101

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,927,613

Page 9 of 23

APPLICATION NO.: 10/660,202

DATED : April 19, 2011

INVENTORS : Orn Almarsson, Magali Bourghol Hickey, Matthew L. Peterson,
Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 176, Table IV,

Column "CAS No.", Row "calcium polycarbophil"

"9003-97-9" should read --9003-97-8--.

Column 180, Table IV,

Column "API Chemical Name", Row "carboplatin"

"Platinum, diammine[1,1-cyclobutanedicarboxylate(2-)]-, (SP-4-2)- [CAS]"
should read

--Platinum, diammine[1,1-cyclobutanedicarboxylato(2-)]-, (SP-4-2)- [CAS]--.

Column 187, Table IV,

Column "API Generic Name"

"cefotazime" should read --cefotaxime--.

Column 189, Table IV,

Column "API Chemical Name", Row "cefprozil"

"5-Thio-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[amino(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-(1-propenyl)-, [6R-[6Alpha,7Beta(R*)]]-[CAS]"

should read

--5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[amino(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-(1-propenyl)-, [6R-[6Alpha,7Beta(R*)]]-[CAS]--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

NPC-UNIV-000006344

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 1066 of 1101

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,927,613

Page 10 of 23

APPLICATION NO.: 10/660,202

DATED : April 19, 2011

INVENTORS : Orn Almarsson, Magali Bourghol Hickey, Matthew L. Peterson,
Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 189, Table IV,

Column "CAS No.", Row "cefprozil"

"92665-29-7" should read --92665-29-7
121123-17-9--.

Column "Patent Reference", Row "cefsulodin"

"GB" should read --GB 1387656--.

Column 190, Table IV,

Column "Patent Reference", Row "ceftibuten"

"EP" should read --EP 136721--.

Column 191, Table IV,

Row "Cefuzonam"

"Patent Reference	Example of Therapeutic Use	Example of Indication
U.S. 5,760,068	Antiarthritic, other	Arthritis rheumatoid"

should read

--Patent Reference	Example of Therapeutic Use	Example of Indication--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

NPC-UNIV-000006345

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 1067 of 1101

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,927,613

Page 11 of 23

APPLICATION NO.: 10/660,202

DATED : April 19, 2011

INVENTORS : Orn Almarsson, Magali Bourghol Hickey, Matthew L. Peterson,
Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 191, Table IV,

Row "celecoxib"

"Patent Reference	Example of Therapeutic Use	Example of Indication"
should read		
--Patent Reference	Example of Therapeutic Use	Example of Indication
U.S. 5,760,068	Antiarthritic, other	Arthritis Rheumatoid--.

Row "Cellulose Ethyl Hydroxyethyl Ether"

"API	API	CAS No.
Generic Name	Chemical Name	
Cellulose Ethyl Hydroxyethyl Ether"		
should read		
--API	API	CAS No.
Generic Name	Chemical Name	
Cellulose Ethyl		9004-58-4
Hydroxyethyl Ether--.		

MAILING ADDRESS OF SENDER:
Saliwanchik, Lloyd & Eisenschenk
P.O. Box 142950
Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,927,613

Page 12 of 23

APPLICATION NO.: 10/660,202

DATED : April 19, 2011

INVENTORS : Orn Almarsson, Magali Bourghol Hickey, Matthew L. Peterson,
Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 191, Table IV.

"API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
----------------------	----------------------	---------	---------------------	-------------------------------	--------------------------

Cellulose Ethyl
Hydroxyethyl Ether

CEP-1347	9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-	156177-65-0	WO 9731002	Antiparkinsonian	Parkinson's disease"
----------	---	-------------	------------	------------------	----------------------

should read

--API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
-----------------------	----------------------	---------	---------------------	-------------------------------	--------------------------

Cellulose Ethyl
Hydroxyethyl Ether

Centchroman		9004-58-4			
CEP-1347	9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-	31477-60-8	WO 9731002	Antiparkinsonian	Parkinson's disease--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

NPC-UNIV-000006347

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 1069 of 1101

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,927,613

Page 13 of 23

APPLICATION NO.: 10/660,202

DATED : April 19, 2011

INVENTORS : Orn Almarsson, Magali Bourghol Hickey, Matthew L. Peterson,
Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 193, Table IV,

Column "API Chemical Name", Row "cethromycin"

"2H-Oxacyclotetradecino(4,3-d)oxazole-2,6,8,14(1H,7H,9H)-tetrone 4-ethyloctahydro-3a,7,9,11,13,15-hexamethyl-11-((3-(3-quinolinyl)-2-propenyl)oxy)-10-((3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexapyranosyl)oxy)-,(3aS,4R,7R,9R,10R,11R,13R,15R,15aR)- [CAS]" should read

--2H-Oxacyclotetradecino(4,3-d)oxazole-2,6,8,14(1H,7H,9H)-tetrone 4-ethyloctahydro-3a,7,9,11,13,15-hexamethyl-11-((3-(3-quinolinyl)-2-propenyl)oxy)-10-((3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexapyranosyl)oxy)-,(3aS,4R,7R,9R,10R,11R,13R,15R,15aR)- [CAS]--.

Column 195, Table IV,

Column "API Generic Name",

"Chloriazepoxide" should read --Chlordiazepoxide--.

Column 197, Table IV,

Column "API Generic Name",

"Chlorthenoxazine(e)" should read --Chlorthenoxazin(e)--.

Column 203, Table IV,

Column "API Generic Name",

"Clemizol" should read --Clemizole--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,927,613

Page 14 of 23

APPLICATION NO.: 10/660,202

DATED : April 19, 2011

INVENTORS : Orn Almarsson, Magali Bourghol Hickey, Matthew L. Peterson,
Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 205, Table IV,

Column "API Generic Name",

"Clofibrat" should read --Clofibrate--.

Column 207, Table IV,

Column "Patent Reference", Row "cloxazolam"

"3,442,371" should read --3,772,371--.

Column 214, Table IV,

Column "API Generic Name",

"Cycloniumelodide" should read --Cyclonium Iodide--.

Column 218, Table IV,

Column "API Generic Name",

"DAX<SciClone" should read --DAX, SciClone--.

"d-Camphocarboxylic" should read --d-Camphocarboxylic Acid--.

Column 221, Table IV,

Column CAS No.", Row "Deoxycorticosterone"

"64-85-7" should read --64-58-7

56-47-3--.

Column 236, Table IV,

Column CAS No.", Row "doxylamine"

"469-21-4" should read --469-21-6--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

NPC-UNIV-000006349

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 1071 of 1101

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,927,613

Page 15 of 23

APPLICATION NO.: 10/660,202

DATED : April 19, 2011

INVENTORS : Orn Almarsson, Magali Bourghol Hickey, Matthew L. Peterson,
Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 239, Table IV,

Column "API Generic Name",

"Dyphyllin" should read --Dyphylline--.

Column 248, Table IV,

Column "API Generic Name",

"eoinephrine" should read --epinephrine--.

Column 253, Table IV,

Column "API Generic Name",

"Ethadion" should read --Ethadione--.

Column 263, Table IV,

Column "CAS No.", Row "fepradinol"

"36981-91-6

67704-50-1

63075-57-8" should read --36981-91-6

67704-50-1

63075-47-8--.

Column "Patent Reference", Row "fexofenadine"

"5,345,693" should read --5,375,693--.

Column 268, Table IV,

Column "API Generic Name",

"Fluroxen" should read -- Fluroxene--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

NPC-UNIV-000006350

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 1072 of 1101

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,927,613

Page 16 of 23

APPLICATION NO.: 10/660,202

DATED : April 19, 2011

INVENTORS : Orr Almarsson, Magali Bourghol Hickey, Matthew L. Peterson,
Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 273, Table IV,

Column "API Generic Name",

"Gadobenat

Dimeglumine" should read --Gadobenate

Dimeglumine--.

Column 279, Table IV,

Column "API Generic Name",

"Gold Sodium

Thiematat" should read --Gold Sodium

Thiomalate--.

Column 291, Table IV,

Column "API Generic Name",

"Indecainid" should read --Indecainide--.

Column 292, Table IV,

Column "API Generic Name",

"Induclem" should read --Inducterm--.

Column 295, Table IV,

Column "API Generic Name",

"Iproclozid" should read --Iproclozide--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,927,613

Page 17 of 23

APPLICATION NO.: 10/660,202

DATED : April 19, 2011

INVENTORS : Orn Almarsson, Magali Bourghol Hickey, Matthew L. Peterson,
Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 295, Table IV,

Column "API Generic Name",
"Ipsapiron" should read --Ipsapirone--.

Column 297, Table IV,

Column "API Generic Name",
"Asocarboxazid" should read --Isocarboxazid--.

Column 299, Table IV,

Column "CAS No.", Row "itraconazole"
"84625-61-8" should read --84625-61-6--.

Column 303, Table IV,

Column "Patent Reference", Row "KNI-272"
"5,466,028" should read --5,644,028--.

Column 304, Table IV,

Column "Example of Therapeutic Use", Row "L-758298"
"Antimetic" should read --Antiemetic--.

Column 312, Table IV,

Column "CAS No.", Row "LH"
"902-67-9" should read --9002-67-9--.

Column "CAS No.", Row "LH-RH"
"934-40-6" should read --9034-40-6--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk
P.O. Box 142950
Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,927,613

Page 18 of 23

APPLICATION NO.: 10/660,202

DATED : April 19, 2011

INVENTORS : Orn Almarsson, Magali Bourghol Hickey, Matthew L. Peterson,
Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 312, Table IV,

Column "API Generic Name",

"liarozote" should read --liarozole--.

"Lindan" should read --Lindane--.

Column 313, Table IV,

Column "API Generic Name",

"Lipo-dexamethasone" should read --Lipo-dexamethasone palmitate--.

"Lisofyllin" should read --Lisofylline--.

Column 325, Table IV,

Column "API Generic Name",

"Meglumin" should read --Meglumine--.

Column 328, Table IV,

Column "Patent Reference", Row "merimepodib"

"5,807,878" should read --5,807,876--.

Column 331, Table IV,

Column "API Generic Name"

"Methylhexaneamide" should read --Methylhexanamine--.

Column 336, Table IV,

Column "API Generic Name"

"iltefosine" should read --miltefosine--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,927,613

Page 19 of 23

APPLICATION NO.: 10/660,202

DATED : April 19, 2011

INVENTORS : Orn Almarsson, Magali Bourghol Hickey, Matthew L. Peterson,
Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 342, Table IV,

Column "API Generic Name",

"Muscarin" should read --Muscarine--.

Column 360, Table IV,

Column "API Generic Name",

"loanzapine" should read --olanzapine--.

Column 366, Table IV,

Column "API Generic Name",

"Oxetoron" should read --Oxetorone--.

"Oxolamin" should read --Oxolamine--.

"Oxolinix Acid" should read --Oxolinic Acid--.

Column 368, Table IV,

Column "API Generic Name",

"pactitaxel" should read --paclitaxel--.

Column 369, Table IV,

Column "API Generic Name"

"pamicogral" should read --pamicogrel--.

Column 374, Table IV,

Column "API Generic Name"

"Pentam thonium" should read --Pentamethonium--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

NPC-UNIV-000006354

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 1076 of 1101

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,927,613

Page 20 of 23

APPLICATION NO.: 10/660,202

DATED : April 19, 2011

INVENTORS : Orn Almarsson, Magali Bourghol Hickey, Matthew L. Peterson,
Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 407, Table IV,

Column "Patent Reference", Row "ribavirin"

"4,122,771" should read --4,211,771--.

Column 410, Table IV,

Column "Cas No.", Row "Risedronic Acid"

"105492-24-6" should read --105462-24-6--.

Column 413, Table IV,

Column "API Generic Name",

"Roxindol" should read --Roxindole--.

Column 415, Table IV,

Column "API Chemical Name", Row "RWJ-54428"

"5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2Z)-(2-amino-5-chloro-4-thiazolyl)(hydroxyimino)acetyl]amino]-3-[(3-[(2-aminoethyl)thio]methyl)-4-pyridinyl]thio]-methyl]-4-pyridinyl]thio]-8-oxo-, (6R,7R)-[CAS]"
should read

--5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2Z)-(2-amino-5-chloro-4-thiazolyl)(hydroxyimino)acetyl]amino]-3-[(3-[(2-aminoethyl)thio]methyl)-4-pyridinyl]thio]-8-oxo-, (6R,7R)- [CAS]--.

Column "Patent Reference", Row "RWJ-54428"

"3,713,772" should read --9,713,772--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

NPC-UNIV-000006355

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 1077 of 1101

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,927,613

Page 21 of 23

APPLICATION NO.: 10/660,202

DATED : April 19, 2011

INVENTORS : Orn Almarsson, Magali Bourghol Hickey, Matthew L. Peterson,
Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 418, Table IV.

Column "API Generic Name"

"Salicylsilfuric Acid" should read --Salicylsulfuric Acid--.

Column 435, Table IV.

Column "API Generic Name",

"stepronim" should read --stepronin--.

Column 439, Table IV.

Column "API Generic Name",

"silprostone" should read --sulprostone--.

Column 451, Table IV.

Column "Cas No.", Row "terbinafine"

"91191-71-6" should read --91161-71-6--.

Column 455, Table IV.

Column "API Generic Name",

"Thioimrag" should read --Thioimreg--.

Column "API Chemical Name", Row "Thioimrag"

"L-Thiolyrosinyl-glycinyl-glycine" should read

--L-Thiotyrosinyl-glycinyl-glycine--.

Column 461, Table IV.

Column "API Generic Name",

"Tolazamid" should read --Tolazamide--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

NPC-UNIV-000006356

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 1078 of 1101

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,927,613

Page 22 of 23

APPLICATION NO.: 10/660,202

DATED : April 19, 2011

INVENTORS : Orn Almarsson, Magali Bourghol Hickey, Matthew L. Peterson,
Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 461, Table IV.

Column "API Generic Name"

"Tolazolin" should read --Tolazoline--.

Column 463, Table IV.

Column "Patent Reference", Row "topotecan"

"231122" should read --321122--.

Column 465, Table IV.

Column "Cas No.", Row "tretoquinol"

"18559-59-8" should read --18559-59-6--.

Column 466, Table IV.

Column "Cas No.", Row "triapine"

"236392-56-5" should read --236392-56-6--.

Column 484, Table IV.

Column "Cas No.", Row "zofenopril"

"75176-37-3

81872-10-8

81972-10-8

81938-43-4"

should read

--75176-37-3

81872-10-8

81938-43-4--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

NPC-UNIV-000006357

NOVARTIS EXHIBIT 1523

Novartis v. Regents, IPR2023-01347

Page 1079 of 1101

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,927,613

Page 23 of 23

APPLICATION NO.: 10/660,202

DATED : April 19, 2011

INVENTORS : Orn Almarsson, Magali Bourghol Hickey, Matthew L. Peterson,
Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 463, Table IV,

Column "Patent Reference", Row "zuclopenthixol"

"27082" should read --270282--.

MAILING ADDRESS OF SENDER:
Saliwanchik, Lloyd & Eisenschenk
P.O. Box 142950
Gainesville, FL 32614-2950

Electronic Patent Application Fee Transmittal				
Application Number:		10660202		
Filing Date:		11-Sep-2003		
Title of Invention:		PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS		
First Named Inventor/Applicant Name:		Orn Almarsson		
Filer:		Frank Christopher Eisenschenk/Amanda LaScala		
Attorney Docket Number:		TPI.350C1		
Filed as Large Entity				
Utility under 35 USC 111(a) Filing Fees				
Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Certificate of correction	1811	1	100	100
Extension-of-Time:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Miscellaneous:				
Total in USD (\$)				100

Electronic Acknowledgement Receipt	
EFS ID:	12555555
Application Number:	10660202
International Application Number:	
Confirmation Number:	6536
Title of Invention:	PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS
First Named Inventor/Applicant Name:	Orn Almarsson
Customer Number:	23557
Filer:	Frank Christopher Eisenschenk/Amanda LaScala
Filer Authorized By:	Frank Christopher Eisenschenk
Attorney Docket Number:	TPI.350C1
Receipt Date:	17-APR-2012
Filing Date:	11-SEP-2003
Time Stamp:	08:11:21
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Credit Card
Payment was successfully received in RAM	\$ 100
RAM confirmation Number	7768
Deposit Account	190065
Authorized User	EISENSCHENK,FRANK C.
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows: Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees) Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)	

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)					
Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)					
Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)					
File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Request for Certificate of Correction	COC-Req.pdf	2868866 6bffd3f11f6b18e2c5aa1af6b16c22bd4ee0deb	no	42
Warnings:					
Information:					
2	Fee Worksheet (SB06)	fee-info.pdf	29766 ed76281c819a71c16822c1b927b366b8e0177843	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			2898632		
This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503. <u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application. <u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course. <u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.					

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,927,613 B2
APPLICATION NO. : 10/660202
DATED : April 19, 2011
INVENTOR(S) : Orn Almarsson et al.

Page 1 of 13

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 6,

Lines 18-19, "Pure phenyloin and a co-crystal with phenyloin" should read
--Pure phenytoin and a co-crystal with phenytoin--.

Column 12,

Line 32, "200 150 100," should read --200, 150, 100,--.
Line 34, "200 150, 100 90," should read --200, 150, 100, 90,--.

Column 14,

Line 33, "C_{max}" should read --C_{max}--.

Column 20,

Line 23, "AgF₃CSO₃" should read --AgF₃CSO₃--.


Column 30,

Line 6, "+/- 10 degrees" should read --+/- 1.0 degrees--.
Line 11, "(82001 TA" should read --(⁸2001 TA--.

Column 37,

Line 7, "β80.291(2)," should read --β=80.291(2),--.
Line 16, "by π-ν" should read --by π- π--.
Line 27, "Phenyloin:" should read --Phenytoin:--.
Line 28, "phenyloin and" should read --phenytoin and--.
Line 31, "phenyloin/" should read --phenytoin/--.
Line 46, "phenyloin-phenyloin" should read --phenytoin-phenytoin--.
Lines 56-57, "(phenyloin" should read --(phenytoin--.
Line 66, "0.02= 2θ" should read --0.02° 2θ--.

Signed and Sealed this
Twenty-second Day of May, 2012



David J. Kappos
Director of the United States Patent and Trademark Office

CERTIFICATE OF CORRECTION (continued)
U.S. Pat. No. 7,927,613 B2

Page 2 of 13

Column 38,

Lines 59-60, " $\lambda=200$ (2) K" should read --T=200 (2) K--.

Column 40,

Line 23, " $I>20$ (I)," should read -- $I>2\sigma$ (I)--.

Column 41,

Line 52, " $2\theta_{\max} = 56.600^\circ$," should read -- $2\theta_{\max} = 56.60^\circ$ --.

Column 42,

Line 17, "(22.0)" should read --(22.0)--.

Line 26, "cocrystal" should read --co-crystal--.


Column 51, Table 1,

Column "MP", Row "Adenine"

"200 (sub.)" should read --220 (sub.)--.


Column 58, Table 1,

Column "Molecular Structure", Row "Lactobionic acid"



Column 62, Table 1,

Column "Molecular Structure", Row "Pyridoxine"



Column 104, Table III, Column "Functional Group":

“pyridine thiol n-heterocyclic ring thionedisulfide pyrrolidindione iodine
hydrazone thiocyanate *bromine aromatic”

CERTIFICATE OF CORRECTION (continued)
U.S. Pat. No. 7,927,613 B2

Page 3 of 13

should read:

--pyridine *chlorine alkyne thiol n-heterocyclic ring thionedisulfide
pyrrolidindione iodine hydrazone--.

Column 105, Table III,

Column "Functional Group"

"thio ster" should read --thioester--.

Column 107, Table III,

Column "Functional Group"

"nitrate est r alcohol ether acetate" should read
--nitrate ester bromine alcohol ether acetate--.

Column 108, Table III,

Column "Functional Group"

"nitrat ester" should read --nitrate ester--.
"st r-O" should read --ester-O--.

Column 110, Table III,

Column "Functional Group"

"Amin t rtiary" should read --Amine tertiary--.

Column 119, Table IV,

Column "API Chemical Name", Row "(R)-salbutamol"

"1,3-Benzenedimethanol, Alpha 1-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-
[CAS]"
should read
--1,3-Benzenedimethanol, Alpha 1-(((1,1-dimithylethyl)amino)methyl)-4-
hydroxy-[CAS]--.

Column 125, Table IV,

Column "API Chemical Name", Row "aceglutamide"

"Aluminum, pentakis(N2-acetyl-L-glutaminoato)tetrahydroxytri- [CAS]"
should read
--Aluminum, pentakis(N2-acetyl-L-glutaminato)tetrahydroxytri- [CAS]--.

Column 127, Table IV,

Column "CAS No.", Row "ACTH"

"900-60-2" should read --9002-60-2--.

Column 130, Table IV,

Column "API Chemical Name", Row "albaconazole"

"4(3H)-Quinazolinone, 7-chloro-3-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-
methyl-3-(1H01,2,4-triazol-1-yl)propyl]- [CAS]"
should read

CERTIFICATE OF CORRECTION (continued)
U.S. Pat. No. 7,927,613 B2

Page 4 of 13

--4(3H)-Quinazolinone, 7-chloro-3-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]- [CAS]--.

Column 134, Table IV,

Column "API Chemical Name", Row "alsactide"

"Alpha 1-17-Carticotropin, 1-β-alanine-17-[N-(4-aminobutyl)-L-lysineamide]-[CAS]"

should read

--Alpha 1-17-Corticotropin, 1-β-alanine-17-[N-(4-aminobutyl)-L-lysineamide]-[CAS]--.

Column "API Generic Name"

"Althiazid" should read --Althiazide--.

Column 136, Table IV,

Column "API Generic Name"

"Ambazon" should read --Ambazone--.

"Ambusid" should read --Ambuside--.

Column 141, Table IV,

Column "API Generic Name"

"amrinose" should read --amrinone--.

Column "Example of Indication", Row "amtolmetin guacil"

"rheumatiod" should read --rheumatoid--.

Column 144, Table IV,

Column "Patent Reference Row", Row "Antiprogesterin"

"19703061" should read --19706061--.

Column 148, Table IV,

Column "API Generic Name"

"Aesthinol" should read --Arsthinol--.

Column 149, Table IV,

Column "CAS No.", Row "asoprisnil"

"199396-76-1" should read --199396-76-4--.

Column 151, Table IV,

Column "CAS No.", Row "atomoxetine"

"83015-36-3" should read --83015-26-3--.

Column 153, Table IV,

Column "API Generic Name"

"azasertron" should read --azasetron--.

"azathiprine" should read --azathioprine--.

CERTIFICATE OF CORRECTION (continued)
U.S. Pat. No. 7,927,613 B2

Page 5 of 13

Column 162, Table IV,

Column "API Chemical Name", Row "bexarotene"

"Benzoic acid, 4-(1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-
[CAS]" should read
--Benzoic acid, 4-(1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-
naphthalenyl)ethenyl)- [CAS]--.

Column 164, Table IV,

Column "API Generic Name"

"birlcodar" should read --biricodar--.

Column 166, Table IV,

Column "API Generic Name"

"Bitoscanat" should read --Bitoscanate--.

Column 168, Table IV,

Column "API Generic Name"

"Brozuridine" should read --Broxuridine--.

Column 176, Table IV,

Column "CAS No.", Row "calcium polycarbophil"

"9003-97-9" should read --9003-97-8--.

Column 180, Table IV,

Column "API Chemical Name", Row "carboplatin"

"Platinum, diammine[1,1-cyclobutanedicarboxylate(2-)]-, (SP-4-2)- [CAS]"
should read
--Platinum, diammine[1,1-cyclobutanedicarboxylato(2-)]-, (SP-4-2)- [CAS]--.

Column 187, Table IV,

Column "API Generic Name"

"cefotazime" should read --cefotaxime--.

Column 189, Table IV,

Column "API Chemical Name", Row "cefprozil"

"5-Thio-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[amino(4-
hydroxyphenyl)acetyl]amino]-8-oxo-3-(1-propenyl)-, [6R-[6Alpha,7beta(R*)]]-
[CAS]"
should read
--5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[amino(4-
hydroxyphenyl)acetyl]amino]-8-oxo-3-(1-propenyl)-, [6R-[6Alpha,7beta(R*)]]-
[CAS]--.

CERTIFICATE OF CORRECTION (continued)
U.S. Pat. No. 7,927,613 B2

Page 6 of 13

Column 189, Table IV,

Column "CAS No.", Row "cefprozil"

"92665-29-7" should read --92665-29-7
121123-17-9--.

Column "Patent Reference", Row "cefsulodin"

"GB" should read --GB 1387656--.

Column 190, Table IV,

Column "Patent Reference", Row "ceftibuten"

"EP" should read --EP 136721--.

Column 191, Table IV,

Row "Cefuzonam"

"Patent Reference	Example of Therapeutic Use	Example of Indication
U.S. 5,760,068	Antiarthritic, other	Arthritis rheumatoid"

should read

--Patent Reference	Example of Therapeutic Use	Example of Indication--.
-------------------------------	---------------------------------------	-------------------------------------

Column 191, Table IV,

Row "celecoxib"

"Patent Reference	Example of Therapeutic Use	Example of Indication"
------------------------------	---------------------------------------	-----------------------------------

should read

--Patent Reference	Example of Therapeutic Use	Example of Indication
U.S. 5,760,068	Antiarthritic, other	Arthritis Rheumatoid--.

Row "Cellulose Ethyl Hydroxyethyl Ether"

"API	API	CAS No.
Generic Name	Chemical Name	
Cellulose Ethyl		
Hydroxyethyl Ether"		

should read

--API	API	CAS No.
Generic Name	Chemical Name	
Cellulose Ethyl		9004-58-4
Hydroxyethyl Ether--.		

CERTIFICATE OF CORRECTION (continued)
U.S. Pat. No. 7,927,613 B2

Page 7 of 13

Column 191, Table IV,

“API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Cellulose Ethyl Hydroxyethyl Ether CEP-1347	9,12-Epoxy-1H- diindolo[1,2,3-fg:3',2',1'-	156177-65-0	WO 9731002	Antiparkinsonian	Parkinson's disease”
should read					

--API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Cellulose Ethyl Hydroxyethyl Ether Centchroman CEP-1347	9,12-Epoxy-1H- diindolo[1,2,3-fg:3',2',1'-	9004-58-4 31477-60-8 156177-65-0	WO 9731002	Antiparkinsonian	Parkinson's disease--.

Column 193, Table IV,

Column “API Chemical Name”, Row “cethromycin”

“2H-Oxacyclotetradecino(4,3-d)oxazole-2,6,8,14(1H,7H,9H)-tetrone 4-ethyloctahydro-3a,7,9,11,13,15-hexamethyl-11-((3-(3-quinoliny)-2-propenyl)oxy)-10-((3,4,6-trideoxy-3-(dimethylamino)-β-D-xylohexapyranosyl)oxy)-, (3aS,4R,7R,9R,10R,11R,13R,15R,15aR)- [CAS]”
should read

--2H-Oxacyclotetradecino(4,3-d)oxazole-2,6,8,14(1H,7H,9H)-tetrone 4-ethyloctahydro-3a,7,9,11,13,15-hexamethyl-11-((3-(3-quinoliny)-2-propenyl)oxy)-10-((3,4,6-trideoxy-3-(dimethylamino)-β-D-xylohexapyranosyl)oxy)-, (3aS,4R,7R,9R,10R,11R,13R,15R,15aR)- [CAS]--.

Column 195, Table IV,

Column “API Generic Name”,

“Chloriazepoxide” should read --Chlordiazepoxide--.

Column 197, Table IV,

Column “API Generic Name”,

“Chlorthenoxazine(e)” should read --Chlorthenoxazin(e)--.

Column 203, Table IV,

Column “API Generic Name”,

“Clemizol” should read --Clemizole--.

CERTIFICATE OF CORRECTION (continued)
U.S. Pat. No. 7,927,613 B2

Page 8 of 13

Column 205, Table IV,

Column "API Generic Name",

"Clofibrat" should read --Clofibrate--.

Column 207, Table IV,

Column "Patent Reference", Row "cloxazolam"

"3,442,371" should read --3,772,371--.

Column 214, Table IV,

Column "API Generic Name",

"Cycloniumelodide" should read --Cyclonium Iodide--.

Column 218, Table IV,

Column "API Generic Name",

"DAX<SciClone" should read --DAX, SciClone--.

"d-Camphocarboxylic" should read --d-Camphocarboxylic Acid--.

Column 221, Table IV,

Column CAS No.", Row "Deoxycorticosterone"

"64-85-7" should read --64-58-7

56-47-3--.

Column 236, Table IV,

Column CAS No.", Row "doxylamine"

"469-21-4" should read --469-21-6--.

Column 239, Table IV,

Column "API Generic Name",

"Dyphyllin" should read --Dyphylline--.

Column 248, Table IV,

Column "API Generic Name",

"eoinephrine" should read --epinephrine--.

Column 253, Table IV,

Column "API Generic Name",

"Ethadion" should read --Ethadione--.

Column 263, Table IV,

Column "CAS No.", Row "fepradinol"

"36981-91-6

67704-50-1

63075-57-8" should read --36981-91-6

67704-50-1

63075-47-8--.

CERTIFICATE OF CORRECTION (continued)
U.S. Pat. No. 7,927,613 B2

Page 9 of 13

Column "Patent Reference", Row "fexofenadine"
"5,345,693" should read --5,375,693--.

Column 268, Table IV,
Column "API Generic Name",
"Fluroxen" should read --Fluroxene--.

Column 273, Table IV,
Column "API Generic Name",
"Gadobenat
Dimeglumine" should read --Gadobenate
Dimeglumine--.

Column 279, Table IV,
Column "API Generic Name",
"Gold Sodium
Thiematat" should read --Gold Sodium
Thiomalate--.

Column 291, Table IV,
Column "API Generic Name",
"Indecainid" should read --Indecainide--.

Column 292, Table IV,
Column "API Generic Name",
"Induclem" should read --Inducterm--.

Column 295, Table IV,
Column "API Generic Name",
"Iproclozid" should read --Iproclozide--.

Column 295, Table IV,
Column "API Generic Name",
"Ipsapiron" should read --Ipsapirone--.

Column 297, Table IV,
Column "API Generic Name",
"Asocarboxazid" should read --Isocarboxazid--.

Column 299, Table IV,
Column "CAS No.", Row "itraconazole"
"84625-61-8" should read --84625-61-6--.

CERTIFICATE OF CORRECTION (continued)
U.S. Pat. No. 7,927,613 B2

Page 10 of 13

Column 303, Table IV,

Column "Patent Reference", Row "KNI-272"
"5,466,028" should read --5,644,028--.

Column 304, Table IV,

Column "Example of Therapeutic Use", Row "L-758298"
"Antimetic" should read --Antiemetic--.

Column 312, Table IV,

Column "CAS No.", Row "LH"
"902-67-9" should read --9002-67-9--.
Column "CAS No.", Row "LH-RH"
"934-40-6" should read --9034-40-6--.

Column 312, Table IV,

Column "API Generic Name",
"liarozote" should read --liarozole--.
"Lindan" should read --Lindane--.

Column 313, Table IV,

Column "API Generic Name",
"Lipo-dexamethasone" should read --Lipo-dexamethasone palmitate--.
"Lisofyllin" should read --Lisofylline--.

Column 325, Table IV,

Column "API Generic Name",
"Meglumin" should read --Meglumine--.

Column 328, Table IV,

Column "Patent Reference", Row "merimepodib"
"5,807,878" should read --5,807,876--.

Column 331, Table IV,

Column "API Generic Name"
"Methylhexaneamide" should read --Methylhexanamine--.

Column 336, Table IV,

Column "API Generic Name"
",iltefosine" should read --miltefosine--.

Column 342, Table IV,

Column "API Generic Name",
"Muscarin" should read --Muscarine--.

CERTIFICATE OF CORRECTION (continued)
U.S. Pat. No. 7,927,613 B2

Page 11 of 13

Column 360, Table IV,

Column “API Generic Name”,
“loanzapine” should read --olanzapine--.

Column 366, Table IV,

Column “API Generic Name”,
“Oxetoron” should read --Oxetorone--.
“Oxolamin” should read --Oxolamine--.
“Oxolinx Acid” should read --Oxolinic Acid--.

Column 368, Table IV,

Column “API Generic Name”,
“pactitaxel” should read --paclitaxel--.

Column 369, Table IV,

Column “API Generic Name”
“pamicogral” should read --pamicogrel--.

Column 374, Table IV,

Column “API Generic Name”
“Pentam thonium” should read --Pentamethonium--.

Column 407, Table IV,

Column “Patent Reference”, Row “ribavirin”
“4,122,771” should read --4,211,771--.

Column 410, Table IV,

Column “Cas No.”, Row “Risedronic Acid”
“105492-24-6” should read --105462-24-6--.

Column 413, Table IV,

Column “API Generic Name”,
“Roxindol” should read --Roxindole--.

Column 415, Table IV,

Column “API Chemical Name”, Row “RWJ-54428”
“5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2Z)-(2-amino-5-chloro-4-thiazolyl)(hydroxyimino)acetyl]amino]-3-[(3-[[[(2-aminoethyl)thio]methyl]-4-pyridinyl]thio]-methyl]-4-pyridinyl]thio]-8-oxo-, (6R,7R)-[CAS]”
should read
--5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2Z)-(2-amino-5-chloro-4-thiazolyl)(hydroxyimino)acetyl]amino]-3-[(3-[[[(2-aminoethyl)thio]methyl]-4-pyridinyl]thio]-8-oxo-, (6R,7R)- [CAS]--.

CERTIFICATE OF CORRECTION (continued)
U.S. Pat. No. 7,927,613 B2

Page 12 of 13

Column "Patent Reference", Row "RWJ-54428"
"3,713,772" should read --9,713,772--.

Column 418, Table IV,
Column "API Generic Name"
"Salicylsilfuric Acid" should read --Salicylsulfuric Acid--.

Column 435, Table IV,
Column "API Generic Name",
"stepronim" should read --stepronin--.

Column 439, Table IV,
Column "API Generic Name",
"silprostone" should read --sulprostone--.

Column 451, Table IV,
Column "Cas No.", Row "terbinafine"
"91191-71-6" should read --91161-71-6--.

Column 455, Table IV,
Column "API Generic Name",
"Thioimrag" should read --Thioimreg--.
Column "API Chemical Name", Row "Thioimrag"
"L-Thiolyrosinyl-glycinyl-glycine" should read
--L-Thiotyrosinyl-glycinyl-glycine--.

Column 461, Table IV,
Column "API Generic Name",
"Tolazamid" should read --Tolazamide--.

Column 461, Table IV,
Column "API Generic Name"
"Tolazolin" should read --Tolazoline--.

Column 463, Table IV,
Column "Patent Reference", Row "topotecan"
"231122" should read --321122--.

Column 465, Table IV,
Column "Cas No.", Row "tretoquinol"
"18559-59-8" should read --18559-59-6--.

Column 466, Table IV,
Column "Cas No.", Row "triapine"
"236392-56-5" should read --236392-56-6--.

CERTIFICATE OF CORRECTION (continued)
U.S. Pat. No. 7,927,613 B2

Page 13 of 13

Column 484, Table IV,

Column “Cas No.”, Row “zofenopril”

“75176-37-3
81872-10-8
81972-10-8
81938-43-4”

should read

--75176-37-3
81872-10-8
81938-43-4--.

Column 486, Table IV,

Column “Patent Reference”, Row “zuclopenthixol”

“27082” should read --270282--.

“FEE ADDRESS” INDICATION FORM

**Address to:
Mail Stop M Correspondence
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**

Fax to:
571-273-6500

- OR -

INSTRUCTIONS: The issue fee must have been paid for application(s) listed on this form. In addition, only an address represented by a Customer Number can be established as the fee address for maintenance fee purposes (hereafter, fee address). A fee address should be established when correspondence related to maintenance fees should be mailed to a different address than the correspondence address for the application.

When to check the first box below: If you have a Customer Number to represent the fee address. **When to check the second box below:** If you have no Customer Number representing the desired fee address, in which case a completed Request for Customer Number (PTO/SB/125) must be attached to this form. For more information on Customer Numbers, see the Manual of Patent Examining Procedure (MPEP) § 403.

For the following listed application(s), please recognize as the "Fee Address" under the provisions of 37 CFR 1.363 the address associated with:

X	Customer Number:	23628
---	------------------	-------

OR

☐ The attached Request for Customer Number (PTO/SB/125) form.

PATENT NUMBER (if known)	APPLICATION NUMBER
7,927,613	

Completed by (check one):

☐ Applicant/Inventor

/Edward R. Gates/
Signature

X	Attorney or Agent of record	<u>31,616</u> (Reg. No.)
---	-----------------------------	-----------------------------

Edward R. Gates
Typed or printed name

☐ Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed.
(Form PTO/SB/96)

617.646.8000
Requester's telephone number

Assignee recorded at Reel _____ Frame _____

June 29, 2018
Date

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more that one signature is required, see below*.

☐ * Total of 1 forms are submitted.

Certificate of Electronic Filing under 37 C.F.R. § 1.8

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office's electronic filing system in accordance with 37 C.F.R. § 1.6(a)(4).

Dated: July 12, 2018 Electronic Signature for Brenda M. White: /Brenda M. White/

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office's electronic filing system in accordance with 37 C.F.R. § 1.6(a)(4).

Dated: July 12, 2018

Electronic Signature for Brenda M. White: /Brenda M. White/

Electronic Acknowledgement Receipt	
EFS ID:	33161462
Application Number:	10660202
International Application Number:	
Confirmation Number:	6536
Title of Invention:	PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS
First Named Inventor/Applicant Name:	Orn Almarsson
Customer Number:	23557
Filer:	Edward R. Gates/Brenda White
Filer Authorized By:	Edward R. Gates
Attorney Docket Number:	TPI.350C1
Receipt Date:	12-JUL-2018
Filing Date:	11-SEP-2003
Time Stamp:	14:43:33
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment		no			
File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Transmittal Letter	U015770030US00-TRN-ERG.pdf	25346 f0705d6819e750cc4aa1f2b7e0d48a68d2d0c8f7	no	1
Warnings:					

Information:					
2	Change of Address	U015770030US00-CHA-ERG.pdf	22926 8616e828af4b005d60ab877c520715e2004061e8	no	1
Warnings:					
Information:					
Total Files Size (in bytes):			48272		
This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503. <u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application. <u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course. <u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.					

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	Patent#: 7,927,613	
	Filing Date	Issued: April 19, 2011	
	First Named Inventor	Örn Almarsson	
	Art Unit	1627	
	Examiner Name	D. R. Claytor	
Total Number of Pages in This Submission	2	Attorney Docket Number	U0157.70030US00

ENCLOSURES (Check all that apply)			
☐ Fee Transmittal Form ☐ Fee Attached ☐ Amendment/Reply ☐ After Final ☐ Affidavits/declaration(s) ☐ Extension of Time Request ☐ Express Abandonment Request ☐ Information Disclosure Statement ☐ Certified Copy of Priority Document(s) ☐ Reply to Missing Parts/Incomplete Application ☐ Reply to Missing Parts under 37 CFR 1.52 or 1.53	☐ Drawing(s) ☐ Licensing-related Papers ☐ Petition ☐ Petition to Convert to a Provisional Application ☐ Power of Attorney, Revocation Change of Correspondence Address ☐ Terminal Disclaimer ☐ Request for Refund ☐ CD, Number of CD(s) _____ ☐ Landscape Table on CD	☐ After Allowance Communication to TC ☐ Appeal Communication to Board of Appeals and Interferences ☐ Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) ☐ Proprietary Information ☐ Status Letter ☒ Other Enclosure(s) (please identify below): Fee Address Indication Form	
<table border="1"><tr><td>Remarks</td></tr></table>			Remarks
Remarks			

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	WOLF, GREENFIELD & SACKS, P.C.		
Signature	/Edward R. Gates/		
Printed name	Edward R. Gates		
Date	June 29, 2018	Reg. No.	31,616

Certificate of Electronic Filing under 37 C.F.R. § 1.8	
I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office's electronic filing system in accordance with 37 C.F.R. § 1.6(a)(4).	
Dated: July 12, 2018	Electronic Signature for Brenda M. White: /Brenda M. White/